Publications du Service

Sommaire de cette page

ANNEE 2022

Publié le 12/12/2023 à 12h04 (mis à jour le 22/12/2023 à 10h40)

PHARMACOLOGIE FONDAMENTALE ET CLINIQUE, RECHERCHE CLINIQUE

Aguersf A, Sarton B, Bouharaoua S, Gaillard L, Standarovski D, Faucoz O, Martin Blondel G, Khallel H, Thalamas C, Sommet A, Riu B, Morand E, Bataille B, Silva S. Lung Ultrasound to Assist ICU Admission Decision-Making Process of COVID-19 Patients With Acute Respiratory Failure. Crit Care Explor. 2022 Jun 8 ;4(6):e0719.-

Belančić A, Sans-Pola C, Jouanjus E, Alcubilla P, Arellano AL, Žunić M, Nogueiras-Álvarez R, Roncato R, Sáez-Peñataro J ; EACPT Young Clinical Pharmacologists Working Group. European association for clinical pharmacology and therapeutics young clinical pharmacologists working group : a cornerstone for the brighter future of clinical pharmacology. Eur J Clin Pharmacol. 2022 Apr ;78(4):691-694.

Betrouni N, Moreau C, Rolland AS, Carrière N, Viard R, Lopes R, Kuchcinski G, Eusebio A, Thobois S, Hainque E, Hubsch C, Rascol O, Brefel C, Drapier S, Giordana C, Durif F, Maltête D, Guehl D, Hopes L, Rouaud T, Jarraya B, Benatru I, Tranchant C, Tir M, Chupin M, Bardinet E, Defebvre L, Corvol JC, Devos D ; PREDISTIM Study Group. Can Dopamine Responsiveness Be Predicted in Parkinson’s Disease Without an Acute Administration Test ? J Parkinsons Dis. 2022 ;12(7):2179-2190.

Bordet R, Dontonel JC, Vacaresse E, Le Jeune C, Benhabiles N, Beretz A, Boitard C, Debette S, Duluc G, Frogel P, Garbil B, Lyonnet S, Mahfoudi A, Marquet P, Mouthon F, Rascol O, Richard V, Simon E, Varoqueaux N, Watier H, Zins M. How has the future investment program stimulated research and innovation in health ?
Therapie. 2022 Jan-Feb ;77(1):19-24

Boussac M, Arbus C, Colin O, Laurencin C, Eusebio A, Hainque E, Corvol JC, Versace N, Rascol O, Rousseau V, Harroch E, Ory-Magne F, Fabbri M, Moreau C, Rolland AS, Jarraya B, Maltête D, Drapier S, Marques A-R, Auzou N, Wirth T, Meyer M, Giordana B, Tir M, Rouaud T, Devos D, Brefel-Courbon C ; PREDISTIM study group. Personality assessment with Temperament and Character Inventory in Parkinson’s disease. Parkinsonism Relat Disord. 2022 Oct ;103:34-41.

Bourneau-Martin D, Babin M, Grandvuillemin A, Mullet C, Salvo F, Singier A, Cellier M, Fresse A, de Canecaude C, Pietri T, Drablier G, Geniaux
H, Lagarce L, Laroche ML, Briet M ; French Network of Regional Pharmacovigilance Centres. Adverse drug reaction related to drug shortage : A retrospective study on the French National Pharmacovigilance Database. Br J Clin Pharmacol. 2023 Mar ;89(3):1080-1088

Calviere L, Gathier C S, Rafiq M, Koopman I, Rousseau V, Raposo N, Albucher JF, Viguier A, Geeraerts T, Cognard C, Rinkel G J E, Vergouwen M D I, Olivot JM. Rebleeding After Aneurysmal Subarachnoid Hemorrhage in Two Centers Using Different Blood Pressure Management Strategies.
Front Neurol. 2022 Feb 21 ;13:836268

Chaudhuri K R, Odin P, Ferreira J J, Antonini A, Rascol O, Kurtis M M, Storch A, Bannister K, Soares-da-Silva P, Costa R, Magalhães D, Rocha JF. Opicapone versus placebo in the treatment of Parkinson’s disease patients with end-of-dose motor fluctuation-associated pain : rationale and design of the randomised, double-blind OCEAN (OpiCapone Effect on motor fluctuations and pAiN) trial.
BMC Neurol. 2022 Mar 12 ;22(1):88.

Chelban V, Nikram E, Perez-Soriano A, Wilke C, Foubert-Samier A, Vijiaratnam N, Guo T, Jabbari E, Olufodun S, Gonzalez M, Senkevich K, Laurens B, Péran P, Rascol O, Le Traon AP, Todd EG, Costantini AA, Alikhwan S, Tariq A, Ng BL, Muñoz E, Painous C, Compta Y, Junque C, Segura B, Zhelcheska K, Wellington H, Schöls L, Jaunmuktane Z, Kobylecki C, Church A, Hu MTM, Rowe JB, Leigh PN, Massey L, Burn DJ, Pavese N, Foltynie T, Pchelina S, Wood N, Heslegrave AJ, Zetterberg H, Bocchetta M, Rohrer JD, Marti MJ, Synofzik M, Morris HR, Meissner WG, Houlden H. Neurofilament light levels predict clinical progression and death in multiple system atrophy. Brain. 2022 Dec 19 ;145(12):4398-4408.

Clarke Lorenzia, Castor-Newton Marie Josiane, Angénieux Olivier, Lapeyre-Mestre Maryse, Gardette Virginie. La population âgée en Guyane : état des lieux et enjeux pour le système de santé. Anal Chem. 2023 Jan ;10 ;95(1):49-69

Coarelli G, Heinzmann A, Ewenczyk C, Fischer C, Chupin M, Monin M L, Hurmic H, Calvas F, Calvas P, Goizet C, Thobois S, Anheim M, Nguyen K, Devos D, Verny C, Ricigliano V A G, Mangin J-F, Brice A, Tezenas du Montcel S, Durr A. Safety and efficacy of riluzole in spinocerebellar ataxia type 2 in France (ATRIL) : a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2022 Mar ;21(3):225-23

Corvol J-C, Azulay J-P, Bosse B, Dauvilliers Y, Defebvre L, Klostermann F, Kovacs N, Maltête D, Ondo W G, Pahwa R, Rein W, Thobois S, Valis M, Videnovic A, Rascol O ; THN102-202 Study Investigators. THN 102 for Excessive Daytime Sleepiness Associated with Parkinson’s Disease : A Phase 2a Trial.
Mov Disord. 2022 Feb ;37(2):410-415.

Dague E, Pons V, Roland A, Azaïs J-M, Arcucci S, Lachaize V, Velmont S, Trevisiol E, N’Guyen D, Sénard J-M, Galés C. Atomic force microscopy-single-molecule force spectroscopy unveils GPCR cell surface architecture. Commun Biol. 2022 Mar 10 ;5(1):221

Devignes Q, Daoudi S, Viard R, Lopes R, Betrouni N, Kuchcinski G, Rolland A-S, Moreau C, Defebvre L, Bardinet E, Bonnet M, Brefel-Courbon C, Delmaire C, El Mountassir F, Fluchère F, Fradet A, Giordana C, Hainque E, Houvenaghel J-F, Jarraya B, Klinger H, Maltête D, Marques A, Meyer M, Rascol O, Rouaud T, Tir M, Wirth T, Corvol J-C, Devos D, Dujardin K ; PREDISTIM working group. Heterogeneity of PD-MCI in Candidates to Subthalamic Deep Brain Stimulation : Associated Cortical andSubcortical Modifications. J Parkinsons Dis. 2022 ;12(5):1507-1526.

Devos D, Labreuche J, Rascol O, Corvol J-C, Duhamel A, Guyon Delannoy P, Poewe W, Compta Y, Nicola P, Růžička E, Dušek P, Post B, Bloem B R, Berg D, Maetzler W, Otto M, Habert M-O, Lehericy S, Ferreira J, Dodel R , Tranchant C, Eusebio A, Thobois S, Marques A-R, Meissner W G, Ory-Magne F, Walter U, de Bie R M A, Gago M, Vilas D, Kulisevsky J, Januario C, Coelho M V S , Behnke S, Worth P, Seppi K, Ouk T, Potey C, Leclercq C, Viard R, Kuchcinski G, Lopes R, Pruvo J-P, Pigny P, Garçon G, Simonin O, Carpentier J, Rolland A-S, Nyholm D, Scherfler C, Mangin J-F, Chupin M, Bordet R, Dexter D T, Fradette C, Spino M, Tricta F, Ayton S, Bush A I, Devedjian J-C, Duce J A, Cabantchik I, Defebvre L, Deplanque D, Moreau C ; FAIRPARK-II Study Group. Trial of Deferiprone in Parkinson’s Disease. N Engl J Med. 2022 Dec 1 ;387(22):2045-2055.

Duvignaud A, Lhomme E, Onaisi R, Sitta R, Gelley A, Chastang J, Piroth L, Binquet C, Dupouy J, Makinson A, Lefèvre B, Naccache J-M, Roussillon C, Landman R, Wallet C, Karcher S, Journot V, Nguyen D, Pistone T, Bouchet S, Lafon M-E, Molimard M, Thiébaut R, de Lamballerie Xa, Joseph J-P, Richert L, Saint-Lary O, Djabarouti S, Wittkop L, Anglaret X, Malvy D, Coverage Study Group. Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes : a randomised controlled trial (COVERAGE). Clin Microbiol Infect. 2022 Jul ;28:1010-1016

Faggianelli F Jr, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T ; NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson’s disease. Rev Neurol (Paris). 2022 Apr ;178(4):347-354

Ferré F, Piel-Julian M-L, Tincres F, BA C, Menut R, Ferrier A, Bosch L, Martin C, Labaste F, Montastruc F, Sommet A, Balardy L, Minville V. A High Postoperative Atropinic Burden is Associated with Postoperative Delirium in Elderly Patients with Hip Fracture : Results of the Prospective, Observational, ATROPAGE Trial. Clin Interv Aging. 2022 Dec 30 ;17:1931-1938

Ferreira J J, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimarães B, Rocha J-F, Soares-da-Silva P. Effect of Opicapone on Levodopa Pharmacokinetics in Patients with Fluctuating Parkinson’s Disease. Mov Disord. 2022 Nov ;37(11):2272-2283.

Ferreira Joaquim J, Poewe Werner, Rascol Olivier, Stocchi Fabriozio, Antonini Angelo, Moreira Joana, Pereira Ana, Rocha José-Francisco, Soares-da-Silva Patricio. Opicapone as an Add-on to Levodopa in Patients with Parkinson’s Disease Without Motor Fluctuations : Rationale and Design of the Phase III, Double-Blind, Randomised, Placebo-Controlled EPSILON Trial. Neurol Ther. 2022 Sep ;11(3):1409-1425.

Foubert-Samier A, Pavy-Le Traon A, Saulnier T, Le-Goff M, Fabbri M, Helmer C, Rascol O , Proust-Lima C, Meissner W G. An Item Response Theory analysis of the Unified Multiple System Atrophy Rating Scale. Parkinsonism Relat Disord. 2022 Jan ;94:40-44

Georges C, Lloret-Perez S, Ory-Magne F, Fabbri M, Foubert-Samier A, Meissner W G, Rascol O, Pavy-Le Traon A. Alterations in electrochemical skin conductance as a marker of autonomic dysfunction in multiple system atrophy. Parkinsonism Relat Disord. 2022 Oct ;103:56-59.

Gollion Cédric, Guidolin Brigitte, Lerebours Fleur, Rousseau Vanessa, Barbieux-Guillot Marianne, Larrue Vincent. Migraine and large artery atherosclerosis in young adults with ischemic stroke. Headache. 2022 Feb ;62(2):191-197.

Gomez-Brouchet A, Illac C, Ledoux A, Fortin P-Y, de Barros S, Vabre C, Despas F, Peries S, Casaroli C, Bouvier C, Aubert S, de Pinieux G, Larousserie F, Galmiche L, Talmont F, Pitson S, Maddelein M-L, Cuvillier O. Sphingosine Kinase-1 Is Overexpressed and Correlates with Hypoxia in Osteosarcoma : Relationship with Clinicopathological Parameters. Cancers. 2022 Jan 19 ;14(3):499

Groussolles M, Winer N, Sentilhes L, Biquart F, Massoud M, Vivanti A J, Bouchghoul H, Rozenberg P, Olivier P, Desbriere R, Chauleur C, Perrotin F, Coatleven F, Fuchs F, Bretelle F, Tsatsaris V, Salomon L J, Sananes N, Kayem G, Houflin-Debarge V, Schmitz T, Benoist G, Arnaud C, Ehlinger V, Vayssière C ; Groupe de Recherche en Gynecologie Obstétrique. Arabin pessary to prevent adverse perinatal outcomes in twin pregnancies with a short cervix : a multicenter randomized controlled trial (PESSARONE). Am J Obstet Gynecol. 2022 Aug ;227(2):271.e1-271.e13.

Habek M, Leys F, Krbot Skorić M, Carneiro D R, Calandra-Buonaura G, Camaradou J, Chiaro G, Cortelli P, Falup-Pecurariu C, Granata R, Guaraldi P, Helbok R, Hilz M, Iodice V, Jordan J, Kaal E CA, Kamondi A, Pavy Le Traon A, Rocha I, Sellner J, Senard J-M, Terkelsen A, Wenning G K, Berger T, Thijs R D, Struhal W, Fanciulli A, Collaborators of European Network of Clinical ANS laboratories. Clinical Autonomic Nervous System Laboratories in Europe . Eur J Neurol. 2022 Dec ;29(12):3633-3646.

Jucaite A, Cselényi Z, Kreisl W C, Rabiner E A, Varrone A, Carson R E, Rinne J O, Savage A, Schou M, Johnström P, Svenningsson P, Rascol O, Meissner W G, Barone P, Seppi K, Kaufmann H, Wenning G K, Poewe W, Farde L. Glia Imaging Differentiates Multiple System Atrophy from Parkinson’s Disease : A Positron Emission Tomography Study with [11 C]PBR28 and Machine Learning Analysis.Mov Disord. 2022 Jan ;37(1):119-129.

Kermorgant M, Ferngut P-O, Meissner W G, Arvanitis D N, N’Guyen D, Senard J M, Pavy-Le Traon A. Age and gender differences in cardiovascular autonomic failure in the transgenic PLP-syn mouse, a model of multiple system atrophy. Frontiers in Neurology. 2022 Jun 2 ;13:874155

Kermorgant M, Labrunée M, Despas Fab, Hélissen O, Geeraerts T, Lambert E, Schmidt E, Senard J-M, Arvanitis D N, Nasr N, Traon A P. How does head position induced intracranial pressure changes impact sympathetic activity and cerebral blood flow ? . Auton neurosci. 2022 Dec ;243:103036.

Khedher Khedher L, Bonny JM, Marques A, Durand E, Pereira B, Chupin M, Vidal T, Chassain C, Defebvre L, Carriere N, Fraix V, Moro E, Thobois S, Metereau E, Mangone G, Vidailhet M, Corvol JC, Lehéricy S, Menjot de Champfleur N, Geny C, Spampinato U, Meissner W, Frismand S, Schmitt E, Doé de Maindreville A, Portefaix C, Remy P, Fénelon G, Luc Houeto J, Colin O, Rascol O, Peran P, Durif F ; R study group. Intrasubject subcortical quantitative referencing to boost MRI sensitivity to Parkinson’s disease. Neuroimage Clin. 2022 ;36:103231.

Krismer F, Palma JA, Calandra-Buonaura G, Stankovic I, Vignatelli L, Berger AK, Falup-Pecurariu C, Foubert-Samier A, Höglinger G, Kaufmann H, Kellerman L, Kim HJ, Klockgether T, Levin J, Martinez-Martin P, Mestre TA, Pellecchia MT, Perlman S, Qureshi I, Rascol O, Schrag A, Seppi K, Shang H, Stebbins GT, Wenning GK, Singer W, Meissner WG. The Unified Multiple System Atrophy Rating Scale : Status, Critique, and Recommendations. Mov Disord. 2022 Dec ;37(12):2336-2341.

Lang AntonyE, Siderowf Andrew D, Macklin Eric A, Poewe Werner, Brooks David J, Fernandez Hubert H, Rascol Olivier, Giladi Nir, Stocchi Fabrizio, Tanner Caroline M, Postuma Ronald B, Simon David K, Tolosa Eduardo, Mollenhauer Brit, Cedarbaum Jesse M, Fraser Kyle, Xiao James, Evans Karleytonnnn C, Graham DanielleL, Sapir Inbal, Inra ennifer, Hutchison R Matthew, Yang Minhua, Fox Tara, Budd Haeberlein Samantha, Dam Tien ; SPARK Investigators. Trial of Cinpanemab in Early Parkinson’s Disease. N Engl J Med. 2022 Aug 4 ;387(5):408-420.

Montastruc J L, Biron P, Sommet A. Efficacy of COVID-19 vaccines : Several modes of expression should be presented in scientific publications.
Fundam Clin Pharmacol. 2022 Feb ;36(1):218-220

Montastruc J L, Biron P, Sommet A. NVX-Cov2373 Novavax Covid-19 vaccine : A further analysis of its efficacy using multiple modes of expression.
Fundam Clin Pharmacol. 2022 Dec ;36(6):1125-1127

Olivot J-M, Heit J J, Mazighi M, Raposo N, Albucher J-F, Rousseau V, Guenego A, Thalamas C, Mlynash M, Drif A, Christensen S, Sommet A, Viguier A, Darcourt J, Januel A-C, Calviere L, Menegon P, Caparros F, Bonneville F, Tourdias T, Sibon I, Albers GW, Cognard C ; FRAME Investigators. What predicts poor outcome after successful thrombectomy in early time window ? J Neurointerv Surg. 2022 Nov ;14(11):1051-1055.

Pavy-Le Traon A, Foubert-Samier A,Ory-Magne F, Fabbri M, Senard J M, Meissner W G, Rascol O, Amar J. Ambulatory blood pressure and drug treatement for orthostatic hypotension as predictors of mortality in patients with multiple system atrophy. Eur J Neurol. 2022 Apr ;29(4):1025-1034

Rascol O, Medori R, Baayen C, Such P, Meulien D ; AMBLED Study Group. A Randomized, Double-Blind, Controlled Phase II Study of Foliglurax in Parkinson’s Disease. Mov Disord. 2022 May ;37(5):1088-1093.

Rascol O, Tönges L, deVries T, Jaros M, Quartel A, Jacobs D ; ALLAY-LID I and ALLAY-LID II study groups. Immediate-release/extended-release amantadine (OS320) to treat Parkinson’s disease with levodopa-induced dyskinesia : Analysis of the randomized, controlled ALLAY-LID studies.
Parkinsonism Relat Disord. 2022 Mar ;96:65-73.

Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhães D, Gama H, Soares-da-Silva P. The safety/tolerability of opicapone when used early in Parkinson’s disease patients with levodopa-induced motor fluctuations : A post-hoc analysis of BIPARK-I and II.
Front Neurol. 2022 Aug 23 ;13:994114.

Roussel M, Lauwers-Cances V, Macro M, Leleu X, Royer B, Hulin C, Karlin L, Perrot A, Touzeau C, Chrétien M-L, Rigaudeau S, Dib M, Nicolas-Virelizier E, Escoffre-Barbe M, Belhadj K, Mariette C, Stoppa A-M, Araujo C, Doyen C, Fontan J, Kolb B, Garderet L, Brechignac S, Malfuson J-V, Jaccard A, Lenain P, Borel C, Hebraud B, Benbrahim O, Dorvaux V, Manier S, Augeul-Meunier K, Vekemans M-C, Randriamalala E, Chaoui D, Caers J, Chaleteix C, Benboubker L, Vincent L, Glaisner S, Zunic P, Slama B, Eveillard J-R, Humbrecht-Kraut C, Morel M, Mineur P, Eisenmann JC, Demarquette H, Richez V, Vignon M, Caillot D, Facon T, Moreau P, Colin AL, Olivier P, Wuilleme S, Avet-Loiseau H, Corre J, Attal M. Bortezomib and high-dose melphalan conditioning regimen in frontline multiple myeloma : an IFM randomized phase 3 study.
Blood. 2022 May 5 ;139(18):2747-2757.

Ruyssen-Witrand A, Rousseau V, Sommet A, Goupille P, Degboe Y, Constantin A. Factors associated with drug-free remission at 5-year in early onset axial spondyloarthritis patients : Data from the DESIR cohort. Joint Bone Spine. 2022 Jul ;89(4):105358

Saulnier T, Philipps V, Meissner W G, Rascol O, Pavy-Le Traon A, Foubert-Samier A, Proust-Lima C. Joint models for the longitudinal analysis of measurement scales in the presence of informative dropout.
Methods. 2022 Jul ;203:142-151.

Suc Anja, Cayzac D, Iannuzzi Stéphanie, Garnier Camille, Bonneau Baptiste, Sommet Agnès. Peacefull : A French mindfulness-based intervention for adolescents with chronic pain a feasibility study. Arch Pediatr. 2022 Nov ;29(8):581-587

Tödt Inken, Al-Fatly Bassam, Granert Olivier, Kühn Andrea, Krack Paul, Rau Joern, Timmermann Lars, Schnitzler Alfons, Paschen Steffen, Helmers Ann-Kristin, Hartmann Andrea, Bardinet Eric, Schuepbach Michael, Barbe Michael T, Dembek TillA, Fraix Valérie, Kübler Dorothee, Brefel-Courbon Christine, Gharabaghi Alireza, Wojtecki Lars, Pinsker Marcus O, Thobois Stephane, Damier Philippe, Witjas Tatiana, Houeto Jean-Luc, Schade-Brittinger Carmen, Vidailhet Marie, Horn Andreas, Deuschl Günther. The Contribution of Subthalamic Nucleus Deep Brain Stimulation to the Improvement in Motor Functions and Quality of Life.
Mov Disord. 2022 Feb ;37(2):291-301.

Van Munster M, Stümpel J, Thieken F, Ratajczak F, Rascol , Fabbri M, Clemens T, Czabanowska K, Mestre T A, Pedrosa D J ; iCARE-PD consortium. The Role of Parkinson Nurses for Personalizing Care in Parkinson’s Disease : A Systematic Review and Meta-Analysis. J Parkinsons Dis. 2022 ;12(6):1807-1831.

PHARMACOVIGILANCE

Aghnatios Lucas , Karsenty Clément, Viard Caroline, de Canecaude Claire, Durrieu Geneviève. Severe hepatitis after sevoflurane anesthesia in an 8-month old child with a Down syndrome : Case report and review of the literature.
Therapie. 2023 Jul-Aug ;78(4):459-462

Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Lacroix I. Topical sertaconazole during in the EFEMERIS database. Mycoses. 2022 April ;65(4):481-489

Azam C, Buscail L, Culetto A, Lapeyre-Mestre M. Cannabinoid-Related Acute Pancreatitis : An Update from International Literature and Individual Case Safety Reports. Drug Saf. 2022 Mar ;45(3):215-235.

Balon M, Tessier S, Damase-Michel C, Cottin J, Lambert A, Thompson M-A, Benevent J, Lacroix I. Adverse drug reactions in pregnant women : Do they differ from those in non-pregnant women of childbearing age ? Thérapie 78(2023) 165-173

Da Costa J, Very E, Rousseau V, Virolle J, Redon M, Taïb S, Revet A, Montastruc F. Comparative Effects of 30 Antipsychotics on Risk of catatonia—An analysis of the WHO Pharmacovigilance Database. J Clin Psychiatry. 2022 Dec 14 ;84(1):21m14238.

Bouhanick B, Brusq C, Bongard V, Tessier S, Montastruc J-L, Senard J-M, Montastruc F, Herin F. Blood pressure measurements after mRNA-SARS-CoV-2 tozinameran vaccination : a retrospective analysis in a university hospital in France. Blood pressure measurements after mRNA-SARS-Cov-2 tozinameran vaccination : a retrospective analysis in a university hospital in France. J Hum Hypertens. 2022 Jun ;36(6):580-581

Foltran D, Delmas C, Flumian C, De P P, Salvo F, Gautier S, Drici M-D, Karsenty C, Montastruc F. Myocarditis and pericarditis in adolescents after first and second doses of mRNA COVID-19 vaccines. Eur Heart J Qual Care Clin Outcomes. 2022 Mar ;2 ;8(2):99-103

Guion-Firmin J, Tessier S, Lepelley M, Faillie J L, Montastruc J-L. Diarrhoea with the angiotensin receptor neprilysin inhibitor sacubitril + valsartan : A pharmacovigilance study. Fundam Clin Pharmacol. 2022 Apr ;36(2):378-389

Guion-Firmin J, Tessier S, Montastruc J-L. Diarrhoea and angiotensin II receptor blockers : Is there any difference between the different drugs ? Fundam Clin Pharmacol. 2022 Apr ;36(2):443-447

Hamard J, Rigal M, Gony M, Bagheri H. Lacosamide-induced personality changes : An unexpected adverse effect. Fundam Clin Pharmacol. 2022 Feb ;36(1):224-226.

Hofferer A, Dolladille C, Chretien B, Sassier M, Laugier D, Atzenhoffer M, Bagheri H, Alexendre J, Fedrizzi S, Humbert X. Antidépresseurs et hypertension artérielle : étude cas / non-cas dans la base nationale de pharmacovigilance. L’Encéphale. 2022 Aug ;48(4):404-408

Icard C, Mocquot P, Nogaro JC, Despas F, Gauthier M. Lenalidomide-induced arthritis : A case report and review of literature and pharmacovigilance databases. J Oncol Pharm Pract. 2022 Mar ;28(2):453-456.

[Levy A, Very E, Montastruc F, Birmes P, Jullien A, Richaud L. Case Report : A Case of Valproic Acid-Induced Hyperammonemic Encephalopathy Associated With the Initiation of Lithium : A Re-duplicable Finding.
Front Psychiatry. 2022 May 2 ;13:875636.

Montastruc F, Lafaurie M, Flumian C, De Cnecaude C. Increased reporting of venous and arterial thromboembolic events reported with tixagevimab-cilgavimag for coronavirus disease 2019. Clinical Microbiology and infection. 2022 Dec 1 ;S1198-743X(22)00599-7

Montastruc J L, Durrieu G. Drug-induced hypohidrosis and anhidrosis : analysis of the WHO pharmacovigilance database 2000-2020.
Eur J of clincal Pharmacol. 2022 May ;78(5):887-889

Montastruc J L, Bagheri H, Durrieu G, Lacroix I, Montastruc F. Adverse drug reactions, iatrogenic diseases, drug safety and pharmacovigilance : importance and interest for patients and their physicians. Drug-induced oral complication. 2022 1-6

Moulis G, Crickx E, Thomas L, Massy N, Mahévas M, Valnet-Rabier M-B, Atzenhoffer M, Michel M, Godeau B, Bagheri H, Salvo F ; French Covigilance COVID-19 Vaccine-ITP Study Group. De novo and relapsed immune thrombocytopenia after COVID-19 vaccines : results of French safety monitoring. Blood. 2022 Apr 21 ;139(16):2561-2565.

Murarasu A, Bertoliatti-Fontana G, Massy N, Bagheri H, Treluyer J-M, Regent A, Chouchana L. Immune thrombocytopenia following ChAdOx1 vaccine and positive rechallenge with BNT162b2 vaccine : A case report with pharmacovigilance analysis. Therapie. 2022 May 21:S0040-5957(22)00102-0.

Ouldali Naïm, Bagheri Haleh, Salvo Francesco, Antona Denise, Pariente Antoine, Leblanc Claire, Tebacher Martine, Micallef Joëlle, Levy Corinne, Cohen Robert, Javouhey Etienne, Bader-Meunier Brigitte, Ovaert Caroline, Renolleau Sylvain, Hentgen Veronique, Kone-Paut Isabelle, Deschamps Nina, De Pontual Loïc, Iriart Xavier, Gras le Guen Christelle, Angoulvant François, Belot Alexandre French Covid-19 Paediatric Inflammation Consortium[Corporate Author] French Pharmacovigilance network[Corporate Author]. Correction to "Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children : A national post-authorization pharmacovigilance study". Lancet Reg Health Eur. 2022 Oct ;21:100468

Ouldali N, Bagheri H, Salvo F, Antona D, Pariente A, Leblanc C, Tebacher M, Micallef J, Levy C, Cohen R, Javouhey E, Bader-Meunier B, Ovaert C, Renolleau S, Hentgen V, Kone-Paut I, Deschamps N, De Pontual L, Iriart X, Gras le Guen C, Angoulvant F, Belot A, French Covid-19 Paediatric Inflammation Consortium[Corporate Author] French Pharmacovigilance network[Corporate Author]. Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children : A national post-authorization pharmacovigilance study.
Lancet Reg Health Eur. 2022 Jun ;17:100393

Quilichini J B, Revet A, Garcia P, Bouquié R, Hamard J, Yrondi A, Montastruc F. Comparative effects of 15 antidepressants on the risk of withdrawal syndrome : A real-world study using the WHO pharmacovigilance database. J Affect Disord. 2022 Jan 15 ;297:189-193

Ramdani Y, Bettuzzi T, Bouznad A, Delaitre L, Nassarmadji K, Didier K, Paul C, Liozon E, Tieu A, Richard-Colmant G, Terrier B, Moulis G, Lafaurie M, Pillebout E, Maillot F, Audemard-Verger A. IgA Vasculitis Following COVID-19 Vaccination/ A French Multicenter Case Series Including 12 Patients. Rheumatol. 2022 Nov 1 ;jrheum. 220545

Saint-Lary L, Diallo a, de Monteynard L A, Paul C, Marchand L, Tubiana R, Warszawski J, Mandelbrot L, Rekacewicz C, Petrov-Sanchez V, Faye A, Sibiude J, Dabis F, Sommet A, Leroy V. In utero exposure to antiretroviral drugs and pregnancy outcomes : Analysis of the French ANRS pharmacovigilance database.
Br J Clin Pharmacol. 2022 Mar ;88(3):942-964.

Strumia M, Perrin M L, Patras de compaigno E, Conte C, Montastruc F, Lapeyre-Mestre M, Sibaud V, Despas Fabien. Dermatological adverse drug reactions of anticancer drugs : International data of pharmacovigilance : Vigibase. Therapie. 2022 Mar-Apr ;77(2):219-227

Teboul A, Chouchana L, Durrieu G, Eftekhari P, Treluyer J M, Mouthon L, Chaigne B. Drug-induced eosinophilic fasciitis : A dual pharmacovigilance analysis. J Am Acad Dermatol. 2022 Jun ;86(6):1372-1375.

ADDICTOVIGILANCE

Delage N, Cantagrel N, Delorme J, Pereira B, Dualé C, Bertin C, Chenaf C, Kerckhove N, Laporte C, Picard P, Roussin A, Authier N. Transcultural validation of a French–European version of the Prescription Opioid Misuse Index Scale (POMI-5F). Can J Anaesth. 2022 Aug ;69(8):1042-1052

Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M ; OSIAP Working Group on Opioid cough suppressants. Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France. Br J Pharmacol. 2022 Apr ;88(4):1713-1721

Lapeyre-Mestre M. Addictovigilance in women, the hidden part of the iceberg ? . Therapie 2022 Oct 7 ;S0040-5957(22)00175-5.

Revol B, Lapeyre-Mestre M, Fouilhé Sam-Laï N, Jouanhus E. Association between NMDAR antagonists, drug abuse and dependance : A disproportionality analysis from the WHO pharmacovigilance database.
Br J Clin Pharmacol. 2022 Nov ;88(11):4937-4940

Roussin A, Soeiro T, Fouque C, Jouanjus E, Frauger E, Fouilhé N, Mallaret M, Micallef J, Lapeyre-Mestre M, the French addictovigilance Network Increase of high-risk tramadol use and harmful consequences in France from 2013 to 2018 : Evidence from the triangulation of addictovigilance data. Br J Clin Pharmacol. 2022 Aug ;88:3789-3802

PHARMACO-EPIDEMIOLOGIE

Benevent J, Hurault-Delarue C, Araujo M, Revet A, Sommet A, Lacroix I, Damase-Michel C. Prenatal Drug Exposure in Children with a History of Neuropsychiatric Care : A Nested Case-Control Study.
Front Psychiatry. 2022 Mar 22 ;13:795890

Blayac L, Ponte C, Lavaud M, Micallef J, Lapeyre-Mestre M. Increase of cannabis and cocaine use by pregnant women in France from 2005 to 2018 : Insights of the annual cross sectional OPPIDUM survey . Thérapie. 2022 Oct 8 ;S0040-5957(22)00171-8.

Cao Thi Xuan D, Filliter C, Montastruc F, Yu Oriana Hoi Y, Fergusson E, Rej S, Azoulay L, Renoux C. Selective serotonin reuptake inhibitors and the risk of type 2 diabetes mellitus in youths. J Affect Disord. 2022 Dec 1 ;318:231-237.

Chu Thanh H, Rueter M, Palmaro A, Lapeyre-Mestre M. Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. Br J Clin Pharmacol. 2022 Feb ;88(4):1691-1703.

Conte C, Vayr F, Pajiep M-C, Despas F, Huguet F, Lapeyre Mestre M, Gauthier M, Herin F. Impact of the treatment of chronic myeloid leukaemia by tyrosine-kinase inhibitors on sick leaves refund : a nationwide cohort study. Support Care Cancer. 2022 Jun ;30(6):5431-5440.

Dolk H, Damase-Michel C, Morris J K, Loane M. COVID-19 in pregnancy-what study designs can we use to assess the risk of congenital anomalies in relation to COVID-19 disease, treatment and vaccination ?
Paediatr Perinat Epidemiol. 2022 Jul ;36(4):493-507

Errahmani MY, Thariat J, Ferrières J, Panh L, Locquet M, Lapeyre-Mestre Maryse, Guernec G, Bernier MO, Boveda S, Jacob S. Risk of pacemaker implantation after radiotherapy for breast cancer : A study based on French nationwide health care database sample. Int J Cardiol Heart Vasc. 2021 Dec 25 ;38:100936.

Ferreira de Matos C, Comont T, Castex M-P, Lafaurie M, Walter O, Moulis G. Risk of vaso-occlusive episodes in patients with sickle cell disease exposed to systemic corticosteroids : a comprehensive review. Expert Rev of Hematol. 2022 Dec ;15(12):1045-1054

Freyche C, Zacarin A, Bagheri H. [Potentially inappropriate psychotropic drug prescription in elderly people in West Occitanie area].
Therapie. 2022 Sep-Oct ;77(5):541-548.

Gosset A, Denuelle M, Valton L, Sommet A, Bénévent J, Tremollières F. Interactions between antiseizure medications and contraception : A study about the knowledge of patients and their specialist physicians. Epilepsy Behav. 2022 Apr ;129:108627

Guilleminault L, Mounié M, Sommet A, Camus C, Didier A, Reber L L, Costa N, Conte C. Healthcare resource consumption prior to asthma-related death : a nationwide descriptive study. Ther Adv Respir Dis. 2022 Jan-Dec ;16:17534666221130217

Hirtz C, Adam G, Raposo N, Fabre N, Ducros A, Calviere L, Rousseau V, Albucher J F, Olivot J M, Bonneville F, Viguier A. Diagnostic utility of T2*-weighted GRE in migraine with aura attack. The cortical veins sign. Cephalalgia. 2022 Jul ;42(8):730-738

Jordan S, Bromley R, Damase-Michel C, Given J, Komninou S, Loane M, Marfell N, Dolk H. Breastfeeding, pregnancy, medecines, neurodevelopment, and population databases : the information desert.
Int Breastfeed j. 2022 Aug 2 ;17(1):55

Jourdes A, Lafaurie M, Moulis G, Delobel P, Faruch M, Sommet A, Martin-Blondel G. Comparison of the first and second wawes of coronavirus disease in Toulouse, France. Infectious Diseases Now. 2022 Feb ;52(1):49-52

Khosrow-Khavar F, Azoulay L, Montastruc J L, Montastruc F, Renoux C. Aromatase inhibitors and the incidence of Parkinson disease : A population-based cohort study. Cancer. 2022 Jun 15 ;128(12):2339-2347

Lafaurie M, Lapeyre-Mestre M, Sailler L, Sommet A, Moulis G. Risk of Immune Thrombocytopenia After Influenza Vaccine.
JAMA Intern Med. 2022 Apr 1 ;182(4):444-445

Lajaunie R, Mainardi I, Gasnault J, Rousseau V, Tarantino A G, Sommet A, Cinque P, Martin-Blondel G, PML study group. Outcome of progressive Multifocal Leukoencephalopathy Treated by Interleukin-7. Ann Neurol. 2022 Apr ;91(4):496-505

Lavergne J, Debin M, Blanchon T, Colizza V, Dassieu L, Gimenez L, Kengne-Kuetche C, Lapeyre-Mestre M, Dupouy J. Perceived risk of opioid use disorder secondary to opioid analgesic medication use by the general population in France.
Eur J Pain. 2022 Mar ;26(3):729-739

Lee Siang I, Azcoaga-Lorenzo A, Agrawal U, Kennedy J I, Fagbamigbe Adeniyi F, Hope H, Subramanian A, Anand A, Taylor B, Nelson-Piercy C, Damase-Michel C, Yau C, Crowe F, Santorelli G, Eastwood K-A, Vowles Z, Loane M, Moss N, Brocklehurst P, Plachcinski R, Thangaratinam S, Black M, O’Reilly D, Abel K M, Brophy S, Niranthnarakumar K, McCowan C, MuM-PreDICT Group. Epidemiology of pre-existing multimorbidity in pregnant wome in the UK in 2018 : a cross-sectional study.
The Lancet. 2022 Feb 11 ;22(1):120

Lépine B, Debin M, Dassieu L, Gimenez L, Palmaro A, Ponté C, Swital M, Lapeyre-Mestre M, Blanchon T, Dupouy J. Prescribing buprenorphine for opioid use disorder in primary care : A survey of French general practitioners in the sentinelles network.
J Subst Abuse Treat. 2022 Dec ;143:108891

Moulis G, Germain J, Rueter M, Lafaurie M, Aroichane M, Comont T, Mahévas M, Viallard J-F, Chèze S, Ebbo M, Audia S, Leclerc-Teffahi S, Sommet A, Beyne-Rauzy O, Michel M, Godeau B, Lapeyre-Mestre M, CARMEN investigators group. Eltrombopag in adult patients with immune thrombocytopenia in the real-world in France, including off-label use before 6 months of disease duration : The multicenter, prospective ELEXTRA study. Am J Hematol. 2022 Feb 1 ;97(2):E40-E44

Paternoster M, Steichen O, Lapeyre-Mestre M, Blanchon T, Rossignol L, Vilcu A-M, Launay T, Sarazin M, Bagheri H, Conte C, Turbelin C, Hanslik T, Souty C. Risk of Bleeding Associated With Nonsteroidal Anti-inflammatory Drug Use in Patients Exposed to Antithrombotic Therapy : A Case-Crossover Study.
J Clin Pharmacol. 2022 May ;62(5):636-645.

Perri-Plandé J, Miremont-Salamé G, Micallef J, Herman C, Baumevieille M, Abriat F, Lapeyre-Mestre M, Haramburu F, Daveluy A ; French Addictovigilance Network. A 13-Year National Monitoring Study to Assess Narcotic Prescriptions and Indications (2007-2019).
Drug Saf. 2022 Jan ;45(1):37-44

Revet A, Moulis G, Raynaud J P, Bui Eric, Lapeyre-Mestre M. Use of the French national health insurance information system for research in the field of mental health : Systematic review and perspectives.
Fundam Clin Pharmacol. 2022 Feb ;36(1):16-34

Rueter M, Baricault B, Lapeyre-Mestre M. Patterns of opioid analgesic prescribing in cancer outpatients during the last year of life in France : A pharmacoepidemiological cohort study based on the French health insurance database. Therapie. 2022 Nov-Dec ;77(6):703-711.

Scailteux L M, Despas F, Balusson F, Campillo-Gimenez B, Mathieu R, Vincendeau S, Happe A, Nowak E, Kerbrat S, Oger E. Hospitalization for adverse events under abiraterone or enzalutamide exposure en real-world setting : A French population-based study on prostate cancer patients. Br J Clin Pharmacol. 2022 Jan ;88(1):336-346

Souty C, Vilcu A M, Conte C, Saint-Salvi B, Sarazin M, Rossignol L, Blanchon T, Hanslik T, Lapeyre-Mestre M, Steichen O. Risk of hospitalisation for serious colchicine intoxication after concomitant exposure to pristinamycin : A nationwide healthcare database study.Therapie. 2023 Nov-Dec ;78 (6)769-772

Thurin H N, Pajouheshnia R, Roberto G, Dodd C, Hyeraci G, Bartolini C, Paoletti O, Nordeng H, Wallach-Kildemoes H, Ehrenstein V, Dudukina E, MacDonald T, De Paoli G, Loane M, Damase-Michel C, Beau A-B, Droz-Perroteau C, Lassalle R, Bergman J , Swart K , Schink T, Cavero-Carbonell C, Barrachina-Bonet L, Gomez-Lumbreras A, Giner-Soriano M, Aragón M, Neville A J, Puccini A, Pierini A, Ientile V, Trifirò G, Rissmann A, Leinonen M K, Martikainen V, Jordan S, Thayer D, Scanlon I, Georgiou M E, Cunnington M, Wood M E, Lupattelli A, Palmsten K, Bandoli G, Hurault-Delarue C, Damase-Michel C, Chambers CD, Nordeng HME, van Gelder MMHJ. From Inception to ConcePTION : Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clin Pharmacol Ther. 2022 Jan ;111(1):321-331

Vabre Cl, Araujo M, Damase-Michel C, Hurault-Delarue C, Lacroix I. Initial data on the safety of metopimazine during pregnancy and the risk of major birth defects and pregnancy loss – An observational study using the EFEMERIS database. Thérapie 2022 Jul-Aug ;77(4):405-412

Vabre C, Zelmat Y, Gauthier M, Pajiep M, Conte C, Lapeyre-Mestre M, Dray-Spira R, Zureik M, Despas F. Incident users of tyrosine kinase inhibitors in patients with chronic myeloid leukemia : Analysis of anticancer treatment trajectories-A French population-based study using the French national health data system. Am J Hematol. 2022 Aug ;97(8):E307-E309.

Walter O, Cougoul P, Maquet J, Bartolucci P, Lapeyre-Mestre M, Lafaurie M, Moulis G. Risk of vaso-occlusive episode after exposure to corticosteroids in patients with sickle cell disease. Blood 2022 Jun ;139(26):3771-3777

Wood Mollie E, Lupattelli A, Palmsten K, Bandoli G, Hurault-delarue C, Damase-Michel C, Chambers C D, Nordeng H M E, Van Gelder mM M.H.J. Longitudinal methods for modeling exposures in Pharmacoepidemiologic studies in pregnancy. Epidemiol rev. 2022 Jan 14 ;43(1):130-146

Zacarin A, Zogheib ML, Ruiz AC, Bagheri H. [Prevalence of statins prescriptions among the elderly in nursing homes in West Occitania]. Therapie. 2022 May-Jun ;77(3):384-386.

Zelmat Y, Conte C, Noize P, Vabre C, Pajiep M, Lafaurie M, Lapeyre-Mestre M, Despas F. Incidence of heart failure following exposure to a protein kinase inhibitor, a French population-based study.Br J Clin Pharmacol. 2022 Oct 26.

INFORMATIONS SUR LE MEDICAMENT

Fabbri M, Ferreira J J, Rascol O. COMT Inhibitors in the Management of Parkinson’s Disease. CNS Drugs. 2022 Mar ;36(3):261-282.

Kiladjian J-J, Despas F. Hemato-oncopharmacology : Drugs and cancer. Thérapies. 2022 Mar-Apr ;77(2):149-150

Mocquot P, Mossazadeh Y, Lapierre L, Pineau F, Despas F. The pharmacology of blinatumomab : state of the art on pharmacodynamics, pharmacokinetics, adverse drug reactions and evaluation in clinical trials. J Clin Pharm Ther. 2022 Sep ;47(9):1337-1351.

Pericaud A, Straczek C, Montastruc f, Leboyer M, Yrondi A, Arbus C. Use of antidepressants in unipolar depression in the elderly. Encephale. 2022 Aug ;48(4):445-454

Taillefer de Laportalière T, Yrondi A, Jullien A, Cestac P, Montastruc F. How to deprescribe esketamine in resistant depression ? A point of view after first clinical uses. Epidemiol Psychiatr Sci. 2022 Jan 11 ;31:e4.

Retour en haut de page

ANNEE 2021

Publié le 18/10/2022 à 10h29 (mis à jour le 25/10/2022 à 11h10)

PHARMACOLOGIE FONDAMENTALE

Gallais F, Ysebaert L, Despas F, De Barros S, Obéric L, Allal B, Chatelut E, White-Koning M.Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Clin Pharmacol Ther. 2021 Jul ;110(1):220-228.

Kermorgant M, Ben Salem J, Iacovoni JS, Calise D, Dahan L, Guiard B, Lopez S, Lairez O, Lasbories A, Nasr N, Pavy Le-Traon A, Beaudry F, Senard JM, Arvanitis DN. Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure.Front Physiol. 2021 Jul 14 ;12:692361.

PHARMACOLOGIE CLINIQUE

Besse-Pinot E, Pereira B, Durif F, Fantini ML, Durand E, Debilly B, Derost P, Moreau C, Hainque E, Rouaud T, Eusebio A, Benatru I, Drapier S, Guehl D, Rascol O, Maltête D, Lagha-Boukbiza O, Giordana C, Tir M, Thobois S, Hopes L, Hubsch C, Jarraya B, Rolland AS, Corvol JC, Devos D, Marques A ; Predistim Study Group. Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.Neurology. 2021 Nov 16 ;97(20):e1994-e2006.

Boucherie DM, Duarte GS, Machado T, Faustino PR, Sampaio C, Rascol O, Ferreira JJ. Parkinson’s Disease Drug Development Since 1999 : A Story of Repurposing and Relative Success. J Parkinsons Dis. 2021 ;11:421-429.

Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, Rousseau H, Lepage B, Olivier P, Papadopoulos P, Trillaud H, Cremer A ; ADERADHTA group*. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension : ADERADHTA, a pilot study. J Hypertens. 2021 ;39:759-765.

Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C ; PREDI-STIM study group. Personality dimensions of patients can change during the course of parkinson’s disease. PLoS One. 2021 ;16:e0245142.

Bureau C, Thabut D, Jezequel C, Archambeaud I, D’Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.

Chevreau C, Massard C, Flechon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Fizazi K, Mourey L, Paci A, Guitton J, Thomas F, Lelièvre B, Ciccolini J, Moeung S, Gallois Y, Olivier P, Culine S, Filleron T, Chatelut E. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.

Del Campo N, Phillips O, Ory-Magne F, Brefel-Courbon C, Galitzky M, Thalamas C, Narr KL, Joshi S, Singh MK, Péran P, Pavy-LeTraon A, Rascol O. Broad white matter impairment in multiple system atrophy.

Delavoipière E, Fourage C, Macro M, Olivier-Abbal P, Fleck C, Mouchel C, Gavard M, Petitpain N, Muller C, Franceschi MP, Savary C, Fournel F, Chaillot F, Alix A, Peyro-Saint-Paul L, pour le groupe REVISE. Déclaration des erreurs médicamenteuses dans la recherches portant sue le medicament : place du pharmacien des essais cliniques ?

Dreyfus I, Maza A, Rodriguez L, Merlos M, Texier H, Rousseau V, Sommet A, Mazereeuw-Hautier J. Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease : an open-label 6-month pilot interventional study.

Faggianelli F Jr, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson’s disease.

Fernández-Rodríguez B, Dupouy J, Harroch E, Fabre-Delcros MH, Barthélémy C, Loubière P, Barange K, Brefel-Courbon C, Rascol O, Ory-Magne F. Body mass index variations in patients with Parkinson’s disease treated with levodopa-carbidopa intestinal gel infusion : A case control study versus standard of care and subthalamic nucleus deep brain stimulation.

Fontaine L, Sibon I, Raposo N, Albucher JF, Mazighi M, Rousseau V, Darcourt J, Thalamas C, Drif A, Sommet A, Viguier A, Guenogo A, Januel A-C, Calvière L, Menegon P, Bonneville F, Tourdias T, W. Albers G, Cognard C, Olivot J-M, on behalf of the FRAME investigators. ASCOD Phenotyping of stroke with anterior large vessel occlusion treated by mechanical thrombectomy.

Frison E, Proust-Lima C, Mangin, JF, Habert MO, Bombois S, Ousset, PJ & al. Diabetes Mellitus and Cognition : Pathway Analysis in the MEMENTO.

Gaudineau A, Senat MV, Ehlinger V, Gallini A, Morin M, Olivier P, Roth E, Orusco E,, Javoise S, Fort J, Lvergne C, Arnaud C, Rozenberg P, Vayssiere C . Induction of labor at term with vaginal misoprostol or a prostaglandin E2 pressary : a noninferiority randomized controlled trial.

Hauser RA, Hattori N, Fernandez H, Isaacson SH, Mochizuki H, Rascol O & al. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease : A Pooled Analysis of 8 Phase 2b/3 Trials.

He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.

Jackson, H, Anzures-Cabrera, J, Taylor, KI, Pagano G. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression.

Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease : the role of opicapone.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A. Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations : Results of the open-label phase of the TOLEDO study.

Kermorgant M, Sadegh A, Geeraerts T, Varenne F, Liberto J, Roubelat FP, Bataille N, Bareille MP, Beck A, Godard B, Golemis A, Nasr N, Arvanitis DN, Hélissen O, Senard JM, Pavy-Le Traon A, Soler V. Effects of Venoconstrictive Thigh Cuffs on Dry Immersion-Induced Ophthalmological Changes.

Magnin A, Iversen VC, Calvo G, Čečetková B, Dale O, Demlová R, Blaskó G, Keane F, Kovacs GL, Levy-Marchal C, Monteiro EC, Palmisano L, Pella D, Portolés A, Rascol O, Schmid C, Tay F, von der Leyen H, Ohmann C. European survey on national harmonization in clinical research.

Marques A, Brefel-Courbon C. Chronic pain in Parkinson’s disease : Clinical and pathophysiological aspects.

Meyer M, Lamare F, Asselineau J, Foubert-Samier A, Mazère J, Zanotti-Fregonara P, Rizzo G, Delamarre A, Spampinato U, Rascol O, Pavy-Le Traon A, Tison F, Fernandez P, Sibon I, Meissner WG. Brain 5-HT1A receptor binding in multiple system atrophy : An [18 F]-MPPF PET Study.

Montastruc J-L, Biron P, Sommet A. Efficacy of COVID-19 vaccines : Several modes of expression should be presented in scientific publications .

Montfort A, Filleron T, Virazels M, Dufau C, Milhès J, Pagès C, Olivier P, Ayyoub M, Mounier M, Lusque A, Brayer S, Delord JP, Andrieu-Abadie N, Levade T, Colacios C, Ségui B, Meyer N. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma : First results of a Phase Ib clinical trial.

Mourey L, Le Louedec F, Ravaud A, Paludetto MN, Digue L, Gomez-Roca CA, Valentin T, Balardy L, Olivier P, Cabarrou B, Filleron T, Chatelut E. VOTRAGE study : Phase I dose-escalation study of pazopanib in unfit older patients.

Olivot JM, Albucher JF, Guenego A, Thalamas C, Mlynash M, Rousseau V, Drif A, Christensen S, Sommet A, Viguier A, Darcourt J, Calvière L, Menegon P, Raposo N, Januel AC, Bonneville F, Tourdias T, Mazighi M, Sibon I, Albers GW, Cognard C ; FRAME Investigators*. Mismatch Profile Influences Outcome After Mechanical Thrombectomy.

Pagano, G ; Boess, FG ; Taylor, KI ; Ricci, B ; Mollenhauer, B ; Poewe, W & al ; A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA) : Rationale, Design, and Baseline Data.

Pan, H ; Peto, R ; Henao-Restrepo, AM ; Preziosi, MP ; Sathiyamoorthy, V ; Abdool Karim, Q & al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Péran, P ; Salabert, AS ; Dondaine, T ; Leclerc, X ; Gros-Dagnac, H ; Ranjeva, JP & al. Functional connectivity and cognitive changes after donepezil treatment in healthy participants.

Petitpain N, Olivier P, Crépin S, Leone E, Ouk T, Villeneuve C, Muller C, Ruault S, Jamet A, Franceschi MP, Duranton S, Gavard M.  Overview of clinical trials vigilance units in French institutional sponsors. A study from the REVISE working group.

Poewe, W ; Volc, D ; Seppi, K ; Medori, R ; Lührs, P ; Kutzelnigg, A & al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease : A Randomized, Placebo-Controlled, Phase 1 Study.

Raffin, J ; Rolland, Y ; Aggarwal, G ; Nguyen, AD ; Morley, JE ; Li, Y & al. Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults : The MAPT Study.

Rascol O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, Thalamas C, Sommet A, Rousseau V, Perez-Lloret S, Fabbri M, Azulay JP, Corvol JC, Couratier P, Damier P, Defebvre L, Durif F, Geny C, Houeto JL, Remy P, Tranchant C, Verin M, Tison F, Meissner WG ; MSA-FLUO Study Group. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy : The MSA-FLUO Trial.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Correction to : Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort.

Rocha JF, Ebersbach G , Lees A , Tolosa E , Ferreira JJ , Poewe W & al. The Added Benefit of Opicapone When Used Early in Parkinson’s Disease Patients With Levodopa-Induced Motor Fluctuations : A Post-hoc Analysis of BIPARK-I and -II.

Roullet P, Vaiva G, Véry E, Bourcier A, Yrondi A, Dupuch L & al. Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms : a randomised clinical trial.

Santin MDN, Voulleminot P, Vrillon A, Hainque E, Béreau M, Lagha-Boukbiza O, Wirth T, Montaut S, Bardinet E, Kyheng M, Rolland AS, Voirin J, Drapier S, Durif F, Eusebio A, Giordana C, Auzou N, Houeto JL, Hubsch C, Jarraya B, Laurencin C, Maltete D, Meyer M, Rascol O, Rouaud T, Tir M, Moreau C, Corvol JC, Proust F, Grabli D, Devos D, Tranchant C, Anheim M ; Predistim Study Group. Impact of subthalamic deep brain stimulation on impulse control disorders in parkinson’s disease : A prospective study.

Seners P, Oppenheim C, Turc G, Albucher JF, Guenego A, Raposo N, Christensen S, Calvière L, Viguier A, Darcourt J, Januel AC, Mlynash M, Sommet A, Thalamas C, Sibon I, Rousseau V, Tourdias T, Menegon P, Bonneville F, Mazighi M, Charron S, Legrand L, Cognard C, Albers GW, Baron JC, Olivot JM and on behalf of FRAME investigators. Perfusion Imaging and Clinical Outcome in acute Ischemic stroke with large core.

Shadrin AA, Mucha S, Ellinghaus D, Makarious MB, Blauwendraat C, Sreelatha AAK, Heras-Garvin A, Ding J, Hammer M, Foubert-Samier A, Meissner WG, Rascol O, Pavy-Le Traon A, Frei O, O’Connell KS, Bahrami S, Schreiber S, Lieb W, Müller-Nurasyid M, Schminke U, Homuth G, Schmidt CO, Nöthen MM, Hoffmann P, Gieger C, Wenning G. European Multiple System Atrophy Study Group, Gibbs JR, Franke A, Hardy J, Stefanova N, Gasser T, Singleton A, Houlden H, Scholz SW, Andreassen OA, Sharma M.  Shared genetics of multiple system atrophy and inflammatory bowel disease.

Tolosa E , Ebersbach G , Ferreira JJ , Rascol O , Antonini A , Foltynie T & al. The Parkinson’s Real-World Impact Assessment (PRISM) Study : A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers.

PHARMACOVIGILANCE

Araujo M, Vabre C, Benevent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I. Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure : A Study in the EFEMERIS Database.Drug Saf. 2021 ; 44:787-796.

Azam C, Durrieu G, Deuilhe E, Lafaurie M. Amlodipine and perindopril-induced hypertrichosis in a six-year-old girl : a case report*. Therapies. 2021 ;76:481-483

Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L & al. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021 ;20(11):102951.

Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors : Diagnostic and Therapeutic Strategies. Diagnostics (Basel). 2021 Jun 30 ;11(7):1187.

Bouhanick B, Montastruc F,Tessier F, Brusq C, Bongard V, Senard JM, Montastruc JL, Herin . Hypertension and Covid-19 vaccines : are there any differences between the different vaccines ? A safety signal. Eur J Clin Pharmacol. 2021 ;77:1937-1938.

Braillon A , Bewley S, Blumsohn A, Naudet F, Montastruc JL, Lexchin JR. Antidepressants are not safe during pregnancy and in women of child-bearing age. Br J Clin Pharmacol. 2021 ; 88(5):2448.

Chouchana L, Preta LH, Tisseyre M, Terrier B, Treluyer JM, Montastruc F. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019 : a retrospective case-noncase study.Kidney Int. 2021 ;99(5):1235-1236.

De Canecaude C, Gazagne C, Paraire M, Durrieu G. Tobramycine eye drops and ocular myasthenia gravis reactivation : A case report. Therapies. 2021 ;76:252-253.

De Canecaude C, Rousseau V, Sommet A, Montastruc JL. Tramadol-induced hypoglycemia : A pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;35:933-936

De Germay S, Lafaurie M, Dupuy M, de Germay B. Meningiomas after cyproterone acetate exposure : Case reports in twin sisters. Therapies. 2021 ;76:255-257.

De Germay S, Lapeyre-Mestre M, Montastruc JL, Montastruc F. Atropinic burden and anticholinergic drugs : Interest and application in clinical practice in the elderly. Poids atropinique et medicaments anticholinergiques : interêt et application en pratique Clinique chez la personne âgée. Therapies. 2021 ;76(6):665-673.

Defer G, Fedrizzi S, Chevanne D, Montastruc F, Briant AR, Parienti JJ, Peyro-Saint-Paul L ; French Vigip SEP Study Group ; Société Francophone de la Sclérose en Plaques (SFSEP). Adverse drug reaction reporting using a mobile device application by persons with multiple sclerosis : A cluster randomized controlled trial. Drug Saf. 2021 ;44:223-233.

Gainville A, Rousseau V, Kaguelidou F, Boyer Gervoise M, Michot J, Pizzoglio‑Bellaudaz V, Chebane L, Weckel A, Montastruc JL, Durrieu G. Drug‑induced hearing loss in children : An analysis of spontaneous reports in the french pharmacovigilance database. Pediatric Drugs. 2021 ;23:87-93.

Grandvuillemin A, Drici MD, Jonville‑Bera AP, Micallef J, Montastruc JL, the French Pharmacovigilance Network. French pharmacovigilance public system and COVID‑19 Pandemic. Drug Saf. 2021 ;44:405-408.

Gras-Champel V, Liabeuf S, Baud M, Albucher JF, Benkebil M, Boulay C,Bron A, Kaddissi AL,Gautier S, Geeraerts T,Girot M, Grandvuillemin A, Laujin H, Jonville-Béra AP, Masmoudi K, Massardier E, Micallef J, Mounier C, Montastruc F, Pariente A, Perez J, Raposo N, Salvo F, Valnet-Rabier MB, Vial T and the French Network. Atypical thrombosis associated with VaxZevria (AstraZeneca) vaccine : Data from the french network of regional Pharmacovigilance centres. Therapies. 2021 ;76:361-382.

Guion-Firmin J, Tessier S, Marion Lepelley, Faillie J-L, Montastruc J-L. Diarrhoea with the angiotensin receptor neprilysin inhibitorsacubitril + valsartan : A pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;1–12

Guion-Firmin J, Tessier S, Montastruc J-L. Diarrhoea and angiotensin II receptor blockers : Is there any difference between the different drugs ? Fundam Clin Pharmacol. 2021 ;1-5.

Hamard J, Rigal M, Gony M, Bagheri H. Lacosamide-induced personality changes : An unexpected adverse effect. Fundam Clin Pharmacol. 2021 ;36(1) :224-226.

Icard C, Mocquot P, Nogaro JC, Despas F, Gauthier M. Lenalidomide-induced arthritis : A case report and review of literature and pharmacovigilance databases. J Oncol Pharm Pract. 2022 Mar ;28(2):453-456.

Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics. 2021 ;10:540.

Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalel L, Damase-Michel C. Use of triptans during pregnancy ? With caution ! Therapies. 2021 ;76:477-478

Montastruc JL , Durrieu G. Amiodarone and Parkinsonism : a pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;35:781-784.

Montastruc JL, Guion Firmin1 J, de Canecaude C, Ruyssens Witrand A, Durrieu G, Lafaurie M, Sommet A. Drugs and Dupuytren’s disease : a pharmacovigilance study in VigiBase®. European Journal of Clinical Pharmacology. 2021 ;77:1587–1588.

Montastruc JL, Lafaurie M, de Canecaude C, Durrieu G, Sommet A, Montastruc F, Bagheri H. Fatal adverse drug reactions : a worldwide perspective in the World health organisation pharmacovigilance database. Br J Clin Pharmacol. 2021 ;87:4334-4340.

Nguyen KD, Vu DH, Nguyen HA, Dao VT, Montastruc JL, Bagheri H. Risk comparison of beta-lactam-induced anaphylaxis : Therapeutic stratification analysis in a Vietnamese pharmacovigilance database. J Clin Pharm Ther. 2021:46:950-956 .

Quinta JB, Montastruc F, Sommet A, Touafchia A, Galinier M, Reber L, Rousseau V, Guilleminault L. Cardiovascular adverse effects of anti-IL5/IL5Rα therapies : a real-world study. J Allergy Clin Immunol Pract. 2021 ;9:1411-1413.

Rousset S, Lafaurie M, Guet-Revillet H, Protin C, Le Grusse J, Derumeaux H, Gandia P, Nourhashemi F, Sailler L, Sommet A, Delobel P, Martin-Blondel G. Safety of pyrazinamide for the treatment of tuberculosis in older patients over 75 years of age : A retrospective monocentric cohort study. Drugs Aging. 2021 ;38:43-52.

Saint-Lary L, Diallo A, De Monteynard LA, Paul C, Marchand L, Tubiana R, Warszawski J, Mandelbrot L, Rekacewicz C, Petrov-sanchez V, Faye A, Sibuide J, Dabis F, Sommet A, Leroy V. In utero ex posure to antiretroviral drugs and pregnancy outcomes : Analysis of the French ANRS parmacovigilance database. Br J Clin Pharmacol. 2021 ;1-23.

Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E ; et le réseau français des Centres régionaux de pharmacovigilance. Adverse drug reactions profiles for abiraterone and enzalutamide : A pharmacovigilance descriptive analysis. Therapies. 2021 ; 76:455-465.

Strumia M, Perrin ML, Patras de Compaigno E, Conte C, Montastruc F, Lapeyre-Mestre M, Sibaud V, Despas F. Dermatological adverse drug reactions of anticancer drugs : International data of pharmacovigilance : VigiBase®. Therapie. 2021 Dec 11:S0040-5957(21)00257-2.

Teboul A, Chouchana L, Durrieu G, Eftekhari P, Treluyer JM, Mouthon L, Chaigne B. Drug-induced eosinophilic fasciitis : A dual pharmacovigilance analysis. J Am Acad Dermatol. 2021 May 27:S0190-9622(21)01019-7.

Touafchia A, Bagheri H, Carrié D, Durrieu G, Sommet A, Chouchana L, Montastruc F. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19) : a new safety concerns. Clin Microbiol Infect. 2021 ;27:791.e5-791.e8.

Tournon N, Bertrand L, Bagheri H, Amar J. Severe hypertensive flare-up after intravitreal injection of ranibizumab for retinal venous branch occlusion. Fundam Clin Pharmacol. 2021 ;35:785-788.

Vasseur M, Tambon M, Gony M, Lebrun N, Bagheri H. Pneumopathie médicamanteuse ou liée à la COVID-19 : un train peu en cacher un autre ! Therapies. 2021 ;76:374-376

ADDICTOVIGILANCE

Bouquet E, Pain S, Eiden C, Jouanjus E, Richard N, Fauconneau B, Pérault-Pochat MC ; French Addictovigilance Network. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017). Br J Clin Pharmacol. 2021 Oct ;87(10):3925-3937.

Eiden C, Vincent M, Serrand C, Serre A, Richard N, Picot MC & al. Health consequences of cocaine use in France : data from the French Addictovigilance Network. Fundam Clin Pharmacol.2021 ;35 :455-465.

Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Péré M, Jolliet P, FAN-Network (Jouanjous E), Feuillet F, Victorri-Vigneau C. Benzodiazepine withdrawal in older people : what is the prevalence, what are the signs, and which patients ? Eur J Clin Pharmacol. 2021 ;77:171-177.

Jouanjus E, Sans-Pola C, Mainoli B, Javid FA, Ekheden I, Working Group on Medical Cannabis Projets of the EACPT Young Clinical Parmacologists. Establishing and Evaluating a Study Questionnaire on Knowledge and Attitudes of Healthcare Professionals Towards Recreational and Medical Cannabis Across Europe. Clin Drug Investig. 2021 ;41(8) :701-710

Lapeyre-Mestre M.  Bacterial infections in people who inject psychoactive substances : An observational study in a French university hospital. A comment - Therapies. 2021 ;76(6) :525-526

Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P. French Association of Addictovigilance Centres. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapies. 2021 ; 76 :478-479.

Soeiro T , Lacroix C , Pradel V , Lapeyre-Mestre M , Micallef J. Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases : Illustration From the Experience of the French Addictovigilance Network. Front Psychiatry. 2021 ;12 :640120.

Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M ; French Addictovigilance Network (FAN). Gabapentinoid Abuse in France : Evidence on Health Consequences and New Points of Vigilance. Front Psychiatry. 2021 ;12:639780.

Victorri-Vigneau C , Laforgue EJ, Grall-Bronnec M, Guillou-Landreat M, Rousselet M, Guerlais M & al. Are Seniors Dependent on Benzodiazepines ? A National Clinical Survey of Substance Use Disorder. Clin Pharmacol Ther.2021 ;109(2) :528-535 .

PHARMACO - EPIDEMIOLOGIE

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M Antidepressant Use and Progression of Mild to Moderate Alzheimer’s Disease : Results from the European ICTUS Cohort. JAMDA. 2021 ;22:433-439.

Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016 : A study in the EGB database. Therapies. 2021 ;76:239-247.

Bagheri H. Ambulatory drug changes in the elderly after hospital discharge : A cohort study. Therapies. 2021 ;76(6):523-524.

Blotière PO, Damase-Michel C, Weill A, Maura C. Dispensing of Potentially Harmful Prescription drugs in 1.8 million pregnant women in France : A nationwide study based on two risk classification systems.Dug Saf. 2021 ;44 :1323-1339.

Chu TH, Rueter M, Palmaro A, Lapeyre-Mestre M. Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. Br J Clin Pharmacol. 2021.

Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Corand V, Victorri-Vigneau C, Batisse A, Le Boisselier R, Peyrière H, Frauger E, Lapeyre-Mestre M, Haramburu F. Ten-year trend of opioid and nonopioid analgesic use in the French adult population. Br J Clin Pharmacol. 2021 ;87:555-564.

Fabbri M, Leung C, Baille G, Bereau M, Brefel-Courbon C, Castelnovo G,Carriere N, Damier P, Defebvre L, de Maindreville AD, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson’s disease. The ERCOPARK study. Parkinsonism and related disorders. 2021 ;89:128-133.

Garcia P, Montastruc JL, Rousseau V, Hamard J, Sommet A, Montastruc F. β-adrenoceptor antagonists and nightmares : A pharmacoepidemiological-pharmacodynamic study. J Psychopharmcol. 2021 ; Dec ;35(12):1441-1448.

Gault, N ; Esposito-Farèse, M ; Revest, M ; Inamo, J ; Cabié, A ; Polard, É & al. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19 : A multicenter prospective cohort and literature review. Fundam Clin Pharmacol. 2021 ;35(6) :1141-1158.

Gerardin M, Rousselet M, Couec ML, Masseau A, Guerlais M, Authier N, Deheul S, Roussin A, Micallef J, Djezzar S, French Addictovigilance Network (FAN) ; Feuillet F, Jolliet P, Victorri-Vigneau C. Descriptive analysis of sickle cell patients living in France : The PHEDRE cross-sectional study. PLoS One. 2021 ;16:e0248649.

Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, Dankwa EA & al. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19 : An observational cohort. Elife. 2021 ;Nov 23 ;10:e70970.

Herin F, Othenin J, Jouanjus E, Rousseau V, Niezborala M, Lapeyre-Mestre M. Evolution of medication consumption in a working environment in France : Results of the four waves of the "Drugs and Work" study (1986-2016). Pharmacoepidemiol Drug Saf. 2021 ;30:661-668.

Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France ? Fundam Clin Pharmacol. 2021 ;35:1159-1167.

Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M, OSIAP Working Group on opioid cough suppressants. Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France. Br J Clin Pharmacol. 2021 ;1-9.

Lafaurie M, Maquet J, Baricault B, Ekstrand C, Christiansen CF, Linder M, Bahmanyar S, Nogaard M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. Risk factors of hospitalization for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments : a French nationwide cohort study. British Journal of Heamatology. 2021 ;195:456-465.

Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G. Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France : results of the ACE-CoV study. Fundam Clin Pharmacol. 2021 ;35:194-203.

Lafaurie M, Martin-Blondel G, Delobel P, Kamar N, Charpentier S, Sommet A, Moulis G ; Covid-Clinic-Toul investigators. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. BMC Pharmacol Toxicol. 2021 ;Mar11 ;22:14.

Lapeyre-Mestre M, Boyer A, Ponté C, Daveluy A, Godeau E. Consommation de substances chez les jeunes : du médicament aux substances illicites. Therapies. 2021 ;76:31-35.

Larcin L, Lona M, Karakaya G, Van Espen A, Damase-Michel C, Kirakoya- Samadoulougou F. Using administrative healthcare database records to study trends in prescribed medication dispensed during pregnancy in Belgium from 2003 to 2017. Pharmacoepidemiol Drug Saf 2021 ;30 :1224-1232

Maquet J, Lafaurie M, Sailler L, Lapeyre-Mestre M, Moulis G. Correspondence on risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia : a nationwide French study. Ann Rheum Dis. 2021 ; Dec 11 : annrheumdis-2020-219470.

Maquet J, Lafaurie M, Walter O, Sailler L, Sommet A, Lapeyre-Mestre M, Michel M, Moulis G. Epidemiology of autoimmune hemolytic anemia : a nationwide population-based study in France. Am J Hematol. 2021 Aug 1 ;96(8):E291-E293.

Neumane S, Câmara-Costa H, Francillette L, Araujo M, Toure H, Brugel D, Laurent-Vannier A, Ewing-Cobbs L, Meyer P, Dellatolas G, Watier L, Chevignard M. Functional outcome after severe childhood traumatic brain injury : Results of the TGE prospective longitudinal study. Ann Phys Rehabil Med. 2021 ;64:101375.

Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia : An Exhaustive Population-Based Study in France. Front Oncol. 2021 ;30 ;11:675609.

Rahman A, Kane J, Montastruc F, Renoux C. Trends in new prescription of gabapentinoids and of coprescription with opioids in the four nations of the United Kingdom, 1993-2017. Br J Clin Pharmacol. 2021 ;87:3349-3353.

Revol B, Delorme J, Jouanjus E, Spadari M, Djezzar S, Lepelley M, Khouri C, Fouilhé Sam-laï N, Mallaret M, et le réseau français des centre d’addictovigilance. Trente ans d’abus de néfopam en France. Therapies. 2021 ;76:527-537.

Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide : a direct comparison based on a 2014-2018 French population study (the SPEAR cohort). Am J Epidemiol. 2021 ;190:413-422.

Soeiro T, Pradel V, Lapeyre-Mestre M, Micallef J. Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Pain. 2021 ;162:770-777.

Tran VT , Mahévas M , Bani-Sadr F , Robineau O , Perpoint T , Perrodeau E & al. Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen : observational comparative study using routine care data. Clin Microbiol Infect.2021 ;27 :603-610.

Walter O, Maquet J, Derumeaux H, Moulis G, Lafaurie M. Validation of Discharge Diagnosis of Sickle Cell Disease Vaso-Occlusive Episodes in the French Hospital Electronic Database. Clin Epidemiol.2021 ;13 :717-720.

INFORMATIONS SUR LE MEDICAMENT

Carton L, Bordet R, Montastruc F, Guilhaumou R. Towards personalized pharmacology : Antipsychoticsand schizophrenia. Therapies. 2021 ;76:137-147.

Castanié M, Juillard-Condat B, Galian C, Giroud JP, Bagheri H. Analyse des modifications de statut règlementaire des médicaments en France. Therapies. 2021 ;76:31-47.

Cottin J, Benevent J, Khettar S, Lacroix I. COVID-19 vaccines and pregnancy : Wath do we know ? Thérapie 2021 ; 76:361-382.

Geeraerts T, Montastruc F, Bonneville F, Mémier V, Raposo N ; Toulouse Vitt Study Group. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia : A missed opportunity for a rapid return of experience. Anaesth Crit Care Pain Med. 2021 Aug ;40(4):100889.

Huguier M, Tillement JP, Montastruc JL, Olié JP, Lechat P, Bouvenot G, Milhaud G. Rapport 21-01. Le bon usage des médicaments. Bull Acad Natl Med. 2021 ;205:331-336.

Montastruc JL. 1921-2021, from insulin to new hypoglycaemic drugs : 100 years of pharmacological reseach in diabetes mellitus. Therapies. 2021 ;76:517-521.

Montastruc JL. Therapies celebrated its 75th anniversary ! Therapies.2021 ;76:1-4.

Montastruc JL, Lafaurie M, de Canecaude C, Montastruc F, Bagheri H, Durrieu G, Sommet A. COVID-19 vaccines : A perspective from social pharmacology. Therapies. 2021 ;76 :311-315.

Montastruc JL. Vitamine D et Covid-19 : qu’en est-il vraiment ? Rev Prescrire. 2021 ;41:74.

Montastruc JL. La France malade du médicament : 110 milliards d’euros plus tard, B. Bégaud.Ed. de l’obervatoire, Paris (2020). Therapies. 2021 ;76:516

Olanow CW, Poewe W, Rascol O, Stocchi F. On-Demand Therapy for OFF Episodes in Parkinson’s Disease. Mov Disord. 2021 ;36(10):2244-2253.

Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol. 2021 ;20(12):1048-1056.

Vaysse C, Fize AL, Despas F, Chantalat E, Serrano E, Beyne-Rauzy O, Rougé-Bugat ME. Small private online course in teaching oncology-feedback after 1 Year : What Lessons ? J Cancer Educ. 2021 ;36:65-71.

Retour en haut de page

ANNEE 2020

Publié le 25/02/2021 à 09h19 (mis à jour le 25/10/2022 à 12h13)

PHARMACOVIGILANCE

Barthez S, Revet A, Chouchana L, Jonville-Bera AP, Pizzoglio V, Raynaud JP, Chebane L, Lapeyre-Mestre M, Montastruc F. Adverse drug reactions in infants, children and adolescents exposed to antidepressants : a French pharmacovigilance study. Eur J Clin Pharmacol. 2020 ;76:1591-1599.

Bertrand V, Massy N, Pigneur B, Coopman S, Durrieu G, Gaboriau L, Langlois V, Gower-Rousseau C, Hugot JP, Ruemmele FM ; GETAID (Groupe d’Etude thérapeutique des Affections Inflammatoires du Tube Digestif) Pediatrique1. Neurological Adverse Effects Associated With Anti-tumor Necrosis Factor Alpha Antibodies in Pediatric Inflammatory Bowel Diseases. J Pediatr Gastroenterol Nutr. 2020 ;70:841-848.

Bordet C, Rousseau V, Montastruc F, Montastruc JL. QT prolongation and vortioxetine : a post-marketing study and comparison with other serotonin reuptake inhibitors. Psychopharmcology. 2020 ;237:1245-1247.

Baudou E, Lespine A, Durrieu G, André F, Gandia P, Durand C, Cunat S. Serious Ivermectin Toxicity and Human ABCB1 Nonsense Mutations. N Engl J Med. 2020 ;383:787-789.

Bourrel C, Zacarin A, Rousseau V, Montastruc JL, Bagheri H. Are potentially inappropriate and anticholinergic medications being prescribed for institutionalized elderly subjects ? Fundam Clin Pharmacol. 2020 ;34:743-748.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Yu et al. "Levothyrox® New and Old Formulations : Are They Switchable for Millions of Patients ?". Clin Pharmacokinet. 2020 ;59:283-285.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Krebs-Brown et al. Comment on : "Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ?". Clin Pharmacokinet. 2020 ;59:269-271.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Nicolas : Why Were More than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ? Clin Pharmacokinet. 2020 ;59:277-279.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One ? Clin Pharmacokinet. 2020 ;59:1-5.

Conte C, Rousseau V, Vert C, Montastruc F, Montastruc JL, Durrieu G, Olivier P. Adverse drug reactions of statins in children and adolescents : a descriptive analysis from VigiBase, the WHO global database of individual case safety reports. Fundam Clin Pharmacol. 2020 ;34:518-520.

Cottin J, Pierre S, Pizzoglio V, Simon C, Durrieu G, Bleyzac N, Gouraud A, Dumortier J. Methylprednisolone-related liver injury : A descriptive study using the French pharmacovigilance database. Clin Res Hepatol Gastroenterol. 2020 ;44:662-673.

de Germay S, Bagheri H, Despas F, Rousseau V, Montastruc F. Abatacept in rheumatoid arthritis and the risk of cancer : a world observational post-marketing study. Rheumatology (Oxford). 2020 ;59:2360-2367.

de Germay S, Montastruc F, Carvajal A, Lapeyre-Mestre M, Montastruc JL. Drug-induced parkinsonism : Revisiting the epidemiology using the WHO pharmacovigilance database. Parkinsonism Relat Disord. 2020 ;70:55-59.

Foubert-Samier A, Pavy-Le Traon A, Guillet F, Le-Goff M, Helmer C, Tison F, Rascol O, Proust-Lima C, Meissner WG. Disease progression and prognostic factors in multiple system atrophy : A prospective cohort study. Neurobiol Dis. 2020 ;139:104813.

Fouque C, Martin R, Seguro F, Montastruc JL, de Canecaude C. Splenic Infarction in a Narcoleptic Patient Treated With Methylphenidate, Venlafaxine, and Pitolisant. Ann Pharmacother. 2020 ;54:189-190.

Garcia P, Revet A, Yrondi A, Rousseau V, Degboe Y, Montastruc F. Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID‑19) : A VigiBase Study. Drug Saf. 2020 ;43:1315-1322.

Hakimi Y, Petitpain N, Pinzani V, Montastruc JL, Bagheri H. Paradoxical adverse drug reactions : descriptive analysis of French reports. Eur J Clin Pharmacol. 2020 ;76:1169-1174.

Hillaire-Buy D, Mousset, Allouchery M, Azzouz B, Babin M, Bellet F, Béné B, Default A, Durrieu G, Géniaux H, Grandvuillemin A, Gras-Champel V, Jantzem H, Lambert A, Lepelley M, Massy N, Petitpain N, Rocher F, sanchez-Pena P, Sassier M, Simon C, Triquet L, Valnet-Rabier MB, Veyrac G, Faillie JL, Zenut MC. Liquid formulation of ifosfamide increased risk of encephalopathy : A case-control study in a pediatric population. Therapies. 2020 ;75:471-780.

Jacquot J, Rousseau V, de Canecaude C, Montastruc JL, Durrieu G. Interest of a general practitioner pharmacovigilance network to provide drug information : A comparative study in Franc. Therapies. 2020 ;75:617-622.

Lafaurie M, Olivier P, Khouri C, Atzenhoffer M, Bihan K, Durrieu G, Montastruc JL. Myocardial infarction and ischemic stroke with vasoconstrictors used as nasal decongestant for common cold : a French pharmacovigilance survey. Eur J Clin Pharmacol. 2020 ;76:603-604.

Lemaitre F, Solas C, Grégoire M, Lagarce L, Elens L, Polard E, Saint-Salvi B, Sommet A, Tod M, Barin-Le Guellec C. Potential drug–drug interactions associated with drugs currently proposed for COVID-19 treatment in patients receiving other treatments. Fundam Clin Pharmacol. 2020 ;34:530-547.

Maquet J, Lafaurie M, Sommet A, Moulis G. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020 ;190:e276-e279.

Maquet J, Derumeaux H, Lapeyre-Mestre M, Sailler L, Moulis G. Validation of hemolytic anemia discharge diagnosis codes in the French hospital database. Eur J Intern Med. 2020 ;79:136-138.

Montastruc F, Thuriot S, Durrieu G. Hepatic Disorders With the Use of Remdesivir for Coronavirus 2019. Clin Gastroenterol Hepatol. 2020 ;18:2835-2836.

Montastruc JL, Rousseau V, de Canecaude C, Roussin A, Montastruc F. Role of serotonin and norepinephrine transporters in antidepressant-induced arterial hypertension : a pharmacoepidemiological-pharmacodynamic study. Eur J Clin Pharmacol. 2020 ;76:1321-1327.

Montastruc JL, Toutain PL. A New Drug–Drug Interaction Between Hydroxychloroquine and Metformin ? A Signal Detection Study. Drug Saf. 2020 ;43:657-660.

Montastruc JL, Rousseau V, Durrieu G, Bagheri H. Serious adverse drug reactions with hydroxychloroquine : a pharmacovigilance study in Vigibase®. Eur J Clin Pharmacol. 2020 ;76:1479-1480.

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Parkinsonism associated with gabapentinoid drugs : A pharmacoepidemiologic study. Mov Disord. 2020 ;35:176-180.

Pacheco-Paez T, Montastruc F, Rousseau V, Chebane L, Lapeyre-Mestre M, Renoux C, Montastruc JL. Reply to : Comment on "Parkinsonism associated with gabapentinoid drugs : A pharmacoepidemiological study". Mov Disord. 2020 ;35:376-377.

Pradhan R, Montastruc F, Rousseau V, Patorno E, Azoulay L. Exendin-based glucagon-like peptide-1 receptor agonists and anaphylactic reactions : a pharmacovigilance analysis. Lancet Diabetes Endocrinol. 2020 ;8:13-14.

Strumia M, Felipe Guerrero F, Maurel-Ribes A, Garcia E, Payrastre B, Haleh Bagheri H. Platelet function defects and sertraline-induced bleeding : a case report. Fundam Clin Pharmacol. 2020 ;34:632-636.

Vacher R, Lagarce L, Ghamrawi S, Laugier‐Castellan D, Vial T, Bagheri H, Babin M, Briet M. Drug interactions related to self‐medication : a French pharmacovigilance database study. Fundam Clin Pharmacol. 2020 ;34:623-631.

Watson S, Durrieu G. Midostaurin, photosensitivity reaction. WHO Pharm. 2020 ;2:19.

Zacarin A, Strumia M, Piau A, Bagheri H. Potentially inappropriate medication : Adaptation of EU(7)PIM criteria to the French medical practice. Therapies. 2020 ;75:663-673.

Zelmat Y, Rousseau V, Chebane L, Montastruc JL, Bagheri H, Sommet A. Fluoroquinolone-Induced Photosensitivity : A Chemical Fragment-Based Approach by a Case/Non-case Study in VigiBase®. Drug Saf. 2020 ;43:561-566.

ADDICTOVIGILANCE

Dupouy J, Maumus-Robert S, Mansiaux Y, Pariente A, Lapeyre-Mestre M. Primary Care of Opioid use Disorder : The End of “the French Model” ? Eur Addict Res. 2020 ;26:346-354.

Gentile G, Lapeyre-Mestre M, Micallef J. Combatting the misuse of benzodiazepines and related Z drugs in French general practice : a clinical review. BJGP Open. 2020 ;4:1-7.

Jouanjus E, Wolff V. Cannabis et atteintes vasculaires cérébrales. État des connaissances sur les pathologies cérébrovasculaires observées dans un contexte d’usage de cannabis. Presse Med Form. 2020 ;1:364-372.

Lapeyre-Mestre M. Novel forms of injectable buprenorphine and French model of opioid use disorder treatment. Therapies. 2020 ;75:393-395.

Lapeyre-Mestre M, Jouanjus E. Cannabis et pathologies cardio-vasculaires. Synthèse des données récentes sur les caractéristiques des complications cardiovasculaires dues aux cannabinoïdes. Presse Med Form. 2020 ;1:355-363.

Lapeyre-Mestre M. The challenges of pharmacoepidemiology of orphan drugs in rare diseases. Therapies. 2020 ;75:215-220.

Lapeyre-Mestre M, Boucher A, Daveluy A, Gibaja V, Jouanjus E, Mallaret M, Peyrière H, Micallef J. Addictovigilance contribution during COVID-19 epidemic and lockdown in France. Therapie. 2020 ;75:343-354.

Mongiatti M, Bayle P, Lagarrigue A, Fabre D, Telmon N, Lapeyre-Mestre M, Jouanjus E. The cardiovascular health of prisoners who use cannabis : An exploratory study among hospitalized prisoners. Therapies. 2020 ;75:579-589.

PHARMACOÉPIDÉMIOLOGIE

Bagheri H. Characteristics of self-medication in French students. Therapies. 2020 ;75:417-418

Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Pariente A. Impact of pregnancy on antidepressant treatment course : a population-based comparative cohort study in France. Arch Womens Ment Health. 2020 ;23:699-707.

Conte C, Lapeyre-Mestre M, Hanaire H, Ritz P. Diabetes Remission and Relapse After Bariatric Surgery : a Nationwide Population-Based Study. Obes Surg. 2020 ;30:4810-4820.

Couret A, Gallini A, Poncet M, Renoux A, Maryse Lapeyre-Mestre M, Gardette V. Benzodiazepine Dispensing to Persons With Dementia in France 2011-2016 : A Nationwide Study. JAMDA. 2020 ;21:830-836.

De Almeida Chaves S, Derumeaux H, Do Minh P, Lapeyre-Mestre M, Moulis G, Pugnet G. Assessment of the Accuracy of Using ICD-10 Codes to Identify Systemic Sclerosis. Clin Epidemiol. 2020 ; 12 : 1355–1359.

de Germay S, Conte C, Rascol O, Montastruc JL, Lapeyre-Mestre M.  β-Adrenoceptor Drugs and Parkinson’s Disease : A Nationwide Nested Case-Control Study. CNS Drugs. 2020 ;34:763-772.

Dumas PY, Bertoli S, Bérard E, Leguay T, Tavitian S, Galtier J, Alric C, Bidet A, Delabesse E, Rieu JB, Vial JP, Vergez F, Lechevalier N, Luquet I, Klein E, Sarry A, Rey H, de Grande AC, Despas F, Pigneux A, Récher C. Delivering HDAC over 3 or 5 days as consolidation in AML impacts health care resource consumption but not outcome. Blood Adv. 2020 ;4:3840-3849.

Gauthier M, Conte C, Palmaro A, Patras De Campaigno E, De Barros S, Huguet F, Laurent G, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation in patients diagnosed with chronic myeloid leukemia : a population-based study in France. Fundam Clin Pharmacol. 2020 ;34:612-622.

Ihle J, Artaud F, Bekadar S, Mangone G, Sambin S, Mariani LL, Bertrand H, Rascol O, Durif F, Derkinderen P, Scherzer C, Elbaz A, Corvol JC ; DIGPD study group ; Steering committee, Corvol JC, Elbaz A, Vidailhet M, Brice A ; Statistical analyses, Elbaz A, Artaud F ; Principal investigators for sites, Bourdain F, Brandel JP, Corvol JC, Derkinderen P, Durif F, Levy R, Pico F, Rascol O ; Co-investigators (alphabetical order), Bonnet AM, Bonnet C, Brefel-Courbon C, Cormier-Dequaire F, Degos B, Debilly B, Elbaz A, Galitsky M, Grabli D, Hartmann A, Klebe S, Kraemmer J, Lacomblez L, Leder S, Mangone G, Mariani LL, Marques AR, Mesnage V, Muellner J, Ory-Magne F, Planté-Bordeneuve V, Roze E, Tir M, Vidailhet M, You H ; Neuropsychologists, Benchetrit E, Socha J, Pineau F, Vidal T, Pomies E, Bayet V ; Genetic core, Brice A, Lesage S, Tahiri K, Bertrand H, Mangone G ; Sponsor activities and clinical research assistants, Mallet A, Villeret C, Mazmanian M, Manseur H, Hajji M, Le Toullec B, Brochard V, Roy M, Rieu I, Bernard S, Faurie-Grepon A. Parkinson’s disease polygenic risk score is not associated with impulse control disorders : A longitudinal study. Parkinsonism Relat Disord. 2020 ;75:30-33.

Jourdes A, Lafaurie M, Martin-Blondel G, Delobel P, Faruch M, Charpentier S, Minville V, Silva S, Thalamas C, Sommet A, Moulis G. Clinical characteristics and outcome of hospitalized patients withSARS-CoV-2 infection at Toulouse University hospital (France).Results from the Covid-clinic-Toul cohort. Rev Med Int. 2020 ;41:732-740.

Lacroix I, Bénévent J, Damase-Michel C. Chloroquine and hydroxychloroquine during pregnancy : What do we know ? Therapies. 2020 ;384-385.

Lafaurie M, Baricault B, Soler V, Cassagne M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. No increased risk of cataract in adult patients with primary immune thrombocytopenia treated with eltrombopag. A French nationwide nested case-control study. B J Haemat. 2020 ;189:e137-e140.

Lastennet D, Mariani LL, Rascol O, Turc JD, Alfaisal H, Lapeyre-Mestre M, Corvol JC, Tubach F. Evaluation of Prescription Practices of Domperidone in Parkinson’s Disease : A Cross Sectional Study Among French Neurologists. CNS Drugs. 2020 ;34:1267-1274.

Maquet J, Lafaurie M, Sommet A, Moulis G. Thrombocytopenia is independently associated with poor outcome in patients hospitalized for COVID-19. Br J Haematol. 2020 ;190:e276-e279.

Montastruc F, Romano C, Montastruc JL, Silva S, Seguin T, Minville V, Georges B, Riu-Poulenc B, Fourcade O. Pharmacological characteristics of patients infected with SARS-Cov-2 admitted to Intensive Care Unit in South of France. Therapies. 2020 ;75:381-388.

Moulis G, Comont T, Germain J, Sommet A, Lapeyre-Mestre M, Beyne-Rauzy O, Adoue D ; CARMEN investigators group. Significance of antinuclear antibodies in primary immune thrombocytopenia : results of the CARMEN registry. Blood Adv. 2020 ;4:1974-1977.

Mounié M, Costa N, Conte C, Petiot D, Fabre D, Despas F, Lapeyre-Mestre M, Laurent G, Savy N, Molinier L. Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France. J Med Econ. 2020 ;23:235-242.

Piel-Julian ML, Thiercelin-Legrand MF, Moulis G, Voisin S, Claeyssens S, Sailler L. Antithrombotic therapy management in patients with inherited bleeding disorders and coronary artery disease : A single-centre experience. Haemophilia. 2020 ;26:e34-e37.

Poncet M, Gardette V, Couret A, Renoux A, Lapeyre-Mestre M, Gallini A. Benzodiazepine exposure in subjects with incident Alzheimer’s disease and related syndromes in France : a longitudinal study 2011-2017. Int Clin Psychopharmacol. 2020 ;35:270-278.

Pugnet G, Mounié M, Lapeyre-Mestre M, Moulis G, Sailler L. Insufficient influenza vaccination coverage in giant cell arteritis. A French population-based study. Rev Med Interne. 2020 ;41:446-450.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort. J Neural Transm. 2020 ;127:1607-1617.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Utilization Patterns of Amantadine in Parkinson’s Disease Patients Enrolled in the French COPARK Study. Drugs Aging. 2020 ;37:215-223.

Rousset S, Treiner E, Moulis G, Pugnet G, Astudillo L, Paricaud K, Puissant-Lubrano B, Arlet P, Blancher A, Sailler L. High rate of indeterminate results of the QuantiFERON-TB Gold in-tube test, third generation, in patients with systemic vasculitis. Rheumatology (Oxford). 2020 ;59:1006-1010.

Roustit R, Guilhaumou R, Molimard M, Drici MD, laporte S, Montastruc JL. On behalf of the French Society of Pharmacology and Therapeutics (SFPT). Chloroquine and hydroxychloroquine in the management of COVID-19 : Much kerfuffle but little evidence. Therapies. 2020 ;75:363-370.

Souty C, Launay T, Steichen O, Conte C, Turbelin C, Sarazin M, Vilcu AM, Rossignol L, Blanchon T, Lapeyre-Mestre M, Hanslik T. Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. Eur J Clin Pharmacol. 2020 ;76:1675-1682.

Vayr F, Montastruc M, Savall F, Despas F, Judic E, Basso M, Dunet C, Dalenc F, Laurent G, Soulat JM, Herin F. Work adjustments and employment among breast cancer survivors : a French prospective study. Support Care Cancer. 2020 ;28:185-192.

Zacarin A, Pradalié P, Bourgade B, Bayle H, Mestery D, Bagheri H. Evolution of drug prescription pattern in elderly : Retrolective study in a general hospital center in France. Therapies. 2020 ;75:271-279.

PHARMACOLOGIE CLINIQUE

Barbe MT, Tonder L, Krack P, Debû B, Schüpbach M, Paschen S, Dembek TA, Kühn AA, Fraix V, Brefel-Courbon C, Wojtecki L, Maltête D, Damier P, Sixel-Döring F, Weiss D, Pinsker M, Witjas T, Thobois S, Schade-Brittinger C, Rau J, Houeto JL, Hartmann A, Timmermann L, Schnitzler A, Stoker V, Vidailhet M, Deuschl G ; EARLYSTIM study group. Deep Brain Stimulation for Freezing of Gait in Parkinson’s Disease With Early Motor Complications. Mov Disord. 2020 ;35:82-90.

Blin O, Lefebvre MN, Rascol O, Micallef J. Orphan drug clinical development. Therapies. 2020 ;75:141-147.

Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Ory-Magne F, Rascol O, Moreau C, Maltête D, Rouaud T, Meyer M, Houvenaghel JF, Marsé C, Tranchant C, Hainque E, Jarraya B, Ansquer S, Bonnet M, Belamri L, Tir M, Marques AR, Danaila T, Eusebio A, Devos D, Brefel-Courbon C ; PREDI-STIM study group*. Personality Dimensions Are Associated with Quality of Life in Fluctuating Parkinson’s Disease Patients (PSYCHO-STIM). J Parkinsons Dis. 2020 ;10:1057-1066.

Brosseron F, Kolbe CC, Santarelli F, Carvalho S, Antonell A, Castro-Gomez S, Tacik P, Namasivayam AA, Mangone G, Schneider R, Latz E, Wüllner U, Svenningsson P, Sánchez-Valle R, Molinuevo JL, Corvol JC, Heneka MT, Rascol O ; AETIONOMY study group. Multicenter Alzheimer’s and Parkinson’s disease immune biomarker verification study. Alzheimers Dement. 2020 ;16:292-304.

Crepin S, Chiffoleau A, Gavard M, Olivier-Abbal P, Roussillon C, Ruault S, Muller C, Peyro-Saint-Paul L, Ouk T, Franceschi MP, Mouchel C, Duranton S, Petitpain N, Coubret-Dumas A. Compliance of French academic clinical trials with the Clinical Trial Facilitation and Coordination Group recommendations on contraception and pregnancy testing requirements. Clin Trials. 2020 ;17:314-322.

Del Campo N, Phillips O, Ory-Magne F, Brefel-Courbon C, Galitzky M, Thalamas C, Narr KL, Joshi S, Singh MK, Péran P, Pavy-LeTraon A, Rascol O. Broad white matter impairment in multiple system atrophy. Hum Brain Mapp. 2020 ;42:357-66.

Fabbri M, Kauppila LA, Ferreira JJ, Rascol O. Challenges and Perspectives in the Management of Late-Stage Parkinson’s Disease. J Parkinsons Dis. 2020 ;10:S75-S83.

Fabbri M, Perez-Lloret S, Rascol O. Therapeutic strategies for Parkinson’s disease : promising agents in early clinical development. Expert Opin Investig Drugs. 2020 ;29:1249-1267.

Gallais F, Ysebaert L, Despas F, De Barros S, Dupré L, Quillet-Mary A, Protin C, Thomas F, Obéric L, Allal B, Chatelut E, White-Koning M. Population Pharmacokinetics of Ibrutinib and Its Dihydrodiol Metabolite in Patients with Lymphoid Malignancies. Clin Pharmacokinet. 2020 ;59:1171-1183.

Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson’s disease patients with OFF periods : A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2020 ;71:4-10.

Kermorgant M, Nasr N, Czosnyka M, Arvanitis DN, Hélissen O, Senard JM, Pavy-Le Traon A. Impacts of Microgravity Analogs to Spaceflight on Cerebral Autoregulation. Front Physiol. 2021 Jul 3 ;11:778.

Kermorgant M, Ben Salem J, Iacovoni JS, Calise D, Dahan L, Guiard BP, Lopez S, Lairez O, Lasbories A, Nasr N, Pavy Le-Traon A, Beaudry F, Senard JM, Arvanitis DN Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure. Acta Physiol (Oxf). 2021 Apr ;231(4):e13601.

Leal Rato M, Rascol O, Ferreira JJ. The "long and winding road" of the disease-modifying effects of levodopa has not ended yet. Mov Disord. 2020 ;35:397-399.

LeWitt PA, Aradi SD, Hauser RA, Rascol O. The challenge of developing adenosine A2A antagonists for Parkinson disease : Istradefylline, preladenant, and tozadenant. Parkinsonism Relat Disord. 2020 ;80:S54-S63.

Markaki I, Bergström S, Tsitsi P, Remnestål J, Månberg A, Hertz E, Paslawski W, Sorjonen K, Uhlén M, Mangone G, Carvalho S, Rascol O, Meissner WG, Magnin E, Wüllner U, Corvol JC, Nilsson P, Svenningsson P. Cerebrospinal Fluid Levels of Kininogen-1 Indicate Early Cognitive Impairment in Parkinson’s Disease. Mov Disord. 2020 ;35:2101-2106.

Meissner WG, Traon AP, Foubert-Samier A, Galabova G, Galitzky M, Kutzelnigg A, Laurens B, Lührs P, Medori R, Péran P, Sabatini U, Vergnet S, Volc D, Poewe W, Schneeberger A, Staffler G, Rascol O ; AFF009 Study Investigators. A Phase 1 Randomized Trial of Specific Active α-Synuclein Immunotherapies PD01A and PD03A in Multiple System Atrophy. Mov Disord. 2020 ;35:1957-1965.

Meyrignac O, Bal L, Zadro C, Vavasseur A, Sewonu A, Gaudry M, Saint-Lebes B, De Masi M, Revel-Mouroz P, Sommet A, Darcourt J, Negre-Salvayre A, Jacquier A, Bartoli JM, Piquet P, Rousseau H, Moreno R. Combining Volumetric and Wall Shear Stress Analysis from CT to Assess Risk of Abdominal Aortic Aneurysm Progression.Radiology. 2020 ;295:722-729.

Pellecchia MT, Stankovic I, Fanciulli A, Krismer F, Meissner WG, Palma JA, Panicker J, Seppi K, Wenning GK, Antonini A, Bajaj S, Bang J, Barone P, Berardelli A, Berg D, Biaggioni I, Bloem B, Brooks DJ, Calandra‐Buonaura G, Colosimo C, Cortelli P, Ferreira J, Fox S, Frauscher B, Freeman R, Fung V, Gasser T, Gerhard A, D. Goldstein, Hallett M, Halliday G, Höglinger GU, Holton JL, Houlden H, Iodice V, Kaufmann H, Klockgether T, Kostic V, Lang A, Ling H, Low P, Litvan I, Miki Y, Nomura T, Orimo S, Ozawa T, Pantelyat A, Postuma R, Quinn N, Rascol O, Robertson D, Sabanovic M, Sakakibara R, Sampaio C, Schmahmann JD, Scholz S, Senard JM, Weintrau D, Siebert U, Poewe W. Can autonomic testing and imaging contribute to the early diagnosis of MSA ? A systematic review and recommendations by the MDS multiple system atrophy (MoDiMSA) study group. Mov Disord Clin Pract. 2020 ;7:750-762.

Phillipps C, Longato N, Béreau M, Carrière N, Lagha-Boukbiza O, Mengin AC, Monga B, Defebvre L, Ory-Magne F, Castrioto A, Lhommée E, Rascol O, Krack P, Tranchant C, Corvol JC, Anheim M. Is Motor Side Onset of Parkinson’s Disease a Risk Factor for Developing Impulsive-Compulsive Behavior ? A Cross-Sectional Study. Mov Disord. 2020 ;35:1080-1081.

Olivot JM, Albucher JF, Guenego A, Thalamas C, Mlynash M, Rousseau V, Drif A, Christensen S, Sommet A, Viguier A, Darcourt J, Calvière L, Menegon P, Raposo N, Januel AC, Bonneville F, Tourdias T, Mazighi M, Sibon I, Albers GW, Cognard C ; FRAME Investigators*. Mismatch Profile Influences Outcome After Mechanical Thrombectomy. Stroke. 2021 ;52:232-240.

Tolosa E, Vila M, Klein C, Rascol O. LRRK2 in Parkinson disease : challenges of clinical trials. Nat Rev Neurol. 2020 ;16:97-107.

INFORMATIONS SUR LE MEDICAMENT

Bagheri H. Analyse de livre. Automédication, le Guide Expert, J.-P. Giroud. Éditions De La Martinière, Paris (2017). 2020 ;75:125-126.

Montastruc JL. Analyse de livre. Le sport dans la douleur : de l’automédication au mental training, T. Bujon, F. Mougeot, in : Collections sports, cultures, sociétés, Presses universitaires de Grenoble, 38600, Fontaine, France (2017), 108 pp, ISBN : 9782706127038. Therapies. 2020 ;45:126.

Montastruc JL. Analyse de livre. Neuropsychopharmacologie, R. Bordet, L. Carton, J. Deguil, T. Dondaine, sous l’égide de la Société française de pharmacologie et de thérapeutique (SFPT) et du Collège national de pharmacologie médicale (CNPM), Elsevier Masson (2019), EISBN : 9782294754241, 277 pp., ISBN : 9782294752995. Therapies. 2020 ;75:126-127.

Retour en haut de page

ANNEE 2019

Publié le 14/02/2020 à 10h34 (mis à jour le 18/10/2022 à 10h38)

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Andre L, Gallini A, Montastruc F, Coley N, Montastruc JL, Vellas B, Andrieu S, Gardette V ; MAPT/DSA study group. Anticholinergic exposure and cognitive decline in older adults : Effect of anticholinergic exposure definitions in a 3-year analysis of the Multidomain Alzheimer Preventive Trial (MAPT) study. Br J Clin Pharmacol. 2019 ;85:71-99.

Andre L, Gallini A, Montastruc F, Montastruc JL, Piau A, Lapeyre-Mestre M, Gardette V. Association between anticholinergic (atropinic) drug exposure and cognitive function in longitudinal studies among individuals over 50 years old : a systematic review. Eur J Clin Pharmacol. 2019 ;75:1631-1644.

Bagheri H. Interest of pharmacoepidemiology for the study of anticoagulants. Therapie. 2019 ;74:245-248.

Bataillard M, Beyens MN, Mounier G, Vergnon-Miszczycha D, Bagheri H, Cathebras P. Muscle Damage Due to Fusidic Acid-Statin Interaction : Review of 75 Cases From the French Pharmacovigilance Database and Literature Reports. Am J Ther. 2019 ;26:e375-e379.

Bégaud B, Montastruc JL. Pharmacoepidemiology, the new paradigm of drug evaluation. Therapie. 2019 ;74:167-168.

Berger E, Delpierre C, Despas F, Bertoli S, Bérard E, Bombarde O, Bories P, Sarry A, Laurent G, Récher C, Lamy S. Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization ? Results from a French longitudinal observational study among older patients. BMC Cancer. 2019 ;19:883.

Carr DF, Francis B, Jorgensen AL, Zhang E, Chinoy H, Heckbert SR, Bis JC, Brody JA, Floyd JS, Psaty BM, Molokhia M, Lapeyre-Mestre M, Conforti A, Alfirevic A, van Staa T, Pirmohamed M. Genomewide Association Study of Statin-Induced Myopathy in Patients Recruited Using the UK Clinical Practice Research Datalink. Clin Pharmacol Ther. 2019 ;106:1353-1361

Clapes V, Rousseau R, Despas F, Montastruc JL, Olivier P. Adverse Drug Reactions Involving Protein Kinase Inhibitors : A French Pharmacovigilance Database Study Comparing Safety in Younger and Older Patients (≥ 75 years) with Cancer. Pharmaceutical Medicine. 2018 ;33:21-27.

Caudrelier L, Moulis G, Lapeyre-Mestre M, Sailler L, Pugnet G. Validation of giant cell arteritis diagnosis code in the French hospital electronic database. Eur J Intern Med. 2019 ;60:e16-e17.

Compaci G, Conte C, Oberic L, Ysebaert L, Laurent G, Despas F. Sustained degradation of quality of life in a subgroup of lymphoma survivors : a two-year prospective survey. BMC Cancer. 2019 ;19:1178.

Conte C, Vaysse C, Bosco P, Noize P, Fourrier-Reglat A, Despas F, Lapeyre-Mestre M. The value of a health insurance database to conduct pharmacoepidemiological studies in oncology. Therapie. 2019 ;74:279-288.

Conte C, Bourrel R, Despas F, Lapeyre-Mestre M. Is there overuse of proton pump inhibitors in B-cell non-Hodgkin lymphomas ? A cohort study based on the French health insurance database in the Midi-Pyrénées region. Fundam Clin Pharmacol. 2019 ;33:327-338.

Crickx E, Poullot E, Moulis G, Goulabchand R, Fieschi C, Galicier L, Meignin V, Coppo P, Delarue R, Casasnovas O, Roos-Weil D, de Leval L, Parrens M, Michel M, Dupuis J, Le Bras F, Fataccioli V, Martin-Garcia N, Godeau B, Haïoun C, Gaulard P, Mahévas M. Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic T-cell lymphoma. Eur J Haematol. 2019 ;103:35-42.

Dardonville Q, Salguiero E, Rousseau V, Chebane L, Faillie JL, Gautier S, Montastruc JL, Carvajal A, Bagheri H. Drug-induced osteoporosis/osteomalacia : analysis in the French and Spanish pharmacovigilance databases. Eur J Clin Pharmacol. 2019 ;75:1705-1711.

De Barros S, Vayr F, Despas F, Strumia M, Podevin C, Gauthier M, Delabesse E, Soulat JM, Laurent G, Huguet F, Herin F. The impact of chronic myeloid leukemia on employment : the French prospective study. Ann Hematol. 2019 ;98:615-623.

De Germay S, Rueter M, Montastruc F, Rousseau V, Lapeyre-Mestre M, Montastruc JL. Trends of atropinic (anticholinergic) exposure in the elderly : a 10-year analysis in the French EGB database. Fundam Clin Pharmacol. 2019 ;33:471-478.

Despas F, Rousseau V, Lafaurie M, De Canecaude C, Durrieu G, Bagheri H, Montastruc F, Montastruc JL. Are lipid-lowering drugs associated with a risk of cataract ? A pharmacovigilance study. Fundam Clin Pharmacol. 2019:33 ;695-702.

Dupui M, Micallef J, Lapeyre-Mestre M. Interest of large electronic health care databases in addictovigilance : Lessons from 15 years of pharmacoepidemiological contribution. Therapie. 2019 ;74:307-314.

Duret-Aupy N, Lagarce L, Blouet A, Kettani S, Conte C, Bourneau-Martin D, Drablier G, Umlil A, Briet M. Liver sinusoidal obstruction syndrome associated with trastuzumab emtansine treatment for breast cancer. Therapie. 2019 ;74:675-688.

Durrieu G, Dardonville Q, Clanet M, Montastruc JL. Cervical dysplasia in a patient with multiple sclerosis treated with natalizumab. Fundam Clin Pharmacol. 2019 ;33:125-126.

Ekstrand C, Linder M, Baricault B, Lafaurie M, Sailler L, Lapeyre-Mestre M, Kieler H, Moulis G, Bahmanyar S.Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts. Thromb Res. 2019 ;178:124-131.

Favrelière S, Lafay-Chebassier C, Fauconneau B, Quillet A, Yéléhé-Okouma M, Montastruc F, Pérault-Pochat MC. Illogical association nalmefene and opioids : Analysis in the French pharmacovigilance database.Therapie. 2019 ;79:365-374.

Floyd JS, Bloch KM, Brody JA, Maroteau C, Siddiqui MK, Gregory R, Carr DF, Molokhia M, Liu X, Bis JC, Ahmed A, Liu X, Hallberg P, Yue QY, Magnusson PKE, Brisson D, Wiggins KL, Morrison AC, Khoury E, McKeigue P, Stricker BH, Lapeyre-Mestre M, Heckbert SR, Gallagher AM, Chinoy H, Gibbs RA, Bondon-Guitton E, Tracy R, Boerwinkle E, Gaudet D, Conforti A, van Staa T, Sitlani CM, Rice KM, Maitland-van der Zee AH, Wadelius M, Morris AP, Pirmohamed M, Palmer CAN, Psaty BM, Alfirevic A ; PREDICTION-ADR Consortium and EUDRAGENE. Pharmacogenomics of statin-related myopathy : Meta-analysis of rare variants from whole-exome sequencing. PLoS One. 2019 ;14:e0218115.

Humbert X, Fedrizzi S, Chrétien B, Sassier M, Bagheri H, Combret S, Drici MD, Le Bas F, Puddu PE, Alexandre J. Hypertension induced by serotonin reuptake inhibitors : Analysis of two pharmacovigilance databases. Fundam Clin Pharmacol. 2019 ;33:296-302.

Kaguelidou F, Durrieu G, Clavenna A. Pharmacoepidemiological research for the development and evaluation of drugs in pediatrics. Therapie. 2019 ;74:315-324.

Koffi KG, Silué DA, Laurent C, Boidy K, Koui S, Compaci G, Adeba ZH, Kamara I, Botty RP, Bognini AS, Sanogo I, Despas F, Laurent G. AMAFRICA, a patient-navigator program for accompanying lymphoma patients during chemotherapy in Ivory Coast : a prospective randomized study. BMC Cancer. 2019 ;19:1247.

Lacroix C, Kheloufi F, Montastruc F, Bennis Y, Pizzoglio V, Micallef J. Serious central nervous system side effects of cephalosporins : A national analysis of serious reports registered in the French Pharmacovigilance Database. J Neurol Sci. 2019 ;398:196-201.

Lafaurie M, Montastruc F. Interest of a pharmacovigilance medical consultation : Example of metformin-induced-vitamin B12 deficiency. Presse Med. 2019 ;48:1216-1221.

Lapeyre-Mestre M. Benzodiazepines, cognitive decline and dementia : A review of causality criteria from published observational studies. Therapie. 2019 ;74:407-419.

Lapeyre-Mestre M, Montastruc F. Interest of pharmacoepidemiology for pharmacodynamics and analysis of the mechanism of action of drugs. Thérapie. 2019 ;74:209-2014.

Mahevas M, Van Eeckhoudt S, Moulis G, Limal N, Languille L, Bierling P, Dossier A, Duriez F, Galicier L, Morin AS, Tamburini J, Chaoui D, Bouscary D, Jijakli AAL, Khellaf M, Vaida I, Michel M, Vercellino L, Jaddi H, Yollant A, Dosquet C, Godeau B, Chomienne C. Autologous111 Indium-oxinate-labelled platelet sequestration study in patients with immune thrombocytopenia treated by thrombopoietin receptor-agonists. Br J Haematol. 2019 ;186:e44-e47.

Mariani LL, Doulazmi M, Chaigneau V, Brefel-Courbon C, Carrière N, Danaila T, Defebvre L, Defer G, Dellapina E, Doé de Maindreville A, Geny C, Maltête D, Meissner WG, Rascol O, Thobois S, Torny F, Tranchant C, Vidailhet M, Corvol JC, Degos B ; NS-Park/F-CRIN Network study group. Descriptive analysis of the French NS-Park registry : Towards a nation-wide Parkinson’s disease cohort ? Parkinsonism Relat Disord. 2019 ;64:226-234.

Mines ML, Pacheco T, Castel-Lacana E, de Boissezon X, Marque P, Montastruc F. Venous thrombosis after botulinum therapy in lower limb : A case report and literature review. Ann Phys Rehabil Med. 2019 ;62:457-458.

Montastruc F, Nie R, Loo S, Rej S, Dell’Aniello S, Micallef J, Suissa S, Renoux C. Association of Aripiprazole With the Risk for Psychiatric Hospitalization, Self-harm, or Suicide. JAMA Psychiatry. 2019 ;76:409-417.

Montastruc F, Renoux C, Dell’Aniello S, Simon TA, Azoulay L, Hudson M, Suissa S. Abatacept initiation in rheumatoid arthritis and the risk of cancer : a population-based comparative cohort study. Rheumatology (Oxford). 2019 ;48:1053-1058.

Montastruc F, Khosrow-Khavar F, Sommet A, Renoux C, Montastruc JL. Tamoxifen administration and the risk of Parkinsonism. Eur J Clin Pharmacol. 2019 ;75:135-136.

Montastruc F, Benevent J, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Risk of Diabetes with Fibrates and Statins : a pharmacoepidemiological study in Vigibase®. Fundam Clin Pharmacol. 2018 ;33:108-112.

Montastruc JL, Benevent J, Montastruc F, Bagheri H, Despas F, Lapeyre-Mestre M, Sommet A. What is pharmacoepidemiology ? Definition, methods, interest and clinical applications. Therapie. 2019 ;74:169-174.

Montastruc JL, Montastruc F, Benevent J, Durrieu G, du Plantier JM, Bagheri H, Sommet A, Damase-Michel C. Tintin in the land of drugs : a pharmacological, pharmacovigilance approach. Therapie. 2019 ; 74:445-447.

Mounié M, Pugnet G, Savy N, Lapeyre-Mestre M, Molinier L, Costa N. Additional costs of polymyalgia rheumatica with giant-cell arteritis. Arthritis Care Res (Hoboken). 2019 ;71:1127-1131.

Nguyen KD, Nguyen HA, Vu DH, Le TT, Nguyen HA Jr, Dang BV, Nguyen TN, Nguyen DH, Nguyen TB, Montastruc JL, Bagheri H. Drug-Induced Anaphylaxis in a Vietnamese Pharmacovigilance Database : ends and Specific Signals from a Disproportionality Analysis. Drug Saf. 2019 ;42:671-682.

Nguyen KD, Tran TN, Nguyen MT, Nguyen HA, Nguyen HA Jr, Vu DH, Nguyen VD, Bagheri H. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database : A subgroup approach to disproportionality analysis. J Clin Pharm Ther. 2019 ;44:69-77.

Nicol C, Moulis F, Bondon-Guitton E, Durrieu G, Montastruc JL, Bagheri H. Does spontaneous adverse drug reactions’ reporting differ between different reporters ? A study in Toulouse Pharmacovigilance Centre. Therapie. 2019 ;5:521-525.

Petitpain N, Devos D, Bagheri H, Rocher F, Gouraud A, Masmoudi K, Coquerel A. Is TNF inhibitor exposure a risk factor foramyotrophic lateral sclerosis ? Fundam Clin Pharmacol. 2019 ;33:689-694.

Peyro-Saint-Paul L, Besnier P, Demessine L, Biour M, Hillaire-Buys D, de Canecaude C, Fedrizzi S, Parienti JJ. Cushing’s syndrome due to interaction between ritonavir or cobicistat and corticosteroids : a case-control study in the French Pharmacovigilance Database. J Antimicrob Chemother. 2019 ;74:3291-3294.

Sabatier P, Amar J, Montastruc F, Rousseau V, Chebane L, Bouhanick B, Montastruc JL. Breast cancer and spironolactone : an observational postmarketing study. Eur J Clin Pharmacol. 2019 ;75:1593-98.

Sommet A, Pariente A. Methods in pharmacoepidemiology. Therapie. 2019 ;74:187-197.

Sommet A. Interest of pharmacoepidemiology for the study of antibiotic drugs. Therapie. 2019 ;74:249-253.

Sommet A, Bénévent J, Rousseau V, Chebane L, Douros A, Montastruc JL, Montastruc F. What Fluoroquinolones Have the Highest Risk of Aortic Aneurysm ? A Case/Non-case Study in VigiBase®. J Gen Intern Med. 2019 ;34:502-503.

Tournier M, Montastruc F. Interest of pharmacoepidemiology for the study of psychotropic drugs. Therapie. 2019 ;74:239-244.

Tranchard F, Gauthier J, Hein C, Lacombe J, Brett K, Villars H, Sallerin B, Montastruc JL, Despas F. Drug identification by the patient : Perception of patients, physicians and pharmacists.Therapie. 2019 ;74:591-598.

Walburg V, Rueter M, Lamy S, Compaci G, Lapeyre-Mestre M, Laurent G, Despas F. Fear of cancer recurrence in Non- and Hodgkin lymphoma survivors during their first three years of survivorship among French patients. Psychol Health Med. 2019 ;24:1-7.

Ysebaert L, Larcher M, Compaci G, Oberic L, Sahnes L, Banos A, Araujo C, Sommet A, Laurent G, Despas F. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy : results of the randomized FORTIS study in chronic lymphocytic leukemia. Ann Hematol. 2019 ;98:931-939.

Watson S, Durrieu G. Midostaurin, photosensitivity reaction. WHO U M C, 2019:1-7.

PHARMACOLOGIE CLINIQUE

Arribarat G, Pasternak O, De Barros A, Galitzky M, Rascol O, Péran P. Substantia nigra locations of iron-content, free-water and mean diffusivity abnormalities in moderate stage Parkinson’s disease. Parkinsonism Relat Disord. 2019 ;65:146-152.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:827-833.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Lechat et al. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:1353-1354.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Nicolas. Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:961-963.

Concordet D, Gandia P, Montastruc JL, Bousquet‑Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Castello‑Bridoux et al. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:973-975.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Authors’ Reply to Coste et al. “Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ?” Clinical Pharmacokinetics. 2019 ;58:967-968.

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL. Author’s Reply to Trechot. Comment on Levothyrox® New and Old Formulations : Are they Switchable for Millions of Patients ? Clinical Pharmacokinetics. 2019 ;58:979-980.

Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O ; French NS-Park/F-CRIN Network. Naftazone in advanced Parkinson’s disease : An acute L-DOPA challenge randomized controlled trial. Parkinsonism Relat Disord. 2019 ;60:51-56.

Coutens B, Mouledous L, Stella M, Rampon C, Lapeyre-Mestre M, Roussin A, Guiard BP, Jouanjus E. Lack of correlation between the activity of the mesolimbic dopaminergic system and the rewarding properties of pregabalin in mouse. Psychopharmacology (Berl). 2019 ;236:2069-2082.

Delamarre A, Tison F, Li Q, Galitzky M, Rascol O, Bezard E, Meissner WG. Assessment of plasma creatine kinase as biomarker for levodopa-induced dyskinesia in Parkinson’s disease. J Neural Transm (Vienna). 2019 ;126:789-793.

Dellapina E, Pellaprat J, Adel D, Llido J, Harroch E, Martini JB, Kas A, Salabert AS, Ory-Magne F, Payoux P, Brefel-Courbon C. Dopaminergic denervation using [123I]-FPCIT and pain in Parkinson’s disease : a correlation study. J Neural Transm (Vienna). 2019 ;126:279-287.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P. Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients : a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol. 2019 ;26:953-960.

Gollion C, Dupouy J, Roberts M, Simonetta-Moreau M, Brefel Courbon C, Rascol O, Honnorat J, Magne FO. Reversible myoclonus-ataxia encephalitis related to anti-mGLUR1 autoantibodies. Mov Disord. 2019 ;34:438-439.

Grosset DG, Dhall R, Gurevich T, Kassubek J, Poewe WH, Rascol O, Rudzinska M, Cormier J, Sedkov A, Oh C. Inhaled levodopa in Parkinson’s disease patients with OFF periods : A randomized 12-month pulmonary safety study. Parkinsonism Relat Disord. 2019 ;71:4-10.

Knudsen K, Krack P, Tonder L, Houeto JL, Rau J, Schade-Brittinger C, Hartmann A, Hälbig TD, Paschen S, Barbe MT, Kühn A, Fraix V, Brefel-Courbon C, Vesper J, Maltête D, Sixel-Döring F, Weiss D, Witjas T, Thobois S, Agid Y, Schnitzler A, Schuepbach WMM, Timmermann L, Damier P, Vidailhet M, Deuschl G ; EARLYSTIM study group. Programming parameters of subthalamic deep brain stimulators in Parkinson’s disease from a controlled trial. Parkinsonism Relat Disord. 2019 ;65:217-223.

Lee PC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Brice A, Vidailhet M, Corvol JC, Elbaz A ; DIGPD Study Group. Examining the Reserve Hypothesis in Parkinson’s Disease : A Longitudinal Study. Mov Disord. 2019 ;34:1663-1671.

Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, Soares-da-Silva P. Safety Profile of Opicapone in the Management of Parkinson’s Disease. J Parkinsons Dis. 2019 ;9:733-740.

Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C. How to diagnose parkinsonian central pain ? Parkinsonism Relat Disord. 2019 ;64:50-53.

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F ; DIGPD study group. French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease-Rating Scale (QUIP-RS). Parkinsonism Relat Disord. 2019 ;63:117-123.

Meissner WG, Fernagut PO, Dehay B, Péran P, Traon AP, Foubert-Samier A, Lopez Cuina M, Bezard E, Tison F, Rascol O. Multiple System Atrophy : Recent Developments and Future Perspectives. Mov Disord. 2019 ;34:1629-1642.

Mouly S, Roustit M, Bagheri H, Perault-Pochat MC, Molimard M, Bordet R. The French Levothyrox® crisis : We did the best we could but…. Therapie. 2019 ;74:431-435.

Pérez-Lloret S, Quarracino C, Otero-Losada M, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension in neurodegenerative diseases. Expert Opin Pharmacother. 2019 ;20:635-645.

Rascol O. CVT-301 for Parkinson’s disease : dose and effect size issues. Lancet Neurol. 2019 ;18:128-130.

Revel-Mouroz P, Viguier A, Cazzola V, Calviere L, Patsoura S, Rousseau V, Sommet A, Albucher JF, Cognard C, Olivot JM, Bonneville F, Raposo N. Acute ischaemic lesions are associated with cortical superficial siderosis in spontaneous intracerebral hemorrhage. Eur J Neurol. 2019 ;26:660-666.

Schuepbach WMM, Tonder L, Schnitzler A, Krack P, Rau J, Hartmann A, Hälbig TD, Pineau F, Falk A, Paschen L, Paschen S, Volkmann J, Dafsari HS, Barbe MT, Fink GR, Kühn A, Kupsch A, Schneider GH, Seigneuret E, Fraix V, Kistner A, Chaynes PP, Ory-Magne F, Brefel-Courbon C, Vesper J, Wojtecki L, Derrey S, Maltête D, Damier P, Derkinderen P, Sixel-Döring F, Trenkwalder C, Gharabaghi A, Wächter T, Weiss D, Pinsker MO, Regis JM, Witjas T, Thobois S, Mertens P, Knudsen K, Schade-Brittinger C, Houeto JL, Agid Y, Vidailhet M, Timmermann L, Deuschl G ; EARLYSTIM study group. Quality of life predicts outcome of deep brain stimulation in early Parkinson disease. Neurology. 2019 ;92:e1109-e1120.

Taib S, Ory-Magne F, Brefel-Courbon C, Moreau Y, Thalamas C, Arbus C, Simonetta-Moreau M. Repetitive transcranial magnetic stimulation for functional tremor : A randomized, double-blind, controlled study. Mov Disord. 2019 ;34:1210-1219.

Truffert E, Fournier Charrière E, Treluyer JM, Blanchet C, Cohen R, Gardini B, Haas H, Liard F, Montastruc JL, Nicollas R, Pondaven S, Stahl JP, Wood C, Couloigner V. Guidelines of the French Society of Otorhinolaryngology (SFORL) : Nonsteroidal anti-inflammatory drugs (NSAIDs) and pediatric ENT infections. Short version. Eur Ann Otorhinolaryngol Head Neck Dis. 2019 ;136:289-294.

Vardon Bounes F, Pichon X, Ducos G, Ruiz J, Samier C, Silva S, Sommet A, Fourcade O, Conil JM, Minville V. Remifentanil for Procedural Sedation and Analgesia in Central Venous Catheter Insertion : A Randomized, Controlled Trial. Clin J Pain. 2019 ;35:691-695.

Vergnet S, Hives F, Foubert-Samier A, Payoux P, Fernandez P, Meyer M, Dupouy J, Brefel-Courbon C, Ory-Magne F, Rascol O, Tison F, Pavy-Le Traon A, Meissner WG. Dopamine transporter imaging for the diagnosis of multiple system atrophy cerebellar type. Parkinsonism Relat Disord. 2019 ;63:199-203.

PHARMACOLOGIE DE LA REPRODUCTION

Araujo M, Hurault-Delarue C, Bouilhac C, Petiot D, Benevent J, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C, Lacroix I. Non-Steroidal Anti-Inflammatory Drug (NSAID) Prescriptions from the 6th Month of Pregnancy : Impact of Advice from Health Authorities. Fundam Clin Pharmacol. 2019 ;33:581-588.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc JL, Lacroix I, Damase-Michel C. POMME : The New Cohort to Evaluate Long-Term Effects After Prenatal Medicine Exposure. Drug Saf. 2019 ;42:45-54.

Benevent J, Hurault-Delarue C, Araujo M, Montastruc F, Montastruc JL, Lacroix I, Damase-Michel C. Higher intake of medications for digestive disorders in children prenatally exposed to drugs with atropinic properties. Fundam Clin Pharmacol. 2018 ;33:314-326.

Benevent J, Lacroix I. Medication and pregnancy, asssessing the risk-benefit balance. Actualités pharmaceutiques. 2019 ;588:21-27.

Benevent J, Araujo M, Hurault-Delarue C, Montastruc JL, Sommet A, Lacroix I, Damase-Michel C. Pharmacoepidemiology in pregnancy. Therapie. 2019 ;74:289-300.

Baudou E, Benevent J, Montastruc JL, Touati G, Hachon Le Camus C. Adverse Effects of Treatment with Valproic Acid during the Neonatal Period. Neuropediatrics. 2019 ;50:31-40.

Charlton R, Damase-Michel C, Hurault-Delarue C, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Morris JK ; EUROmediSAFE consortium. Did advice on the prescription of sodium valproate reduce prescriptions to women ? An observational study in three European countries between 2007 and 2016. Pharmacoepidemiol. Drug Saf. 2019 ;28:1519-1528.

Hurault-Delarue C, Morris JK, Charlton R, Gini R, Loane M, Pierini A, Puccini A, Neville A, Snowball J, Damase-Michel C ; EUROmediSAFE consortium. Prescription of antiepileptic medicines including valproate in pregnant women : A study in three European countries. Pharmacoepidemiol Drug Saf. 2019 ;28:1510-1518.

Hurault-Delarue C , Lacroix I , Bénard-Laribière A , Montastruc JL , Pariente A , Damase-Michel C. Antidepressants During Pregnancy : A French Drug Utilisation Study in EFEMERIS Cohort. Eur Arch Psychiatry Clin Neurosci. 2019 ; 269:841-849.

ADDICTOVIGILANCE

Auffret M, Rolland B, Béhal H, Labreuche J, Jouanjus E, Bordet R, Gautier S. A capture-recapture method for estimating theincidence of off-label prescriptions : the example of baclofen for alcohol use disorder in France. Therapies. 2019 ;74:645-650.

Cantagrel N, Lestrade C, Roussin A. Differing Perception of Attachment to Analgesic Treatment between Pain Specialist and Patient. Douleur analg. 2019 ;32:105-107.

Driot D, Jouanjus E, Oustric S, Dupouy J, Lapeyre-Mestre M. Patterns of gabapentin and pregabalin use and misuse : Results of a population-based cohort study in France. Br J Clin Pharmacol. 2019 ;6:1260-1269.

Jouanjus E, Lapeyre-Mestre M, Nodot M, Roussin A, Franchitto N, Boyes JP, Nasr N, Oustric S, Dupouy J. Teaching Basic Knowledge on Substance Use Disorders : the Impact of e-Learning on Health Professionals. Clin Ther. 2019 ;41:2154-2161.

Jouanjus E, Micallef J, Mallaret M, Lapeyre-Mestre M. Comment on : An Insight Into Z-Drug Abuse and Dependence : An Examination of Reports to the European Medicines Agency Database of Suspected Adverse Drug Reactions. Int J Neuropsychopharmacol. 2019 ;22:528-530.

Jouanjus E, Goyal H. Editorial commentary : Cardiovascular complications of cannabis use. Trends Cardiovasc Med. 2019 ;29:408-409.

Micallef J, Jouanjus E, Mallaret M, Lapeyre Mestre M. Safety signal detection by the French Addictovigilance Network : Innovativemethods of investigation, examples and usefulness for public health.Therapie. 2019 ;74:579-590.

Ponté C, Giron A, Crequy M, Lapeyre-Mestre M, Fabre N, Salles J. Cluster Headache in Subjects With Substance Use Disorder : A Case Series and a Review of the Literature. Headache. 2019 ;59:576-589.

Roussin A, Roche G, Delage N, Chenaf C, Cantagrel N, Authier N. Réseau français des centres d’addictovigilance. Weak Opioids Withdrawal Strategies : a Comparative Study between Pain and Addiction Physicians. Douleur analg. 2019 ;32:99-104.

PHARMACOLOGIE FONDAMENTALE

Besnier F, Labrunée M, Richard L, Faggianelli F, Kerros H, Soukarié L, Bousquet M, Garcia JL, Pathak A, Gales C, Guiraud T, Sénard JM. Short-term effects of a 3-week interval training program on heart rate variability in chronic heart failure. A randomised controlled trial.Ann Phys Rehabil Med. 2019 ;62:321-328.

Blanc C, Viguier A, Calviere L, Planton M, Albucher JF, Rousseau V, Sommet A, Bonneville F, Pariente J, Olivot JM, Raposo JN. Underlying small vessel disease associated with mixed cerebral microbleeds. Front Neurol. 2019 ;10:1126.

Franchini DM, Lanvin O, Tosolini M, Patras de Campaigno E, Cammas A, Péricart S, Scarlata CM, Lebras M, Rossi C, Ligat L, Pont F, Arimondo PB, Laurent C, Ayyoub M, Despas F, Lapeyre-Mestre M, Millevoi S, Fournié JJ. Microtubule-Driven Stress Granule Dynamics Regulate Inhibitory Immune Checkpoint Expression in T Cells. Cell Rep. 2019 ;26:94-107.

Garcia C, Maurel-Ribes A, Nauze M, N’Guyen D, Martinez LO, Payrastre B, Sénard JM, Galés C, Pons V. Deciphering biased inverse agonism of cangrelor and ticagrelor at P2Y12 receptor. Cell Mol Life Sci. 2019 ;76:561-576.

Guilbeau-Frugier C, Cauquil M, Karsenty C, Lairez O, Dambrin C, Payré B, Cassard H, Josse C, Seguelas MH, Allart S, Branchereau M, Heymes C, Mandel F, Delisle MB, Pathak A, Dague E, Sénard JM, Galés C. Structural evidence for a new elaborate 3D-organization of the cardiomyocyte lateral membrane in adult mammalian cardiac tissues. Cardiovasc Res. 2019 ;115:1078-1091.

Kermorgant M, Ben Salem J, Santelli J, Calise D, Oster AC, Lairez O, Coudret C, Verelst M, Gales C, Sénard JM, Beaudry F, Pavy-Le Traon A, Roux C, Mauricot R, Arvanitis DN. Evaluation of upconverting nanoparticles towards heart theranostics. PLoS One. 2019 ;14:e0225729.

Kermorgant M, Nasr N, Custaud MA, Navasiolava N, Arbeille P, Guinet P, Labrunée M, Besnier F, Arvanitis DN, Czosnyka M, Senard JM, Pavy-Le Traon A. Effects of Resistance Exercise and Nutritional Supplementation on Dynamic Cerebral Autoregulation in Head-Down Bed Rest. Front Physiol. 2019 ;10:1114.

Retour en haut de page

ANNEE 2018

Publié le 06/02/2019 à 12h16 (mis à jour le 25/10/2022 à 11h21)

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Bagheri H. Médicament et cicatrisation. Revue Francophone de cicatrisation. 2018 ;2:22-25.

Béné J, Rousselin C, Bagheri H, Vial T, Gautier S, Lambert M. Nonhemorrhagic joint disorders and vitamin K antagonists : an under-recognized adverse drug reaction ?. Fundam Clin Pharmacol. 2018 ;32:663-668.

Bories P, Lamy S, Simand C, Bertoli S, Delpierre C, Malak S, Fornecker L, Moreau S, Récher C, Nebout A. Physician uncertainty aversion impacts medical decision making for older patients with acute myeloid leukemia : results of a national survey. Haematologica. 2018 ;103:2040-2048.

Bouquet É, Star K, Jonville-Béra AP, Durrieu G. Pharmacovigilance in pediatrics.Therapie. 2018 ;73:171-180.

Comont T, Moulis G, Delavigne K, Cougoul P, Parant O, Guyard-Boileau B, Derumeaux H, Adoue D, Beyne-Rauzy O. Re : Severe Primary Autoimmune Thrombocytopenia (ITP) in Pregnancy : a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study. BJOG. 2018 ;125:629-630.

Cool C, Cestac P, McCambridge C, Rouch L, de Souto Barreto P, Rolland Y, Lapeyre-Mestre M. Reducing potentially inappropriate drug prescribing in nursing home residents : effectiveness of a geriatric intervention. Br J Clin Pharmacol. 2018 ;84:1598-1610.

Couderc S, Lapeyre-Mestre M, Bourrel R, Carle P, Montastruc JL, Sommet A. Infectious risk of biological drugs versus traditional systemic treatments in moderate to severe psoriasis : a cohort analysis in the French insurance database. Fundam Clin Pharmacol. 2018 ;32:436-449.

Defer G, Le Caignec F, Fedrizzi S, Montastruc F, Chevanne D, Parienti JJ, Peyro-Saint-Paul L. Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study) : study protocol for a randomized controlled trial.Trials. 2018 ;19:174.

Diaz H, Bagheri H, Palmaro A, Rousseau V, Bourrel R, Montastruc JL, Birebent J. Patterns of direct oral anticoagulant drug prescription in France in 2010-2013 : a study in the Midi-Pyrénées area. Eur J Clin Pharmacol. 2018 ;74:945-951.

Driot D, Figuet L, Birebent J, Coste S, Durrieu G, Jacquot J, Bismuth M. Satisfaction of a pharmacovigilance declaration support network in general practice. Therapie. 2018 ;73:483-493.

Durrieu G, Maupiler M, Rousseau V, Chebane L, Montastruc F, Bondon-Guitton E, Montastruc JL. Frequency and Nature of Adverse Drug Reactions Due to Non-Prescription Drugs in Children : A Retrospective Analysis from the French Pharmacovigilance Database. Paediatr Drugs. 2018 ;20:81-87.

Essilini A, Comont T, Germain J, Brun N, Dingremont C, Castel B, Arista S, Madaule S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D, Moulis G ; CARMEN investigators group. Pretreatment with standard-dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (ITP). Eur J Haematol. 2018 ;100:412-418.

Fuzier R, Serres I, Bourrel R, Palmaro A, Lapeyre-Mestre M. Analgesic Drug Prescription After Carpal Tunnel Surgery : A Pharmacoepidemiological Study Investigating Postoperative Pain. Reg Anesth Pain Med. 2018 ;43:19-24.

Garnier C, Ribes D, Chauveau D, Huart A, Pugnet G, Adoue D, Prevot G, Alric L, Delobel P, Derumeaux H, Mengelle C, Sailler L, Moulis G. Zoster after Cyclophosphamide for Systemic Lupus Erythematosus or Vasculitis : Incidence, Risk Factors, and Effect of Antiviral Prophylaxis. J Rheumatol. 2018 ;45:1541-1548.

Guillaume M, Christol C, Plessier A, Corbic M, Péron JM, Sommet A, Rautou PE, Consigny Y, Vinel JP, Valla CD, Bureau C. Bleeding risk of variceal band ligation in extrahepatic portal vein obstruction is not increased by oral anticoagulation. Eur J Gastroenterol Hepatol. 2018 ;30:563-568.

Kaguelidou F, Sommet A, Lapeyre-Mestre M. Use of French healthcare insurance databases in pediatric pharmacoepidemiology. Therapie. 2018 ;73:127-133.

Kaguelidou F, Kassai Koupai B, Durrieu G. Pediatric pharmacology.Therapie. 2018 ;73:111-112.

Khouri C, Lepelley M, Roustit M, Montastruc F, Humbert M, Cracowski JL. Comparative safety of drugs targeting the nitric oxide pathway in pulmonary hypertension : a mixed approach combining a meta-analysis of clinical trials and a disproportionality analysis from the WHO pharmacovigilance database. Chest. 2018 ;154:136-147.

Lafaurie M, Pochard L, Lotiron C, Molinier L, Lapeyre-Mestre M, Jouanjus E. Identification of Somatic Disorders Related to Psychoactive Drug Use from an Inpatient Database in a French University Hospital. Clin Drug Investig. 2018 ;38:977-982.

Mahé J, de Campaigno EP, Chené AL, Montastruc JL, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors : Identification of suspicious targets by disproportionality analysis from VigiBase. Br J Clin Pharmacol. 2018 ;84:2373-2383.

Montastruc F. Intérêt de la pharmaco-épidémiologie dans l’évaluation des médicaments antipsychotiques. Lettre du Pharmacologue. 23018 ;32 :116-119.

Montastruc F, Bénard-Laribière A, Noize P, Pambrun E, Diaz-Bazin F, Tournier M, Bégaud B, Pariente A. Antipsychotics use : 2006-2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol. 2018 ;74:619-626.

Montastruc F, Benevent J, Touafchia A, Chebane L, Araujo M, Guitton-Bondon E, Durrieu G, Arbus C, Schmitt L, Begaud B, Montastruc JL. Atropinic (Anticholinergic) Burden in Antipsychotic-Treated Patients. Fundam Clin Pharmacol. 2018 ;32:114-119.

Montastruc F, Bagheri H, Lacroix I, Damase-Michel C, Chebane L, Rousseau V, Jouanjus E, Lapeyre-Mestre M, Durrieu G, Montastruc JL. Adverse Drug Reaction Reports Received Through the Mobile App, VigiBIP® : A Comparison with Classical Methods of Reporting. Drug Saf. 2018 ;41:511-514.

Montastruc F, Benevent J, Chebane L, Rousseau V, Durrieu G, Sommet A, Montastruc JL. Vomiting and constipation associated with tramadol and codeine : a comparative study in VigiBase®. Eur J Clin Pharmacol. 2018 ;74:1673-1674.

Montastruc F, Khosrow-Khavar F, de Germay S, Renoux C, Rousseau V, Durrieu G, Montastruc M, Rascol O, Sommet A, Lapeyre-Mestre M, Benevent J, Montastruc JL. Tamoxifen and the risk of Parkinsonism : a case/non-case study. Eur J Clin Pharmacol. 2018 ;74:1181-1184.

Montastruc F, Loo SY, Renoux C. Trends in First Gabapentin and Pregabalin Prescriptions in Primary Care in the United Kingdom, 1993-2017. JAMA. 2018 ;320:2149-2151.

Moulis F, Rousseau V, Chebane L, Gouverneur A, Gaboriau L, Faillie JL, Durrieu G, Montastruc F, Montastruc JL. Serious adverse drug reactions with sacubitril/valsartan Entresto® : a French pharmacovigilance survey. Eur J Clin Pharmacol. 2018 ;74:983-84.

Moulis F, Durrieu G, Masmoudi K, Gervoise Boyer M, Rocher F, Montastruc F, Montastruc JL. Medication errors with tramadol drops in children. Eur J Clin Pharmacol. 2018 ;74:247-248.

Moulis F, Durrieu G, Lapeyre-Mestre M. Off-label and unlicensed drug use in children population. Therapie. 2018 ;73:135-149.

Moulis G, Christiansen CF, Darvalics B, Nørgaard M. Prevalence of thrombocytopenia and thrombocytosis upon acute hospital admission to internal medicine units. A cross-sectional study in Denmark. Eur J Intern Med. 2018 ;57:e34-e37.

Moulis G, Germain J, Comont T, Arrouy A, Lapeyre-Mestre M, Adoue D ; CARMEN investigators group. Cardiovascular risk factors in immune thrombocytopenia adults : Results from the CARMEN registry. Am J Hematol. 2018 ;93:E181-E184.

Moulis G, Ibañez B, Palmaro A, Aizpuru F, Millan E, Lapeyre-Mestre M, Sailler L, Cambra K. Cross-national health care database utilization between Spain and France : results from the EPICHRONIC study assessing the prevalence of type 2 diabetes mellitus. Clin Epidemiol. 2018 ;10:863-874.

Mounié M, Costa N, Gauthier M, Palmaro A, Delpierre C, Despas F, Lapeyre-Mestre M, Laurent G, Savy N, Molinier L. Cost evaluation of Chronic Myeloid Leukemia (CML) management in Midi-Pyrenees region : economic impact of different Tyrosine Kinase Inhibitors. JGEM. 2018 ;36:109-122.

Mounié M, Costa N, Sailler L, Lapeyre-Mestre M, Bourrel R, Savy N, Molinier L, Pugnet G. Incremental Costs in Giant Cell Arteritis. Arthritis Care Res (Hoboken). 2018 ;70:1074-1081.

Nguyen TTH, Roussin A, Rousseau V, Montastruc JL, Montastruc F. Role of Serotonin Transporter in Antidepressant-Induced Diabetes Mellitus : A Pharmacoepidemiological-Pharmacodynamic Study in VigiBase. Drug Saf. 2018 ;41:1087-1096.

Nguyen KD, Bagheri B, Bagheri H. Drug-induced bone loss : a major safety concern in Europe. Expert Opin Drug Saf. 2018 ;17:1005-1014.

Nguyen KD, Nguyen PT, Nguyen HA, Roussin A, Montastruc JL, Bagheri H, Olsson S. Overview of Pharmacovigilance System in Vietnam : Lessons Learned in a Resource-Restricted Country. Drug Saf. 2018 ;41:151-159.

Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Correction to : Drug-Induced Dental Caries : A Disproportionality Analysis Using Data from VigiBase. Drug Saf. 2018 ;41:827.

Perez C, Olivier P, Lortal B, Duranton S, Montastruc JL, Colin AL, Toulza E, Becker M, Hamy L, Crepin S, Roussillon C, Gimbert A, Petitpain N, Salvo F. Detection of drug safety signals from clinical trials data : Role of SUSARs. Pharmacol Res. 2018 ;131:218-223.

Petitpain N, Argoullon L, Masmoudi K, Fedrizzi S, Cottin J, Latarche C, Mertes PM, Gillet P ; French Network of Regional Pharmacovigilance Centres. Neuromuscular blocking agents induced anaphylaxis : Results and trends of a French pharmacovigilance survey from 2000 to 2012. Allergy. 2018 ;73:2224-2233.

Piel-Julian ML, Mahévas M, Germain J, Languille L, Comont T, Lapeyre-Mestre M, Payrastre B, Beyne-Rauzy O, Michel M, Godeau B, Adoue D, Moulis G ; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. J Thromb Haemost. 2018 ;16:1830-1842.

Piel-Julian ML, Moulis G, Fournier P, Dupont R, Geiger D, Astudillo L, Faurie T, Pozzo J, Petermann A, Lairez O, Pugnet G, Sailler L. Early use of anakinra in adult-onset Still’s disease myocarditis. Scand J Rheumatol. 2018 ;47:511-512.

Prat M, Derumeaux H, Sailler L, Lapeyre-Mestre M, Moulis G. Positive predictive values of peripheral arterial and venous thrombosis codes in French hospital database. Fundam Clin Pharmacol. 2018 ;32:108-113.

Revet A, Montastruc F, Raynaud JP, MD, Baricault B, Montastruc JL, Maryse Lapeyre-Mestre M. Trends and Patterns of Antidepressant Use in French Children and Adolescents From 2009 to 2016. A Population-Based Study in the French Health Insurance Database. Journal of Clinical Psychopharmacology. 2018 ;38:327-335.

Reynolds E, Guénette L, Lexchin J, Cassels A, Wilkes MS, Durrieu G, Beaulieu MD, Mintzes B. Reconciling a "pleasant exchange" with evidence of information bias : A three-country study on pharmaceutical sales visits in primary care. Health Policy. 2018 ;122:250-255.

Rioufol C, Lamy S, Conte C, Jeanneau P, Compaci G, Delpierre C, Lapeyre-Mestre M, Laurent G, Despas F. Non-cancer drug consumption during the early trajectory of lymphoma survivorship. Therapie. 2018 ;73:307-317.

Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, Sommet A. Generic antiretroviral drug use in HIV-infected patients : A cohort study from the French health insurance database. Therapie. 2018 ;73:257-266.

Rwagitinywaa J, Sommet A, Palmaro A, Montastruc JL, Lapeyre-Mestre M. Utilization and costs of HIV antiretroviral drugs in Europe during thelast ten years : Impact of generic antiretroviral drugs on cost reduction. Health Policy. 2018 ;122:237-242.

Rwagitinywa J, Lapeyre-Mestre M, Bourrel R, Montastruc JL, Sommet A. Comparison of adherence to generic multi-tablet regimens versus brand multi-tablet and brand single-tablet regimens likely to incorporate generic antiretroviral drugs by breaking or not fixed-dose combinations in HIV-infected patients. Fundam Clin Pharmacol. 2018 ;32:450-458.

Wadelius M, Eriksson N, Kreutz R, Bondon-Guitton E, Ibañez L, Carvajal A, Lucena MI, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Kohnke H, Yue QY, Magnusson PKE, Bengtsson M, Hallberg P ; EuDAC. Sulfasalazine-induced agranulocytosis is associated with the human leukocyte antigen locus. Clin Pharmacol Ther. 2018 ;103:843-853.

PHARMACOLOGIE CLINIQUE

Antonini A, Tinazzi M, Abbruzzese G, Berardelli A, Chaudhuri KR, Defazio G, Ferreira J, Martinez-Martin P, Trenkwalder C, Rascol O. Pain in Parkinson’s disease : facts and uncertainties. Eur J Neurol. 2018 ;25:917-924.

Bagheri H, Sohrabi B, Salarian S, Bagheri B. Lipoglycopeptide antibiotics : reliable fighters against gram-positive pathogens. Arch Clin Infect Dis. 2018 ;13:e59526.

Blanchet PJ, Brefel-Courbon C. Chronic pain and pain processing in Parkinson’s disease. Prog Neuropsychopharmacol Biol Psychiatry. 2018 ;87:200-206.

Borm CDJM, Krismer F, Wenning GK, Seppi K, Poewe W, Pellecchia MT, Barone P, Johnsen EL, Østergaard K, Gurevich T, Djaldetti R, Sambati L, Cortelli P, Petrović I, Kostić VS, Brožová H, Růžička E, Marti MJ, Tolosa E, Canesi M, Post B, Nonnekes J, Bloem BR, Rascol O ; European MSA Study Group (EMSA-SG). Axial motor clues to identify atypical parkinsonism : A multicentre European cohort study. Parkinsonism Relat Disord. 2018 ;56:33-40.

Charvin D, Medori R, Hauser RA, Rascol O. Therapeutic strategies for Parkinson disease : beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 ;17:804-822.

Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC ; BADGE-PD study group. Suggestive association between OPRM1 and impulse control disorders in Parkinson’s disease. Mov Disord. 2018 ;33:1878-1886.

Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A ; DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 ;91:e189-e201.

Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C ; PARKMIP group. Cognitive complaint in early Parkinson’s disease : A pilot study. Acta Neurol Scand. 2018 ;137:59-66.

Fabbri M, Ferreira JJ, Lees A, Stocchi F, Poewe W, Tolosa E, Rascol O. Opicapone for the treatment of Parkinson’s disease : A review of a new licensed medicine. Mov Disord. 2018 ;33:1528-1539.

Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P. Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. 2018 ;90:e1849-e1857.

Gourdy P, Cazals L, Thalamas C, Sommet A, Calvas F, Galitzky M, Vinel C, Dray C, Hanaire H, Castan-Laurell I, Valet P. Apelin administration improves insulin sensitivity in overweight men during hyperinsulinaemic-euglycaemic clamp. Diabetes Obes Metab. 2018 ;20:157-164.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Spivey K, Vel S, Staines H, Lees A. Apomorphine subcutaneous infusion in patients with Parkinson’s disease with persistent motor fluctuations (TOLEDO) : a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018 ;17:749-759.

Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P ; EARLYSTIM study group. Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson’s disease with early motor complications (EARLYSTIM trial) : secondary analysis of an open-label randomised trial. Lancet Neurol. 2018 ;17:223-231.

Massabeau C, Khalifa J, Filleron T, Modesto A, Bigay-Gamé L, Plat G, Dierickx L, Aziza R, Rouquette I, Gomez-Roca C, Mounier M, Delord JP, Toulas C, Olivier P, Chatelut E, Mazières J, Cohen-Jonathan Moyal E. Continuous Infusion of Cilengitide Plus Chemoradiotherapy for Patients With Stage III Non-Small-cell Lung Cancer : A Phase I Study. Clin Lung Cancer. 2018 ;19:e277-e285.

Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D. FAIRPARK-II study group. Iron as a therapeutic target for Parkinson’s disease. Mov Disord. 2018 ;33:568-574.

Moulis G, Pugnet G, Costedoat-Chalumeau N, Mathian A, Leroux G, Boutémy J, Espitia O, Bouillet L, Berthier S, Gaultier JB, Jeandel PY, Konaté A, Mékinian A, Solau-Gervais E, Terrier B, Wendling D, Andry F, Garnier C, Cathébras P, Arnaud L, Palmaro A, Cacoub P, Amoura Z, Piette JC, Arlet P, Lapeyre-Mestre M, Sailler L. Efficacy and safety of biologics in relapsing polychondritis : a French national multicentre study. Ann Rheum Dis. 2018 ;77:1172-1178.

Ory-Magne F, Pellaprat J, Harroch E, Galitzsky M, Rousseau V, Pavy-Le Traon A, Rascol O, Gerdelat A, Brefel-Courbon C. Abnormal pain perception in patients with Multiple System Atrophy. Parkinsonism Relat Disord. 2018 ;48:28-33.

Pavy-LeTraon A, Brefel-Courbon C, Dupouy J, Ory-Magne F, Rascol O, Senard JM. Combined cardiovascular and sweating autonomic testing to differentiate multiple system atrophy from Parkinson’s disease. Neurophysiol Clin. 2018 ;48:103-110.

Pavy-Le Traon A, Cotterill N, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Tison F, Wenning GK, Goetz CG, Poewe W, Sampaio C, Schrag A, Rascol O, Martinez-Martin P, Stebbins GT ; Members of the MDS Committee on Rating Scales Development. Clinical Rating Scales for Urinary Symptoms in Parkinson Disease : Critique and Recommendations. Mov Disord Clin Pract. 2018 ;5:479-491.

Péran P, Barbagallo G, Nemmi F, Sierra M, Galitzky M, Traon AP, Payoux P, Meissner WG, Rascol O. MRI supervised and unsupervised classification of Parkinson’s disease and multiple system atrophy. Mov Disord. 2018 ;33:600-608.

Perez-Lloret S, Rascol O. Efficacy and safety of amantadine for the treatment of L-DOPA-induced dyskinesia. J Neural Transm (Vienna). 2018 ;125:1237-1250.

Schrag A, Khan K, Hotham S, Merritt R, Rascol O, Graham L. Experience of care for Parkinson’s disease in European countries : a survey by the European Parkinson’s Disease Association. Eur J Neurol. 2018 ;25:1410-1416.

Tesson C, Brefel-Courbon C, Corvol JC, Lesage S, Brice A ; French Parkinson’s Disease Genetics Study Group. LRP10 in α-synucleinopathies. Lancet Neurol. 2018 ;17:1034.

Thobois S, Brefel-Courbon C, Le Bars D, Sgambato-Faure V. Molecular Imaging of Opioid System in Idiopathic Parkinson’s Disease. Int Rev Neurobiol. 2018 ;141:275-303. Walsh RR, Krismer F, Galpern WR, Wenning GK, Low PA, Halliday G, Koroshetz WJ, Holton J, Quinn NP, Rascol O, Shaw LM, Eidelberg D, Bower P, Cummings JL, Abler V, Biedenharn J, Bitan G, Brooks DJ, Brundin P, Fernandez H, Fortier P, Freeman R, Gasser T, Hewitt A, Höglinger GU, Huentelman MJ, Jensen PH, Jeromin A, Kang UJ, Kaufmann H, Kellerman L, Khurana V, Klockgether T, Kim WS, Langer C, LeWitt P, Masliah E, Meissner W, Melki R, Ostrowitzki S, Piantadosi S, Poewe W, Robertson D, Roemer C, Schenk D, Schlossmacher M, Schmahmann JD, Seppi K, Shih L, Siderowf A, Stebbins GT, Stefanova N, Tsuji S, Sutton S, Zhang J. Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting. Neurology. 2018 ;90:74-82.

PHARMACOLOGIE DE LA REPRODUCTION

Bénard-Laribière A, Pambrun E, Sutter-Dallay AL, Gautier S, Hurault-Delarue C, Damase-Michel C, Lacroix I, Bégaud B, Pariente A. Patterns of antidepressant use during pregnancy : a nationwide population-based cohort study. Br J Clin Pharmacol. 2018 ;84:1764-1775.

Danet C, Araujo M, Bos-Thompson MA, Portolan G, Gautier S, Vanlemmens L, Bonenfant S, Jonville-Béra AP, Cottin J, Vial T, Bavoux F, Montastruc JL, Damase-Michel C, Benevent J, Bourgeois-Mondon I, Lacroix I. Pregnancy outcomes in women exposed to cancer chemotherapy. Pharmacoepidemiol Drug Saf. 2018 ;27:1302-1308.

Foch C, Araujo M, Weckel A, Damase-Michel C, Montastruc JL, Benevent J, Durrieu G, Lacroix I. In utero drug exposure and hearing impairment in 2-year-old children A case-control study using the EFEMERIS database. Int J Pediatr Otorhinolaryngol. 2018 ;113:192-197.

ADDICTOVIGILANCE

Daveluy A, Sauvaget L, Bastien A, Lapeyre-Mestre M, Collin C, Richard N, Haramburu F. Tamper-resistant prescription forms for narcotics in France : Should we generalize them ?. Fundam Clin Pharmacol. 2018 ;32:571-577.

Gentile G, Jego M, Spadari M, Griffiths K, Jouanjus E, Micallef J. Identification and tracking of Addictovigilance signals in general practice : which interactions between the general practitioners and the French Addictovigilance Network ?. Fundam Clin Pharmacol. 2018 ;32:643–651.

Jouanjus E, Guernec G, Lapeyre-Mestre M ; French Addictovigilance Network. Medical prescriptions falsified by the patients : a 12-year national monitoring to assess prescription drug diversion. Fundam Clin Pharmacol. 2018 ;32:306-322.

Jouanjus E, Falcou A, Deheul S, Roussin A, Lapeyre-Mestre M. Detecting the diverted use of psychoactive drugs by adolescents and young adults : A pilot study. Pharmacoepidemiol Drug Saf. 2018 ;27:1286-1292.

Lapeyre-Mestre M. Identification and tracking of addictovigilance signals in general practice : which interactions between the general practitioners and the French addictovigilance network ?. Fundam Clin Pharmacol.2018 ;32:641-642

Micallef J, Dupouey J, Jouve E, Truillet R, Lacarelle B, Taillard J, Daurat A, Authié C, Blin O, Rascol O, Philip P, Mestre D. Cannabis smoking impairs driving performance on the simulator and real driving : a randomized, double-blind, placebo-controlled, crossover trial. Fundam Clin Pharmacol. 2018 ;32:558-570.

Pochard L, Dupouy J, Frauger E, Giocanti A, Micallef J, Lapeyre-Mestre M ; French Addictovigilance Network. Impact of pregnancy on psychoactive substance use among women with substance use disorders recruited in addiction specialized care centers in France. Fundam Clin Pharmacol. 2018 ;32:188-197.

Ponté C, Lepelley M, Boucherie Q, Mallaret M, Lapeyre Mestre M, Pradel V, Micallef J. Doctor shopping of opioid analgesics relative to benzodiazepines : A pharmacoepidemiological study among 11.7 million inhabitants in the French countries. Drug Alcohol Depend. 2018 ;187:88-94.

PHARMACOLOGIE FONDAMENTALE

Smolyakov G, Dague E, Roux C, Seguelas MH, Galés C, Senard JM, Arvanitis DN. Nanoscale structural mapping as a measure of maturation in the murine frontal cortex. Brain Struct Funct. 2018 ;223:255-265.

INFORMATIONS SUR LE MEDICAMENT

Bouhanick B, Doucet J, Zulfigar AA, Arcani R, Daumas A, Villani P, Trouvin AP, Perrot S, Benevent J, Montastruc JL, Orlikowski D, Puigrenier S, Yelnik C, Lambert M. Principe du bon usage du médicament et des thérapeutiques non médicamenteuses. La Revue du praticien (item 318). 2018 ;68:e383-e392.

Bouvenot G, Sassard J, Montastruc JL. Pour une utilisation optimale des associations fixes de médicaments. Recommandations de prescription. Bull. Acad. Natle Méd. 2017 ;201:41-44.

El Chaer G, Lapeyre Mestre M. Tramadol : la crise des opioïdes de l’Afrique. Revue Prescrire. 2018 ;418:631.

Montastruc JL. « I have a dream ». Prescrire. 2018 ;38:419.

Revet A, Yrondi A, Montastruc F. Règles de bon usage des benzodiazépines. Presse Med. 2018 ;47:872-877.

Vorspan F, Barré T, Pariente A, Montastruc F, Tournier M. Should the duration of treatment be limited using benzodiazepines ? Presse Med. 2018 ;47:892-898.

DIVERS

Colineaux H, Le Querrec F, Pourcel L, Gallart JC, Azéma O, Lang T, Kelly-Irving M, Charpentier S, Lamy S. Is the use of emergency departments socially patterned ? Int J Public Health. 2018 ;63:397-407.

Massip C, Guet-Revillet H, Grare M, Sommet A, Dubois D. Enhanced culture recovery of Campylobacter with modified Cary-Blair medium : A practical field experience. J Microbiol Methods. 2018 ;149:53-54.

Moulis G, Lapeyre-Mestre M. Score de propension : intérêts, utilisation et limites. Un guide pratique pour le clinicien. Rev Med Interne.2018 ;39:805-812.

Vaysse C, Chantalat E, Beyne-Rauzy O, Morineau L, Despas F, Bachaud JM, Caunes N, Poublanc M, Serrano E, Bugat R, Rougé Bugat ME, Fize AL. The Impact of a Small Private Online Course as a New Approach to Teaching Oncology : Development and Evaluation. JMIR Med Educ. 2018 ;4:e6.

Verga-Gérard A, Afonso M, Bénard A , Chapron A, Chau K, Doussiet E, Guillemin F, Guillo S, Gonthier D, Lafarge S, Lapeyre-Mestre M, Oriol M , Tubach F. Le groupe Soins primaires du réseau Recherche en épidémiologie clinique et en santé publique (RECaP) ; Le groupe Soins primaires du réseau Recherche en épidémiologie clinique et en santé publique (RECaP). Primary care : A definition of the field to develop research.Rev Epidemiol Sante Publique. 2018 ;66:157-162.

Raposo N, Calviere L, Cazzola V, Planton M, Patsoura S, Wargny M, Albucher JF, Sommet A, Olivot JM, Chollet F, Pariente J, Bonneville F, Viguier A. Cortical superficial siderosis and acute convexity subarachnoid hemorrhage in cerebral amyloid angiopathy. Eur J Neurol. 2018 ;25:253-259.

Struhal W, Thijs RD, Pavy-Le Traon A, Wenning G, Senard JM. In memoriam : Sir Roger Bannister 1929-2018. Clin Auton Res. 2018 ;28:351.

Piel-Julian ML, Moulis G, Doumerc N, Seguin P, Astudillo L, Pugnet G, Sailler L. Positional paroxysmal abdominal pain. Rev Med Interne. 2018 ;39:667-668.

Retour en haut de page

ANNEE 2017

Publié le 06/03/2018 à 10h55

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Abadie D, Essilini A, Montastruc F, Fulda V, Gouraud A, Yéléhé-Okouma M, Jean-Pastor M, Montastruc JL. Drug-induced panic attacks : analysis of cases registered in the French pharmacovigilance database. J Psychiatr Res. 2017 ;90:60-66.

Allain N, Leven C, Falissard B, Allain JS, Batail JM, Polard E, Montastruc F, Drapier D, Naudet F. Manic switches induced by antidepressants : an umbrella review comparing randomized controlled trials and observational studies. Acta Psychiatr Scand. 2017 ;135:106-116.

Bondon-Guitton E, Mourgues T, Rousseau V, Cousty S, Cottin J, Drablier G, Micallef J, Montastruc JL. Gingival bleeding, a possible "serious" adverse drug reaction : An observational study in the French PharmacoVigilance Database. J Clin Periodontol. 2017 ;44:898-904.

Bounes V, Charriton-Dadone B, Levraut J, Delangue C, Carpentier F, Mary-Chalon S, Houze-Cerfon V, Sommet A, Houze-Cerfon CH, Ganetsky M. Predicting morphine related side effects in the ED : An international cohort study. Am J Emerg Med. 2017 ;35:531-535.

Cabarrot A, Montastruc JL, Chebane L, Rousseau V, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Montastruc F. Neurological and Digestive Bleeding with Direct Oral Anticoagulants versus Vitamin K Antagonists : the differences do not stop there ! A pharmacovigilance study. Pharmacol Res. 2017 ;118:119-120.

Caillet C, Sichanh C, Assemat G, Malet-Martino M, Sommet A, Bagheri H, Sengxeu N, Mongkhonmath N, Mayxay M, Syhakhang L, Lapeyre-Mestre M, Newton PN, Roussin A. Role of Medicines of Unknown Identity in Adverse Drug Reaction-Related Hospitalizations in Developing Countries : Evidence from a Cross-Sectional Study in a Teaching Hospital in the Lao People’s Democratic Republic. Drug Saf. 2017 ;40:809-821.

Casaurancq MC, Patras de Campaigno E, Ruetera M, Baricault B, Bourrel R, Lapeyre-Mestre M, Sommet A. Outpatient consumption of antibiotics with a bacterial resistance risk in 2014 in France. Therapie. 2017 ;72:593-604.

Chatelet JN, Auffret M, Combret S, Bondon-Guitton E, Lambert M, Gautier S. Hydroxychloroquine-induced hearing loss : First case of positive rechallenge and analysis of the French pharmacovigilance database. Rev Med Interne. 2017 ;38:340-343.

Couture G, Delzor F, Bagheri H, Micallef J, Ruyssen-Witrand A, Laroche M. First cases of calcium pyrophosphate deposition disease after zoledronic acid therapy. Joint Bone Spine. 2017 ;84:213-215.

Durrieu G, Jacquot J, Baudrin D, Mège M, Rousseau V, Bagheri H, Bondon-Guitton E, Abadie D, Montastruc F, Bismuth M, Oustric S, Montastruc JL. Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits. Therapie. 2016 ;72:351-355.

Faillie JL, Ferrer P, Gouverneur A, Driot D, Berkemeyer S, Vidal X, Martínez-Zapata MJ, Huerta C, Castells X, Rottenkolber M, Schmiedl S, Sabaté M, Ballarín E, Ibáñez L. A new risk of bias checklist applicable to randomized trials, observational studies, and systematic reviews was developed and validated to be used for systematic reviews focusing on drug adverse events. J Clin Epidemiol. 2017 ;86:168-175.

Falkowski S, Woillard JB, Postil D, Tubiana-Mathieu N, Terrebonne E, Pariente A, Smith D, Guimbaud R, Thalamas C, Rouguieg-Malki K, Marquet P, Picard N. Common variants in glucuronidation enzymes and membrane transporters as potential risk factors for colorectal cancer : a case control study. BMC Cancer. 2017 ;17:901.

Formoso G, Font-Pous M, Ludwig WD, Phizackerley D, Bijl D, Erviti D, Pospisilova B, Montastruc JL. Drug information by public health and regulatory institutions : results of an 8-coutry survey in Europe. Health Policy. 2017:121 ;257-264.

Fuzier R, Puel F, Izard P, Sommet A, Pierre S. Prospective cohort study assessing chronic pain in patients following minor surgery for breast cancer. J Anesth. 2017 ;31:246-254.

Gallini A, Coley N, Andrieu S, Lapeyre-Mestre M, Gardette V. Effect of dementia on receipt of influenza vaccine : a cohort study in French older adults using administrative data : 2007-2012. Fundam Clin Pharmacol. 2017 ;31:471-80.

Gautier Y, Montastruc F. Pharmacovigilance, une consultation pour les pathologies médicamenteuses. Le Moniteur des Pharm. 2017 ;3158:19.

Gicquel C, Moulis F, Chenaf C, Gouraud A, Drici M, Bondon-Guitton E, Montastruc F, Montastruc JL. Duloxetine and gingival bleeding : a case-report and reviews of the French and World PharmacoVigilance Databases and literature. Eur J Clin Pharmacol. 2017 ;73:1197-98.

Humbert X, Dolladille C, Sassier M, Valnet-Rabier MB, Vial T, Guitton E, Page A, Sole E, Auriche P, Coquerel A, Alexandre J, Fedrizzi S. Fibrates and risk of venous thromboembolism : Case/no-case study in French pharmacovigilance database. Therapie. 2017 ;72:677-682.

Linselle M, Sommet A, Bondon-Guitton E, Moulis F, Durrieu G, Benevent J, Rousseau V, Chebane L, Bagheri H, Montastruc F, Montastruc JL. Can drugs induce or aggravate Sleep Apneas ? A case non case Study in Vigibase®, the WHO Pharmacovigilance Database. Fundam Clin Pharmacol. 2017 ;31:359-366.

Mezaache S, Derumeaux H, Ferraro P, Capdepon P, Steinbach JC, Abballe X, Palas D, Saichi N, Desboeuf K, Lapeyre-Mestre M, Sailler L, Moulis G. Validation of an algorithm identifying incident primary immune thrombocytopenia in the French national health insurance database. Eur J Haematol. 2017 ;99:344-349.

Molinier A, Palmaro A, Rousseau V, Sommet A, Bourrel R, Montastruc JL, Bagheri H. Does substitution of brand name medications by generics differ between pharmacotherapeutic classes ? A population-based cohort study in France. Eur J Clin Pharmacol. 2017.73 ;471-77.

Montastruc J, Marque P, Moulis F, Bourg V, Lambert V, Durrieu G, Montastruc JL, Montastruc F. Adverse drug reactions of botulinum neurotoxin type A in children with cerebral palsy : a pharmaco-epidemiological study in VigiBase. Dev Med Child Neurol. 2017 ;59:329-334.

Montastruc JL, Durrieu G, Lacroix I, Lapeyre-Mestre M, Damase-Michel C, Bagheri H, Sommet A. Quelle Pharmacovigilance pour les vaccins ?. Bull. Acad. Natle. Mèd. Publi 2016. 2017 ;200:35.

Montastruc F, Sommet A, Montastruc JL. Concomitant medications and obstructive sleep apnoea. Br J Clin Pharmacol. 2017 ;83:2315-2316.

Montastruc F, Moulis F, Araujo M, Chebanne L, Rascol O, Montastruc JL. Ergot and non-ergot dopamine agonists and heart failure in patients with parkinson’s disease. Eur Jour Clin Phar. 2017 ;73:99-103.

Montastruc F, Benevent J, Rousseau V, Chebane L, Bondon‐Guitton E, Durrieu D, Montastruc JL, Sommet A. Statins and diabetes : Is there any difference between the different statins ?. Pharmacoepidemiol Drug Saf. 2017 ;26:1296-1297.

Moulis F, Rousseau V, Abadie D, Masmoudi K, Micallef J, Vigier C, Pierre S, Dautriche A, Montastruc F, Montastruc JL. Serious adverse drug reactions with tramadol reported to the French pharmacovigilance database between 2011 and 2015.Therapie. 2017 ;72:615-624.

Moulis G, Lapeyre-Mestre M, Adoue D, Sailler L. Epidemiology and pharmacoepidemiology of immune thrombocytopenia. French. Rev Med Interne. 2017 ;38:444-449.

Moulis G, Lapeyre-Mestre M, Palmaro A, Sailler L. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults : risk factors and vaccination effect. J Thromb Haemost. 2017 ;15:1-7.

Moulis G, Germain J, Comont T, Brun N, Dingremont C, Castel B, Arista S, Sailler L, Lapeyre-Mestre M, Beyne-Rauzy O, Godeau B, Adoue D ; CARMEN investigators group.. Newly diagnosed immune thrombocytopenia adults : clinical epidemiology, exposure to treatments and evolution. Results of the CARMEN multicenter prospective cohort. Am J Hematol. 2017 ;92:493-500.

Moulis G, Guénin S, Limal N, Michel M, Bierling P, Godeau B, Mahévas M.  Seasonal variations of incident primary immune thrombocytopenia in adults : An ecological study. Eur J Intern Med. 2017 ;37:e26-e28.

Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, Barnhart HX, Bondon-Guitton E, Hayashi PH, Bessone F, Carvajal A, Cascorbi I, Cirulli ET, Chalasani N, Conforti A, Coulthard SA, Daly MJ, Day CP, Dillon JF, Fontana RJ, Grove JI, Hallberg P, Hernández N, Ibáñez L, Kullak-Ublick GA, Laitinen T, Larrey D, Lucena MI, Maitland-van der Zee AH, Martin JH, Molokhia M, Pirmohamed M, Powell EE, Qin S, Serrano J, Stephens C, Stolz A, Wadelius M, Watkins PB, Floratos A, Shen Y, Nelson MR, Urban TJ, Daly AK ; International DILI consortium (iDILIC), Drug-induced liver injury network (DILIN) investigators and International Serious Adverse Events Consortium (iSAEC). Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-wide Association Study. Gastroenterology. 2017 ;152:1078-1089.

Nguyen TTH, Pariente A, Montastruc JL, Lapeyre-Mestre M, Rousseau V, Rascol O, Bégaud B, Montastruc F. An original pharmacoepidemiologic - pharmacodynamic method : application to antipsychotic-induced movement disorders. Br J Clin Pharmacol. 2017 ;83:612-622.

Ojero-Senard A, Benevent J, Bondon-Guitton E, Durrieu G, Chebane L, Araujo M, Montastruc F, Montastruc JL. A comparative study of QT prolongation with serotonin reuptake inhibitors. Psychopharmacology. 2017 ;234:3075-81.

Palmaro A, Boucherie Q, Dupouy J, Micallef J, Lapeyre-Mestre M. Immeasurable time bias due to hospitalization in medico-administrative databases : which impact for pharmacoepidemiological studies ?. Pharmacoepidemiol Drug Saf. 2017 ;26:544-553.

Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M. Real-life practices for preventing venous thromboembolism in multiple myeloma patients : a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf. 2017 ;26:578-586.

Palmaro A, Gauthier M, Despas F, Lapeyre-Mestre M.  Identifying cancer drug regimens in French health insurance database : An application in multiple myeloma patients. Pharmacoepidemiol Drug Saf. 2017 ;26:1492-1499.

Palmaro A, Gauthier M, Conte C, Grosclaude P, Despas F, Lapeyre-Mestre M.  Identifying multiple myeloma patients using data from the French health insurance databases : Validation using a cancer registry. Medicine (Baltimore). 2017 ;96:e6189.

Patras de Campaigno E, Kebir I, Montastruc JL, Rueter M, Maret D, Lapeyre-Mestre M, Sallerin B, Despas F. Drug-Induced Dental Caries : A Disproportionality Analysis Using Data from VigiBase. Drug Saf. 2017 ;40:1249-1258.

Patras de Campaigno E, Bondon-Guitton E, Laurent G, Montastruc F, Montastruc JL, Lapeyre-Mestre M, Despas F. Identification of Cellular targets involved in cardiac failure caused by PKI in oncology : an approach combining Pharmacovigilance and Pharmacodynamics. Br J Clin Pharmacol. 2017 ;83:1544-1555.

Récoché I, Lebaudy C, Cool C, Sourdet S, Piau A, Lapeyre-Mestre M, Vellas B, Cestac P. Potentially inappropriate prescribing in a population of frail elderly people. Int J Clin Pharm. 2017 ;39:113-119.

Severino-Freire M, Lamant L, Bagheri H, Mazereeuw-Hautier J, Paul C. Drug eruption with clomifene citrate in a bodybuilder. Ann Dermatol Venereol. 2017 ;144:636-637.

Sommet A, Lapeyre-Mestre M. Drug Use and Mortality in Parkinson Disease. J Am Med Dir Assoc. 2017 ;18:989.

Thu Trang D, Cool C, Laffon de Mazieres C, Lapeyre-Mestre M, Montastruc JL, Rascol O, Rolland Y, Sommet A. Mortality and Antipsychotic Drug Use in Elderly Patients With Parkinson Disease in Nursing Homes. J Am Med Dir Assoc. 2017 ;18:791-796.

Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P. Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study. Rev Med Interne. 2017 ;38:167-175.

PHARMACOLOGIE CLINIQUE

Bouvenot G, Sassard J, Montastruc JL. For an optimal use of fixed drug combinations. Therapie. 2017 ;72:665-668.

Castro Caldas A, Levin J, Djaldetti R, Rascol O, Wenning G, Ferreira JJ. Movement Disorders Society MSA Study Group. Critical appraisal of clinical trials in multiple system atrophy : Toward better quality. Mov Disord. 2017 ;32:1356-1364.

Chevassus H, Duchesne C, Sailly A, Vigouroux C, Foulon C, Kubiak C, Binquet C, Felin AL, Chaud P, Thalamas C, Cornu C ; QUALI-CIC. Good professional practices of French CICs - version n° 2. Therapie. 2017 ;72:525-538.

Dupouy J, Ory-Magne F, Brefel-Courbon C. Other care in Parkinson’s disease : Psychological, rehabilitation, therapeutic education and new technologies. Presse Med. 2017 ;46:225-232.

Dupouy J, Ory-Magne F, Mekies C, Rousseau V, Puel M, Rerat K, Pariente J, Brefel-Courbon C ; PARKMIP group. Cognitive complaint in early Parkinson’s disease : A pilot study. Acta Neurol Scand. 2018 ;137:59-66.

Gueyffier F, Piedbois P, Bergmann JF, the participants of Giens XXXII Round Table No. 2, Avouac B,Borel T, Boussageon R, Brun-Strang C, Braunstein D, Cazeneuve B, Diviné M, Dufour P, Girerd N, Laigle V, Le Jeunne C, Liard F, Marsot A, Montastruc JL, Trinh-Duc A, Vicaut E. How to measure the net benefit of treatment ?. Thérapie. 2017 ;72:51-61.

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P ; BIPARK-2 Study Investigators.. Opicapone as Adjunct to Levodopa Therapy in Patients With Parkinson Disease and Motor Fluctuations : A Randomized Clinical Trial. JAMA Neurol. 2017 ;74:197-206.

Lees AJ, Ferreira J, Rascol O, Reichmann H, Stocchi F, Tolosa E, Poewe W. Opicapone for the management of end-of-dose motor fluctuations in patients with Parkinson’s disease treated with L-DOPA. Expert Rev Neurother. 2017 ;17:649-659.

Montastruc JL. Comment exprimer les résultats des études cliniques. Actual Pharmacol Clin. 2017 ;109 ;12.

Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Rascol O ; of the COPARK Study Group. L-DOPA-induced dyskinesias, motor fluctuations and health-related quality of life : the COPARK survey. Eur J Neurol. 2017 ;24:1532-1538.

Ravoire S, Lang M, Perrin E ; participants of Giens XXXII Round Table No. 6. Audry A, Bilbault P, Chekroun M, Demerville L, Escudier T, Guéroult-Accolas L, Guillot C, Malbezin M, Maugendre P, Micallef J, Molimard M, Montastruc F, Pierron E, Reichardt L, Thiessard F. Advantages and limitations of online communities of patients for research on health products. Therapie. 2017 ;72:135-143.

Séverac Cauquil A, Ory-Magne F, Jardiné V, Galitzky M, Rosito M, Brefel-Courbon C, Celebrini S. Parkinson’s patients can rely on perspective cues to perceive 3D space. Brain Res. 2017 ;1663:161-165.

Stocchi F, Rascol O, Hauser RA, Huyck S, Tzontcheva A, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt DJ ; Preladenant Early Parkinson Disease Study Group. Randomized trial of preladenant, given as monotherapy, in patients with early Parkinson disease. Neurology. 2017 ;88:2198-2206.

Thibault L, Rascol O, Corvol JC, Ferreira J, Defebvre L, Deplanque D, Bordet R, Moreau C, Devos D. New perspectives on study designs for evaluating neuroprotection in Parkinson’s disease. Mov Disord. 2017 ;32:1365-1370.

Vey N, Prebet T, Thalamas C, Charbonnier A, Rey J, Kloos I, Liu E, Luan Y, Vezan R, Graef T, Recher C. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia. Leuk Lymphoma. 2017 ;58:1880-1886.

PHARMACOLOGIE DE LA REPRODUCTION

Beau AB, Tauber M, Chollet C, Hurault-Delarue C, Bouilhac C, Montastruc JL, Lacroix I, Damase-Michel C. A contemporary description of French newborns’ growth using the Efemeris cohort. Arch Pediatr. 2017 ;24:424-431.

Beau AB, Didier A, Hurault-Delarue C, Montastruc JL, Lacroix I, Damase-Michel C. Prescription of asthma medications before and during pregnancy in France : An observational drug study using the EFEMERIS database. J Asthma. 2017 ;54:258-264.

Benevent J, Montastruc F, Damase-Michel C. The importance of pharmacoepidemiology in pregnancy-implications for safety. Expert Opin Drug Saf. 2017 ;16:1181-90.

Benevent J, Bouton J, Damase-Michel C. Effets indésirables gynécologiques des anti-facteur de nécrose tumorale ; Gynaecological side effects of TNF-inhibitors. Rep Gyn End. 2017 ;19:146-52.

Graner S, Svensson T, Beau AB, Damase-Michel C, Engeland A, Furu K, Hviid A, Haberg SE, Molgaard-Nielsen D, Pasternak B, Kieler H. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations : population based European register study. BMJ. 2017 ;356:j629.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. Interest of the trajectory method for the evaluation of outcomes after in utero drug exposure : example of anxiolytics and hypnotics. Pharmacoepidemiol Drug Saf. 2017 ;26:561-569

Salgues M, Damase-Michel C, Montastruc JL, Lacroix I. Women’s knowledge of folic acid. Therapie. 2017 ;72:339-343.

ADDICTOVIGILANCE

Dupouy J, Palmaro A, Fatséas M, Auriacombe M, Micallef J, Oustric S, Lapeyre-Mestre M. Mortality Associated With Time in and Out of Buprenorphine Treatment in French Office-Based General Practice : A 7-Year Cohort Study. Ann Fam Med. 2017 ;15:355-358.

Dupouy J, Lapeyre-Mestre M, Oustric S. Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder : a commentary. Pain. 2017 ;158:6-7.

Frauger E, Pochard L, Boucherie Q, Giocanti A, Chevallier C, Daveluy A, Gibaja V, Caous AS, Eiden C, Authier N, Le Boisselier R, Guerlais M, Jouanjus É, Lepelley M, Pizzoglio V, Pain S, Richard N, Micallef J ; le Réseau français d’addictovigilance. Surveillance system on drug abuse : Interest of the French national OPPIDUM program of French addictovigilance network. Therapie. 2017 ;72:491-501.

Jouanjus E, Mallaret M, Micallef J, Ponté C, Roussin A, Lapeyre-Mestre M. Comment on : "Social Media Mining for Toxicovigilance : Automatic Monitoring of Prescription Medication Abuse from Twitter". Drug Saf. 2017 ;40:183-185.

Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is the Current Knowledge About the Cardiovascular Risk for Users of Cannabis-Based Products ? A Systematic Review. Curr Atheroscler Rep. 2017 ;19:26.

Wolff V, Jouanjus E. Strokes are possible complications of cannabinoids use. Epilepsy Behav. 2017 ;70:355-363.

Ponté C, Lapeyre-Mestre M. Psychoactive effects of ’legal high’ : About lysergic acid amide (LSA). Therapie. 2017 ;72:605-608.

Ponté C, Pi C, Palmaro A, Jouanjus E, Lapeyre-Mestre M ; French Addictovigilance Network. Early Signal of Diverted Use of Tropicamide Eye Drops in France. Br J Clin Pharmacol. 2017 ;83:1791-1800.

Rolland B, Auffret M, Labreuche J, Lapeyre-Mestre M, Dib M, Kemkem A, Grit I, Drelon M, Duhamel A, Cabe N, Vabret F, Guillin O, Baguet A, Masquelier C, Dervaux A, Deheul S, Bordet R, Carton L, Cottencin O, Jardri R, Gautier S. Phone-based safety monitoring of the first year of baclofen treatment for alcohol use disorder : the BACLOPHONE cohort study protocol. Expert Opin Drug Saf. 2017 ;16:125-132.

PHARMACOLOGIE FONDAMENTALE

Onfroy L, Galandrin S, Pontier SM, Seguelas MH, N’Guyen D, Sénard JM, Galés C. G protein stoichiometry dictates biased agonism through distinct receptor-G protein partitioning. Sci Rep. 2017 ;7:7885.

Smolyakov G, Cauquil M, Severac C, Lachaize V, Guilbeau-Frugier C, Sénard JM, Galés C, Dague E. Biophysical properties of cardiomyocyte surface explored by multiparametric AFM. J Struct Biol. 2017 ;198:28-37.

DIVERS

Besnier F, Labrunée M, Pathak A, Pavy-Le Traon A, Galès C, Sénard JM, Guiraud T. Exercise training-induced modification in autonomic nervous system : An update for cardiac patients. Ann Phys Rehabil Med. 2017 ;60:27-35.

Besnier F, Sénard JM, Grémeaux V, Riédel M, Garrigues D, Guiraud T, Labrunée M. The efficacy of transcutaneous electrical nerve stimulation on the improvement of walking distance in patients with peripheral arterial disease with intermittent claudication : study protocol for a randomised controlled trial : the TENS-PAD study. Trials. 2017 ;18:373.

Boudou N, Despas F, Van Rothem J, Lairez O, Elbaz M, Vaccaro A, Lebrin M, Pathak A, Carrié D. Direct evidence of sympathetic hyperactivity in patients with vasospastic angina. Am J Cardiovasc Dis. 2017 ;7:83-88.

Guiraud T, Labrunée M, Besnier F, Sénard JM, Pillard F, Rivière D, Richard L, Laroche D, Sanguignol F, Pathak A, Gayda M, Gremeaux V. Whole-body strength training with Huber Motion Lab and traditional strength training in cardiac rehabilitation : A randomized controlled study. Ann Phys Rehabil Med. 2017 ;60:20-26.

Retour en haut de page

ANNEE 2016

Publié le 11/04/2017 à 13h57 (mis à jour le 12/04/2017 à 10h55)

PHARMACOLOGIE FONDAMENTALE

Hijona E, Aguirre L, Pérez-Matute P, Villanueva-Millán MJ, Mosqueda-Solis A, Hasnaoui M, Nepveu F, Senard JM, Bujanda L, Aldámiz-Echevarría L, Llarena M, Andrade F, Perio P, Leboulanger F, Hijona L, Arbones-Mainar JM, Portillo MP, Carpéné C. Limited beneficial effects of piceatannol supplementation on obesity complications in the obese Zucker rat : gut microbiota, metabolic, endocrine, and cardiac aspects. J Physiol Biochem. 2016 ;72:567-82.

Galandrin S, Onfroy L, Poirot MC, Sénard JM, Galés C. Delineating biased ligand efficacy at 7TM receptors from an experimental perspective. Int J Biochem Cell Biol. 2016 ;77:251-63.

Galandrin S, Denis C, Boularan C, Marie J, M’Kadmi C, Pilette C, Dubroca C, Nicaise Y, Seguelas MH, N’Guyen D, Banères JL, Pathak A, Sénard JM, Galés C. Cardioprotective Angiotensin-(1-7) Peptide Acts as a Natural-Biased Ligand at the Angiotensin II Type 1 Receptor. Hypertension. 2016 ;68:1365-1374.

PHARMACOLOGIE CLINIQUE

Barbagallo G, Sierra-Peña M, Nemmi F, Traon AP, Meissner WG, Rascol O, Péran P. Multimodal MRI assessment of nigro-striatal pathway in multiple system atrophy and Parkinson disease. Mov Disord.2016 ;31:325-34.

Bonenfant D, Rompré PH, Rei N, Jodoin N, Soland VL, Rey V, Brefel-Courbon C, Ory-Magne F, Rascol O, Blanchet PJ. Characterization of Burning Mouth Syndrome in Patients with Parkinson’s Disease. J Oral Facial Pain Headache. 2016 ;30:318-322.

Bouvenot G, Bounhoure JP, Montastruc JL , Vacheron A. Rapport sur les anticoagulants oraux directs (AOD), (antérieurement appelés « nouveaux anticoagulants oraux » ou NACO). Bull. Acad. Natle Méd..2014 ;198:1157-1195.

Breu-Dejean N, Driot D, Dupouy J, Lapeyre-Mestre M, Rostaing L. Efficacy of Psychoeducational Intervention on Allograft Function in Kidney Transplant Patients : 10-Year Results of a Prospective Randomized Study. Exp Clin Transplant. 2016 ;14:38-44.

Canivet C, Costa N, Ory-Magne F, Arcari C, Mohara C, Pourcel L, Derumeaux H, Bérard E, Bourrel R, Molinier L, Brefel-Courbon C. Clinical Impact and Cost-Effectiveness of an Education Program for PD Patients : A Randomized Controlled Trial. PLoS One. 2016 ;11:e0162646.

Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O ; NS-Park network. French consensus procedure for assessing cognitive function in Parkinson’s disease. Rev Neurol (Paris). 2016 ;172:696-702.

Dupouy J. Study protocol of the ESUB-MG cluster randomized trial : a pragmatic trial assessing the implementation of urine drug screening in general practice for buprenorphine maintained patients. Bmc Family Practice. 2016 ;17:24.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P ; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Lancet Neurol. 2016 ;15:154-65.

Ferreira JJ, Mestre T, Guedes LC, Coelho M, Rosa MM, Santos AT, Barra M, Sampaio C, Rascol O. Espresso Coffee for the Treatment of Somnolence in Parkinson’s Disease : Results of n-of-1 Trials. Front Neurol. 2016 ;7:27.

Giroud JP, Montastruc JL. Séance thématique : La Pharmacoépidémiologie. Bull Acad Natle Med. 2015 ;199:261-62.

Lesage S, Drouet V, Majounie E, Deramecourt V, Jacoupy M, Nicolas A, Cormier-Dequaire F, Hassoun SM, Pujol C, Ciura S, Erpapazoglou Z, Usenko T, Maurage CA, Sahbatou M, Liebau S, Ding J, Bilgic B, Emre M, Erginel-Unaltuna N, Guven G, Tison F, Tranchant C, Vidailhet M, Corvol JC, Krack P, Leutenegger AL, Nalls MA, Hernandez DG, Heutink P, Gibbs JR, Hardy J, Wood NW, Gasser T, Durr A, Deleuze JF, Tazir M, Destée A, Lohmann E, Kabashi E, Singleton A, Corti O, Brice A ; French Parkinson’s Disease Genetics Study (PDG). International Parkinson’s Disease Genomics Consortium (IPDGC).. Loss of VPS13C Function in Autosomal-Recessive Parkinsonism Causes Mitochondrial Dysfunction and Increases PINK1/Parkin-Dependent Mitophagy. Am J Hum Genet. 2016 Mar 3 ;98:500-13.

Nonnekes J, Timmer MH, de Vries NM, Rascol O, Helmich RC, Bloem BR. Unmasking levodopa resistance in Parkinson’s disease. Mov Disord. 2016 ;31:1602-1609.

Pavy-Le Traon A, Piedvache A, Perez-Lloret S, Calandra-Buonaura G, Cochen-De Cock V, Colosimo C, Cortelli P, Debs R, Duerr S, Fanciulli A, Foubert-Samier A, Gerdelat A, Gurevich T, Krismer F, Poewe W, Tison F, Tranchant C, Wenning G, Rascol O, Meissner WG. European MSA Study Group. New insights into orthostatic hypotension in multiple system atrophy : a European multicentre cohort study. J Neurol Neurosurg Psychiatry. 2016 ;87:554-61.

Perez-Lloret S, Rascol O. The safety and efficacy of safinamide mesylate for the treatment of Parkinson’s disease. Expert Rev Neurother. 2016 ;16:245-58.

Perez-Lloret S, Rascol O. Piribedil for the Treatment of Motor and Non-motor Symptoms of Parkinson Disease. CNS Drugs. 2016 ;30:703-17.

Pouclet-Courtemanche H, Rouaud T, Thobois S, Nguyen JM, Brefel-Courbon C, Chereau I, Cuny E, Derost P, Eusebio A, Guehl D, Laurencin C, Mertens P, Ory-Magne F, Raoul S, Regis J, Ulla M, Witjas T, Burbaud P, Rascol O, Damier P. Long-term efficacy and tolerability of bilateral pallidal stimulation to treat tardive dyskinesia. Neurology. 2016 ;86:651-9.

Rascol O, Hauser RA, Stocchi F, Fitzer-Attas CJ, Sidi Y, Abler V, Olanow CW ; AFU Investigators.. Long-term effects of rasagiline and the natural history of treated Parkinson’s disease. Mov Disord. 2016 ;31:1489-1496.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson’s Disease-Associated Chronic Pain. J Clin Pharmacol. 2016 ;56:852-61.

Sailer A, Scholz SW, Nalls MA, Schulte C, Federoff M, Price TR, Lees A, Ross OA, Dickson DW, Mok K, Mencacci NE, Schottlaender L, Chelban V, Ling H, O’Sullivan SS, Wood NW, Traynor BJ, Ferrucci L, Federoff HJ, Mhyre TR, Morris HR, Deuschl G, Quinn N, Widner H, Albanese A, Infante J, Bhatia KP, Poewe W, Oertel W, Höglinger GU, Wüllner U, Goldwurm S, Pellecchia MT, Ferreira J, Tolosa E, Bloem BR, Rascol O, Meissner WG, Hardy JA, Revesz T, Holton JL, Gasser T, Wenning GK, Singleton AB, Houlden H ; European Multiple System Atrophy Study Group and the UK Multiple System Atrophy Study Group.. A genome-wide association study in multiple system atrophy. Neurology. 2016 ;87:1591-1598.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson’s Disease. Mov Disord. 2016 ;31:1373-80.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Mov Disord. 2016 ;31:1049-54.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE

Alberto C, Konstantinou MP, Martinage C, Casassa E, Tournier E, Bagheri H, Sibaud V, Mourey L, Mazereeuw-Hautier J, Meyer N, Paul C, Bulai Livideanu C. Enzalutamide induced acute generalized exanthematous pustulosis. J Dermatol Case Rep. 2016 ;10 : 35-38.

Audemard-Verger A, Martin Silva N, Verstuyft C, Costedoat-Chalumeau N, Hummel A, Le Guern V, Sacré K, Meyer O, Daugas E, Goujard C, Sultan A, Lobbedez T, Galicier L, Pourrat J, Le Hello C, Godin M, Morello R, Lambert M, Hachulla E, Vanhille P, Queffeulou G, Potier J, Dion JJ, Bataille P, Chauveau D, Moulis G, Farge-Bancel D, Duhaut P, Saint-Marcoux B, Deroux A, Manuzak J, Francès C, Aumaitre O, Bezanahary H, Becquemont L, Bienvenu B. Glutathione S Transferases Polymorphisms Are Independent Prognostic Factors in Lupus Nephritis Treated with Cyclophosphamide. PLoS One. 2016 ;11:e0151696.

Authier N, Binder P, Dupouy J, Di Patrizio P, Gentile G, Kahn JP, Lapeyre-Mestre M, Laporte C, Letrilliart L, Maynié C, Micallef J, Mallaret M, Oustric S, Perault-Pochat MC. MG Study Group.. Study protocol of the ESUB-MG cluster randomized trial : a pragmatic trial assessing ESUB-the implementation of urine drug screening in general practice for buprenorphine maintained patients. BMC Fam Pract. 2016 ;17:24..

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : What is the usefulness of the social networks in pharmacovigilance ?. Therapie. 2016 ;71:235-39.

Bagheri H, Lacroix I, Guitton-Bondon E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance : les réseaux sociaux sont-ils utiles en pharmacovigilance ?. Therapie. 2016 ;71:229-33.

Bagheri H, Laroche ML, Montastruc JL. Les nouveaux défis de la pharmacovigilance. Therapie. 2 016 ;71:119-20.

Bagheri H, Laroche ML, Montastruc JL. Pharmacovigilance : The new challenges. Therapie. 2016 ;71:121-22.

Béné J, Moulis G, Bennani I, Auffret M, Coupe P, Babai S, Hillaire-Buys D, Micallef J, Gautier S ; French Association of Regional PharmacoVigilance Centres. Bullous pemphigoid and dipeptidyl peptidase IV-inhibitors : A Case/Non-Case study in the French Pharmacovigilance Database. Br J Dermatol. 2016 ;175:296-301.

Bondon-Guitton E, Combret S, Pérault-Pochat MC, Stève-Dumont M, Bagheri H, Huguet F, Despas F, Pathak A, Montastruc JL. Cardiovascular risk profile of patients with peripheral arterial occlusive disease during nilotinib therapy. Target Oncol. 2016 ;11:549-552.

Bondon-Guitton E, Despas F, Becquemont L. The contribution of pharmacogenetics to pharmacovigilance. Therapie. 2016 ;71:223-28.

Bondon-Guitton E, Despas F, Becquemont L. Apport de la Pharmacogénétique à la pharmacovigilance. Therapie. 2016 ;71:217-22.

Bounhoure JP, Bouvenot G, Montastruc JL. Cardiovascular risks and nonsteroidal anti-inflammatory drugs in the elderly recommendations for prescription. Bull. Acad. Natle Méd., 2015 ;199:949-957.

Bourgeois AL, Auriche P, Palmaro A, Montastruc JL, Bagheri H. Risk of hormonotherapy in transgender people : Literature review and data from the French Database of Pharmacovigilance. Ann Endocrinol (Paris). 2016 ;77:14-21.

Cailhol L, Francois M, Thalamas C, Garrido C, Birmes P, Pourcel L, Lapeyre-Mestre M, Paris J. Is borderline personality disorder only a mental health problem ? Personal Ment Health. 2016 ;10:328-336.

De Germay S, Montastruc JL, Rousseau V, Chebane L, Bondon-Guitton E, Moulis F, Durrieu G, Bagheri H, Rascol O, Pariente A, Bégaud B, Montastruc F. Atropinic (Anticholinergic) Burden in Parkinson’s Disease. Mov Disord. 2016 ;31:632-6.

Conte C, Rueter M, Laurent G, Bourrel R, Lapeyre-Mestre M, Despas F. Psychotropic drug initiation during the first diagnosis and the active treatment phase of B cell non-Hodgkin’s lymphoma : a cohort study of the French national health insurance database. Support Care Cancer. 2016 ;24:4791-9.

Durrieu G, Jacquot J, Mège M, Bondon-Guitton E, Rousseau V, Montastruc F, Montastruc JL. Completeness of Spontaneous Adverse Drug Reaction Reports Sent by General Practitioners to a Regional Pharmacovigilance Centre : A Descriptive Study. Drug Saf. 2016 ;39:1189-1195.

Faillie JL, Hillaire-Buys D. Examples of how the pharmaceutical industries distort the evidence of drug safety : the case of pioglitazone and the bladder cancer issue. Pharmacoepidemiol Drug Saf. 2016 ;25:212-4.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. L’apport de la pharmaco-épidémiologie à la pharmacovigilance. Therapie. 2016 ;71:203-09.

Faillie JL, Montastruc F, Montastruc JL, Pariente A. Pharmacoepidemiology and its input to pharmacovigilance. Therapie. 2016 ;71:211-16.

Giroud JP, Montastruc JL. Les médicaments du rhume à base de vasoconstricteurs doivent être prescrits sur ordonnance. Bull. Acad. Natle Méd..2015 ;199:947-48.

Guinard E, Bulai Livideanu C, Barthelemy H, Viguier M, Reguiai Z, Richard MA, Jullien D, Beneton N, Bara C, Vabres P, Grandvuillemin A, Marguery MC, Amelot F, Konstantinou MP, Bagheri H, Paul C ; for the French Psoriasis Research Group. Active tuberculosis in psoriasis patients treated with TNF antagonists : a French nationwide retrospective study. JEADV. 2016 ;30:1336-41.

Hallberg P, Eriksson N, Ibañez L, Bondon-Guitton E, Kreutz R, Carvajal A, M Isabel Lucena M, Sancho Ponce E, Molokhia M, Martin J, Axelsson T, Yue QY, K E Magnusson P, Wadelius M, for the EuDAC collaborators*. Genetic variants associated with antithyroid drug-induced agranulocytosis : a genome-wide association study in a European population. Lancet Diabetes Endocrinol. 2016 ;4:507-16.

Hauviller L, Eyvrard F, Garnault V, Rousseau V, Molinier L, Montastruc JL, Bagheri H. Hospital re-admission associated with adverse drug reactions in patients over the age of 65 years. Eur J Clin Pharmacol. 2016 ;72:631-9.

Laconi S, Caihol L, Pourcel L, Thalamas C, Lapeyre-Mestre M, Chabrol H. Personnality disorders sreening with the French version of the Personality diagnostic questionnaire-4+ in a psychiatric population : A preliminary study. Ann Med Psy. 2016 ;174:39-44.

Lamy S, Bettiol C4, Grosclaude P, Compaci G, Albertus G, Récher C, Nogaro JC, Despas F, Laurent G, Delpierre C. The care center influences the management of lymphoma patients in a universal health care system : an observational cohort study. BMC Health Serv Res. 2016 ;16:336.

Lapeyre-Mestre M. Adverse effects of drugs for respiratory allergy : Is this related to chronic use of anti-H1 drugs ?. Rev. Fran. Allergol.2016 ;56:492-93.

Mauran A, Goze T, Abadie D, Bondon-Guitton E, Chevrel P, Schmitt L, Montastruc JL, Montastruc F. Mania associated to Ranitidine : a case report and review of literature. Fundam Clin Pharmacol. 2016 ;30:294-6.

Montastruc F, Montastruc G, Montastruc JL, Revet A. Cardiovascular safety of methylphenidate should also be considered in adults !. Bmj. 2016 ;353:i3418.

Montastruc JL, Sommet A, Montastruc F, Moulis G, Bagheri H, Damase-Michel M, Lapeyre-Mestre M. Qu’est-ce que la pharmacoépidémiologie. Pharmacoepidemiology : definition, methods and applications. Bull Acad Natle Med. 2015 ;199:263-73.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance : Risques et effets indésirables de l’automédication. Therapie. 2016 ;71:249-255.

Montastruc JL, Emmanuelle Bondon-Guitton E, Abadie D, Lacroix I, Berrenia A, Pugnet G, Durrieu G, Sailler L, Giroudb JP, Damase-Michel M, Montastruc F. Pharmacovigilance, risks and adverse effects of self-medication. Therapie. 2016 ;71:257-262.

Montastruc JL, Chebane L, Bagheri H. Comment on : "Drug-Induced Hyperglycaemia and Diabetes". Drug Saf. 2016 ;39:465-66.

Moulis G, Luxembourger C, Tournier E, Pugnet G, Astudillo L, Laurent G, Arlet P, Sailler L, Samson M. Asthenia and chronic joint pain in a 73-year-old woman. Rev Med Interne. 2016 ;37:292-95.

Moulis G, Audemard-Verger A, Arnaud L, Luxembourger C, Montastruc F, Gaman AM, Svenungsson E, Ruggeri M, Mahévas M, Gerfaud-Valentin M, Brainsky A, Michel M, Godeau B, Lapeyre-Mestre M, Sailler L. Risk of thrombosis in patients with primary immune thrombocytopenia and antiphospholipid antibodies : A systematic review and meta-analysis. Autoimmun Rev. 2016 ;15:203-9.

Moulis G, Germain J, Adoue D, Beyne-Rauzy O, Derumeaux H, Sailler L, Lapeyre-Mestre M. Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. Eur J Intern Med. 2016 ;32:e21-e22.

Olivier-Abbal P. Mesure de l’évitabilité des effets indésirables médicamenteux en France : état des lieux en 2015. Therapie. 2016 ;71:187-194.

Olivier-Abbal P. Measuring the preventability of adverse drug reactions in France : A 2015 overview. Therapie. 2016 ;71:195-202.

Olivier-Abbal P, Gimbert A, Colin AL, Salvo F, Becker M, Marty V, Montastruc JL, Petitpain N. Serious adverse drug events related to non-investigational drugs in academic clinical trials : another source of safety data for risk assessment ? Br J Clin Pharmacol. 2016 ;82:1069-75.

Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fund Clin Pharm. 2016 ;30:616-624.

Pugnet G, Sailler L, Fournier JP, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Predictors of Cardiovascular Hospitalization in Giant Cell Arteritis : Effect of Statin Exposure. A French Population-based Study. J Rheumatol. 2016 ;43:2162-2170.

Récoché I, Rousseau V, Bourrel R, Lapeyre-Mestre M, Chebane L, Despas F, Montastruc JL, Bondon-Guitton E. Drug-drug interactions with imatinib : An observational study. Medicine (Baltimore). 2016 ;95:e5076.

Sahli L, Lapeyre-Mestre M, Derumeaux H, Moulis G. Positive predictive values of selected hospital discharge diagnoses to identify infections responsible for hospitalization in the French national hospital database. Pharmacoepidemiol Drug Saf. 2016 ;25:785-89.

Saliba L, Moulis G, Abou Taam M, Rousseau V, Chebane L, Petitpain N, Baldin B, Pugnet G, Montastruc JL, Bagheri H. Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone : a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundam Clin Pharmacol. 2016 ;30:162-71.

Thorel J, McCambridge C, Piau A, Secher M, Magre É, Montastruc JL, Bagheri H. Proton pump inhibitors : Real indication or trivialized prescription ?. Therapie. 2016 ;71:589-93.

Tournaire G, Despas F, Huguet F, Montastruc JL, Bondon-Guitton E. Peripheral arterial occlusive disease during ponatinib therapy after failure of imatinib : a case report. J Clin Pharm Ther. 2016 ;41:360-61.

Villars H, Montastruc JL, Despas F. Medication errors and look-alike tablets : the splitting issue. Pharmacoepidemiol Drug Saf. 2016 ;25:1002-3.

MEDECINE ET REPRODUCTION

Beau AB, Montastruc JL, Lacroix I, Montastruc F, Hurault-Delarue C, Damase-Michel C. Atropinic burden of drugs during pregnancy and psychological development of children : a cohort study in the EFEMERIS database. Br J Clin Pharmacol. 2016 ;82:478-486.

Hurault-Delarue C, Chouquet C, Savy N, Lacroix I, Beau AB, Montastruc JL, Damase-Michel C. How to take into account exposure to drugs over time in pharmacoepidemiology studies of pregnant women ? Pharmacoepidemiol Drug Saf. 2016 ;25:770-77.

Hurault-Delarue C, Damase-Michel C, Finotto L, Guitard C, Vayssière C, Montastruc JL, Montastruc F, Lacroix I. Psychomotor developmental effects of prenatal exposure to psychotropic drugs : a study in EFEMERIS database. Fund Clin Pharmacol. 2016 ;30:476-482.

Lacroix I, Beau AB, Hurault-Delarue C, Bouilhac C, Petiot D, Vayssière C, Vidal S, Montastruc JL, Damase-Michel C. First epidemiological data for venotonics in pregnancy from the EFEMERIS database. Phlebology. 2016 ;31:344-8.

Montastruc F, Salvo F, Arnaud M, Bégaud B, Pariente A. Signal of Gastrointestinal Congenital Malformations with Antipsychotics After Minimising Competition Bias : A Disproportionality Analysis Using Data from Vigibase®. Drug Saf. 2016 ;39:689-96.

Palosse-Cantaloube L, Hurault-Delarue C, Beau AB, Montastruc JL, Lacroix I, Damase-Michel C. Risk of infections during the first year of life after in utero exposure to drugs acting on immunity : a population-based cohort study. Pharmacol Res. 2016 ;113:557-52.

Villeneuve C, Laroche ML, Essig M, Merville P, Kamar N, Coubret A, Lacroix I, Bouchet S, Fruit D, Marquet P, Rousseau A ; EPIGREN study group. Evolution and Determinants of Health-Related Quality-of-Life in Kidney Transplant Patients Over the First 3 Years After Transplantation. Transplantation. 2016 ;100:640-7.

ADDICTOVIGILANCE

Bossard JB, Ponté C, Dupouy J, Lapeyre-Mestre M, Jouanjus E. Disproportionality Analysis for the Assessment of Abuse and Dependence Potential of Pregabalin in the French Pharmacovigilance Database. Clin Drug Investig. 2016 ;36:735-42.

De Souto Barreto P, Lapeyre-Mestre M, Cestac P, Vellas B, Rolland Y. Effects of a geriatric intervention aiming to improve quality care in nursing homes on benzodiazepine use and discontinuation. Br J Clin Pharmacol. 2016 ;81:759-67.

Driot D, Chicoulaa B, Jouanjus E, Dupouy J, Oustric S, Lapeyre-Mestre M.  Pregabalin use disorder and secondary nicotine dependence in a woman with no substance abuse history. Therapie. 2016 ;71:575-78.

Dupouy J, Lapeyre-Mestre M, Oustric S. Psychiatric disorders as predictors of long-term opioid therapy and the need for treating chronic pain correctly in patients with prior opioid substance use disorder : a commentary. Pain. 2017 ;158:6-7.

Lapeyre-Mestre M.  A Review of Adverse Outcomes Associated with Psychoactive Drug Use in Nursing Home Residents with Dementia. Drugs Aging. 2016 ;33:865-888.

Roussin A, Palmaro A, Lapeyre-Mestre M. Weak Opioid Analgesics Abuse and Addiction : A Comparison of the Pharmacology and Pharmacoepidemiology of Codeine, Dihydrocodeine, and Tramadol. Neuropathology of Drug Addictions and Substance Misuse. 2016 ;3:375-391.

Spadari M, Batisse A, Guerlais M, Boucher A, Daveluy A, Le Boisselier R, Gibaja V, Eiden C, Lepelley M, Roussin A, Deheul S, Frauger E, Debruyne D. The current aspects of the use of ecstasy/MDMA in France. Therapie. 2016 ;71:553-562.

Retour en haut de page

ANNEE 2015

Publié le 31/03/2016 à 15h00 (mis à jour le 10/04/2017 à 11h00)

PHARMACOLOGIE FONDAMENTALE

Bellot M, Galandrin S, Boularan C, Matthies HJ, Despas F, Denis C, Javitch J, Mazères S, Sanni SJ, Pons V, Seguelas MH, Hansen JL, Pathak A, Galli A, Sénard JM, Galés C. Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling. Nat Chem Biol. 2015 ;11:271-9.

PHARMACOLOGIE CLINIQUE

Antonini A, Bauer L, Dohin E, Oertel WH, Rascol O, Reichmann H, Schmid M, Singh P, Tolosa E, Chaudhuri KR. Effects of rotigotine transdermal patch in patients with Parkinson’s disease presenting with non-motor symptoms - results of a double-blind, randomized, placebo-controlled trial. Eur J Neurol. 2015 ;22:1400-7.

Chaudhuri KR, Rizos A, Trenkwalder C, Rascol O, Pal S, Martino D, Carroll C, Paviour D, Falup-Pecurariu C, Kessel B, Silverdale M, Todorova A, Sauerbier A, Odin P, Antonini A, Martinez-Martin P ; EUROPAR and the IPMDS Non Motor PD Study Group. King’s Parkinson’s disease pain scale, the first scale for pain in PD : An international validation. Mov Disord. 2015 ;30:1623-31.

Dhainaut JF, Diebolt V, Pouletty-Lefèbvre B ; the participants of round table N°6 at Giens XXX :, Baker A, Bassompierre F, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Misse C, Molon A, Rascol O, Ravoire S, Schwartz B, Donne N, Donne N, Fusaï G, Pouletty P, Vicaut E. What Strategy Should France Implement for H2020 ? Therapie. 2015 ;70:103-109.

Dhainaut JF, Diebolt V, Pouletty-Lefèbvre B ; les participants à la table ronde N°6 de Giens XXX :, Baker A, Bassompierre F, Borel T, Braunstein D, Demotes J, François B, Huet S, Micallef J, Misse C, Molon A, Rascol O, Ravoire S, Schwartz B, Donne N, Fusaï G, Pouletty P, Vicaut E. Quelle stratégie française dans le cadre H2020 ? Therapie. 2015 ;70:95-102.

Fuzier R, Rousset J, Bataille B, Salces-y-Nédéo A, Maguès JP. One half of patients reports persistent pain three months after orthopaedic surgery. Anaesth Crit Care Pain Med. 2015 ;34:159-64.

Hauser RA, Stocchi F, Rascol O, Huyck SB, Capece R, Ho TW, Sklar P, Lines C, Michelson D, Hewitt D. Preladenant as an Adjunctive Therapy With Levodopa in Parkinson Disease : Two Randomized Clinical Trials and Lessons Learned. JAMA Neurol. 2015 ;72:1491-500.

Mahfoud F, Böhm M, Azizi M, Pathak A, Durand Zaleski I, Ewen S, Tsioufis K, Andersson B, Blankestijn PJ, Burnier M, Chatellier G, Gafoor S, Grassi G, Joner M, Kjeldsen SE, Lüscher TF, Lobo MD, Lotan C, Parati G, Redon J, Ruilope L, Sudano I, Ukena C, van Leeuwen E, Volpe M, Windecker S, Witkowski A, Wijns W, Zeller T, Schmieder RE. Proceedings from the European clinical consensus conference for renal denervation : considerations on future clinical trial design. Eur Heart J. 2015 ;36:2219-27.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D ; Parkgait-II Study Group. Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson’s disease. Brain. 2015 ;138:1271-83.

Morgan DA, Despas F, Rahmouni K. Effects of leptin on sympathetic nerve activity in conscious mice. Physiol Rep. 2015 ;3. pii : e12554.

Nemmi F, Sabatini U, Rascol O, Péran P. Parkinson’s disease and local atrophy in subcortical nuclei : insight from shape analysis. Neurobiology of Aging. 2015 ;36:424-33.

Odin P, Ray Chaudhuri K, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W ; National Steering Committees. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinson’s disease : Consensus from an international survey and discussion program. Parkinsonism Relat Disord. 2015 ;21:1133-44.

Paris A, Deygas B, Cornu C, Thalamas C, Maison P, Duale C, Kane M, Hodaj E, Cracowski JL. Improved informed consent documents for biomedical research do not increase patients’ understanding but reduce enrolment : a study in real settings. Br J Clin Pharmacol. 2015 ;80:1010-20.

Pathak A, Coleman L, Roth A, Stanley J, Bailey L, Markham P, Ewen S, Morel C, Despas F, Honton B, Senard JM, Fajadet J, Mahfoud F. Renal sympathetic nerve denervation using intraluminal ultrasound within a cooling balloon preserves the arterial wall and reduces sympathetic nerve activity. Euro Intervention. 2015 ;11:477-84.

Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, Giladi N, Barone P, Sampaio C, Eyal E, Rascol O ; for the Rasagiline-for-MSA investigators. Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy : a randomised, placebo-controlled trial. Lancet Neurol. 2015 ;14:145-52.

Rascol O, Zesiewicz T, Chaudhuri KR, Asgharnejad M, Surmann E, Dohin E, Nilius S, Bauer L. A Randomized Controlled Exploratory Pilot Study to Evaluate the Effect of Rotigotine Transdermal Patch on Parkinson’s Disease-Associated Chronic Pain. J Clin Pharmacol. 2015 ;doi : 10.1002/jcph.678.

Rascol O, Perez-Lloret S, Damier P, Delval A, Derkinderen P, Destée A, Meissner WG, Tison F, Negre-Pages L.Falls in ambulatory non-demented patients with Parkinson’s disease. J Neural Transm (Vienna). 2015 ;122:1447-55.

Rascol O, Perez-Lloret S, Ferreira JJ. New treatments for levodopa-induced motor complications. Mov Disord. 2015 ;30:1451-60.

Ratti PL, Sierra-Peña M, Manni R, Simonetta-Moreau M, Bastin J, Mace H, Rascol O, David O. Distinctive features of NREM parasomnia behaviors in parkinson’s disease and multiple system atrophy. PLoS One. 2015 ;10:e0120973.

Ratti PL, Nègre-Pagès L, Pérez-Lloret S, Manni R, Damier P, Tison F, Destée A, Rascol O. Subjective sleep dysfunction and insomnia symptoms in Parkinson’s disease : Insights from a cross-sectional evaluation of the French CoPark cohort. Parkinsonism Relat Disord. 2015 ;21:1323-9.

Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F. International validation of a behavioral scale in Parkinson’s disease without dementia. Mov Disord. 2015 ;30:705-13.

Trenkwalder C, Chaudhuri KR, Martinez-Martin P, Rascol O, Ehret R, Vališ M, Sátori M, Krygowska-Wajs A, Marti MJ, Reimer K, Oksche A, Lomax M, DeCesare J, Hopp M ; PANDA study group. Prolonged-release oxycodone-naloxone for treatment of severe pain in patients with Parkinson’s disease (PANDA) : a double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2015 ;14:1161-70.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Abadie D, Rousseau V, Logerot S, Cottin J, Montastruc JL, Montastruc F. Serotonin Syndrome : Analysis of Cases Registered in the French Pharmacovigilance Database. J Clin Psychophar. 2015 ;35:382-8.

Abadie D, Hurault-Delarue C, Damase-Michel C, Montastruc JL, Lacroix I. Medication exposure and spontaneous abortion : a case-control study using a French medical database. Clin Exp Obstet Gynecol. 2015 ;42:431-6.

Ballard C, Isaacson S, Mills R, Williams H, Corbett A, Coate B, Pahwa R, Rascol O, Burn DJ. Impact of Current Antipsychotic Medications on Comparative Mortality and Adverse Events in People With Parkinson Disease Psychosis. J Am Med Dir Assoc. 2015 ;16:898.e1-7.

Bénard-Laribière A, Miremont-Salamé G, Pérault-Pochat MC, Noize P, Haramburu F ; EMIR Study Group on behalf of the French network of pharmacovigilance centres. Incidence of hospital admissions due to adverse drug reactions in France : the EMIR study. Fundam Clin Pharmacol. 2015 ;29:106-11.

Bernard N, Jantzem H, Becker M, Pecriaux C, Bénard-Laribière A, Montastruc JL, Descotes J, Vial T ; French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition : a pharmacovigilance survey. BJOG. 2015 ;122:1244-51.

Berreni A, Montastruc F, Bondon-Guitton E, Rousseau V, Abadie D, Durrieu G, Chebane L, Giroud JP, Bagheri H, Montastruc JL. Adverse drug reactions to self-medication : a study in a pharmacovigilance database. Fundam Clin Pharmacol. 2015 Jul 28. doi : 10.1111/fcp.12140.

Borel C, Lamy S, Compaci G, Récher C, Jeanneau P, Nogaro JC, Bauvin E, Despas F, Delpierre C, Laurent G. A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma : implication for survival. BMC Cancer. 2015 ;15:288.

Brefel-Courbon C. Médicament et cognition chez le sujet âgé. Therapie. 2015 ;70:523-26.

Cailhol L, Thalamas C, Garrido C, Birmes P, Lapeyre-Mestre M. Mental health service utilization among borderline personality disorder patients inpatient. Encephale. 2015 ;41:115-122.

Caillet C, Sichanh C, Syhakhang L, Delpierre C, Manithip C, Mayxay M, Lapeyre-Mestre M, Newton PN, Roussin A. Population awareness of risks related to medicinal product use in Vientiane Capital, Lao PDR : a cross-sectional study for public health improvement in low and middle income countries. BMC. 2015 ;15:590.

Carton L, Cottencin O, Lapeyre-Mestre M, Geoffroy PA, Favre J, Simon N, Bordet R, Rolland B. Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals : A Systematic Review of Recent Prescription Trends. Curr Pharm Des. 2015 ;21:3280-97.

Chayé H, Bernard M, Tubéry M, Rousseau V, Ecoiffier M, Montastruc JL, Bagheri H. Hospital readmission induced by adverse drug reaction : A pilot study in a post-emergency unit of a French university hospital. Rev Med Interne. 2015 ;36:450-6.

Chebane L, Bagheri H, Hillaire-Buys D, Géniaux H, Yahioui N, Laroche ML, Cottin J, Spreux A, Mosquet B, Pecriaux C, Bellet F, Lambert A, Montastruc JL. Pancréatites d’origine médicamenteuse. Revue des notifications spontanées en France. Drug-induced pancreatitis. A review of French spontaneous reports. La Revue de médecine interne. 2015 ;36:573-78.

Compaci G, Rueter M, Lamy S, Oberic L, Recher C, Lapeyre-Mestre M, Laurent G, Despas F. Ambulatory Medical Assistance - After Cancer (AMA-AC) : A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy. BMC Cancer. 2015 ;15:781.

Courrier V, Fournier JP, Sommet A, Montastruc JL, Poutrain JC. Parenteral anticoagulants use in general practice : a cross-sectional study in south western France. Clin Appl Thromb Hemost. 2015 ;21:319-24.

Damase-Michel C. Médicament et grossesse. Traiter une femme enceinte : un choix raisonné. Act pharmaceutique. 2015 ;550:15.

de Souto Barreto P, Demougeot L, Pillard F, Lapeyre-Mestre M, Rolland Y. Exercise training for managing behavioral and psychological symptoms in people with dementia : A systematic review and meta-analysis. Ageing Res Rev. 2015 ;24:274-85.

Diot C, Eiden C, Roussin A, Batisse A, Boucher A, Chavant F, Daveluy A, Donadieu-Rigole H, Peyrière H ; et le réseau des centres français d’addictovigilance. Withdrawal syndrome after co-medication of opioid maintenance therapy with nalmefene : unrecognized interaction. Eur J Clin Pharmacol. 2015 ;71:1539-40.

Egron A, Olivier-Abbal P, Gouraud A, Babai S, Combret S, Montastruc JL, Bondon-Guitton E. Preventable and potentially preventable serious adverse reactions induced by oral protein kinase inhibitors through a database of adverse drug reaction reports. Targ Oncol. 2015 ;10:229-34.

Faillie JL. Indication bias or protopathic bias ? Br J Clin Pharmacol. 2015 ;80:779-80.

Faillie JL, Suissa S. Immortal Time Bias in Pharmacoepidemiological Studies : Definition, Solutions and Examples. Thérapie. 2015 ;70:259-63.

Faillie JL, Filion KB, Patenaude V, Ernst P, Azoulay L. Dipeptidyl peptidase-4 inhibitors and the risk of community-acquired pneumonia in patients with type 2 diabetes. Diabetes Obes Metab. 2015 ;17:379-85.

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P ; Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations : a randomised, double-blind, controlled trial. Lancet Neurol. 2015 ;15:154-165.

Fournier JP, Yin H, Nessim SJ, Montastruc JL, Azoulay. Tramadol for non-cancer pain and the risk of hyponatremia. Am J Med. 2015 ;128:418-425.

Fournier JP, Azoulay L, Yin H, Montastruc JL, Suissa S. Tramadol Use and the Risk of Hospitalization for Hypoglycemia in Patients With Noncancer Pain. JAMA Intern Med. 2015 ;175:186-93.

Fuzier R. Yet more on Pecs block nomenclature. Anaesthesia. 2015 ;70:508-509.

Fuzier R, Casalprim J, Bataille B, Harper I, Magues JP. The echogenicity of nerve blockade needles. Anaesthesia. 2015 ;70:462-466.

Fuzier R. Problématique de l’anesthésie locorégionale dans l’obésité. Regional anaesthesia in obese patient. Obésité. 2015 ;10:227-231.

Gallini A, Gardette V, Lapeyre-Mestre M, de Souto Barreto P, Vellas B, Andrieu S, Rolland Y. Dementia Diagnosis and Influenza Vaccination in French Nursing Home Residents. J Am Geriatr Soc. 2015 ;63:1256-8.

Girault D, Trouvin JH, Blachier-Poisson C, Gary F, Laloye D ; participants of round table N°3 of Giens XXX :, Bergmann JF, Casadevall N, Delval C, De Sahb Berkovitch R, Fagon JY, Gersberg M, Lassale C, Lechat P, Le Jeunne C, Montastruc JL, Prugnaud JL, Ratignier-Carbonneil C, Rey-Coquais C. Biosimilars : from Technical to Pharmacoeconomic Considerations. Thérapie. 2015 ;70:47-55.

Girault D, Trouvin JH, Blachier-Poisson C, Gary F, Laloy D ; les participants à la table ronde N°3 de Giens XXX : Bergmann JF, Casadevall N, Delval C, Berkovitch Rde S, Fagon JY, Gersberg M, Lassale C, Lechat P, Le Jeunne C, Montastruc JL, Prugnaud JL, Ratignier-Carbonneil C, Rey-Coquais C. Biosimilaires : de la technique au médicoéconomique. Thérapie. 2015 ;70:37-46.

Guiraud T, Labrunée M, Pillard F, Granger R, Bousquet M, Richard L, Boned A, Pathak A, Gayda M, Gremeaux V. Whole-Body Strength Training Using a Huber Motion Lab in Coronary Heart Disease Patients : Safety, Tolerance, Fuel Selection, and Energy Expenditure Aspects and Optimization. Am J Phys Med Rehabil. 2015 ;94:385-94.

Jacomet C, Allavena C, Peyrol F, Pereira B, Joubert LM, Bagheri H, Cotte L, Garaffo R, Gerbaud L, Dellamonica P. Perception of Antiretroviral Generic Medicines : One-Day Survey of HIV-Infected Patients and Their Physicians in France. PLoS One. 2015 ;10:e0117214.

Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Signal identification in addictovigilance : the functioning of the French system.Thérapie. 2015 ;70:123-31.

Jouanjus E, Gibaja V, Kahn JP, Haramburu F, Daveluy A. Comment identifier un signal en addictovigilance ? Therapie. 2015 ;70:113-22.

Labrunée M, Boned A, Granger R, Bousquet M, Jordan C, Richard L, Garrigues D, Gremeaux V, Sénard JM, Pathak A, Guiraud T. Improved Walking Claudication Distance with Transcutaneous Electrical Nerve Stimulation : An Old Treatment with a New Indication in Patients with Peripheral Artery Disease. Am J Phys Med Rehabil. 2015 ;94:941-9.

Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. Eur Ann Otorhinolaryngol Head Neck Dis. 2015 ;132:31-4.

Laconi S, Cailhol L, Pourcel L, Thalamas C, Lapeyre-Mestre M, Chabrol H. Relationship between defense mechanism and therapeutic alliance. Encephale. 2015 ;41:429-34.

Laffon de Mazières C, Lapeyre-Mestre M, Vellas B, de Souto Barreto P, Rolland Y. Organizational Factors Associated With Inappropriate Neuroleptic Drug Prescribing in Nursing Homes : A Multilevel Approach. J Am Med Dir Assoc. 2015 ;16:590-7.

Laffont MA, Michaud M, Pugnet G, Gigaud M, Arlet P, Sailler L, Astudillo L. Lower limb pain of unusual cause. Rev Med Interne. 2015 ;36:566-67.

Lapeyre-Mestre M, Dupui M. Drug abuse monitoring : which pharmacoepidemiological resources at the European level ? Thérapie. 2015 ;70:157-65.

Lapeyre-Mestre M, Dupui M. Système de surveillance en addictovigilance : quelles données pharmacoépidémiologiques à l’échelle de l’Europe ? Thérapie. 2015 ;70:147-56.

Lacroix I. Médicaments et allaitement. Duel effets pour bébé ? Science et santé. 2015 ;23:36.

Le Querrec F, Bounes V, Mestre ML, Azema O, Longeaux N, Gallart JC. Regional Observatory of Emergency Medicine in Midi-Pyrénées-France (ORU-MiP). Sex and age differences in ED patients with mental and behavioral disorders due to psychoactive substance use. Am J Emerg Med. 2015 ;33:1612-16.

Linselle M, Montastruc F, Jantzen H, Valnet-Rabier MB, Haramburu F, Coquerel A, Gouraud A, Perault-Pochat MC, Bagheri H, Montastruc JL. Drugs and Sleep Apneas ? A review of the French Pharmacovigilance database.Therapie. 2015 ;70:347-50.

Meyrignac O, Moreno R, Baunin C, Vial J, Accadbled F, Sommet A, de Gauzy JS. Low-dose biplanar radiography can be used in children and adolescents to accurately assess femoral and tibial torsion and greatly reduce irradiation. Eur Radiol. 2015 ;25:1752-60.

Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M. Example of an investigation of an "emergent" phenomenon in addiction vigilance : the case of methylphenidate.Thérapie. 2015 ;70:197-202.

Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M. Un exemple d’investigation d’un phénomène « émergent » en addictovigilance : à propos du méthylphénidate. Thérapie. 2015 ;70:191-6.

Micallef J, Lapeyre-Mestre M.  Addictovigilance : le défi pharmacologique de l’évaluation et de la prévention des substances à risque. Thérapie. 2015 ;70:111.

Michaud M, Moulis G, Balardy L, Pourrat J, Huart A, Gaches F, Cougoul P, Blancher A, Puissant B, Arlet P, Sailler L. Cryofibrinogenemia : A single-center study at the University Hospital of Toulouse. Rev Med Interne. 2015 ;36:237-42.

Michaud M, Moulis G, Puissant B, Balardy L, Huart A, Gaches F, Cougoul P, Arlet P, Blancher A, Pourrat J, Sailler L. Cryofibrinogenemia : a marker of severity of cryoglobulinemia vasculitis. Am J Med. 2015 ;8:916-21.

Montastruc F, Rieu J, Letamendia C, Montastruc JL, Pathak A, Schmitt L. Measurement of QT interval and serotoninergic reuptake inhibitor antidepressants : a study in a university psychiatric hospital. L’Encéphale. 2015 ;41:282-283.

Montastruc F, Rouanet S, Gardette V, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescriptions forms in patients with Alzheimer disease : a cross-sectional study in a French PharmacoVigilance Database. Eur J Clin Pharmacol. 2015 ;71:891-5.

Montastruc F. VigiBIP, un nouvel outil pour le bon usage du médicament. Trait d’Union. 2015 ;144:7.

Montastruc F, Palmaro A, Bagheri H, Schmitt L, Montastruc JL, Lapeyre-Mestre M. Role of serotonin 5-HT2C and histamine H1 receptors in antipsychotic-induced diabetes : A pharmacoepidemiological-pharmacodynamic study in VigiBase. Eur Neuropsychopharmacol. 2015 ;25:1556-65.

Montastruc JL, Bagheri H, Montastruc F. Antivitamines K. la maladie thrombo-embolique veineuse, 1 volume, Elsevier Masson SAS. Ph Lacroix. 2015 ;27:243-248.

Montastruc JL, Queneau P. Sur la demande d’avis relatifs à l’autorisation pour la communauté urbaine du Grand Nancy d’exploiter une eau minérale naturelle pour l’alimentation en eaux d’un centre thermal au titre de l’article L 1322-1du code de la santé publique. Rapport 14-04. Bull Acad Natle Méd. 2014 ;198:859-65.

Montastruc JL, Rousseau V, Chebane L, Abadie D, Bondon-Guitton E, Durrieu G, Montastruc F, Bagheri H. Hemorrhagic effects of oral anticoagulants : a comparative study between vitamin K antagonists (VKA) and direct oral anticoagulants (DOA). Eur J Clin Pharmacol. 2015 ;71:1283-84.

Moulis F, Moulis G, Balardy L, Gérard S, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc JL, Rolland Y, Vellas B. Searching for a Polypharmacy Threshold Associated With Frailty. J Am Med Dir Assoc. 2015 ;16:259-61.

Moulis F, Moulis G, Balardy L, Gérard S, Montastruc F, Sourdet S, Rougé-Bugat M, Lapeyre-Mestre M, Montastruc J, Rolland Y, Vellas B. Exposure to Atropinic Drugs and Frailty Status. J Am Med Dir Assoc. 2015 ;16:253-7.

Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015 ;90:301-5.

Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases : What interest for medical research ? Rev Med Interne. 2015 ;36:411-17.

Moulis G, Sailler L, Lapeyre-Mestre M.  Severe bleeding events in adults and children with primary immune thrombocytopenia : a systematic review : comment. J Thromb Haemost. 2015 ;13:1521-31.

Moulis G, Lapeyre-Mestre M, Montastruc JL, Sailler L. Exposure to non-corticosteroid treatments in adult primary immune thrombocytopenia before the chronic phase in the era of thrombopoietin receptor agonists in France. A nationwide population-based study. Autoimmunity Reviews. 2015 ;14:168-73.

Moulis G, Palmaro A, Sailler L, Lapeyre-Mestre M. Corticosteroid Risk Function of Severe Infection in Primary Immune Thrombocytopenia Adults. A Nationwide Nested Case-Control Study. PLoS One. 2015 ;10:e0142217.

Nguyen TTL, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G. Signal for Thrombosis with Eltrombopag and Romiplostim : A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Saf. 2015 ;38:1179-86.

Palmaro A, Bissuel R, Renaud N, Durrieu G, Escourrou B, Oustric S, Montastruc JL, Lapeyre-Mestre M. Off-label prescribing in pediatric outpatients. Pediatrics. 2015 ;135:49-58.

Palmaro A, Dupouy J, Lapeyre-Mestre M. Benzodiazepines and risk of death : Results from two large cohort studies in France and UK. Eur Neuropsychopharmacol. 2015 ;25:1566-77.

Pauly V, Lapeyre-Mestre M, Braunstein D, Rueter M, Thirion X, Jouanjus E, Micallef J. Detection of signals of abuse and dependence applying disproportionality analysis. Eur J Clin Pharmacol. 2015 ;71:229-36.

Pugnet G, Sailler L, Bourrel R, Montastruc JL, Lapeyre-Mestre M. Is Statin Exposure Associated with Occurrence or Better Outcome in Giant Cell Arteritis ? Results from a French Population-based Study. J Rheumatol. 2015 ;42:316-22.

Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list : a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015:1860-9.

Rouge-Bugat ME, Lassoued D, Bacrie J, Boussier N, Delord JP, Oustric S, Bauvin E, Lapeyre-Mestre M, Bertucci F, Grosclaude P. Guideline sheets on the side effects of anticancer drugs are useful for general practitioners. Support Care Cancer. 2015 ;23:3473-80.

Roulet L, Ballereau F, Lapeyre-Mestre M, Joris-Frasseren M, Asseray N. Developing a Terminology in the French Language for Clinical Practice and Research in Drug Safety. Thérapie. 2015 ;70:283-92.

Roussin A, Doazan-d’Ouince O, Géniaux H, Halberer C ; French Network of Centre for Evaluation and Information on Pharmacodependence (Addictovigilance Centres). Evaluation of abuse and dependence in addiction monitoring systems : tramadol as an example. Thérapie. 2015 ;70:213-21.

Roussin A, d’Ouince OD, Géniaux H, Halberer C ; réseau français des Centres d’Évaluation et d’Information sur la Pharmacodépendance (Centres d’Addictovigilance). Un exemple d’évaluation de l’abus et de la dépendance en addictovigilance : à propos du tramadol. Thérapie. 2015 ;70:203-11.

Saliba L, Mondoly P, Duparc A, Bura-Rivière A, Maury P, Calmels V, Sallerin B, Pathak A, Montastruc JL, Bagheri H. Factors Associated with Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients with Non-valvular Atrial Fibrillation. Thérapie. 2015 ;70:485-92.

Sattler V, Acket B, Raposo N, Albucher JF, Thalamas C, Loubinoux I, Chollet F, Simonetta-Moreau M. Anodal tDCS Combined With Radial Nerve Stimulation Promotes Hand Motor Recovery in the Acute Phase After Ischemic Stroke. Neurorehabil Neural Repair. 2015 ;29:743-54.

Sénard JM.  Prise en charge de l’hypotension orthostatique. Cardiologiques. 2015 ;309:1-4.

Terrier B, Dechartres A, Girard C, Jouneau S, Kahn JE, Dhote R, Lazaro E, Cabane J, Papo T, Schleinitz N, Cohen P, Begon E, Belenotti P, Chauveau D, Diot E, Généreau T, Hamidou M, Hayem G, Le Guenno G, Le Guern V, Michel M, Moulis G, Puéchal X, Rivière S, Samson M, Gonin F, Le Jeunne C, Corlieu P, Mouthon L, Guillevin L ; French Vasculitis Study Group. Granulomatosis with polyangiitis : endoscopic management of tracheobronchial stenosis : results from a multicentre experience. Rheumatology. 2015 ;54:1852-57.

Thorel J, Civade E, Quintyn JC, Cestac P, Montastruc JL, Bagheri H. Ischaemic stroke after exposure to aflibercept : interaction with vitamin K antagonist and/or direct pharmacodynamic effect ? J Clin Pharm Ther. 2015 ;40:477-79

Tillement JP, Hauw JJ, Papadopoulos V, Montastruc JL. Vieillissement et démences : un défi médical, scientifique et socio-économique. Thérapie. 2015 ;70:239.

Vallet H, Riviere S, Sanna A, Deroux A, Moulis G, Addimanda O, Salvarani C, Lambert M, Bielefeld P, Seve P, Sibilia J, Pasquali J, Fraison J, Marie I, Perard L, Bouillet L, Cohen F, Sene D, Schoindre Y, Lidove O, Le Hoang P, Hachulla E, Fain O, Mariette X, Papo T, Wechsler B, Bodaghi B, Rigon MR, Cacoub P, Saadoun D ; French Behçet Network. Efficacy of anti-TNF alpha in severe and/or refractory Behçet’s disease : Multicenter study of 124 patients. J Autoimmun. 2015 ;62:67-74.

Retour en haut de page

ANNEE 2014

Publié le 17/03/2015 à 12h15 (mis à jour le 31/08/2015 à 16h06)

PHARMACOLOGIE FONDAMENTALE

Bruzzone A, Saulière A, Finana F, Sénard JM, Lüthy I, Galés C. Dosage-dependent regulation of cell proliferation and adhesion through dual beta2-AR)/cAMP signals. FASEB J 2014 ;28(3):1342-54.

Dague E, Genet G, Lachaize V, Guilbeau-Frugier C, Fauconnier J, Mias C, Payré B, Chopinet L, Alsteens D, Kasas S, Severac C, Thireau J, Heymes C, Honton B, Lacampagne A, Pathak A, Sénard JM, Galés C. Atomic force and electron microscopic-based study of sarcolemmal surface of living cardiomyocytes unveils unexpected mitochondrial shift in heart failure. J Mol Cell Cardiol. 2014 Sep ;74:162-72.

Gargiulo L, Copsel S, Rivero EM, Galès C, Sénard JM, Luthy IA, Davio C, Bruzzone A. Differential B2-adrenergic receptor defines the phenotype of non-tumorigenic and malignant human breast cell lines. Oncotarget.
2014 ;5:1058-69.

PHARMACOLOGIE CLINIQUE

Palfi S, Gurruchaga JM, Scott G, Lepetit H, Lavisse S, Buttery PC, Watts C, Miskin J, Kelleher M, Deeley S, Iwamuro H, Lefauchgeur JP, Thiriez C, Fenelon G, Lucas C, Brugières P, Gabriel I, Abhay K, Drouot X, Tani N, Kas A, Ghaleh B, Le Corvoisier P, Dolphin P, Breen DP, Mason S, Valle Guzman N, Mazarakis ND, Radcliffe PA, Harrop R, Kingsman SM, Rascol O, Naylor S, Barker RA, Hantraye P, Remy P, Cesaro P, Mitrophanous KA. Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkonson’s disease : a dose escalation, open-label, phase 1/2 trial. Lancet. 2014 ;383:1138-46.

Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira A, Rascol O, Debieuvre C, Fräßdorf M. Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of Pramipexole extended release. Parkinson’s Disease. 2014 ;467131:1-8.

Hauser RA, Schapira AH, Barone P, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe M. Pramipexole ER Studies Group. Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2014 ;21:736-43.

Ory-Magne F, Corvol JC, Azulay JP, Bonnet AM, Brefel-Courbon C, Damier P, Dellapina E, Destée A, Durif F, Galitzky M, Lebouvier T, Meissner W, Thalamas C, Tison F, Salis A, Sommet A, Viallet F, Vidailhet M, Rascol O, Ns-Park CIC Network. Withdrawing chronic amantadine therapy in dyskinetic patients with Parkinson disease : the AMANDYSK trial. Neurology. 2014 ;82:300-7.

Ory-Magne F, Rascol O. Author response. Neurology. 2014 Sep 9 ;83(11):1036.

Ory Magne F, Arcari C, Canivet C, Sarrail M, Fabre MH, Mohara C, Brefel Courbon C. A therapeutic educational program in Parkinson’s disease : ETPARK. Rev Neurol (Paris). 2014 Feb ;170(2):128-33.

Ory Magne F, Fabre N, Gu C, Pastorelli C, Tardez S, Marchat JC, Marque P, Brefel Courbon C. An individual rehabilitation program : Evaluation by Parkinsonian patients and their physiotherapists. Rev Neurol (Paris). 2014 Nov ;170(11):680-4.

Perez-Lloret S, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Meissner W, Schelosky L, Tison F, Rascol O. Prevalence, determinants, and effect on Quality of Life of Freezing of Gait in Parkinson’s Disease. JAMA Neurol. 2014 ;71:884-90.

Perez-Lloret S, Rey MV, Crispo J, Krewski D, Lapeyre-Mestre M, Montastruc JL, Rascol O. Risk of heart failure following treatment with dopamine agonists in Parkinson’s disease patients. Expert Opin Drug Saf.
2014 ;13:351-60.

Perez-Lloret S, Rey MV, Pavy-Le Traon A, Rascol O. Droxidopa for the treatment of neurogenic orthostatic hypotension and other symptoms of neurodegenerative disorders. Expert Opinion on Orphan Drugs. 2014 ;2:509-22.

Dodel R, Jönsson B, Reese JP, Winter Y, Martinez-Martin P, Holloway R, Sampaio C, Ruzicka E, McCrone P, Hawthorne G, Oertel W, Poewe W, Stebbins G, Rascol O, Goetz CG, Schrag A. Measurement of costs and scales for outcome evaluation in health Eeconomic studies of patients with Parkinson’s Disease. Mov Disord. 2014 ;29:169-76.

Rascol O. Jejunal levodopa infusion in Parkinson’s disease. Lancet Neurol. 2014 ;13:128-29.

Rascol O, Fox S, Gasparini F, Kenney C, Di Paolo T, Gomez-Mancilla B. Use of metabotropic glutamate 5-receptor antagonists for treatment of levodopa-induced dyskinesias : Parkinsonism Relat Disord. 2014
Sep ;20(9):947-56.

Rascol O. Can a new trial end controversy over when to use levodopa ? Nature Reviews Neurology. -2014 Sep ;10(9):488-9.

Rascol O, Stocchi F, Isaacson S, Ondo W. Apomorphine penject - emerging evidence and treatment strategies for delayed ON and OFF periods in Parkinson’s disease. EMJ Neurol. 2014 ;1:27-35.

Rey MV, Perez-Lloret S, Pavy le Traon A, Meissner WG, Tison F, Rascol O. A cross-sectional study on drug use in multiple system atrophy. CNS Drugs. 2014 ;28:483-90.

Yousfi M, Merbahi N, Pathak A, Eichwald O. Low-temperature plasmas at atmospheric pressure : toward new pharmaceutical treatments in medicine. Fundam and Clin Pharmacol. 2014 ;28:123-35.

Pathak A, Ewen S, Fajadet J, Honton B, Mahfoud F, Marco J, Schlaich M, Schmieder R, Tsioufis K, Ukena C, Zeller T. From SYMPLICITY HTN-3 to the Renal Denervation Global Registry : where do we stand and where should we go ? EuroIntervention. 2014 ;10:21-3.

Pathak A, Morel C, Honton B, Fajadet J, Galinier M, Senard JM.  Bursting of the renal denervation bubble ? La lettre du Cardiologue. 2014 Sept ;477:31.

Honton B, Pathak A, Sauguet A Fajadet J. First report of transradial renal denervation with the dedicated radiofrequency iberis catheter. EuroIntervention. 2014 ;9:1385-8.

Vaccaro A, Despas F, Delmas C, Lairez O, Lambert E, Lambert G, Labrunée M, Guiraud T, Esler M, Galinier M, Senard JM, Pathak A. Direct evidences for sympathetic hyperactivity and baroreflex impairment in Tako Tsubo cardiopathy. Plos One. 2014 ;DOI : 10.137.

Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X ; French Society of Hypertension. Management of hypertension in adults : the 2013 French Society of Hypertension guidelines. Fundam Clin Pharmacol. 2014 Feb ;28(1):1-9.

Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland JG, Cohen-Solal A, Gheorghiade M, Gueyffier F, O’Connor CM, Fiuzat M, Patak A, Piña IL, Rosano G, Sabbah HN, Tavazzi L, Zannad F. Heart rate : a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014 ;16:76-85.

Pellaprat J, Ory-Magne F, Canivet C, Simonetta-Moreau M, Lotterie JA, Radji F, Arbus C, Gerdelat A, Chaynes P, Brefel-Courbon C. Deep brain stimulation of the subthalamic nucleus improves pain in Parkinson’s disease. Parkinsonism Relat Disord. 2014 Jun ;20(6):662-4.

Fernagut PO, Dehay B, Maillard A, Bezard E, Perez P, Traon A, Rascol O, Foubert-Samier A, Tison F, Meissner W. Multiple system atrophy : A prototypical synucleinopathy for disease-modifying therapeutic strategies. Neurobiol Dis. 2014 ;67:133-9.

Bezard E, Pioli EY, Li Q, Girard F, Mutel V, Keywood C, Tison F, Rascol O, Poli SM.  The mGluR5 negative allosteric modulator dipraglurant reduces dyskinesia in the MPTP macaque model. Mov Disord. 2014 ;8:1074-79.

Senard JM. L’hypotension orthostatique neurogène et ses traitements. Neurone. 2014 ;19:45-50.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Molinier A, Acket B, Bourrel R, Lavezzi O, Montastruc JL, Bagheri H. Extrapolation des données physiopathologiques à la pratique clinique : à propos du dabigatran utilisé hors AMM. Press Med. 2014 ;43:468-9.

Bounes V, Jouanjus E, Roussin A, Lapeyre-Mestre M. Acute pain management for patients under opioid maintenance treatment : what physicians do in emergency departments ? Eur J Emerg Med. 2014 Feb ;21(1):73-6.

Petchy MF, Bounes V, Dehours E, Moulie L, Edlow JA. Characteristics of patients with acute ischemic stroke intubated before imaging. Eur J Emerg Med. 2014 Apr ;21(2):145-7.

Cottron N, Larcher C, Sommet A, Fesseau R, Alacoque X, Minville V, Fourcade O, Kern D. The sevoflurane washout profile of seven recent anesthesia workstations for malignant hyperthermia-susceptible adults and infants : a bench test study. Anesth Analg. 2014 ;119:67-75.

Fuzier R, Serres I, Bourrel R, Palmaro A, Montastruc JL, Lapeyre-Mestre M. Analgesic drug consumption increases after knee arthroplasty : a pharmacoepidemiological study investigating postoperative pain. Pain. 2014 ;155:1339-45.

Fuzier R, Lapeyre-Mestre M. Factors affecting chronic pain and increases of analgesic drug consumption after knee arthroplasty : Reply. Pain. 2014 Dec ;155(12):2721-2.

Dehours E, Bounes V, Bagheri H, Valle B, Ducassé JL, Montastruc JL. Adverse drug reactions in an emergency medical dispatching centre. Eur J Clin Pharmacol. 2014 ;70:881-7.

Lapeyre-Mestre M, Gony M, Carvajal A, Macias D, Conforti A, D’Incau P, Heerdink R, Van der Stichele R, Bergman U. A European Community Pharmacy-Based Survey to Investigate Patterns of Prescription Fraud through Identification of Falsified Prescriptions. Eur Addict Res. 2014 ;20(4):174-82.

Lapeyre-Mestre M. Médicaments sans ordonnance : du mésusage à la dépendance. Sciences médicale, Paul Sabatier. 2014 Jan:25.

Dupouy J, Mémier V, Catala H, Lavit M, Oustric S, Lapeyre-Mestre M. Does urine drug abuse screening help for managing patients ? A systematic review. Drug Alcohol Depend. 2014 Mar 1 ;136:11-20.

Dupouy J, Fournier JP, Jouanjus É, Palmaro A, Poutrain JC, Oustric S, Lapeyre-Mestre M. Baclofen for alcohol dependence in France : incidence of treated patients and prescription patterns—a cohort study. Eur Neuropsychopharmacol. 2014 Feb ;24(2):192-9.

Jouanjus E, Lapeyre-Mestre M, Micallef J. Cannabis use : signal of increasing risk of serious cardiovascular disorders. J Am Heart Assoc. 2014 ;3:e000638 doi : 10.1161/JAHA.113.000638.

Vrignaud L, Aouille J, Mallaret M, Durrieu G, Jonville-Béra AP. Hypersexualité induite par l’aripiprazole : à propose d’un cas et revue de la littérature. Thérapie. 2014 ;69(6):525-27.

Saliba L, Boisson L, Sallerin B, Laroche M, Despas F. Défaut d’observance aux médicaments antiostéoporotiques : croisement de deux techniques, la clef pour l’évaluation de l’observance ? Thérapie. 2014 ;69:383-9.

Birebent J, Dupouy J, Bismuth M, Magnaval V, Despas F, Alquier V, Oustric S. La mention "non substituable" de la prescription à la délivrance : comparaison des points de vue des médecins généralistes libéraux et des pharmaciens d’officine de la région Midi-Pyrénées. Thérapie. 2014 ;69:401-17.

Montastruc F, Montastruc G, Taudou MJ, Olivier-Abbal P, Montastruc JL, Bondon-Guitton E. Acute coronary syndrome after nasal spray of oxymetazoline. Chest. 2014 Dec 1 ;146(6):e214-5.

Montastruc F, Retailleau, Rousseau V, Bagheri H, Montastruc JL. Atropinic burden of prescription forms in France : a study in community pharmacies in 2013. Eur J Clin Pharmacol. 2014 ;70:1147-48.

Montastruc F, Duguet C, Rousseau V, Bagheri H, Montastruc JL. Potentially inappropriate medications and adverse drug reactions in the elderly : a study in a pharmacovigilance database. Eur J Clin Pharmacol. 2014 ;70:1123-27.

Montastruc F, Scotto S, Vaz IR, Guerra LN, Escudero A, Sáinz M, Falomir T, Bagheri H, Herdeiro MT, Venegoni M, Montastruc JL, Carvajal A. Hepatotoxicity related to agomelatine and other new antidepressants : a case/noncase approach with information from the portuguese, French, spanish, and italian pharmacovigilance systems. J Clin Psychopharmacol. 2014 ;34:327-30.

Montastruc F, Moulis G, Palmaro A, Gardette V, Durrieu G, Montastruc JL. Interactions between Medical Residents and Drug Companies : A National Survey after the Mediator® Affair. PLoS One. 2014 Oct 3 ;9(10):e104828.

Montastruc JL. Statines : précisions. Rev Med Suisse. 2014 ;10:1089.

Montastruc P. Histoire de la pharmacologie clinique en France : dans une scintillante introspective, l’adaptation, l’évaluation, la défense et l’illustration du médicament en France 1978-1981. Thérapie. 2014 ;69:481-2.

Moulis G, Sailler L, Adoue D, Lapeyre-Mestre M. Pharmacoepidemiology of immune thromobocytopenia : protocols of FAITH and CARMEN studies. Pharmacoepidemiol. 2014 ;69:437-48.

Moulis G, Palmaro A, Montastruc JL, Godeau B, Lapeyre-Mestre M, Sailer L. Epidemiology of incident immune thrombocytopenia : a nationwide population-based study in France. Blood 2014 ;124:3308-15.

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL ; on behalf of the Association Française des Centres Régionaux de PharmacoVigilance. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor ? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology.
2014 ;53:1864-71.

Moulis G, Bagheri H, Sailler L, Jonville-Bera AP, Weber E, Guy C, Petitpain N, Laroche ML, Favrelière S, Béné J, Baldin B, Villeval-Federici L, Tebacher-Alt M, Bres V, Veyrac G, Grandvuillemin A, The French Association of PharmacoVigilance Centers. Are adverse drug reaction patterns different between romiplostim and eltrombopag ? 2009-2013 French Pharmacovigilance assessment. Eur J Int Med. 2014 ;25:777-80.

Moulis G, Sommet A. How to read a meta-analysis ? Rev Med Interne. 2014 Apr ;35(4):250-8.

Moulis G, Sailler L, Bonneville F, Wagner T. Imaging in Erdheim-Chester disease : classic features and new insights. Clin Exp Rheumatol. 2014 May-Jun ;32(3):410-4.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Derumeaux H, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia : an adjusted comparison of mortality and morbidity. Am J Hematol. 2014 Jan ;89(1):41-6.

Mouly C, Hanaire H, Sénard JM, Gerdelat A, Pavy-LeTraon A. Sudoscan : Intérêt en pratique Clinique. Diabète & Obésité • 2014 ; 9 (81) : 2-5.

Abou Taam M, Rossard C, Cantaloube L, Bouscaren N, Roche G, Pochard L, Montastruc F, Herxheimert A, Montastruc JL, Bagheri H. Analysis of patients narratives posted on social media websites on benfluorex’s (Mediator) withdrawal in France. J of Clin Pharmacy and Therapeutics. 2014 ; 39:53-5.

Allavena C, Jacomet C, Pereira B, Morand-Joubert L, Bagheri H, Cotte L, Garaffo R, Gerbaud L, Dellamonica P. Acceptability and confidence in antiretroviral generics of physicians and HIV-infected patients in France. J Int AIDS Soc. 2014 Nov 2 ;17(4 Suppl 3):19608.

Béné J, Moulis G, Auffret M, Lefevre G, Coquerelle P, Coupe P, Péré P, Gautier S. Alopecia induced by tumour necrosis factor-alpha antagonists : description of 52 cases and disproportionality analysis in a nationwide pharmacovigilance database. Rheumatology (Oxford). 2014 ;53:1465-9.

Bondon-Guitton E. Pharmacogénétique en pratique. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Cool C, Cestac P, Laborde C, Lebaudy C, Rouch L, Lepage L, Vellas B, de Souto Barreto P, Rolland Y, Lapeyre-Mestre M. Potentially inappropriate drug prescribing and associated factors in nursing homes. J Am Med Dir Assoc. 2014 ;15(11):850.e1-9.

Courrier V, Fournier JP, Sommet A, Montastruc JL, Poutrain JC. Parenteral anticoagulants use in general practice : a cross-sectional study in south western France. Clin Appl Thrombosis. 2014, DOI : 10.1177/1076029614548057.

D’Incau P, Lapeyre-Mestre M, Carjaval A, Donati M, Salado I, Rodriguez L, Sainz M, Escudero A, Conforti A. No difference between men and women in adverse drug reactions related to psychotropic drugs : a survey from France, Italy and Spain. Fundam and Clin Pharmacol. 2014 ;28:342-348.

Durrieu G, Batz A, Rousseau V, Bondon-Guitton E, Petiot D, Montastruc JL. Use of administrative database to identify adverse drug reactions in a pediatric university hospital. Eur J Clin Pharmacol. 2014 ;70:1519-26.

Elghozi JL, Senard JM. Prise en charge de l’hypotension orthostatique. Arch Mal Cœur 2014 ; 232:14-22.

Eschalier A, Montastruc JL. Hommage au professeur Pierre DUCHÊNE-MARULLAZ (1921-2014). Therapie. 2014 Nov-Dec ;69(6):479.

Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. More on the « triple whammy » : antihypertensive drugs, non-steroidal anti-inflammatory agents and acute kidney injury – a case/non-case study in the french pharmacovigilance database. Ren Fail. 2014 Aug ;36(7):1166-8.

Fournier JP, Sommet A, Durrieu G, Poutrain JC, Lapeyre-Mestre M, Montastruc JL. Drug interactions between antihypertensive drugs and non-steroidal anti-inflammatory agents : a descriptive study using the French pharmacovigilance database. Fundam and Clin Pharmacol. 2014 ;28:230-5.

Gallini A, Andrieu S, Donohue JM, Oumouhou N, Lapeyre-Mestre M, Gardette V. Trends in use of antipsychotics in elderly patients with dementia : Impact of national safety warnings. Eur Neuropsychopharmacol. 2014 Jan ;24(1):95-104.

Gardette V, Lapeyre-Mestre M, Piau A, Gallini A, Cantet C, Montastruc JL, Vellas B, Andrieu S. A 2-year prospective cohort studuy of antidementia drug non-persistency in mild-to-moderate Alzheimer’s disease in Europe : predictors of discontinuation and switch in the ICTUS study. CNS Drugs. 2014 ;28:157-70.

Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, Bounes V, Mas A, Payen D, Petrie D, Roessler MS, Weitz G, Ducros L, Plaisance P. Prehospital noninvasive ventilation for acute respiratory failure : systematic review, network meta-analysis, and individual patient data meta-analysis. Acad Emerg Med. 2014 Sep ;21(9):960-70.

Hein C, Forgues A, Piau A, Sommet A, Nourhashémi F, Vellas B. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014 ;15(11):850.e11-5.

Honton B, Despas F, Dumonteil N, Rouvellat C,Roussel M, Carrie D, Galinier M, Montastruc JL. Bortezomib and heart failure : case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2014 ;28:349-52.

Jacquot J, Bagheri H, Montastruc JL. La notification d’effet indésirable au secours de l’ordonnance « non substituable » ! Thérapie. 2014 ;69:259-61.

Laffont MA, Sommet A, Alvarez M, Bruyand M, Bonnet J, Marchou B, Delobel P. A-10 : Complications infectieuses des lymphomes liés au VIH pris en charge par une association rituximab-polychimiothérapie. Med Mal Infect. 2014 Jun ;44(6 Suppl):21.

Lauque D, Maupas-Schwalm F, Bounes V, Juchet H, Bongard V, Roshdy A, Botella JM, Charpentier S. Predictive value of the heart-type fatty acid-binding protein and the Pulmonary Embolism Severity Index in patients with acute pulmonary embolism in the emergency department. Acad Emerg Med. 2014 Oct ;21(10):1143-50.

Le Moigne M, Sommet A, Lapeyre-Mestre M, Bourrel R, Molinier L, Paul C, Montastruc JL. Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis : a cohort analysis in the French insurance database. J Eur Acad Dermatol Venereol. 2014 ;28 :1235-44.

Loulergue P, Tubach F, Salmon D, Della monica P, Taillan B, Thorel JB, Marteau P, Bressot C, Ravaud P, Mariette X, Lortholary O, for the RATIO Group. Bacteremia in patients receiving TNF-alpha antagonists - a prospective multicenter study. Journal of Infection. 2013 ;67:524-8 (publié en 2014).

Néel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, Kyndt X, Puechal X, Weiller PJ, Decaux O, Ninet J, Hot A, Aouba A, Astudillo L, Berthelot JM, Bonnet F, Brisseau JM, Cador B, Closs-Prophette F, Dejoie T, de Korwin JD, Dhote R, Fior R, Grosbois B, Hachulla E, Hatron PY, Jardel H, Launay D, Lorleac’h A, Pottier P, Moulis G, Serratrice J, Smail A, Hamidou M. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler’s syndrome : a French multicenter study. Autoimmun Rev. 2014 Oct ;13(10):1035-41.

Pages A, Bondon-Guitton E, Montastruc JL, Bagheri H. Undesirable effects related to oral antineoplastic drugs : comparison between patients’ internet narratives and a national pharmacovigilance database. Drug Saf.
2014 ;37:629-37.

Paricaud K, Moulis G, Combis MS, Sailler L, Arlet P. Causes of protidemia above 100g/L. Eur J Intern Med. 2014 Dec ;25(10):e123

Hurault Delarue C, Montastruc JL, Beau AB, Lacroix I, Damase-Michel C. Pregnancy outcome in women exposed to, dopamine agonists during pregnancy : a pharmacoepidemiology study in EFEMERIS database. Arch Gynecol Obstet. 2014 ;290(2):263-70

Charlton RA, Neville AJ, Jordan S, Pierini A, Damase-Michel C, Klungsoyr K, Nybo Andersen AM, Vinkel Habsen A, Gini R, Bos JHJ, Puccini A, Hurault-Delarue C, Brooks CJ, de Jong-Van Den Berg LTW, de Vries CS. Healthcare databases in Europe for study medicine use and safety during pregnancy. Pharmacoepidemiol and Drug Saf. 2014 ;23:586-94.

Beau AB, Hurault-Delarue C, Vial T, Montastruc JL, Damase-Michel C, Lacroix I. Safety of oseltamivir during pregnancy : a comparative study using the EFEMERIS database. BJOG. 2014 ;121:895-900.

Beau AB, Hurault-Delarue C, Vidal S, Guitard C, Vayssière C, Petiot D, Montastruc JL, Damase-Michel C, Lacroix I. Pandemic A/H1N1 influenza vaccination during pregnancy : a comparative study using the EFEMERIS database. Vaccine. 2014 ;32:1254-8.

Damase-Michel C, Lacroix I, Hurault-Delarue C, Beau AB, Montastruc JL. Evaluation des médicaments chez la femme enceinte : à propos de la base de données française EFEMERIS. Thérapie. 2014 ;69:91-100.

Damase-Michel C. Médicaments et consultation préconceptionnelle. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Damase-Michel C, Hurault-Delarue C. Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern. Evid Based Med. 2014 Apr ;19(2):74.

Abadie D, Chebane L, Bert M, Durrieu G, Montastruc JL. Online reporting of adverse drug reactions : a study from a french regional pharmacovigilance center. Thérapie. 2014 ;69:395-400.

Abadie D. Le syndrome sérotoninergique en pratique. In CD du 26e Forum de la Faculté de Médecine Toulouse Rangueil et Purpan le 26 octobre 2014.

Soussan C, Gouraud A, Portoloan G, Jean-Pastor MJ, Pecriaux C, Montastruc JL, Damase-Michel C. Drug-induced adverse reactions via breastfeeding : a descriptive study in the French pharmacovigilance database. Eur J Clin Pharmacol. 2014 ;70(11):1361-66.

Soussan-Dahan M, Lapeyre-Mestre M, Bondon-Guitton E, Delord JP, Despas F. Cetuximab cutaneous adverse drug reactions : a marker of efficacy for metastatic colorectal cancer and head-neck cancer ?. Thérapie. 2014 Nov-Dec ;69(6):499-507.

Palosse-Cantaloube L, Lacroix I, Rousseau V, Bagheri H, Montastruc JL, Damase-Michel C. Analysis of chats on French internet forums about drugs ad pregnancy. Pharmacoepidemiol and Drug Saf. 2014 ;23(12):1330-3.

Faillie JL, Azoulay L, Patenaude V, Hillaire-Buys D, Suissa S. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes : cohort study. BMJ. 2014. Apr24 ;348:g2780

Faillie JL, Babai S, Crépin S, Bres V, Laroche ML, Le Louet H, Petit P, Montastruc JL, Hillaire-Buys D. French Pharmacovigilance Centers Network. Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors : a case/non-case study from the French Pharmacovigilance Database. Acta Diabetol. 2014 ;51:491-7.

De Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. Multimorbidity type, hospitalizations and emergency department visits among nursing home residents : a preliminary study. J Nutr Health Aging. 2014 Jul ;18(7):705-9.

De Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. Indicators of influenza and pneumococcal vaccination in French nursing home residents in 2011. Vaccine. 2014 Feb 7 ;32(7):846-51.

De Souto Barreto P1, Sanz C, Vellas B, Lapeyre-Mestre M, Rolland Y. Drug treatment for diabetes in nursing home residents. Diabet Med. 2014 May ;31(5):570-6.

De Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rolland Y. From rural to urban areas : differences in behavioural and psychological symptoms of dementia in nursing home residents according to geographical location. Psychogeriatrics. 2014 Dec ;14(4):229-34.

Pochard L, Hauviller L, Cuzin L, Eyvrard F, Sommet A, Montastruc JL, Bagherie H. Apport du logiciel Nadis® dans la collecte des effets indésirables des antirétroviraux : expérience en Midi-Pyrénées. Thérapie. 2014 ;69:149-55.

Vardon F, Bounes V, Ducassé JL, Minville V, Lapostolle F. Out-of-hospital equipment of emergency medical services for hemorrhagic shock management : Can do better !. Ann Fr Anesth Reanim. 2014 Dec ;33(12):621-5.

Sommet A. Génériques : des prescriptions selon la classe. Science et santé. 2014 Jan-fév ;18:36.

Romio S, Weibel D, Dieleman JP, Olberg HK, de Vries CS, Sammon C, Andrews N, Svanström H, Mølgaard-Nielsen D, Hviid A, Lapeyre-Mestre M, Sommet A, Saussier C, Castot A, Heijbel H, Arnheim-Dahlström L, Sparen P, Mosseveld M, Schuemie M, van der Maas N, Jacobs BC, Leino T, Kilpi T, Storsaeter J, Johansen K, Kramarz P, Bonhoeffer J, Sturkenboom MC. Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines : a multinational self-controlled case series in Europe. PLoS One. 2014 Jan 3 ;9(1):e82222.

Retour en haut de page

ANNEE 2013

Publié le 06/02/2014 à 14h45 (mis à jour le 24/07/2023 à 10h03)

PHARMACOLOGIE FONDAMENTALE

Girousse A, Tavernier G, Valle C, Moro C, Mejhert N, Dinel AL, Houssier M, Roussel B, Besse-Patin A, Combes M, Mir L, Monbrun L, Bezaire V, Prunet-Marcassus B, Waget A, Vila I, Caspar-Bauguil S, Louche K, Marques MA, Mairal A, Renoud ML, Galitzky J, Holm C, Mouisel E, Thalamas C, Viguerie N, Sulpice T, Burcelin R, Arner P, Langin D. Partial inhibition of adipose tissue lipolysis improves glucose metabolism and insulin sensitivity without alteration of fat mass. PLoS Biol, 2013, 11, 2, e1001485.

Mias C, Coatrieux C, Denis C, Genet G, Seguelas MH, Laplace N, Rouzaud-Laborde C, Calise D, Parini A, Cussac D, Pathak A, Sénard JM, Galès C. Cardiac fibroblasts regulate sympathetic nerve sprouting and neurocardiac synapse stability. Plos One 2013, 8,(11):e79068.

PHARMACOLOGIE CLINIQUE

Cornu C, Binquet C, Thalamas C, Vigouroux C, Gaillard S, Ginhoux T, Vaz B, Jossan C, Felin A, Sailly A, Gueyffier F, Journot V, Kassai B. Public clinical trials : which kind of monitoring should be used ? Therapie 2013, 68, 135-41.

Moulis G, Gaudin C, Cassaing S, Tournier E, Balardy L. Nodules cutanés révélant une alternariose systémique. Press Med 2013, 42, 1421-23.

Denuelle M, Fabre N. Functional neuroimaging of migraine. Rev Neurol 2013, 169, 380-9.

Schapira AHV, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Success rate, efficacy, and safety/tolerability of overnight switching from immediate – to extended-release pramipexole in advanced Parkinson’s disease. Europ J of Neurol 2013, 20, 180-87.

Schapira AH, McDermott MP, Barone P, Comella CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol, O, Marek K. Pramipexole in patients with early Parkinson’s disease (PROUD) : a randomized delayed-start trial. Lancet Neurol 2013, 12, 747-755.

Schuepbach WM, Rau J, Knudsen K, Volkmann J, Krack P, Timmermann L, Halbig TD, Hesekamp H, Navarro SM, Meier N, Falk D, Mehdorn M, Paschen S, Maarouf M, Barbe MT, Fink GR, Kupsch A, Gruber D, Schneider GH, Seigneuret E, Kistner A, Chaynes P, Ory-Magne F, Brefel-Courbon C, Vesper J, Schnitzler A, Wojtecki L, Houeto JL, Bataille B, Maltete D, Damier P, Raoul S, Sixel-Doering F, Hellwig D, Gharabaghi A, Kruger R, Pinsker MO, Amtage F, Régis JM, Witjas T, Thobois S, Mertens P, Kloss M, Hartmann A, Oertel WH, Post B, Speelman H, Agid Y, Schade-brittinger C, Deuschl G ; EARLYSTIM Study group (Czernecki V, Pineau F, Negovanska V, Welter ML, Corvol JC, Cornu P, Moller B, Nebel A, Witt K, Raethjen J, Meister IG, Kuhn J, Donner K, Kessler J, Kuhn A, Muller B, Faust K, Chabardes S, Pollak P, Fraix V, Rascol O, Arbus C, Danet L, Groiss SJ, Elben S, Hartmann C, Sudmeyer M, Ledily S, Sauvaget A, Trenkwalder C, Richter-Dreske W, Wachter T, Weiss D, Eusebio A, Azulay JP, Polo G, Pinto S, Levin J, Dornier S, Pene F, Hourton D, Quintin M, Hoffart-Jourdain C, Brocvuelle H, Partowinia-Peters M, Balthasar K, Stein M, Harnisch S, Reuss A, Aminossadati B, Nasemann C, Stoker V, Diener HC, Lehmacher W, Keravel Y, Roosen K, Deuschl G, Agid Y, Schade-Brittinger C, Reub A, Burchardi N, Houeto JL, Krack P. Neurostimulation for Parkinson’s disease with early motor complications. N Engl J Med 2013, 368, 610-622.

Rascol O. Extended-release carbidopa-levodopa in Parkinson’s disease. Lancet Neurol 2013, 12, 325-326.

Hauser RA, Hsu A, Espay AJ, Sethi K, Stacy M, Ondo W, O’Connell M, Gupta S. Extended-release carbidopa-levodopa compared with immediate-release carbidopa-levodopa in patients with Parkinson’s Disease and motor fluctuations : a phase 3 randomised, double-blind trial. Lancet Neurol 2013, 12, 346-356.

Wenning GK, Geser F, Krismer F, Seppi K, Duerr S, Boesch S, Kollensperger M, Goebel G, Pfeiffer KP, Barone P, Pellecchia MT, Quinn NP, Koukouni V, Fowler CJ, Schrag A, Mathias CJ, Giladi N, Gurevich T, Dupont E, Ostergaard K, Nilsson CF, Widner H, Oertel W, Eggert KM, Albanese A, Del Sorbo F, Tolosa E, Cardoso A, Deuschl G, Hellriegel H, Klockgether T, Dodel R, Sampaio C, Coelho M, Djaldetti R, Melamed E, Gasser T, Kamm C, Meco G, Colosimo C, Rascol O, Meissner W, Tison F, Poewe W on behalf of EMSA-SG. The natural history of multiple system atrophy : a prospective european cohort study. Lancet Neurology 2013, 12, 264-274.

Lang AE, Melamed E, Poewe W, Rascol O. Trial designs used to study neuroprotective therapy in Parkinson’s disease. Mov Dis 2013, 28, 86-95.

Goetz CG, Stebbins GT, Chung KA, Hauser RA, Miyasaki JM, Nicholas AP, Poewe W, Seppi K, Rascol O, Stacy MA, Nutt JG, Tanner CM, Urkowitz A, Jaglin JA, Song GE. Which dyskinesia scale best detects treatment response ? Mov Disord 2013, 28, 341-346.

Ferreira JJ, Katzenschlager R, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Dietrichs E, Fabbrini G, Friedman A, Kanovsky P, Kostic V, Nieuwboer A, Odin P, Poewe W, Rascol O, Sampaio C, Schupbach M, Tolosa E, Trenkwalder C, Schapira A, Bererdelli A, Oertel WH. Summary of the recommandations of the EFNS/MDS-ES review on therapeutic management of Parkinson’s disease. Eur J Neurol 2013, 20, 5-15.

Peran P, Nemmi F, Méligne D, Cardebat D, Peppe A, Rascol O, Caltagirone C, Demonet JF, Sabatini U. Effect of levodopa on both verbal and motor representations of action in Parkinson’s Disease : A fMRI study. Brain Lang 2013, 125, 324-329.

Perez-Lloret S, Rey MV, Ratti PL, Rascol O. Rotigotine transdermal patch for the treatment of Parkinson’s Disease. Fundam and Clinical Pharmacol 2013, 27, 81-95.

Perez-Lloret S, Rey MV, Ratti PL, Pavy Le Traon A, Rascol O. Emerging drugs for autonomic dysfunction in Parkinson’s disease. Expert Opin. Emerging Drugs 2013, 18, 39-53.

Stocchi F, Rascol O, Destee A, Hattori N, Hauser RA, Lang AE, Poewe W, Stacy M, Tolosa E, Gao H, Nagel J, Merschhemke M, Graf A, Kenney C, Trenkwalder C. AFQ056 in Parkinson patients with L-dopa-induced dyskinesia : 13-week randomized, controlled, dose-finding study. Mov Disord 2013, 28, 1838-46.

Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira A, Emre M, Nissinen H, Leinonen M, Stocchi F. For the Stalevo Reduction in dyskunesia evaluation in Parkinson’s disease (STRIDE-PD) investigators. Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 2013, 28, 1064-71.

Tison F, Nègre-pagès L, Meissner WG, Dupouy S, Li Q, Thiolat ML, Thiollier T, Galitzky M, Ory-Magne F, Milhet A, Marquine L, Spampinato U, Rascol O, Bezard E. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson’s disease patients. Parkinsonism and related Disorders 2013, 19, 416-421.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Debieuvre C, Fraessdorf M, Poewe W. Patient-reported convenience of once-daily versus three-times-daily dosing during long-term studies of pramipexole in early and advanced Parkinson’s disease. Eur J Neurol. 2013, 20, 50-56.

Schapira AH, Albrecht S, Barone P, Comella CL, McDermott MP, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson’s disease : the PROUD study. Mov Disord, 2013, 25, 1627-32.

Rascol O. Jejunal levodopa infusion in Parkinson’s disease. Lancet Neurol. 2013, pii : S1474-4422(13)70291-6. doi :
10.1016/S1474-4422(13)70291-6.

Perez-Lloret S. Apomorphine for the treatment of refractory motor fluctuations in late stage Parkinson’s disease : an old drug revisited. Eur J of Neurol 2013, 20, 1427-8.

Meissner WG, Foubert-Samier A, Dupouy S, Debs R, Gerdelat-Mas A, Cochen de Cok V, Schrag A, Rascol O, Tison F, Pavy-Le Traon A. Validation of the french version of the MSA health-related quality of life scale (MSA-QoL). Rev Neurol 2013, 169, 53-58.

Perez-Lloret S, Videla AJ, Richaudeau A, Vigo D, Rossi M, Cardinali DP, Perez-Chada D. A multi-step pathway connecting short sleep duration to daytime somnolence, reduced attention, and poor academic performance : an exploratory cross-sectional study in teenagers. J Clin Sleep Med. 2013, 15, 469-73.

Rascol O. Physical exercise in Parkinson disease : moving toward more robust evidence ? Mov Disord 2013, 28, 1173-75.

Klebe S, Golmard JL, Nalls MA, Saad M, Subgleton AB, Bras JM, Hardy J, Simon-Sanchez J, Heutink P, Kuhlenbaumer G, Charfi R, Klein C ; Hagenah J, Gasser T, Wurster I, Lesage S, Lorenz D, Deuschl G, Durif F, Pollak P, Damier P, Tison F, Durr A, Amouyel P, Lambert JC, Tzourio C, Maubaret C, Charbonnier-Beaupel F, Tahiri K, Vidailhet M, Martinez M, Brice A, Corvol JC ; French Parkinson’s disease genetics study group : international Parkinson’s disease genomics consortium (IPDGC). The val158MetCOMT polymorphism is a modifier of the age at onset in Parkinson’s disease with a sexual dimorphism. J Neurol Neurosurg Psychiatry 2013, 84, 666-73.

Ferreira JJ, Neutel D, Mestre TA, Galitzky M, Thalamas C, Santos AT, Sampaio C, Rascol O. Usefulness of OSLER test in Parkinson’s disease. Mov Disord 2013, 14, 297-300.

Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, De Bie RMA, Deuschl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Ostergaard K, Poewe W, Pollak P, Van der Linden C, Oertel W. Selecting deep brain stimulation on infusion therapies in advanced Parkinson’s disease : an evidence-based review. J Neurol 2013, 260, 2701-14.

Brefel-Courbon C, Ory-Magne F, Thalamas C, Payoux P, Rascol O. Nociceptive brain activation in patients with neuropathic pain related to Parkinson’s disease. Parkinsonism Relat Disord 2013, 19, 548-552.

Labrunée M, Despas F, Marque P, Guiraud T, Galinier M, Sénard JM. Pathak A. Acute electromyostimulation decresases muscle sympathetic nerve activity in patients with advanced chronic heart failure (EMSICA study). Plos One 2013, Nov 12, 8(11):e7943.

Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GYH, Verheugt FWA, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013, 34, 1708-13

Guiraud T, Labrunée M, Gaucher K, Despas F, Meyer P, Bosquet L, Vaccaro A, Bousquet M, Galinier M, Sénard JM, Pathak A. High-intensity interval exercise improves vagal tone and decreases arrhythmias in patients with chronic heart failure. Med Sci Sport 2013, 45, 1861-7.

Pathak A, Lebrin M, Vaccaro A, Sénard JM, Despas F. Pharmacology of levosimendan : inotropic, vasodilatory and cardioprotective effects. Journal of Clinical Pharmacy and Therapeutics 2013, 38, 341-349.

Hanon O, Lee YS, Pathak A. Association between eprosartan-based hypertension therapy and improvement in cognitive function score : long-term follow-up from the OSCAR observational study. JRAAS 2013, 1-8.

Lantelme P, Courand PY, Pathak A. Renal denervation : a plea for wisdom. Arch of Cardiovasc Dis 2013, 106, 121-3.

Dumonteil N, Vaccaro A, Despas F, Labrunée M, Marcheix B, Lambert E, Esler M, Carrie D. Transcatheter aortic valve implantation (TAVI) reduces sympathetic activity and normalizes arterial spontaneous baroreflex in patients with aortic stenosis. JACC Cardiovasc interv 2013, 6, 1195-1202.

Franchitto N, Despas F, Labrunée M, Galinier M, Sénard JM, Sénard JM, Pathak A. Cardiorenal anaemia syndrome in chronic heart failure contributes to increased sympathetic nerve activity. Int J Cardiol 2013, 168, 2352-57.

Mebazaa A, Gayat E, Lassus J, Meas T, Mueller C, Maggioni A, Peacock F, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Tavazzi L, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Parenica J, Deye N, Boukef R, Collet C, Van den Berghe G, Cohen-Solal A, Januzzi JL Jr ; GREAT Network. Association between elevated blood glucose and outcome in acute heart failure : results from an international observational cohort. J Am Coll Cardiol. 2013, 26 ;61, 820-9.

Lassus J, Gayat E, Mueller C, Peacock WF, Spinar J, Harjola VP, van Kimmenade R, Pathak A, Mueller T, Disomma S, Metra M, Pascual-Figal D, Laribi S, Logeart D, Nouira S, Sato N, Potocki M, Parenica J, Collet C, Cohen-Solal A, Januzzi JL Jr, Mebazaa A ; GREAT-Network. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heart failure : the Multinational Observational Cohort on Acute Heart Failure (MOCA) study. Int J Cardiol. 2013, 168, 2186-94

Lambert E, d’Udekem Y, Cheung M, Ika Sari C, Inman J, Ahimastos A, Eikelis N, Pathak A, King I, Grigg L, Schlaich M, Lambert G. Sympatetic and vascular dysfunction in adult patients with fontan circulation. Int J of Card 2013, 167, 1333-38.

Blacher J, Halimi JM, Hanon O, Mourad JJ, Pathak A, Schnebert B, Girerd X. Management of arterial hypertension in adults : 2013 guidelines of the french society of arterial hypertension. Press Med 2013, 42, 819-25.

Pathak A. Variabilité tensionnelle et rigidité artérielle. Les cahiers de l’artère 2013, 6, 6-7.

Satge J, Gremeaux V, Guiraud T, Granger R, Pathak A, Labrunée M. Comment optimiser l’alliance thérapeutique autour de l’activité physique dans les maladies cardiovasculaires ? Lett Méd Phys et Réadapt 2013, 29, 119-28.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Adoue D. Rituximab versus splenectomy in persistent or chronic adult primary immune thrombocytopenia : an adjusted comparison of mortality and morbidity. Haematologica 2013, 98, 197-8.

Moulis G, Sommet A, Lapeyre-Mestre M. Mortality rates among patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors : comment on the article by Sinard et al. Arthritis and Rheumatism 2013, 65, 1670-74.

Bounes V, Palmaro A, Lapeyre-Mestre M, Roussin A. Long-term consequences of acute pain for patients under Methadone of buprenorphine maintenance treatment. Pain Physician 2013, 16, 739-747.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Mintzes B, Lexchin J, Wilkes MS, Beaulieu MD, Reynolds E, Sutherland J, Durrieu G. Pharmaceutical sales representatives and patient safety. J Gen Med Intern 2013 ; 28, 1395.

Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical sales representatives and patient safety : a comparative prospective study of information quality in Canada, France and the United States. J Gen Med Intern 2013 ; 28, 1368-75.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk on anti-TNF-a at recommended doses in adult rheumatoid arthritis : a meta-analysis with intention to treat and per protocol analyses. Plos One 2013, DOI : 10.1371.

Lapeyre-Mestre M, Grolleau S, Montastruc JL. Adverse drug reactions associated with the use of NSAIDS : a case/non case analysis of spontaneous reports from the french pharmacovigilance database 2002-2006. Fundam and Clinical Pharmacol 2013, 27, 223-230.

Chavant F, Ingrand I, Jonville-Bera AP, Plazanet C, Gras-Champel V, Lagarce L, Zenut M, Disson-Dautriche A, Logerot S, Auffret M, Coubret-Dumas A, Bruel ML, Boyer M, Bos-Thompson MA, Veyrac G, Carlier P, Beyens MN, Lates S, Damase-Michel C, Castot A, Kreft-Jaus C, Pérault-Pochat MC. The PREGVAXGRIP study : a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)V2009 influenza. Drug saf 2013, 36, 455-65.

Gulmez SE, Larrey D, Pageaux GP, Lignot S, Lassalle R, Jové J, Gatta A, McCormick PA, Metselaar HJ, Monteiro E, Thorburn D, Bernal W, Zouboulis-Vafiadis I, de Vries C, Perez-Gutthann S, Sturkenboom M, Bénichou J, Montastruc JL, Horsmans Y, Salvo F, Hamoud F, Micon S, Droz-Perroteau C, Blin P, Moore N. Transplantation for Acute Liver Failure in Patients Exposed to NSAIDs or Paracetamol (Acetaminophen) : The Multinational Case-Population SALT Study. Drug Saf. 2013, 36, 135-44.

Gulmez SE, Moore N, Pageaux GP, Lignot S, Horsmans Y, Stricker B, Bernuau J, Bissoli F, Thorburn D, Montastruc JL, Micon S, Hamoud F, Lassalle R, Jové J, Blin P, Larrey D. Causality of Drugs Involved in Acute Liver Failure Leading to Transplantation : Results from the Study of Acute Liver Transplant (SALT). Drug Saf 2013, 36, 757-64.

Faye E, Bondon-Guitton E, Olivier-Abbal P, Montastruc JL. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors. Eur J Clin Pharmacol 2013, 69, 1819-26.

Olivier-Abbal P, Teisseyre AC, Montastruc JL. Comparison of serious adverse reactions between thalidomide and lenalidomide : analysis in the French pharmacovigilance database. Med Oncol 2013, 30, 733.

Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions : a pharmacovigilance study in France. Eur J Clin Pharmacol 2013, 69,885-888.

Fuzier R, Serres I, Guitton E, Lapeyre-Mestre M, Montastruc JL ; French Network of Pharmacovigilance Centres. Adverse drug reactions to gabapentin and pregabalin : a review of the French pharmacovigilance database. Drug Saf. 2013, 36, 55-62.

Montastruc F, Schmitt L, Montastruc JL, Pathak A. QT interval and antidepressant use : a cross sectional study of electronic health records. BMJ 2013 ;346:f288 doi : 10.1136/bmj.f288

Faillie JL, Petit P, Montastruc JL, Hillaire-Buys D. Scientific evidence and controversies about pioglitazone and bladder cancer : which lessons can be drawn ? Drug Saf 2013, 36, 693-707.

Amar J, Lieber A, Montastruc F, Bagheri H, Pathak A, Montastruc JL. Arterial hypertension and resistance ton antihypertensive treatment : a new adverse drug reaction with Modafinil. Therapie 2013, 68, 53-4.

Bezzina C, Bondon-Guitton E, Montastruc JL. Inhaled corticosteroid-induced hair depigmentation in a child. J Drugs Dermatol. 2013, 1, 119-20.

Abadie D, Durrieu G, Roussin G, Montastruc JL. Effets indésirables "graves" du tramadol : bilan 2010-2011 de pharmacovigilance en France. Thérapie 2013, 68, 77-84.

Durrieu G, Mazau B, Jégu J, Lapeyre-Mestre M, Delord JP, Montastruc JL. Drugs and cancer : an analysis of the french pharmacoviiglance database. Thérapie 2013, 68, 149-54.

Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Senard JM, Pathak A. Effets indésirables cardiaques des chimiothérapies. Press Med 2013, 42, 26-39.

Damase-Michel C, Hurault-Delarue C. Ibuprofen does not seem to increase global malformation risk but NSAID use in late pregnancy remains a concern. Evid Based Med doi:10.1136/eb-2013-101495

Dupouy J, Moulis G, Tubery M, Ecoiffier M, Sommet A, Poutrain JC, Arlet P, Lapeyre-Mestre M. Which adverse events are related to health care during hospitalization in elderly lnpatients ? Int J Med Sci 2013, 9, 1224-30.

Sommet A, Georgel B, Poutrain JC, Oustric S, Bourrel R, Montastruc JL, Birebent J. Différence de taux de substitution des médicaments génériques en Midi-Pyrénées en fonction des classes pharmaco-thérapeutiques. Revue d’Epidémiologie et de Santé Publique 2013, 61, 539-44.

Laroche ML, Perault-Pochat MC, Ingrand I, Merle L, Kreft-Jais C, Casto-Villepelet A, Durrieu G, Gras V, Guy C, Jean-Pastor MJ, Jonville-Béra AP, Merlet-Chicoine I, Miremont-Salamé G, Nourashemi F, Charmes JP. Adverse drug reactions in patients with Alzheimer’s disease and related dementia in France : a national multicentre cross-sectional study. Pharmacoepidemiol and Drug Saf 2013, 22, 952-60.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. The nursing home effect : a case study of residents with potential dementia and emergency departments visits. J Am Dir Assoc 2013, 14, 901-5.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. Prevalence and associations of the use of proton-pump inhibitors in nursing homes : a cross-sectional study. JAMDA 2013, 14, 265-9.

Michaud M, Gaudin C, Brechemier D, Moulis G, Astudillo L, Lavialle-Guillotreau V, Balardy L. Un syndrome de Reynolds révélant un thymome malin. Rev Med Inter 2013, 34, 171-3.

Gallini A, Gardette V, Vellas B, Lapeyre-Mestre M, Andrieu S, Brefel-Courbon C. Persistent use of analgesic medications in mild-to-moderate Alzheumer’s disease. Drugs Aging 2013, 30, 439-45.

Montastruc F, Laffont M, Bagheri H, Montastruc JL. Potentially inappropriate medications in the elderly in France : a study in community pharmacies in 2011-2012. Eur J Clin Pharmacol 2013, 69, 741-2.

De Souto Barreto P, Lapeyre-Mestre M, Vellas B, Rollland Y. Potential underuse of analgesics for recognized pain in nursing home residents with dementia : a cross-sectional study. Pain 2013, 2427-31.

Montastruc F, Gardette V, Cantet C, Piau A, Lapeyre-Mestre M, Vellas B, Montastruc JL, Andrieu S. Potentially inappropriate medication use among patients with Alzheimer disease in the REALFR cohort : be aware of atropinic and benzodiazepine drugs ! Eur J Clin Pharmacol 2013, 69, 1589-97.

Roussin A, Bouyssi A, Pouché L, Pourcel L, Lapeyre-Mestre M. Misuse and dependence on non-prescription codeine analgesics or sedative H1 antihistamines by adults : a cross-sectional investigation in France. Plos One 2013, DOI : 10.1371.

Peyrière H, Eiden C, Micallef J, Lapeyre-Mestre M, Faillie JL, Blayac JP. Slow-release oral morphine sulfate abuse : results of the postmarketing surveillance systems for psychoactive prescription drug abuse in France. Eur Addict Res 2013, 19, 235-244.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. Indicators of benzodiazepine use in nursing home residents in France : a cross-sectional study. JAMDA 2013, 14, 29-33.

Dupouy J, Dassieu L, Bourrel R, Poutrain JC, Bismuth S, Oustric S, Lapeyre-Mestre M. Effectiveness of drug tests in outpatients starting opioid substitution therapy. Journal of Substance abuse treatment 2013, 44, 515-521.

Nordmann S, Pradel V, Lapeyre-Mestre M, Frauger E, Pauly V, Thirion X, Mallaret M, Jouanjus E, Micallef J. Doctor shopping reveals geographical variations in opioid abuse. Pain Physicial 2013, 16, 89-100.

Dupouy J, Bez J, Barsony J, Oustric S, Lapeyre-Mestre M. Cycles de traitement par médicament de substitution aux opiacés dans une cohorte de patients suivis 5 ans en médecine ambulatoire.Thérapie 2013, 68,155-161.

Lapeyre-Mestre M.  Addiction médicamenteuse : quelles données pour évaluer et prévenir ? Cairn.infoPyschotropes 2013, 19, 65-80.

Orriols L, Foubert-Samier A, Gadegbeku B, Delorme B, Tricotel A, Philip P, Moore N, Lagarde E, CESIR Research Group. Prescription of antiepileptics and the risk of road traffic crash. J Clin Pharmacol 2013, 53, 339-44.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. A questionnaire to document self-medication history in adult patients visqiting emergency departments. Pharmacoepidemiology and Drug Saf 2013, 22, 151-9.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Adoue D. Prevalence of pneumococcal vaccination in adult immune thrombocytopenia patients exposed to rituximab or to splenectomy. Eur J Hematol 2013, 90, 438-9.

Le Lay M, Fournier JP, Montastruc JL. Interactions médicamenteuses potentielles en médecine générale : comparaison de deux études transversales en 1997 et 2012. Thérapie 2013, 68, 411-3.

Lapeyre-Mestre M, Sapède C, Moore N et les participants à la table ronde n° 5 de Giens XXVIII : Bidault P, Blin P, Chopy D, Evans D, Gueyffier F, Lacoin L, Malbezin M, Micallef J, Morlet-Vigier D, Muller S, Oger E, Plétan Y, Pons G, Verpillat P, Vigneau C. Pharmacoepidemiology studies : what levels of evidence and how can they be reached ? Thérapie 2013, 68, 247-52.

Despas F, Rocher H, Laurent G. Anticancer drug adherence. Bull cancer 2013, 100, 473-484.

Moulis G, Sailler L, Pugnet G, Astudillo L, Arlet P. Biologics in relapsing polychondritis : a case series. Clin and Experimental Rheum 2013, 31, 937-9.

De Souto Barreto P, Lapeyre-Mestre M, Mathieu C, Piau C, Bouget C, Cayla F, Vellas B, Rolland Y. A multicentric individually-tailored controlled trial of education and professional support to nursing home staff : research protocol and baseline data of the IQUARE study. J Nutr Health Aging. 2013, 17, 173-8.

Moulis G, Pugnet G, Sailler L, Astudillo L, Arlet P. Abatacept in relapsing polychondritis. Ann Rheum Dis 2013 ;72:e27 doi:10.1136/annrheumdis-2013-204336.

Montastruc JL, Laffon de Mazières C, Montastruc F, Moulis G. Réflexions éthiques après l’affaire du Médiator°. Bioethique.com/index. 27 novembre 2013.

Montastruc JL, Montastruc F. Prescribe, but also know how to "deprescribe". Prescrire Int 2013, 22, 192.

Montastruc F, Moulis G, Gardette V, Durrieu G, Montastruc JL. Junior doctors attitudes towards drug companies. Prescrire Int 2013, 22, 195.

Fuzier R, Fabre B. Aiguilles échogènes : intérêt et performance ? Le Praticien en anesthésie Réanimation 2013, 17, 266-269.

Bourlier V, Saint-Laurent C, Louche K, Badin PM, Thalamas C, de Glisezinski I, Langin D, Sengenes C, Moro C. Enhanced glucose metabolism is preserved in cultured primary myotubes from obese donors in response to exercise training. J Clin Endocrinol Metab 2013, 9, 3739-47.

Chollet F, Acket B, Raposo N, Albucher JF, Loubinoux I, Pariente J. Use of antidepressant medications to improve outcomes after stroke : Use of antidepressant medications to improve outcomes after stroke. Curr Neurol Neurosci Rep 2013, 13, 318.

Abadie D. Médicaments, peau et soleil. Bulletin d’information de pharmacologie. Septembre 2013.

Lacroix I. Médicaments de substitution des dépendances aux opiacés/données épidémiologiques. Chapitre du "guide concernant l’usage de substances psychoactives". Edition Respadd 2013.

Michaud M, Balardy L, Moulis G, Gaudin C, Peyrot C, Vellas B, Cesari M, Nourashemi F. Proinflammatory cytokines, aging, and age-related diseases. JAMDA 2013, 1-6.

Montastruc F, Moulis G, Gardette V, Durrieu G, Montastruc JL. Attitudes des internes en médecine vis-à-vis de l’industrie pharmaceutique. Prescrire 2013 355, 387.

Montastruc JL. Actualités sur les antiagrégants. Avril 2013.

PDF Montastruc JL. - Attention aux interactions NACOs et amiodarone. Bulletin d'information de pharmacologie. Septembre 2013. [599.3 ko]

Montastruc JL. Benzodiazépines et démences. Avril 2013.

PDF Montastruc JL. - Effets indésirables systémiques et oro-pharyngés des corticostéroïdes inhalés. Bulletin d'information de pharmacologie. Septembre 2013 [599.3 ko]

PDF Montastruc JL. - Ne pas confondre : hypolipémiants et hypolipémiants ! Bulletin d'information de pharmacologie. Septembre 2013. [599.3 ko]

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Is the risk of tumor necrosis factor inhibitor-induced lupus the same with monoclonal antibodies and soluble receptor ? A case/non case study in a nationwide pharmacovigilance database. Arthritis Rheum 2013, 65, 612-3.

Pathak A. Les génériques : l’avis du pharmacologue. Repères en gériatrie 2013, 15, 30-32.

Retour en haut de page

ANNEE 2012

Publié le 21/02/2013 à 10h04 (mis à jour le 24/07/2023 à 10h23)

PHARMACOLOGIE FONDAMENTALE

Saulière A, Bellot M, Paris H, Denis C, Finana F, Hansen JT, Altié MF, Seguelas MH, Pathak A, Hansen JL, Sénard JM, Galès C. Deciphering biased-agonism complexity reveals a new active AT1 receptor entity. Nature Chemical Biology 2012, 8, 622-630.

Genet G, Guilbeau-Frugier C, Honton B, Dague E, Schneider MD, Coatrieux C, Calise D, Cardin C, Niéto C, Payré B, Dubroca C, Marck P, Heymes C, Dubrac A, Arvanitis D, Despas F, Altié MF, Séguélas MH, Delisle MB, Davy A, Sénard JM, Pathak A, Galès C. Ephrin-B1 is a novel specific component of the lateral membrane of the cardiac tissue architecture cohesion. Circ Res 2012, 110, 688-700.

Denis C, Saulière A, Galandrin S, Sénard JM, Falès C. Probing heterotrimeric G Protein activation : application to biased ligands. Curr Pharm Des 2012, 18, 128-44.

Maïga A, Mourier G, Quinton L, Rouget C, Gales C, Denis C, Lluel P, Sénard JM, Palea S, Servent D, Gilles N. G protein-coupled receptors, an unexploited animal toxin targets : exploration of green mamba venom for novel drug candidates active against adrenoceptors. Toxicon 2012, 15, 487-96.

Engeli S, Birkenfeld AL, Badin M, Bourlier V, Louche K, Viguerie N, Thalamas C, Montastier E, Larrouy D, Harant I, de Glisezinski I, Lieske S, Reinke J, Beckmann B, Langin D, Jordan J, Moro C. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012, 122, 4675-9.

PHARMACOLOGIE CLINIQUE

Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, Vuillaume I, Corvol JC, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha- Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Sablonniere B, Azulay JP, Tison F, Rascol O, Vidailhet M, Destée A, Bloem BR, Bordet R, Devos D ; for the Parkgait-II study group. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson’s disease undergoing subthalamic stimulation : a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012,11, 589-596.

Rascol O, Ferreira J, Nègre-Pages L, Perez-Lloret S, Lacomblez L, Galitzky M, Lemarié JC, Corvol JC, Brotchie JM, Bossi L. A Proof-of-concept, randomized, placebo-controlled, multiple cross-overs (n-of-1) study of naftazone in Parkinson’s disease. Fund Clin Pharmacol 2012, 26, 557-564.

Lees A, Fahn S, Eggert KM, Jankovic J, Lang A, Micheli F, Maral Mouradian M, Oertel WH, Olanow CW, Poewe W, Rascol O, Tolosa E, Squillacote D, Kumar D. Perampanel an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson’s Disease. Mov Disorders 2012, 27, 2, 284-300.

Rascol O, Barone P, Behari M, Emre M, Giladi N, Olanow W, Ruzicka E, Bibbiani F, Squillacote D, Patten A, Tolosa E. Perampanel in Parkinson disease fluctuations : a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 2012, 35, 15-20.

Mizuno Y, Yamamoto M, Kuno S, Hasegawa K, Hattori N, Kagimura T, Sarashina A, Rascol O, Schapira AH, Barone P, Hauser RA, Poewe W. Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa-Undertreated Parkinson Disease : A Double-Blind, Randomized Trial.Clin Neuropharmacol. 2012, 35, 174-181.

Rascol O, Bronzova J, Hauser RA , Lang AE , Sampaio C , Theeuwes A , Van de Witte SV , for the Mondrian Study Group. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson’s disease experiencing motor fluctuations : Results of a double-blind, randomized, placebo-controlled, trial. Parkinsonism & Related Disorders 2012, 18, 370-376.

Krismer F, Seppi K, Tison F, Sampaio C, Zangerl A, Peralta C, Yekhlef F, Ghorayeb I, Ory-Magne F, Galitzky M, Bozi M, Scaravilli T, Colosimo C, Geser F, Rascol O, Poewe W, Quinn NP, Wenning GK. The unified multiple system atrophy rating scale : intrarater reliability. Mov Disord 2012, 27, 13, 1683-85.

Damon-Perrière N, Foubert-Samier A, Cochen De Cock V, Gerdelat-Mas A, Debs R, Pavy-Le Traon A, Senard JM, Rascol O, Tison Fand Meissner WG. Assessment of the Scopa-Aut questionnaire in Multiple System Atrophy : Relation to UMSARS scores and progression over time. Parkinsonism Rel Disord 2012, 18, 612-615.

Dellapina E, Ory-Magne F, Regragui W, Thalamas C, Lazorthes Y, Rascol O, Payoux Brefel-Courbon C. Effect of suthalamic deep brain stimulation on pain in Parkinson’s disease. Pain 2012, 153, 2267-73.

Sagaspe P, Taillard J, Amiéva H, Beck A, Rascol O, Dartigues JF, Capelli A, Philip P. Influence of age, circadian and homeostatic processes on inhibitory motor control : a go/nogo task study. PLoS One. 2012, 7:e39410.

Ratti PL, Terzaghi M, Minafra B, Repetto A, Pasotti C, Zangaglia R, Pacchetti C, Manni R. REM and NREM sleep enactment behaviors in Pakinson’s disease, Parkinson’s disease dementia and dementia with lewy bodies. Sleep Medicine 2012, 13, 926-32.

Millar Vernetti P, Perez-Lloret S, Rossi M, Cerquetti D, Merello M. Validation of a new scale to access olfactory dysfunction in patients with Parkinson’s disease. Parkinsonism and related disorders 2012, 18, 4, 358-61.

Perez-Lloret S, Mezas Rojas G, Menoni MC, Ruiz G, Velazquez C, Rodriguez H, Rey MV, Cardinali D. Pregabalin beneficial effects on sleep quality of life are poorly correlated with reduction on pain intensity after an 8-week treatment course. Clin Neuropharmacol 2012, 35, 1, 21-4.

Perez-Lloret S, Nègre-Pagès L, Ojero-Senard A, Damier P, Destée A, Tison F, Merello M, Rascol O ; COPARK Study Group. Oro-buccal symptoms (dysphagia, dysarthria, and sialorrhea) in patients with Parkinson’s disease : preliminary analysis from the French COPARK cohort. Eur J Neurol 2012, 19, 28-37

Perez-Lloret S, Rascol O. Parkinson disease : Serotonin reuptake inhibitors for depression in PD. Nat Rev Neurol 2012, 8, 365-366.

Perez-Lloret S, Rey MV, Dellapina E, Pellaprat J, Brefel-Courbon C, Rascol O. Emerging analgesic drugs for Parkinson’s disease. Expert Opin Emerg Drugs 2012, 17, 157-171.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Brefel-Courbon C, Montastruc JL, Rascol O. Prevalence and Pharmacological factors associated with impulse-control disorders symptoms in patients with Parkinson disease. Clin Neuropharmacol 2012, 35, 261-5.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Senard JM, Pavy-Le Traon A, Montastruc JL, Rascol O. Factors related to orthostatic hypotension in Parkinson’s disease. Parkinsonism Relat Disord. 2012, 18, 501-5.

Lesage S, Condroyer C, Klebe S, HonoréA, Brefel-Courbon C, Durr A, Brice A. Identification of VPS 35 mutations replicated in French families with Parkinson disease. Neurology 2013, 78, 1449-50.

Montastruc F, Schwarz N, Schmitt L, Bui E. An overview of the symptoms and typical disorders associated with Alice in wonderland syndrome. Neuropsychiatry 2012, 2, 281-9.

Chaveron D, Silva S, Sanchez-Verlaan P, Conil JM, Sommet A, Geeraerts T, Génestal M, Minville V, Fourcade O. The 90 % effective dose of a sufentanil bolus for the management of painful positioning in intubated patients in the ICU. Eur J Anaesthesiol 2012, 29, 280-285.

Attal M, Lauwers-Cances V, Marit G, Caillot D, Moreau P, Facon T, Stoppa AM, Hulin C, Benboubker L, Garderet L, Decaux O, Leyvraz S, Vekemans MC, Vaillat L, Michallet M, Pegourie B, Dumontet C, Roussel M, Leleu X, Mathiot C, Payen C, Avet-Loiseau H, Harousseau JL. Réajkumar V, Spencer A, Chevret S, Nobili-Escruva C, Petillon MO, Olivier P, Cristini C, Llau ME. Lenalidomide maintenance after stem-cell transplantation for multiple myeloma. NEJM 2012, 366, 1782-91.

Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, D.Struthers A, Adriaan V, Ruilope ML, Bakris LG, O’Connor C, Gheorgiade M, Mentz RJ, Cohen-Solal A, Maggioni AP, Beygui F, SFilippatos G, Massy AZ, Pathak A, Pina IL, SabbahH, Sica AD, Tavazi L, Pitt B. Minéralocorticoïde receptor antagonist for heart failure with reduced ejection fraction : integrating evidence into clinical practice. Eur Heart J 2012, aout, 2782-95.

Goudev A, Berrou JP, Pathak A. Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population : preliminary report of the observational POWER study. Vasc Health Risk Manag 2012, 8, 563-8.

Despas F, Lambert E, Vaccaro A, Labrunée M, Franchitto N, Lebrin M, Galinier M, Sénard JM, Lambert G, Murray E, Pathak A. Peripheral chemoreflex activation contributes to sympathetic baroreflex impairment in chronic heart failure. J Clin Hypertens 2012, 30, 753-60.

Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A, OSCAR Publication group. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension : a retrospective subgroup analysis of the observational study on cognitive function and SBP reduction (OSCAR) study. J Clin Hypertens 2012, 14, 78-84.

Arnaudis B, Lairez O, Escamilla R, Fouilloux A, Fournier P, Monteil B, Bouisset F, Arnal JF, Elbaz M, Carrié D, Roncalli J, Pathak A, Galinier M. Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol 2012, 101, 717-26.

Guiraud T, Granger R, Gremeaux V, Bousquet M, Richard L, Soukarie L, Babin T, Labrnuée M, Bosquet L, Pathak A. Accelerometer as a tool to assess sedentarity and adherence to physical activity recommendations after cardiac rehabilitation program. Annals of Physical and Reha Med 2012, 55, 293-374.

Guiraud T, Granger R, Gremeaux V, Bousquet M, Richard L, Soukarié L, Babin T, Labrunée M, Sanguignol F, Bosquet L, Golay A, Pathak A. Telephone support oriented by accelerometric measurements enhances adherence to physical activity recommendations in noncompliant patients after a cardiac rehabilitation program. Arch of Physical Med and Rehab 2012, 93, 2141-7.

Solerno JU, Perez Chada D, Guinjoan SM, Perez Lloret S, Hedderwick A, Vidal MF, Cardinali DP, Vigo DE. Cardiac autonomic activity predicts dominance in verbal over spatial reasoning tasks : results from a preliminary study. Autonomic Neuroscience : Basic and Clinical 2012, 167, 78-80.

Pathak A, Girerd X, Azizi M, Benamer H, Halimi JM, Lantelm P. Renal denervation for the treatment of arterial hypertension. Journal de Radiologie Diagnostique et interventionnelle 2012, 42, 414-22.

Sénard JM, Despas F, Pathak A. Dysautonies centrales. Hupotension orthostatique. Presse Méd 2012, 41, 1122-7.

Labrunée M, Gremeaux V, Guiraud T, Sanguignol F, Golay A, Pathak A. Education thérapeutique du patient dans les pathologies cardiovasculaires. Arch Cardiovasc Dis Suppl 2012, 4, 299-309.

Labrunée M, Pathak A, Loscos M, Coudeyre E, Casillas JM, Gremeaux V. Therapeutic education in cardiovascular diseases : state of the art and perspectives. Ann Phys Rehab Med 2012, 55, 322-341.

Sénard JM, Pathak A, Pavy-Le Traon A. Troubles dysautonomiques. Le livre de l’Interne, Neurologie, 2012, 128-140.

Sénard JM. Hypotension orthostatique : physiopathologie, diagnostic et traitements. EMC Cardiologie 2012, 7, 1-18.

Meissner WG, Foubert-Samier A, Dupouy S, Gerdelat-Mas A, Debs R, Marquant F, Cochen de Cock V, Rascol O, Tison F, Pavy-le Traon A. Assessment of quality of life with the multiple system atrophy health-related quality of life scale. Mov Disorders 2012, 12, 1574-7.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Moulis G, Béné J, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL and The French Association of PharmacoVigilance Centres. Statin-induced lupus : a case/non-case study in a nationwide pharmacovigilance database. Lupus 2012, 21, 885-9.

Moulis G, Sailler L, Montastruc JL. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins. A case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 900-1.

Moulis G, Sailler L, Sommet A, Lapeyre-Mestre M, Montastruc JL and the French Association of Regional Pharmacovigilance Centers. Exposure to inhibitors of the renin-angiotensin system is a major independent risk factor for acute renal failure induced by sucrose-containing intravenous immunoglobulins : a case-control study. Pharmacoepidemiol Drug Saf 2012, 21, 314-319.

Moulis G, Sommet A, Durrieu G, Bagheri H, Lapeyre-Mestre M, Montastruc JL and The French Association of Pharmacovigilance centres. Trends of reporting of "serious" vs. "non serious" adverse drug reactions over time : a study in the French PharmacoVigilance database. Br J Clin Pharmacol 2012, 74, 201-204.

Moulis G, Sommet A, Sailler L, Lapeyre-Mestre M, Montastruc JL, The French Association Of Regional Pharmacovigilance Centers. Drug-induced immune thrombocytopenia : A descriptive survey in the French PharmacoVigilance database. Platelets 2012, 23,490-4.

Moulis G, Sommet A, Béné J, Montastruc F, Sailler L, Montastruc JL, Lapeyre-Mestre M. Cancer risk of anti-TNF- α at recommended doses in adult rheumatoid arthritis : a meta-analysis with intention to treat and per protocol analyses. PLOS 2012, 7(11) : e48991.

Fournier JP, Lapeyre-Mestre M, Sommet A, Dupouy J, Poutrain JC, Montastruc JL. Laboratory monitoring of patients treated with antihypertensive therapy and newly exposed to non steroidal anti-inflammatory drugs. PLoS One 2012, 7, 3, e34187.

Fournier JP, Sommet A, Bourrel R, Oustric S, Pathak A, Lapeyre-Mestre M, Montastruc JL. Non-steroidal anti-inflammatory drugs (NSAIDs) and hypertension treatment intensification : a population-based cohort study. Eur J Clin Pharmacol 2012, 68, 1533-40.

Danton AC, Montastruc F, Sommet A, Durrieu G, Bagheri H, Bondon-Guitton E, Lapeyre-Mestre M, Montastruc JL. Importance of cytochrome P450 (CYP450) in adverse drug reactions due to drug-drug interactions : a pharmacovigilance study in France. Eur J Clin Pharmacol 2012, Sep 21.

Montastruc F, Sommet A, Bondon-Guitton E, Durrieu G, Bui E, Bagheri H, Lapeyre-Mestre M, Schmitt L, Montastruc JL. The importance of drug-drug interactions as a cause of adverse drug reactions : a pharmacovigilance study of serotoninergic reuptake inhibitors in France. Eur J Clin Pharmacol 2012, 68, 767-775.

Gardette V, Lapeyre-Mestre M, Coley N, Cantet C, Montastruc JL, Vellas B, Andrieu S. Antipsychotic use and mortality risk in community-dwelling Alzheimer’s disease patients : evidence for a role of dementia severity. Curr Alzheimer Res 2012, 9, 1106-1116.

Sommet A, Durrieu G, Lapeyre-Mestre M, Montastruc JL and The Association of French PharmacoVigilance Centres. A comparative study of adverse drug reactions during two heat waves that occurred in France in 2003 and 2006. Pharmacoepidemiol Drug Saf 2012, 21, 285-288.

Maschino F, Hurault-Delarue C, Chebbane L, Fabry V, Montastruc JL, Bagheri H ; French Association of Regional Pharmacovigilance Centers. Bleeding adverse drug reactions (ADRs) in patients exposed to antiplatelet plus serotonin reuptake inhibitor drugs : analysis of the French Spontaneous Reporting Database for a controversial ADR. Eur J Clin Pharmacol 2012, 68, 1557-60.

Bondon-Guitton E, Bagheri H, Montastruc JL and The French Network of Regional PharmacoVigilance Centers. Drug-induced gingival overgrowth : a study in the French Pharmacovigilance Database. J Clin Periodontol 2012, 39, 513-518.

Hillaire-Buys D, Faillie JL, Montastruc JL, Petit P. Stay vigilant : a glitazone (pioglitazone) can hide a glitazar !. Eur J Clin Pharmacol 2012, 68, 1681-83.

Caillet C, Moachon L, Montastruc JL, Bagheri H, French Association of Regional Pharmacovigilance Centers. Safety profile of enantiomers versus racemic mixture : it’s the same ? Br J Clin Pharmacol 2012, 74, 886-89.

Perez-Lloret S, Rey MV, Fabre N, Ory F, Spampinato U, Montastruc JL, Rascol O. Do Parkinson’s disease patients disclose their adverse events spontaneously ? Eur J Clin Pharmacol 2012, 5, 857-65.

Perez-Lloret S, Rey MV, Bondon-Guitton E, Rascol O, Montastruc JL. Drugs associated with restless legs syndrome : a case/non case study in the French Pharmacovigilance database. J Clin Psychopharmacol 2012, 32, 827-7.

Paludetto MN, Olivier-Abbal P, Montastruc JL. Is spontaneous reporting always the most important information supporting drug withdrawals for pharmacovigilance reasons in France ? Pharmacoepidemiol Drug Saf 2012, 21, 1289-94.

Durrieu G, Palmaro A, Pourcel L, Caillet C, Faucher A, Jacquet A, Ouaret S, Perault-Pochat MC, Kreft-Jais C, Castot A, Lapeyre-Mestre M, Montastruc JL. First french experience of ADR reporting by patients after a mass immunization campaign with influenza A (H1N1) pandemic vaccines. Drug Saf 2012, 35, 845-854.

Braillon A, Bewley S, Herxheimer A, Mansfield P, Lexchin J, Menkes DB, Ziganshina LE, Montastruc JL. Marketing versus evidence-based medicine. Lancet 2012, 380, 340.

Urban TJ, Shen Y, Stolz A, Chalasani N, Fontana RJ, Rochon J, Ge D, Shianna KV, Daly AK, Lucena MI, Nelson MR, Molokhia M, Aithal GP, Floratos A, Pe’er I, Serrano J, Bonkovsky H, Davern TJ, Lee WM, Navarro VJ, Talwalkar JA, Goldstein DB, Watkins PB, drug-induced injury network , DILIGEN, EUDRAGENE (Bondon-Guitton E, Spanish DILI registry. Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenet Genomics 2012, 22, 784-95.

Jacquot J, Gony M, Baudrin D, Chastel X, Montastruc JL, Bagheri H. Could we Improve Notification of Adverse Drugs Reactions in Hospital ? Assessment of 5 Years of Network PharmacoMIP’s Activities. Therapie 2012, 67, 231-6.

Moulis G, Batz A, Durrieu G, Viard C, Decramer S, Montastruc JL. Severe neonatal hypercalcemia related to maternal exposure to nutritional supplement containing Spirulina. Eur J Clin Pharmacol 2012, 68, 221-222.

Ferrie B, Dupouy J, Lassoued S, Oustric S, Durrieu G, Rouge-Bugat ME, Montastruc JL. Myopathie sévère par intoxication à la colchicine : à propos d’un cas. Thérapie 2012, 67, 482-3.

Lefort A, Arlet P, Bagheri H, Campistron E. Hypomagnésémie avec hypocalcémie sous oméprazole. Thérapie 2012, 67, 191-2.

Blazejewski S, Girodet PO, Orriols L, Capelli A, Moore N, CESIR Group. Factors associated with serious traffic crashes : a prospective study in southwest France. Arch Intern Med 2012, 172, 1039-41.

Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, Suissa S, Lagarde E ; CESIR Research Group. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry 2012, 73, 1088-94.

Avalos M, Adroher ND, Lagarde E, Thiessard F, Grandvalet Y, Contrand B, Oriols L ; CESIR Research Group. Prescription-Drug-Related risk in driving : comparing conventional and lasso shrinkage logistic regressions. Epidemiology 2012, 23, 706-12.

Roulet L, Asseray N, Foucher N, Potel G, Lapeyre-Mestre M, Ballereau F. Etude des comportements d’automédication chez les patients admis dans un service d’urgences médicales. Thérapie 2012, 67, 447-55.

Montastruc F, Montastruc G, Vigreux P, Bruneval P, Guilbeau-Frugier C, Cron C, Bagheri H, Delisle B, Lapeyre-Mestre M, Pathak A, Montastruc JL. Valvular heart disease in a patient taking 3,4-methylenedioxymethamphetamine (MDMA, ’Ecstasy’). Br J Clin Pharmacol 2012, 74, 547-548.

Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M. Use of multiple sources and capture-recapure method to estimate the frequency of hospitalization related to drug abuse. Pharmacoepidemiol Drug Saf 2012, 21, 733-41.

Sommet A, Ferrières N, Jaoul V, Cadieux L, Soulat JM, Lapeyre-Mestre M, Montastruc JL. Use of drugs, tobacco, alcohol and illicit substances in a french student population. Thérapie 2012, 67, 429-35.

Gass-Jégu F, Damase-Michel C, Hurault-Delarue C, Bourrel R, Montastruc JL. Analysis of Prescriptions associated to Hormone Replacement Therapy in Midi-Pyrénées Region. Therapie 2012, 67, 121-8.

Lacroix I, Hurault-Delarue C, Montastruc JL, Damase-Michel C. Can benfluorex induce congenital malformations ? Diabetes Metab 2012, 38, 373-4.

Franchitto N, Cabot C, Dumonteil N, Bounes V, Pathak A, Rouge D. A prehospital acute coronary syndrome in a cocaine user : an unstable clinical situation. J Med Toxicol 2012, 8, 80-2.

Bordenave H, Despas F, Sommet A, Montastruc JL. Patient’s Medicine Cabinet Composition Study of 207 Families in France. Therapie 2012, 67, 137-43

Stamenkovic S, Solesse A, Zanetti L, Zagury P, Vray M, et le groupe "Intérêt de santé publique et études post-inscription (ISPEP) Lapeyre-Mestre M. Guide de la Haute Autorité de Santé (HAS) : les études post inscription sur les technologies de santé (médicaments, dispositifs médicaux et actes) : principes et méthodes. Thérapie 2012, 67, 409-211.

Cornu C, Camberlein C, Binquet C, Robert C, Vigouroux C, Bouyssou C, Felin A, Dupont-Mordelet MF, Sailly A, Kubiak C, Poli G, Gueguen S, Duchesne C, Ploix S, Thalamas C. Manuel de bonnes pratiques professionnelles des centres d’investigation clinique. Thérapie 2012, 67, 11-42.

Bounhoure JP, Montastruc JL. Risque hémorragique et syndromes coronariens aigus chez les sujets âgés. Bull Acad Natle Méd 2011, 195, 1981-1987.

Castel M, Despas F, Modesto A, Gales C, Honton B, Galinier M, Sénard JM, Pathak A. Effets indésirables cardiaques des chimiothérapies. Press Med 2012, 41, 1122-27.

Mias C, Genet G, Pathak A, Sénard JM, Galès C. Le réveil des cardiomyocytes adultes résidents. Médecine Sciences 2012, 28, 1103-9.

Herxheimer A, Vohra S, Montastruc JL, Edwards R. A major rethink is needed on reporting adverse drug reactions. Br Med J 2012, 345, e6379.

Terzaghi M, Ratti PL, Manni F, Manni R. Sleep paralysis in narcolepsy : more than just a motor dissociative phenomenom ? Neurol Sci 2012, 33, 169-72.

Abadie D, Roussin A. Le tramadol, un analgésique à effet opioîde, noradrenergique et sérotoninergiques : gare aux effets indésirables, interactions médicamenteuses et à la pharmacodépendance. Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Bouscaren N. Le dopage génétique : des souris (transgéniques) et des hommes. Bulletin d’Information de l’AMPD 2012, 7-8.

PDF Damase-Michel C, Lacroix I. - Prescrire mieux et plus sûr. Trait d’Union 2012, 135, 6. [4.4 Mo]

Lapeyre-Mestre M. Benzodiazépines et apparentés. Une consommation scrutée de très près par l’Afssaps. Porphyre 2012, Mars.

Lapeyre-Mestre M. Les benzo de A à Z. L’Infirmière Libérale Magazine 2012, Mars.

Lapeyre-Mestre M. Dépendance à l’alcool. Le baclofène devient un outil acceptable pour l’ANSM. Porphyre 2012. Juin.

Lapeyre-Mestre M. Buprénorphine : faut-il sevrer ? La revue du Praticien 2012, Février.

Montastruc JL. Prescrire avec parcimonie, attention et indépendance. Question Santé 2012. Février.

Montastruc JL. Pharmacovigilance en 2011. La Lettre d’Information des programmes qualité et de la certification 2012 du CHU de Toulouse. Juin.

Montastruc JL, Bien utiliser le paracétamol sans abîmer son foie. Que Choisir Santé 2012, 60, 13.

Montastruc JL Quels vrais nouveaux médicaments en Médecine libérale ? Bulletin Audois d’Information de Pharmacologie 2012, Mai.

Montastruc JL, Lapeyre Mestre M. Pharmacovigilance et PharmacoEpidémiologie. Liris 2012, 9, 5.

Montastruc JL, Montastruc F. Abadie D, Bagheri H. Développer la pharmacovigilance. Pratiques 2012, 59, 81-83.

Montastruc JL, Montastruc F. Which role for regional PharmacoVigilance centers (RPVC) in the new european pharmacovigilance regulation ? Gac Med Bilbao 2012, 109, 2-3.

Montastruc JL. Détournement d’usage du topiramate. La Revue Prescrire 2012, 32, 394.

Montastruc JL. Diurétiques dans l’HTA : encore et toujours en 2012 ! Ou les 100 jours de la chlorthalidone. Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Montastruc JL. Les accidents domestiques ne sont pas une fatalité. Participation au dossier paru dans la revue de la SSMP 2012, 152, 12-13.

Montastruc JL. Nicotine et dopage. Sports et Santé 2012, 23, 7.

Montastruc JL. Quel vrai intérêt du suivi intensif de la glycémie dans le diabète de type 2 ? Bulletin Audois d’Information de Pharmacologie 2012, Juin.

Montastruc JL. La prescription des médicaments chez la personne âgée. Projet de communiqué. Académie Nationale de Médecine

Pathak A. Comment intégrer les produits de triple et double combinaison et de monothérapie dans un concept total pour le soin d’hypertension ? Journal de Cardiologie 2012, Février.

Pathak A. Les génériques : l’avis du pharmacologue. Diabète et Obésité 2012, 63.

Pathak A. Lien entre l’hypertension artérielle et la fonction cognitive. Journal de la Cardiologie 2012.

Retour en haut de page

ANNEE 2011

Publié le 09/02/2012 à 14h02 (mis à jour le 12/04/2023 à 10h48)

PHARMACOLOGIE CLINIQUE

Cayla G, Hulot JS, O’Connor SA, Pathak A, Scott SA, Gruel Y, Silvain J, Vignalou JB, Huerre Y, de la Briolle A, Allanic F, Beygui F, Barthélémy O, Montalescot G, Collet JP. Clinical angiographic and genetic factors associated with early coronary stent thrombosis. JAMA 2011, 306, 1765-1774.

Cochen De Cock V, Debs R, Oudiette D, Leu S, Radji F, Tiberge M, Yu H, Bayard S, Roze E, Vidailhet M, Dauvilliers Y, Rascol O, I Arnulf. The improvement of movement and speech during rapid eye movement sleep behaviour disorder in Multiple System Atrophy. Brain 2011, 10, 1-7.

Antonini A, Martinez-Martin P, Chaudhuri RK, Merello M, Hauser R, Katzenschlager R, Odin P, Stacy M, Stocchi F, Poewe W, Rascol O, Sampaio C, Schrag A, Stebbins GT, Goetz CG. Wearing-off scales in Parkinson’s disease : critique and recommendations. Mov Disord 2011, 26, 2169-2175.

Eriksson Dornellof M, Elgh E, Forsgren L. The relation between cognition and motor dysfunction in drug-naive newly diagnosed patients with Parkinson’s disease. Mov Disord 2011,12, 2183-2189.

Fuzier R, Maguès JP, Dupuis E, Pomiès S, Segui S, Sénard JM. Inhibiteurs de la pompe à protons : impact d’une évaluation des pratiques professionnelles sur la pertinence des prescriptions. ANNFAR 2011, 30, 814-818.

Lesage S, Anheim M, Condroyer C, Pollak P, Durif F, Dupuits C, Viallet F, Lohmann E, Corvol JC, Honoré A, Rivaud S, Vidailhet M, Dürr A, Brice A ; French Parkinson’s Disease Genetics Study Group. Large-scale screening of the Gaucher’s disease-related glucocerebrosidase gene in Europeans with Parkinson’s disease. Hum Mol Genet. 2011, 20, 202-210.

Maret D, Caussé E, Lapeyre-Mestre M, Mansuy JM, Delisle MB, Courtade M, Linas MD, Telmon N, Sixou M, Astié F, Grimoud AM. Prélèvements buccaux en pratique clinique. Médecine buccale 2011, 28, 250.

Martinez-Martin P, Jeukens-Visser M, Lyons KE, Rodriguez-Blazquez C, Selai C, Siderowf A, Welsh M, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz GG, Schrag A. Health-related quality-of-life scales in Parkinson’s disease : Critique and recommendations. Mov Disord 2011, 26, 2371-80.

Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM,Tison F, Bezard E. Priorities in Parkinson’s disease research. Nat Rev Drug Discov 2011, 10, 377-393.

Moulis G, Astudillo, L, Pugnet G, Sailler L, Arlet P. Tuberculose cutanée de l’adulte immunocompétent. Med Mal Inf 2011. 41, 663-664.

Moulis G, Delavigne K, Alvarez M, Brassat D, Bonneville F, Massip P, Adoue D. Des céphalées chroniques. Rev Med Int 2011. 32, 46-47.

Moulis G, Delavigne K, Huguet F, Fortenfant F, Beyne-Rauzy O, Adoue D. Profil des anticorps antiphospholipides et risque de thrombose : étude comparative entre thrombopénie immunologique chronique et syndrome des antiphospholipides primaire. Rev Med Int 2011. 32, 724-29.

Pavy-Le Traon A, Amarenco G, Duerr S, Kaufmann H, Lahrmann H, Shaftmann S, Tison F, Wenning G, Goetz C, Poewe W, Sampaio C, Schrag A, Stebbins GT, Rascol O. The Movement Disorders Task Force on review of dysautonomia rating scales in Parkinson’s disease with regard to symptoms of orthostatic hypotension. Mov Disord 2011, 26, 1985-92.

Perez Lloret S, Rey MV, Ratti L, Rascol O. Pramipexole for the treatment of early Parkinson’s disease. Expert Rev Neurother 2011, 11, 925-35.

Perez-Lloret S, Rascol O. Safety of rasagiline for the treatment of Parkinson’s disease. Expert Opin Drug Saf 2011, 10, 633-643.

Radaideh GA, Choueiry P, Eid E, Ismail A, Berrou JP, Sedefdjian A, Sévenier F, Pathak A. Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function : analysis of middle east data from the OSCAR study. Vascular Health and Risk Management 2011, 7, 1-5.

Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, Melamed E, Poewe W, Stocchi F,Tolosa E, Eyal E, Weiss YM, Olanow CW. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study) : prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011, 10, 415-423.

Rascol O, Lozano A, Stern M, Poewe W. Milestones in Parkinson’s disease – Therapeutics. Mov Disord 2011, 6, 1072-1082.

Rascol O. Drugs and drug delivery in PD : optimizing control of symptoms with pramipexole prolonged-release. Eur. J. Neurol 2011, 18, 3-10.

Sampaio C, Bronzova J, Hauser RA, Lang AE, Rascol O, Van de Witte SV, Theeuwes A. for the Rembrandt/Vermeer Study Groups. Pardoprunox in early Parkinson’s disease : results from two large randomized, double-blind trials. Mov Disord 2011, 26, 1464-1476.

Schapira AH, Barone P, Hauser RA, Mizuno Y, Rascol O, Busse M, Salin L, Juhel N, Poewe W MD. in the name of the pramipexole ER Studies Group. Extended-release pramipexole in advanced Parkinson’s disease : a randomized controlled trial. Neurology 2011, 8, 767-74.

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C. The Movement disorder society evidence-based medicine review update : treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 2011, 26, S42-S80.

Smih F, Desmoulin F, Berry M, Turkieh A, Harmancey R, Iacovoni J, Trouillet C, Delmas C, Pathak A, Lairez O, Koukoui F, Massabuau P, Ferrieres J, Galinier M, Rouet P. Blood signature of pre-heart failure : a microarrays study. Plos One 2011, 6, 2041.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Crespin S, Bourrel R, Hurault-Delarue C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Drug prescribing before and during pregnancy in south west France. Drug Saf 2011, 34, 595-604.

Berthet S, Olivier P, Montastruc JL, Lapeyre-Mestre M. Drug safety of rosiglitazone and pioglitazone in France : a study using the French PharmacoVigilance database. BMC Clin Pharmacol 2011, 11,5.

Bismuth M, Oustric S, Boyer P, Escourrou B, Brillac T, Mesthe P, Boutin A, Arlet P, Montastruc JL. La pharmacie phamiliale : enquête auprès d’un échantillon de patients en Midi-Pyrénées. Thérapie 2011, 66, 131-134.

Bismuth S, Laing-Leng E, Oustric S, Montastruc JL, Lapeyre-Mestre M. Quels antalgiques après le retrait du dextropropoxyphène ? Enquête auprès de médecins généralistes de la région Midi-Pyrénées. Thérapie 2011, 66, 25-28.

Bœuf-Cazou O, Bongue B, Ansiau D, Marquié JC, Lapeyre-Mestre M. Impact of long-term benzodiazepine use on cognitive functioning in young adults : the VISAT cohort. Eur J Clin Pharmacol 2011, 67, 1045-52.

Bœuf-Cazou O, Lapeyre-Mestre M, Niezborala M, Montastruc JL. Profil de consommation de substances psychoactives dans le milieu du travail : résultats de l’enquête "mode de vie et travail". Thérapie 2011, 66, 155-165.

Bondon-Guitton E, Perez-Lloret S, Bagheri H, Brefel C, Rascol O, Montastruc JL. Drug-induced parkinsonism : a review of 17 years experience in a regional pharmacovigilance center in France. Mov Disord 2011, 12, 2226-31.

Bondon-Guitton E, Prévot G, Didier A, Montastruc JL. Pulmonary arterial hypertension and benfluorex : 5 case reports. Thérapie 2011, 66, 135-136.

Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-jais C, Castot A, Montastruc JL and French Network of PharmacoVigilance Centres (CRPV) : Autret-Leca E, Baldin B, Bavoux F, Bénard-laribière A, Biour M, Beyens MN, Colin F, Coquerel A, Crepin S, Décréau-Gaillon G, Dos Santos S, Efthekhari P, Favrelière S, Gautier S, Gras-Champel V, Javot L, Jean-Pastor MJ, Le Beller C, Lebrun-Vignes B, Millaret A, Perrazi A, Pinzani V, Riché C, Schir E, Sgro C, Tebacher-Alt M, Trenque T, Valnet-Rabier MB, Veyrac G . Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2011, 67, 649-651.

Castel M, Pathak A, Despas F, Mazières J. Adverse effects of new biological therapies for non-small-cell bronchial cancer. Presse Médicale 2011, 40, 415-419.

Droz-Perroteau C, Dureau-Pournin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, on behalf of the EULEV study group (Vespignani H, Marchal C, Alpérovitch A, Bénichou J, Jager A, Lavernhe G, Mann M, Montastruc JL, Pédespan JM). The EULEV cohort study : rates of and factors associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol 2011, 1, 121-7.

Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Antihypertensive drug prescription pattern before and during pregnancy in France. Pregnancy hypertension : An International Journal of Women’s Cardiovascular Health 2011, 185-189.

Dupouy J. Poutrain JC, Lapeyre-Mestre M. Naltrexone et traitement substitutif aux opiacés. Thérapie 2011. 66, 549-552.

Durrieu G, Caillet C, Lacroix I, Jacquet A, Faucher A, Ouaret S, Sommet A, Perault-Pochat MC, Kreft-Jais C, Castot A, Damase-Michel C, Montastruc JL, et le Réseau Français des centres de pharmacovigilance. Campagne nationale de vaccination contre la grippe A (H1N1)v : suivi national de pharmacovigilance. Thérapie 2011, 66, 527-40.

Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre-Mestre M, Micallef J. Evidence of clonazepam abuse liability : results of the tools developed by the French Centers for Evaluation and Information on Pharmacodependence (CEIP) network. Fundam Clin Pharmacol 2011, 25, 633-41.

Fuzier R, Bataille B, Fuzier V, Richez AS, Maguès JP, Choquet O, Montastruc JL, Lapeyre-Mestre M. Spinal anesthesia failure after local anesthetic injection into cerebrospinal fluid. Regional Anesth and Pain Med 2011, 36, 322-26.

Galinier M, Lairez O, Roncalli J, Dumonteil N, Maury P, Pathak A, Biendel C. Cardiomyopathies dilatées primitives et secondaires. Cardiologie 2011, 11, 44.

Grossac J, Ruiz S, Bondon-Guitton E, Roux FE, Fourcade O, Montastruc JL, Geeraerts T. Severe intracranial bleeding related to vitamin K Antagonist-Ropinirole interaction. Mov Disord. 2011, 26, 1962-63.
Hillaire-Buys D, Faillie JL, Montastruc JL. Pioglitazone and bladder cancer. Lancet 2011, 378, 1543-4.

Hurault-Delarue C, Lacroix I, Vidal S, Montastruc JL, Damase-Michel C. Drugs in pregnancy : study in the EFEMERIS database (2004 to 2008). Gynecol Obstet Fertil 2011, 10, 554-8.

Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment : a systematic review. Br J Clin Pharmacol 2011, 71, 832-843.

Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre M. Cannabis-related hospitalizations : unexpected serious events identified through hospital databases. Br J Clin Pharmacol 2011, 71, 758-765.

Lacroix I, Berrebi A, Garipuy D, Schmitt L, Hammou Y, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine versus methadone in pregnant opioid-dependent women : a prospective multicenter study. Eur J Clin Pharmacol. 2011, 67, 1053-59.

Lacroix I, Damase-Michel C, Kreft-Jais C, Castot A, Montastruc JL. 2009 H1N1 influenza vaccines in pregnant women : the French Pharmacovigilance survey. Vaccine 2011, 7, 1357-8.

Lacroix I, Hurault-Delarue C, Kessler S, Guitard C, Vidal S, Albouy-Cossard C, Montastruc JL, Damase-Michel C. First epidemiologic data about phloroglucinol exposure during first trimester of pregnancy. Gynecol Obstet Fertil 2011, 39, 694-697.

Montastruc JL, Durrieu G, Rascol O. Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy. Vaccine 2011, 29 (11).

Montastruc JL, Sommet A, Bagheri H, Lapeyre-Mestre M. Benefits and Strengths of the disproportionality analysis for identification of Adverse Drug Reactions in a PharmacoVigilance database. Br J Clin Pharmacol. 2011 72, 905-908.

Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL. Life-threatening drug-associated hyperkalemia : a retrospective study from laboratory signals. Pharmacoepidemiol Drug Saf 2011, 20,747-753.

Omon E, Damase-Michel C, Hurault-Delarue C, Lacroix I, Montastruc JL, Oustric S, Escourrou B. Non-adjuvanted 2009 influenza A (H1N1)v vaccine pregnant women : the results of a French prospective descriptive study. Vaccine 2011, 29, 9649-54.

Orriols L, Philip P, Moore N, Castot A, Gadegbeku B, Delorme B, Mallaret M, Lagarde E ; on behalf of the CESIR Research Group : Avalos M, Bazin F, Blazejewski S, Contrand B, Durrieu G, Girodet PO, Goldberg M, Laumon B, Lauque D, Lecoules N, Memes L, Merle L, Merlière Y, Montastruc JL, Noize P, Orsoni N, POariente A, Ribéreau-Gayon R, Salmi LR, Thiessard F, Tricotel A. Benzodiazepine-like hypnotics and the associated risk of road traffic accidents. Clin Pharmacol Ther 2011, 89, 595-601.

Pauly V, Frauger E, Pradel V, Nordman S, Pourcel L, Natali F, SciortinoV, Lapeyre-Mestre M, Micallef J, Thirion X. Monitoring of benzodiazepine diversion using a multi-indicator approach. Psychopharmacol 2011, 26, 268-277.

Perrin-Terrin A, Pathak A, Lapeyre-Mestre M. QT interval prolongation : prevalence, risk factors and pharmacovigilance data among methadone-treates patients in France. Fundam and Clin Pharmacol 2011.25, 503-510.

Pugnet G, Pathak A, Dumonteil N, Sailler L. Giant cell arteritis as a cause of acute myocarditis in the elderly. J Rhumatol 2011, 38, 2497.

Roulet L, Asseray N, Mottier ML, Chiffolleau A, Potel G, Lapeyre-Mestre M, Ballereau F. Consommation de jus de pamplemousse et risque d’interactions médicamenteuses : étude transversale dans un service d’urgences médicales. Thérapie 2011, 66, 421-429.

Rouve N, Bagheri H, Telmon N, Pathak A, Franchitto N, Schmitt L, Rougé D, Lapeyre-Mestre M, Montastruc JL. the French Association of Regional PharmacoVigilance Centres. Prescribed drugs and violence : a case/noncase study in the French PharmacoVigilance Database. Eur J Clin Pharmacol. 2011, 67, 1189-98.

Salmon-Ceron D, Tubach F, Lortholary O, Chosidow O, Bretagne S, Nicolas N, Cuillerier E, Fautrel B, Michelet C, Morel J, Puechal X, Wendling D, Lemann M, Ravaud P, Mariette X, Bagheri H, Blandin B, Breban M, Bretagne S, Castot A, Chichmanian RM, Chosidow O, Dautzenberg B, Dellamonica P, Dufeu-Demazes N, Emilie D, Gillet C, Hugot JP,Kreft Jais C, Leport C, Montastruc JL, Prieur AM, Ravaud P, Roux C, Vittecoq D. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective french RATIO registry. Ann Rheum Dis 2011, 70, 616.

Wagner S, Varet-Legros M, Fabre C, Montastruc JL, Bagheri H. Confounding factors for variation of clozapine plasma levels : drug interactions with proton pump inhibitor or infectious aetiologies ? Eur J Clin Pharmacol 2011, 67, 533-534.

Retour en haut de page

ANNEE 2010

Publié le 09/02/2011 à 10h48 (mis à jour le 13/04/2017 à 11h51)

PHARMACOLOGIE CLINIQUE

Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials. Neurology 2010 ; 74 : 1151.

Barone P, Poewe W , S Albrecht S, Debieuvre C, Massey D, Rascol , Tolosa E, Weintraub D. Pramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease : a randomised double-blind, placebo controlled trial. Lancet Neurol 2010 ; 9 : 573-580.

Bronzova J, Sampaio C, Hauser R, Lang A, Rascol O, Theeuwes A, Van de Witte S, Van Scharrenburg G, for the Bruegel Study Group. Double-blind, study of pardoprunox, a new partial dopamine agonist, in early Parkinson’s disease. Mov Disord 2010 ; 25 : 738-746.

Causse M, Sénard JM, Démonet JF, Pastor J. Monitoring cognitive and emotional processes through pupil and cardiac response during dynamic versus logical task. Appl Psychophysiol Biofeedback. 2010 ; 35(2):115-23.

Colosimo C, Martinez-Martin P, Fabbrini G, Hauser RA, Merello M, Miyasaki J, Poewe W, Sampaio C, Rascol O, Stebbins GT, Schrag A, Goetz CG. Task force report on scales to assess dyskinesia in Parkinson’s disease : critique and recommendations. Mov Dis 2010. 25 : 1131-1142.

Debs R, Cochen De Cock V, Nègre-Pagès L, Aristin M, Senard A, Rascol O, on behalf of the DoPaMiP Study Group. Thought disorders among non-demented outpatients with Parkinson’s disease : prevalence and associated factors. J Neural Transmission. 2010 ;10:1183-8.

Degris E, Delpierre C, Sommet A, Sire S, Lassoued S, Aquilina C, Marchou B, Massip P, Obadia M, Marion-Latard F, Bonnet E, Bernard J. Longitudinal study of body composition of 101 HIV men with lipodistrophy : dual-energy X-ray criteria for lipodistrophy evolution. J Clin Densitom 2010, 13, 237-44.

Dellapina E, Gerdelat-Mas A, Ory-Magne F, Pourcel L, Galitzky M, Calvas F, Simonetta-Moreau M, Thalamas C, Payoux P and Brefel-Courbon C. Apomorphine effect on pain threshold in Parkinson’s disease : A clinical and positron emission tomography study. Mov Disord, 2010.

Despas F, Pathak A, Berry M, Cagnac R, Massabuau P, Liozon E, Galinier M, Sénard JM. DBH deficiency in an elderly patient : efficacy and safety of chronic droxidopa, Clin Auton Res. 2010 Jan 9.

Despas F, Guerriero E, Galinier M, Sénard JM, Pathak A. Limited prognostic value of cardiac metaiodobenzylguanidine in patient with advanced heart failure, J Heart Lung Transplant. 2010 May ;29(5):591-2.

Despas F, Trouillet C, Franchitto N, Galinier M, Sénard JM, Pathak A. Levosimedan improves hemodynamics functions without sympathetic activation in severe heart failure patients : direct evidence from sympathetic neural recording, Acute Card Care. 2010 Mar ;12(1):25-30.

Eggert K, Squillacote, Barone P, Dodel R, Katzenschlager R, Emre M, Lees AJ, Rascol O, Poewe W, Tolosa E, Trenkwalder C, Onofrj M, Stocchi F, Nappi G, Kostic V, Potic J, Ruzicka E, Oertel W. Safety and efficacy of perampanel in advanced Parkinson’s disease : a renadomized, placebo-controlled study. Mov Dis. 2010.

Evangelou E, Maraganore DM, Annesi G, Brighina L, Brice A, Elbaz A, Ferrarese C, Hadjigeorgiou GM, Krueger R, Lambert JC, Lesage S, Markopoulou K, Mellick GD, Meeus B, Pedersen NL, Quattrone A, Van Broeckhoven C, Sharma M, Silburn PA, Tan EK, Wirdefeldt K, Ioannidis JP. Genetic Epidemiology of Parkinson’s Disease (GEOPD) Consortium. Non-replication of association for six polymorphisms from meta-analysis of genome-wide association studies of Parkinson’s disease : large-scale collaborative study. Am J Med Genet B Neuropsychiatr Genet. 2010 ; 153B(1) : 220-8.

Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C. Skin cancer and Parkinson’s disease. Mov Dis 2010, 25, 139-148.

Foussal C, Lairez O, Calise D, Pathak A, Guilbeau-Frugier C, Valet P, Parini A, Kunduzova O. Activation of catalase by apelin prevents oxidative stress-linked cardiac hypertrophy. FEBS Lett. 2010 ; 584(11):2363-70. Epub 2010 Apr 14.

Friedman JH, Alves G, Hagell P, Marinus J, Marsh L, Martinez-Martin P, Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins G, Schrag A. Fatigue rating scales crititque and recommendations by the movement disorders society task force on rating scales for Parkinson’s disease. Mov Dis. 2010. 25 : 805-822.

Ferreira JJ, Rascol O, Poewe W, Sampaio C, Rocha JF, Nunes T, Almeida L, Soares-da-Silva P, on behalf of the BIA-3202-202 Study Investigators. A double-blind, randomized, placebo and active-controlled study of nebicapone for the treatment of motror fluctuations in Parkinson’s disease. CNS Neuroscience & Therapeutics 2010 (in press).

Franchitto N, Despas F, Labrunée M, Boveda S, Galinier M, Sénard JM, Pathak A. Tonic chemoreflex activation contributes to increased sympathetic nerve activity in heart failure-related anemia, Hypertension 2010 Apr ;55(4):1012-7.

Hogl B, Arnulf I, Comella C, Ferreira JJ, Iranzo A, Tilley B, Trenkwalder C and the Steering Committee Poewe W, Rascol O, Sampaio C, Stebbins GT and Goetz CG. Scales to assess sleep impairment in Parkinson’s disease : critique and recommendations. Mov Disord 2010 ; 25 : 2704-2716

Hauser RA, Schapira AHV, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W. Randomized, double-Blind, multi-center evaluation of pramipexole extended-release (ER) once daily in early Parkinson’s disease. Mov Disord. 2010 ;25:2542-9..

Koppo K, Larrouy D, Marques MA, Berlan M, Bazjova M, Polak J, Van de Voorde J, Bulow J, Lafontan M, Crampes F, Langin D, Stitch V, de Glisezinski I. Lipid mobilization in subcutaneous adipose tissue during exercise in lean and obese humans. Roles of insulin and natriuretic peptides. Am J Physiol Endocrinol Metab. 2010 ;299:E258-65.

Lesage S, Patin E, Condroyer C, Leutenegger AL, Lohmann E, Giladi N, Bar-Shira A, Belarbi S, Hecham N, Pollak P, Ouvrard-Hernandez AM, Bardien S, Carr J, Benhassine T, Tomiyama H, Pirkevi C, Hamadouche T, Cazeneuve C, Basak AN, Hattori N, Dürr A, Tazir M, Orr-Urtreger A, Quintana-Murci L, Brice A. French Parkinson’s Disease Genetics Study Group. Parkinson’s disease-related LRRK2 G2019S mutation results from independent mutational events in humans. Hum Mol Genet. 2010 ; 19 :1998-2004.

Lesage S, Condroyer C, Lohman E, Troiano A, Tison F, Viallet F, Damier P, Tranchant C, Vidhaillet M, Ouvrard-Hernandez AM, Dürr A, Brice A. French Parkinson’s Disease Genetics Study Group (FPDGSG). Follow-up study of the GIGYF2 gene in French families with Parkinson’s disease. Neurobiol Aging. 2010 ; 31 : 1069-71.

Nègre-Pagès L, Grandjean H, Lapeyre-Mestre M, Montastruc Jl, Fourrier A, Lépine JP, Rascol O on behalf DOPAMIP study Group. Anxious and depressive symptoms in Parkinson’s Disease : the french cross-sectionnal DOPAMIP study. Mov Dis 2010, 25 ; 157-166.

Olanov CW, Rascol O. The delayed-start study in Parkinson disease : can’t satisfy everyone. Neurology 2010. 74, 1149-1150.

Olanov CW, Rascol O. Commentary published today : Rasagiline in Parkinson’s disease. The authors reply. N Eng J of Med, 2010, 362, 7, 658-659.

Paris A, C. Brandt, C. Cornu, P. Maison, C. Thalamas and J. L. Cracowski. Informed consent documents improvement does not increase patients comprehension in biomedical research. Br J Clin Pharmacol, 2010, 69, 3, 231-237.

Pathak A, Berdeaux A, Mulder P, Thuillez C. Ivabradine dans la maladie coronaire : pharmacologie expérimentale et clinique. Thérapie 2010, 65, 483-489.

Pavy-Le Traon A, Fontaine S, Tap G, Guidolin B, Senard JM and Hanaire H. Cardiovascular autonomic neuropathy and other complications in type 1 diabetes. Clin Auton Res, 2010, 20, 3, 153-60.

Payoux P, Brefel-Courbon C, Ory-Magne F, Regragui W, Thalamas C, Balduyck S, Durif F, Azulay JP, Tison F, Blin O, Esquerre JP, Rascol O. Motor activation in multiple system atrophy and Parkinson’s disease : a PET study. Neurology 2010 (in press).

Péran P, Cherubini A, Assogna F, Piras F, Quattrocchi C, Peppe A, Celsis P, Rascol O, Démonet JF, Stefani A, Pierantozzi M, Pontieri F, Caltagirone C, Spalletta G, Sabatini U. Nigrostriatal signature from MRI markers in Parkinson disease. Brain 2010 ;133:3423-33.

Perez-Lloret S, Rascol O. Dopamine agonists for the treatment of early or advanced Parkinson’s disease. CNS Drugs. 2010 ;24:941-68.

Perez-Lloret S, Rascol O. Rotigotine for the treatment of Advanced Parkinson’s disease. European Neurological Review 2010 ; 4 : 24-28.

Perez Lloret S, Rascol O. Pramipexole extended-release (once-daily formulation) for the treatment of Parkinson’s disease. Exp Opin Pharmacother. 2010 ; 11 : 2221-2230.

Pillard F, Van Wymelbeke V, Garrigue E, Moro C, Crampes F, Guilland JC, Berlan M, De Glisezinski I, Harant I, Rivière D, Brondel L. Lipid oxidation in overweight men after exercise and food intake. Metabolims Clinical and experimental 2010, 267-274.

Rascol O, Azulay JP, Blin O, Bonnet AM, Brefel-Courbons C, Césaro P, Damier P, Debilly B, Durif F, Galitzky M, Grouin JM, Pennaforte S, Villafane G, Yaici S, Agid Y. orodispersible sublingual prirbedil to abort OFF episodes : a single dose placebo-controlled, randomized, double-blinb, cross-over study. Mov Dis 2010, 3, 368-376.

Rascol O, Barone P, Hauser RA, Mizuno Y, Poewe W, Schapira AHV, Salin L, Sohr M, Debieuvre C, for the Pramipexole Switch Study Group. Efficacy, safety, and tolerability of overnight switching from immediate to once daily extended-release pramipexole in early Parkinson’s disease. Mov Disord. 2010 ;25:2326-32.

Rascol O. L’UPDRS est "morte", vive la MDS-UPDRS. A nous d’en valider la traduction française ! Rev. Neurol. 2010 ; 166, 5-6.

Schapira AHV, Albrecht S, Barone P, Comella CL, McDermott M, Mizuno Y, Poewe W, Rascol O, Marek K. Rationale for delayed-start study of pramipexole in Parkinson’s disease : the PROUD study. Mov Disord. 2010 ;25:1627-32.

Senard JM, Pathak A. Neurogenic orthostatic hypotension of Parkinson’s disease : what exploration for what treatment ? Rev Neurol. 2010, 166, 779-784.

Stocchi F, Rascol O , Kieburtz K, Poewe W, Jankovic J, Tolosa E, Barone P, Lang AE, Olanow W. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson’s disease. The STRIDE-PD Study. Ann Neurol 2010 ; 68 : 18-27.

Williams A, Gill S, Varma T, Jenkinson C, Quinn N, Mitchell R, Scott R, Ives N, Rick C, Daniels J, Patel S, Wheatley K, on behalf of the PD SURG Collaborative Group. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial) : a randomised, open-label trial. Lancet Neurol 2010 ; 9 : 581-591.

Bounes V, Barthélémy R, Diez O, Charpentier S, Montastruc JL, Bagheri H. Sulfentanil is not superior to morphine for the treatment of acute traumatic pain in an emergency setting : a randomized, double-blind out of hospital trial. Ann Emerg Med 2010 ;56:509-16.

Wiesner S, Birkenfeld AL, Engeli S, Haufe S, Brechtel L, Wein J, Hermsdorf M, Karnahl B, Berlan M, Lafontan M, Sweep FC, Luft FC, Jordan J. Neurohumoral and metabolic response to exercise in water. Horm Metab Res 2010. 42 ; 334-9.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Bagheri H. Glitazones et hépatites. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Bagheri H. Dermatomyosite et anti TNF alpha. Bulletin Audois d’Information de Pharmacologie. Novembre 2010.

Biboulet M, Lapeyre-Mestre M, Gardette V. Comparaison de la consommation de benzodiazépines selon le type d’usage de la buprénorphine dans une cohorte de nouveaux usagers. Prat Org Soins 2010, 41, 205-213.

Bismuth S, Chalvignac C, Bagheri H, Oustric S. Prescription de médicaments ASMR de niveau V chez les sujets de plus de 65 ans en soins primaire ambulatoires. La Revue du Praticien 2010, 60, 1.

Bœuf-Cazou O, Niezborala M, Marquie JC, Lapeyre-Mestre M. Factors associated with psychoactive drug initiation in a sample of workers in France : results of the VISAT cohort study. Pharmacoepidemiol Drug Saf 2010, 19 : 296-305.

Escourrou B, Bouville B, Bismuth M, Durrieu G, Oustric S. Self-medication in children by parents : a real risk ? A cross sectional descriptive study. Rev Prat 2010, 20, 2734.

Frauger E, Pauly V, Pradel V, Rouby F, Arditti J, Thirion X, Lapeyre-Mestre M. Micallef J. Evidence of clonazepam abuse liability : results of the tools developed by the french centers for evaluation and information on pharmacodependance (CEIP) network. Fundam Clin Pharmacol 2010 PMID 21077937.

Fuzier R. Une surveillance accrue des effets indésirables. Plateaux Techniques actualités 2010. 45. 30.

Julians-Minou G, Bruch S, Peyre N, Sudérie G, Lapeyre-Mestre M, Roussin A. La buprénorphine pour le traitement de la dépendance aux opiacés : une étude sur la substitution par les génériques menée en pharmacie d’officine. Thérapie 2010, 65 : 241-247.

Orriols L, Delorme B, Gadegbeku B, Tricotel A, Contrand B, Laumon B, Salmi LR, Lagarde E, on behalf of the CESIR research group. Prescription medicines and the risk of road traffic crashes : a french registry-based study. Plos Med 2010, 7, e1000366.

Pradel V, Delga C, Rouby F, Micallef J, Lapeyre-Mestre M. Assessment of abuse potential of benzodiazepines from a prescription database using doctor shopping as an indicator. CNS Drugs 2010, 24 : 611-620.

Bagheri H, Montastruc JL, Lavezzi O. Plavix° (clopidogrel) et ses génériques : parfait exemple de confusion règlementaire, au profit de qui ? Rev Prescrire 2010, 30, 553.

Boudal P, Sommet A, Bagheri H, Pathak A , Montastruc JL. Bleedings induced by oral anticoagulants : o study of adverse drug reactions reported to Midi-Pyrénées PharmacoVigilance Centre between 2003 and 2006. Thérapie 2010, 65, 567-569.

Caillet C, Durrieu G, Jacquet A, Faucher A, Ouaret S, Perrault-Pochat MC, Kreft-Jais C, Castot A, Montastruc JL. Safety surveillance on influenza A(H1N1)v monovalent vaccines during the 2009-2010 mass vaccination campaign in France. Eur J Clin Pharmacol 2010. Décembre 2010.

Chebane L, Tavassoli N, Bagheri H, Montastruc JL et le réseau des Centres Régionaux de Pharmacovigilance Français. Hyperglycémies d’origine médicamenteuse : étude dans la Base Nationale Française de PharmacoVigilance (BNPV). Thérapie 2010, 65, 447-458.

Droz-Perroteau C, Dureau-Purnin C, Vespignani H, Marchal C, Blin P, Blazejewski S, Pollet C, Jové J, Robinson P, Moore N, Fourrier-Réglat A, and the scientific committee members of the EULEV Study group : Vespignani H, Marchal C, Alpérovitch A, Bénichou J, Jager A, Lavernhe G, Mann M, Montastruc JL, Pédespan JM. The EULEV cohort study : rates of and factos associated with continuation of levetiracetam after 1 year. Br J Clin Pharmacol 2010, 71, 121-127.

Dupouy J, Petureau F, Montastruc JL, Oustric S, Degano B. Une cause rare de cyanose : sulfhémoglobinémie imputable au thiocolchicoside (Miorel°). Revue des Maladies Respiratoires 2010, 27, 80-83.

Durrieu G, Hurault C, Damase-Michel C, Montastruc JL. Perception of risk of adverse drug reactions : a 3-year follow-up of a cohort of medical students. Fundam Clin Pharmacol 2010, 24, 423-427.

Fuzier R, Serres I, Lapeyre-Mestre M, Montastruc. Pharmacovigilance des médicaments antihyperalgésiants. In compte-rendu du 52e Congrès National d’anesthésie et de réanimation. Evaluation et traitement de la douleur 2010, 1-11.

Gallini A, Degris E, Desplas M, Bourrel R, Archambaud M, Montastruc JL, Lapeyre-Mestre M, Sommet A. Influence of fluoroquinolone consumption in inpatients and outpatients on ciprofloxacin-resistant Escherichia Coli in a university hospital. J Antimicrob Chemother 2010, 65, 2650-2657.

Gardette V, Andrieu S, Lapeyre-Mestre M, Coley N, Cantet C, Ousset PJ, Grand A, Montastruc JL, Vellas B. Predictive factors of discontinuation and switch of cholinesterase inhibitors in community-dwelling patients with Alzheimer’s Disease. Drugs 2010, 24, 431-442.

Gony M, Badie K, Sommet A, Jacquot J, Baudrin D, Gauthier P, Montastruc JL, Bagheri H. Improving adverse drug reaction reporting in hospitals. Results of the French Pharmacovigilance in Midi-Pyrénées Region (PharmacoMIP) Network 2-year pilot study. Drug Saf 2010, 33, 409-416.

Lacroix I, Damase-Michel C, Montastruc JL. : Vaccin de la grippe A(H1N1)v et grossesse. In CD Rom. 22e Forum Medical de Rangueil de Toulouse. Faculté de Médecine de Rangueil.

Moulis G, Bagheri H, Saint Martory J, Bernard P, Montastruc JL. Very late relapse of dapsone-induced methaemoglobinemia. Eur J Clin Pharmacol 2010, 66, 645-646.

Moulis G, Pugnet G, Bagheri H, Courtellemont C, Huart A, Chauveau D, Pourrat J, Montastruc JL. Acquired factor VII haemophilia following influenza vaccination. Eur J Clin Pharmacol 2010, 66, 1069-1070.

Montastruc JL, Bagheri H, Damase C. Rimonabant, benfluorex, sibutramine : l’histoire se répète ! Plaidoyer pour la prise en compte des données pharmacodynamiques de base. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Montastruc JL. Le lien entre inhibiteurs de la Pompe à Protons (IPP) et pneumopathie confirmé par une méta-analyse. Bulletin Audois d’Information de Pharmacologie. Mai 2010.

Montastruc JL. Remède ou médicament ? Réflexions d’un pharmacologue. Prescrire 2010, 315, 73.

Montastruc G, Favreliere S, Sommet A, Pathak A, Lapeyre-Mestre M, Perault-Pochat MC, Montastruc JL and the French Association of regional PharmacoVigilance Centres. Drugs and dilated cardiomyopathies : a case/noncase study in the french PharmacoVigilance Database. Br J Clin Pharmacol 2010, 69, 287-294.

Montastruc JL, Durrieu G, Sommet A, Damase-Michel C, Lapeyre-Mestre M. Anticholinergics, antimuscarinics or atropinics ? About the words in pharmacology. Br JClin Pharmacol 2010, 69, 5 ; 561-562.

Montastruc JL, Danton AC, Durrieu G. Neuropathy as a potential complication of levodopa use in Parkinson’s disease : a pharmacological and pharmacovigilance point of view. Mov Dis 2010, 25, 660-661.

Montastruc JL. Réflexions après le retrait de la rosiglitazone. Bulletin Audois d’Information de Pharmacologie. novembre 2010.

Olivier P, Montastruc JL, et le réseau français des centres régionaux de pharmacovigilance. Profil d’effets indésirables des insaponifiables d’avocat et de soja. Presse Médicament 2010, 39, 211-216.

Perez-Lloret S, Bondon-Guitton E, Rascol O, Montastruc JL, and the French Association of Regional Pharmacovigilance. Adverse drug reactions to dopamine agonists : a comparative study in the French pharmacovigilance database. Mov Disord 2010, 12, 1876-1880.

Roussin A, Montastruc JL, Lapeyre-Mestre M. More about the safety of propofol. Br Med J 2010, 1.

Senard-orejo A, Durrieu G, Depiesse F, Schmitt L, Rivière D, Montastruc JL. Consommation de substances interdites chez le sportif : étude à l’Antenne Médicale de Prévention du Dopage de Midi-Pyrénées (AMPD-MP). Thérapie 2010, 65, 459-463.

Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A. High maintenance dosage of clopidogrel is associated with a reduced risk of stent thrombosis in clopidogrel-resistant patients. American Journal Cardiovascular Drugs 2010, 10, 29-35.

Weill A, Paita W, Tuppin P, Fagot JP, Neumann A, Simon D, Ricordeau P, Montastruc JL, Allemand H. Benfluorex and valvular heart disease : a cohort study of a million people with diabetes mellitus. Pharmacoepidemiol. DrugS. 2010, 19, 1256-1262.

Retour en haut de page

ANNEE 2009

Publié le 15/02/2010 à 10h11 (mis à jour le 26/08/2015 à 11h44)

PHARMACOLOGIE EXPÉRIMENTALE

Cifani C, Durocher Y, Pathak A, Penicaud L, Smih F, Massi M, Rouet P, Polidori C. Possible common central pathway for resisting and insulin irregulating food intake. Acta Physiologica 2009 ; 196 : 395-400.

De Glisezinski I, Larrouy D, Bazjova M, Koppo K, Polak J, Berlan M, Bulow J, Langin D, Marques MA, Crampes F, Lafontan M, Stich V. Adrenaline but not noradrenaline is a determinant of exercise-induced lipid mobilization in human subcutaneous adipose tissue. J Physiol 2009, 587, 3393-3404.

Pillard F, Van Wymelbeke V, Garrigue E, Moro C, Crampes F, Guilland JC, Berlan M, De Glisezinski I, Harant I, Rivière D, Brondel L. Lipid oxidation in overweight men after exercise and food intake. Metabolism Clin Experim. In press.

PHARMACOLOGIE CLINIQUE

Bensimon G, Ludolph A, Agid Y, Vidailhet M, Payan C, Nigel P Leigh and for the NNIPPS Study Group. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders : The NNIPPS Study. Brain 2009 ; 132 : 156-171.

Brefel-Courbon C. Les effets neuropharmacologiques du placebo. La lettre du GRAS Groupe de Recherche et d’Action pour la Santé (Belgique) 2009, 63, 41.

Brefel-Courbon C. Les troubles neurovégétatifs (troubles digestifs) au cours de la maladie de Parkinson. Rev Neurol (Paris) 2009, 165, F63.

Chaumet G, Taillard J, Sagaspe P, Pagani M, Dinges DF, Pavy-le-Traon A, Bareille MP, Rascol O, Philip P. Confinement and sleep deprivation effects on propensity to take risks. Aviation, Space and Environmental Medicine 2009, 80 : 73.

Conchou F, Loubinoux I, Castel-Lacanal E, Le Tinnier A, Gerdelat-Mas A, Faure-Marie N, Gros H, Thalamas C, Calvas F, Berry I, Chollet F, Moreau S. Neural substrates of low-fraquency repetiotive transcranial magnetic stimulation during movement in healthy subjects and acute stroke patients. A pet study. Hum Brain Mapp 2009, 30, 2542-57.

Despas F, Detis N, Franchitto N, Dumonteil N, Labrunée M, Bellon B, Galinier M, Sénard JM, Pathak A. Excessive sympathetic activation in heart failure with chronic renal failure : role of chemoreflex activation. J. Hypertens. 2009, 27 : 1849-54.

Devos D, for the French Duodopa Study Group. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s disease. Mov Disorder 2009 ; 24 : 993-1000.

Evatt ML, Chaudhuri KR, Chou KL, Cubo E, Hinson V, Kompoliti , ang C, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Dysautonomia rating scales in Parkinson’s disease : sialorrhea, dysphagia, and constipation-critique and recommendations by movement disorders task force on rating scales for Parkinson’s disease. Mov Dis 2009, 24, 635-646.

Giladi N, Tal J, Azulay T, Rascol O, Brooks DJ, Melamed E, Oertel W, Poewe WH, Stocchi F, Tolosa E. Validation of the freezing of gait questionnaire in patients with Parkinson’s disease. Mov Dis 2009, 24, 655-661.

Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Vcubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Lohle M, Stocchi F, Grosset J. Adherence to antiparkinson medication in a multicenter european study. Mov Dis 2009, 24, 826-832.

Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O,Theeuwes A, van de Witte SV. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson’s disease. Eur Neurol 2009 ; 62 : 40-48.

Ibáñez P, Lesage S, Janin S, Lohmann E, Durif F, Destée A, Bonnet AM, Brefel-Courbon C, Heath S, Zelenika D, Agid Y, Dürr A, Brice A ; French Parkinson’s Disease Genetics Study Group. Alpha-synuclein gene rearrangements in dominantly inherited parkinsonism : frequency, phenotype, and mechanisms. Arch Neurol 2009 ; 66 : 102-108.

Lesage S, Condroyern C, Lannuzel A, Lohmann E, Troiano A, Tison F, Damier P, Thobois S, Ouvrard-Hernandez AM, Rivaud-Péchoux S, Brefel-Courbon C, Destée A, Tranchant C, Romana M, Leclere L, Dürr A, Brice A, for the French Parkinson’s Disease Genetics Study Group. Molecular analyses of the LRRK2 gene in European and North African autosomal dominant Parkinson’s disease. J Med Genet 2009 ; 46 : 458-464.

Lohmann E, Thobois S, Lesage S, Broussolle E, Tezenas du Montcel, S Ribeiro MJ, Remy P, Pelissolo A, Dubois B, Mallet L, Pollak P Agid Y, Brice A, The French Parkinson’s Disease Genetics Study Group. A multidisciplinary study of patients with early-onset PD with and without parkin mutations. Neurology 2009 ; 72 : 110-116.

Ory-Magne F, Brefel-Courbon C, Payoux P, Debruxelles S, Sibon I, Goizet C, Labauge P, Menegon P, Uro-Coste E, Ghetti B, Delisle MB, Vidal R, Rascol O. Clinical phenotype and neuroimaging findings in a french family with hereditary ferritinopathy (FTL498-499Ins TC). Mov Dis 2009, 24, 1676-83.

Pathak A. L’insuffisance cardiaque à fraction d’éjection préservée : pas de place pour l’irbésartan. Bulletin Audois d’Information de Pharmacologie. Juin 2009.

Payoux P, Remy P, Miloudi, M, Houeto JL, Stadler C, Bejjani BP, Yelnik J, Samson Y, Rascol O, Agid Y, Damier P. Contrasting changes in cortical activation induced by acute high-frequency stimulation within the globus pallidus in Parkinson’s disease. J Cereb Blood Flow Metab 2009 ; 29 : 235-243.

Péran P, Cherubini A, Luccichenti G, Hagberg G, Démonet JF, Rascol O, Celsis P, Camtagirone C, Spalletta G, Sabatini U. Volume and iron content in basal ganglia and thalamus. Hum Brain Mapp 2009 ; 30 : 2667-2675.

Péran P, Gardebat D, Cherubini A, Pira F, Luccichenti G, Peppe A, Caltagirone C, Rascol O, Demonet JF, Sabatini U. Object naming and action-verb generation in Parkinson’s disease : a fMRI study. Cortex 2009 ; 45 : 960-971.

Perez-Lloret S, Rossi M, Cardinali DP, Merello M. Actigraphic evaluation of motor fluctuations in Parkinson’s disease patients. Int J Neurosc 2009, 119:1-14.

Perez-Lloret S, Rossi M, Cardinali DP, Merello M. Activity-rest rhythm abnormalities in Parkinson’s disease patients are related to dopaminergic therapy. Int. J Neurosc 2009, XX:1-14.

Perez-Lloret S, Rossi M, Nouzeilles MI, Trenkwalder C, Cardinali DP, Merello M. Parkinson’s disease sleep scale, sleep logs, and actigraphy in the evaluation of sleep in parkinsonian patients. J Neurol. 2009, 10.1007/s00415-009-5143-3.

Perez-Lloret S, Toblli JE, Cardinali DP, Milei J. Gender differences in age-related increase of asleep blood pressure. Arch. Gerontol. Geriat. 2009, 2049.

Petzold A, Thompson EJ, Keir G, Quinn N, Holmberg B, Dizdar N, Wenning GK, Rascol O, Tolosa E, Rosengren L. Longitudinal one-year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy. J Neurol Sci 2009, 279 : 76-79.

Rascol O, Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson’s disease. Expert Opin Pharmacother 2009 ; 10 : 677-691.

Rascol O, Schelosky L. 123I-Metaiodobenzylguanidine scintigraphy in Parkinson’s disease and related disorders. Mov Disord 2009 ; 24 (supl.2) : S732-S741.

Rascol O. Disease modification » trials in Parkinson’s disease : target populations, endpoints and study design. Neurology 2009 ; 72 (suppl 7) : S51-8.

Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, Combemale P, Ferkal S, Vidaud M, Aubourg P, Vidaud D, Wolkenstein P. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009, 18,15, 2768-78.

Schapira AH, Agid Y, Barone P, Jenner P, Lemke MR, Poewe W, Rascol O, Reichmann H, Tolosa E. Perspectives on recent advances in the understanding and treatment of Parkinson’s disease. Eur Jour Neurol 2009, 16 : 1090-1099.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Bœuf O, Pourcel L, Lapeyre-Mestre M. Impact de la consommation d’alcool sur les fonctions cognitives chez des sujets actifs : résultat de l’étude VISAT (Vieillissement, Santé, Travail). Cahiers de l’IREB 2009, N° 19.

Bœuf-Cazou O, Lapere-Mestre M, Niezborala M, Montastruc JL. Evolution of drug consumption in a sample of French workers since 1986 : the "Drugs and work" study. Pharmacoepidemiology 2009, 18, 335-343.

Bondon-Guitton E, Sommet A, Montastruc JL, and the French Association Regional Centres. Confusion, a rather serious adverse drug reaction with valproic acid : a review of the french pharmacovigilance database. Pharmacopsychiatry 2009, 42 : 61-65.

Brefel-Courbon C, Grolleau S, Thalamas C, Bourrel R, Allaria-Lapierre V, Loi R, Micallef-Roll J, Lapeyre-Mestre M. Comparison of chronic analgesic drugs prevalence in Parkinson’s disease, other chronic diseases and the general population. Pain 2009, 141, 1-2, 14-8.

Burgan F, Montastruc JL, Bagheri H. Dobesilate-induced serious neutropenia. Presse Med 2009, 38, 846-8.
Damase-Michel C, Christaud J, Berrebi A, Lacroix I, Montastruc JL. What do pregnant women know about non-steroidal anti-inflammatory drugs ? Pharmacoepidemiol Drug Saf 2009, 18, 1034-1038.

Damase-Michel C, Lacroix I, Hurault C, Sarramon MF, Guittard C, Berrebi A, Grau M, Albouy-Cossard C, Bourrel R, Elefant E, Montastruc JL. EFEMERIS : une nouvelle base de données française. La Lettre du Pharmacologue 2009. 23 : 3.

Damase-Michel C, Lacroix I. Médicaments indiqués et contre-indiqués pendant la grossesse : actualités 2009. 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Décisier M, Duhalde V, Faure P, Ammoury A, Gony M, Moreau J, Montastruc JL, Bagheri H, Spiller R. Rapid-onset febrile dermatosis. Gut 2009, 58-67.

Do C, Huyghe E, Lapeyre-Mestre M, Montastruc JL, Bagheri H. Statins and erectile dysfunction. Results of a case/non-case study using the french pharmacovigilance system database. Drug Saf 2009, 32, 591-7.

Durrieu G, Hurault C, Damase-Michel C, Montastruc JL. Perception of risk of adverse drug-reactions : a 3-year follow-up of a cohort of medical students. Fundam Clin Pharmacol 2009, oct 21.

Espinasse G, Kamar N, Hurault C, Suc B, Fourtanier G, Montastruc JL, Rostaing L, Bagheri H. Drug exposure and perceived adverse drug events reported by liver-transplant patients. Int J Clin Pharmacol Ther 2009, 47 : 159-164.

Fuzier R, Lapeyre-Mestre M, Mertes PM, Nicolas JF, Beanoit Y, Didier A, Albert N, Montastruc JL. Immediate and delayed type allergic reactions to amide local anesthesics : clinical features and skin testing. Pharmacoepidemiol Drug Saf 2009, 18, 595-601.

Fuzier R, Lapeyre-Mestre M, Samii K, Montastruc JL, and the French Association of Regional Pharmacovigilance Centres. Adverse drug reactions to local anaesthetics : a review of the French pharmacovigilance database. Drug Saf 2009, 32, 345-56.

Gaubert S, Vié M, Damase-Michel C, Pathak A, Montastruc JL. Dextpropoxyphene withdrawal from a french university hospital : impact on analgesic drug consumption. Fundam Clin Pharmacol 2009, 23, 247-252.

Jouanjus E, Lapeyre-Mestre M. Les effets indésirables du cannabis. Webanesthésie 2009, 3:09047.

Lacroix I, Hurault C, Sarramon MF, Guitard C, Berrebi A, Grau M, Albouy-Cossard C, Bourrel R, Elefant E, Montastruc JL, Damase-Michel C. Prescription of drugs during pregnancy : a study using EFEMERIS, the new French database. Eur J Clin Pharmacol 2009, 65, 839-46.

Lapeyre-Mestre M, Roussin A. Addictovigilance : Actualités en pharmacodépendance. 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, Heresbach D, Martin A, Schaeverbeke T, Salmon D, Lemann M, Hermine O, Raphael M, Ravaud P for the RATIO group. Lymphoma in patients treated with anti-TNF. Results of the 3-year prospective french RATIO registry. Ann Rheum Dis 2009, In Press.

Micallef-Roll J, Lapeyre-Mestre M, on behalf of the "Association Française des centres d’Evaluation et d’Information sur la Pharmacodépendance-Addictovigilance. Second meeting of the french CEIP (Centre d’Evaluation et d’Information sur la Pharmacodépendance. Part I : how to evaluate and prevent the abuse and dependence on hypnotic/anxiolytic drugs ? Thérapie 2009, 64 : 355-364.

Montastruc G, Degand B, Montastruc JL, Perault-Pochat MC. Arrêt cardiaque récupéré sous varénicline : à propos d’un cas. Thérapie 2009, 64 : 65-66.

Montastruc JL, Damase C, Bagheri H. Réflexions après le retrait du rimonabant : plaidoyer pour la prise en compte des données de base. Prescrire 2009, 29, 303.

Montastruc JL, Durrieu G, Olivier P, Guitton E, Bagheri H. Actualités 2009 en pharmacovigilance. 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Montastruc JL. De la pharmacovigilance à la pharmacoépidémiologie et aux plans de gestion des risques. Rev Med Int 2009, 30S, S281-S290.

Montastruc JL. Exigeons de vrais comparateurs ! Rev Prescrire 2009, 29, 794.

Montastruc JL. Les vrais nouveaux médicaments pour le médecin généraliste en 2009. 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Montastruc JL. On dope bien aussi les chevaux ! Rev Prescrire 2009, 29, 471-472.

Montastruc JL. Quels vrais nouveaux médicaments en médecine ambulatoire en 2008 ? Bulletin Audois d’Information de Pharmacologie. Juin 2009.

Montastruc P. A la recherche des hypoglycémiants. Prescrire 2009, 306 : 313.

Nègre-Pagès L, Cochen V, Debs R, Damier P, Destée A, Tison F, Rascol O pour le groupe de travail PARKMIP/COPARK. Prévalence et facteurs associés aux hallucinations dans la maladie de Parkinson : données préliminaires de l’étude COPARK dans la région Midi-Pyrénées. Rev Neurol (Paris) 2009, 165 : 54-56.

Olanow CW, Rascol O, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E. A double-blind, delayed start study of rasagiline in early Parkinson’s disease : the ADAGIO Study. NEJM 2009 ; 361 : 1268-1278.

Olivier P, Montastruc JL. La vigilance des essais cliniques : une nouvelle organisation pour le CHU Toulouse. La lettre d’Information de la recherche et de l’Innovation Scientifique du CHU de Toulouse 2009. 3, juin.

Olivier P, Bertrand L, Tubery M, Lauque D, Montastruc JL, Lapeyre-Mestre M. Hospitalizations because of adverse drug reactions in elderly patients admitted through the emergency department. A prospective survey. Drugs Aging 2009, 26, 475-482.

Orriols L, Gaillard J, Lapeyre-Mestre M, Roussin A. A pharmacoepidemiological pilot study based on community pharmacies in France. Drug Saf 2009, 32 : 859-873.

Pathak A. Cytochrome P450 : quelle importance pour le médecin généraliste ? 21ème Forum Médical de Rangueil Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Pathak A. Rozuvastatine et haut risque cardiovasculaure : encore un échec ! La lettre du GRAS Groupe de Recherche et d’Action pour la Santé (Belgique) 2009, 63, 41.

Perez-Lloret S, Amaya M, Merello M. Pregabalin-induced parkinsonism : a case report. Clinical NeuroPharmacol. 2009, 32, 353-354.

Pugnet G, Ysebaert L, Bagheri H, Montastruc JL, Laurent G. Immune thrombocytopenic purpura following human papillomavirus vaccination. Vaccine 2009, 27, 3690.

Reynaud F, Giraud P, Cisterne JM, Verdier D, Kouchakipour Z, Hermelin A, Modesto-Segonds A, Bagheri H, Pourrat J. Néphropathie interstitielle aigue immuno-allergique après traitement par fluindione. A propos de sept cas. Nephrol Ther 2009, 5, 292-298.

Senard-Ojero A, Rivière D, Schmitt L, Montastruc JL. Quoi de neuf en matière de produits dopants en 2009. 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Sommet A, Castot A, Montastruc JL. Heat waves drugs and dehydration in elderly, Br. Med. J. 2009, 339 : 3145.

Sommet A, Duhalde V, Delarue C, Lacroix I, Suarez C, Bourrel R, Montastruc JL, Damase-Michel C. Recherche en médecine générale : étude de prescription d’antihypertenseurs avant et pendant la grossesse. Bulletin de l’Observatoire de la Médecine Générale 2009, 42, juillet-aout 2009.

Sommet A, Pathak A, Montastruc JL. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients : a randomised, double-blind, placebo-controlled trial. Lancet 2009, 373, 1906-13.

Sommet A, Shams R, Valnet-Rabier MB, Jean-Pastor MJ, Castot A, Lapeyre-Mestre M, Montastruc JL. Médicaments et chaleur : étude SIRIUS cas-témoins multicentrique chez les sujets de plus de 65 ans durant l’été 2007 en France. Thérapie 2009, 64 : 295-301.

Sommet A. La stimulation intellectuelle vaut mieux que le ginkgo biloba. Bulletin Audois d’Information de Pharmacologie. Juin 2009.

Sommet A. Que doit savoir un médecin généraliste d’un essai clinique d’équivalence ? 21ème Forum Médical de Rangueil, Réunion commune de FMC des Facultés de Médecine de Toulouse Rangueil et Purpan, Toulouse, 15 octobre 2009. In CD Rom.

Tavassoli N, Lapeyre-Mestre M, Sommet A, Montastruc JL. Reporting rate of adverse drug reactions to the french pharmacovigilance system with three step 2 analgesic drugs : dextropropoxyphene, tramadol and codeine (in combination with paracetamol). Br J Clin Pharmacol 2009, 68, 422-26.

Tavassoli N, Montastruc JL. Is there any relationship between actual benefit and added value of drugs and pharmacovigilance alerts. Br J Clin Pharmacol 2009, 10 : 1365-2125.

Tavassoli N, Voisin S, Carrie D, Lapeyre-Mestre M, Galinier M, Montastruc JL, Pathak A. High maintenance dosage of clopidogrel is associates with a reduced risk of stent thrombosis in clopidogrel-resistants patients. Am J. Cardiovasc Drugs 2009 : 9 : 1-7.

DIVERS

Muscari F, Monastruc JL, Fourtanier G. Evaluation d’une grille de correction révisée de l’exercice de rédaction de résumé pour l’examen de lecture critique d’article scientifique dans le cadre des épreuves classantes nationales en France. Pédagogie Médicale 2009, 10 : 19-28.

Retour en haut de page

ANNEE 2008

Publié le 06/04/2009 à 14h37 (mis à jour le 26/08/2015 à 11h43)

PHARMACOLOGIE EXPÉRIMENTALE

Cayla C, Schaak S, Crassous PA, Buffin-Meyer B, Delage C, Paris H, Sénard JM, Denis C. Transcriptional down-regulation of human x2A-adrenoceptors by IFNy and TNFx in intestinal cells. Europ J of Pharmacol 2008, 588 : 33-40.

Moro C, Pillard F, de Glisezinski I, Klimcakova E, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Exercise-induced lipid mobilization in subcutaneous adipose tissue in mainly related to natriuretic peptides in overweight men. Am. J. Physiol. 2008, 295, E505-513.

Birkenfeld Al, Budziarek P, Boschman M, Moro C, Adams F, Franke G, Berlan M, Marques MA, Sweep F, Luft FC, Lafontan M, Jordan J. Atrial natriuretic peptide induces postprandial lipid oxidation in man. Diabetes 2008, 57, 3199-3204.

Lafontan M, Moro C, Berlan M, Crampes F, Sengenes C, Galitzky J. Control of lipolysis by natriuretic peptides and cyclic GMP. Trends in Endocrinology and metabolism 2008. 14 : 130-137.

Lafontan M, Berlan M, Sengenes C, Moro C, Crampes F, Galitzky J. cAMP-cGMP-dependent control of lipolysis and lipid mobilization in human : putative targets for fat cell management. Rev Insight into receptor function and new drug development targets : foundation IPSEN, Springer 2008, 53-77.

Roussin Anne. Agir sur les cibles pharmacologiques du système endocannabinoïde pour traiter la douleur:où en est-on ? : Webanesthésie 2008, 6 (2):08071.

PHARMACOLOGIE CLINIQUE

Rascol O, Poewe W, Lees A, Aristin M, Salin L, Juhel N, Waldhauser L, Schindler T, for the ADVANS Group. Tesofensine (NS 2330), a monoamine reuptake inhibitor, in patients with advanced Parkinson disease and motor fluctuations. Arch Neurol 2008, 5:577-583.

Nègre-Pagès L, Rascol O, on behalf the DoPaMiP study group. Chronic Pain in Parkinson’s disease : the cross-sectional French DoPaMiP survey. Mov Disord 2008 ; 23 : 1361-1369.

Goetz CG, Tilley B, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern M, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, Le Witt P, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi J, Van Hilten JJ, La Pelle N. Movement disorder society-sponsored revision of the unified Parkinson’s Disease rating scale (MDS-UPDRS) : scale presentation and clinimetric testing results. Mov Dis 2008, 23 : 2129-2170.

Goetz CG, Laska E, Hicking C, Damier P, Muller T, Nutt J, Olanov W, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson’s disease. Mov Dis 2008, 5 : 700-707.

Hernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, Troster A, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Scales to assess psychosis in Parkinson’s disease : critique and recommendations of the MDS task force. Neurology 2008, Abstract 70, 11, suppl 1, A396.

Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia : the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008, 15, 5, 493-6.

Rascol O. treatments in the early stage of Parkinson disease. Rev neurol 2008, 164-spec 2 : 77-84.

Hanon O, Negre-Pages L, Berrou JP, Pathal A. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function : primary results of the OSCAR open-label study. Abstract in Fundam Clin Pharmacol 2008, 22, suppl 1, p 98.

Rascol O. Thérapeutiques du stade précoce de la maladie de Parkinson. Rev. Neurol. 2008, F77-84.

Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Troster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG. Scales to assess psychosis in Parkinson’s disease : critique and recommandations. Mov Dis 2008, 23 : 484-500.

Leentjens AFG , Dujardin K , Marsh L , Martinez-Martin P, Richard IH , Starkstein SE , Weintraub D, Sampaio C, Poewe W , Rascol O. Anxiety rating scales in Parkinson’s disease : Critique and recommendations. Mov Disord 2008 ; 23 : 2015-2025.

Sharma JC, Ross IN, Rascol O, Brooks D. Relationship between weight, levodopa and dyskinesia : the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008, 15, 5, 493-6.

Robert A. Hauser, Olivier Rascol, Amos D.Korczyn, A. Jon Stoessl, Ray L. Watt, Werner Poewe, Peter P.Deyn, and Anthony Lang  : Ten-Yar follow-up of parkinson’s disease patients randomized to initial therapy with ropinirole or levodopa. mov. dis. 2008, 22 : 2409-2417.

C. Warren Olanow, Robert A. Hauser, Joseph Jankovic, W. Langston, Anthony Lang, Werner Poewe, Eduardo Tolosa, Fabrizio Stocchi,Eldad Melamed, Eli Eyal, and Olivier Rascol  : A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in parkinson’s disease (the ADAGIO study):Rationale, design, and baseline characteristics. mov. dis. 2008, 23 : 2194-2201.

Agnieszka Ciarka, Ph. Van De Borne, and Atul Pathak : Myocardial infarction, heart failure and sympathetyc nervous system activity : new pharmacological approaches that affect neirohumoral activation. Expert opin. investg. Drugs 2008, 17 (9) : 1315-1330.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Tavassoli N, Montastruc-Fournier J, Montastruc JL. And the Frenche association of Regional Pharmacovigilance Centres. Psychiatric adverse drug reactions to glucocorticoids in children and adolescents : a much higher risk with elevated doses. BJCP 2008, 66:4, 566-567.

Sommet A, Grolleau S, Bagheri H, Lapeyre-Mestre M, Montastruc JL, French Network of Regional Pharmacovigilance Centres. Was the thrombotic risk of rofecoxib predictible from the French Pharmacovigilance Database before 30 september 2004 ? Eur J Clin Pharmacol. 2008, 64:829-834.

Sailler L, Attane C, Michenot F, Canonge JM, Rostaing L, Arlet-Suau E, Arlet P, Launay F, Montastruc JL, Lapeyre-Mestre M. Rituximab off-label use for immune diseases : assessing adverse events in a single-centre drug-utilization survey. BJCP 2008, 66:320-322.

Sailler L. Rituximab off label use for difficult -to-treat auto-immune diseases : reappraisal of benefits and risks. Clinic Rev Allerg Immunol 2008, 34:103-110.

Molokhia M, Pathak A, Lapeyre-Mestre M, Caturla L, Montastruc JL, L’Association française des Centres Régionaux de Pharmacovigilance (CRPV) and MC Keigue P. Case ascertainment and estimated incidence of drug-induced long-QT syndrome : study and southwest France. BJCP 2008, 66:386-395

Durrieu G, Lacroix I, Olivier P, Sommet A, Sénard JM, Montastruc JL et le Réseau Français des centres régionaux de Pharmacovigilance. Drug-related neuropathies : analysis of the french Adverse Drug Reaction database 1995-2005-. Press médicament 2008, 37:935-42.

Gallini A, Sommet A, Montastruc JL. Does memantine induce bradycardia ? A study in the French PharmacoVigilance database. Pharmacoepidemiology and Drug Safety 2008, 17 : 877-881.

Sommet A, Bagheri H, Lapeyre-Mestre M, Montastruc JL. Did thirst-blockers conribute to the exorbitant number of fatalities during the french 2003 heat wave ? Pharmacoepidemiol. Drug Saf. 2008, 17:312-313.

Damase-Michel C, Pichereau J, Pathak A, Lacroix I, Montastruc JL Perception of teratogenic and foetotoxic risk by health professionals : a survey in Midi-Pyrénées area. Pharmacy Practice 6 : 15-19, 2008.

Burki F, Badie K, Bartoli P, Bernard P, Montastruc JL. Reversible posterior leukoencephalopathy syndrome associated with bevacizumab/doxorubicin regimen. BJCP 2008, 5:793-/94.

Berthet S, Grolleau S, Brefel-Courbon C, Montastruc JL, Lapeyre-Mestre M. Prise en charge thérapeutique des patients diabétiques en France : apport de la Banque Nationale de Pharmacovigilance. Thérapie 2007, 62:483-488.

Fontanel F, Durrieu G, Damase-Michel C, Montastruc JL. Prescription médicamentesue et pharmacovigilance en pratique thermale : étude comparative à 20 ans d’intervalle (1987 versus 2007). Thérapie 2008, 63:135-140.

Montastruc JL, Lugardon S, Desboeuf K, Fernet P, Lapeyre-Mestre M. Utilisation de la méthode capture-recapture pour l’évaluation de la fréquence des effets indésirables "graves" médicamenteux : l’expérience du CHU de Toulouse. Bulletin de l’ Académie Nationale de Médecine 2008, 192, N°2, 421-431, séance du 5 février 2008.

Hurault C, Lacroix I, Bourrel R, Montastruc JL, Damase-Michel C. Prescriptions et délivrances d’anti-inflammatoire non stéroïdiens après le 6e mois de grossesse : impact d’une lettre d’information envoyée par les autorités de santé. Presse Med 2008, 37 : 767-774.

Durrieu G, Lacroix I, Olivier P, Sommet A, Senard JM, Montastruc JL et le réseau français des Centres Régionaux de PharmacoVigilance (CRPVs). Neuropathies médicamenteuses : Analyse de la Banque Française de Pharmacovigilance de 1995 à 2005. Presse Med 2008 ; 37 :935-942

Salomon J, Sommet A, Bernède C, Tonéatti C, Carbon C, Guillemot D. Antibiotics for nasopharyngitis are associated with a lower risk of office-based physicians visit for acute otitis media within 14 days for 3- to 6-year-old children. J Eval Clin Pract. 2008, 14:595-9.

Souyri C, Olivier P, Lapeyre-Mestre M. Severe necrotizing soft tissue infections and non steroidal anti-inflammatory drugs. Clin Exp Dermatol 2008 ;16 ;33(3):249-255.

Damase-Michel C. Médicaments et grossesse : le point en 2008. Genesis 132 : 9-11, 2008.

Bonnet D, Mejdoubi S, Sommet A, Alric L. Hépatite aiguë probablement imputable au fumeterre et à la vigne rouge, produits de phytothérapie. Gastroentérol Clin Biol 2007, 31 : 1041-1042.

Micaleff J, Jolliet P, Victorri-Vigneau C, Mallaret M, Richard N, Haramburu F, Lapeyre-Mestre M, et le réseau français des centres d’Evaluation et d’Information sur la Pharmacodépendance. Premières journées nationales de pharmacodépendance (CEIP). Place de la pharmacodépendance dans l’évaluation du médicament. Thérapie 2008, 63 : 55-65.

Lapeyre-Mestre M. "Les effets indésirables graves liés aux vaccins sont marginaux". Vecteur santé 2008. 25 : 5-6.

Montastruc P, Damase-Michel C. La bouche et le tube digestif : avant-postes fonctionnels du cerveau. Prescrire 2008, 28 : 153.

Montastruc P, Damase-Michel C. Veinotoniques : quel tonus pour quelles veines ? Prescrire 2008, 28 : 291.

Montastruc P, Damase-Michel C. Rétablir l’équilibre humoral pour redonner du souffle à la vie. Prescrire 2008, 28 : 293.

Lapeyre-Mestre M. Les médicament qui font bailler. Que Choisir santé 2008.

Schenckery J, Le Craz S, Damase-Michel C. Médicament familial et grossesse. Le Moniteur des Pharmacies-Formation, Cahier II du n°2718 : 1-16, 2008.

Retour en haut de page

ANNEE 2007

Publié le 03/10/2008 à 15h39 (mis à jour le 26/08/2015 à 11h42)

PHARMACOLOGIE EXPÉRIMENTALE

Roncalli J, Smih F, Desmoulin F, Dumonteil N, Harmancey R, Henning S, Perez L, Pathak A, Galinier M, Massabuau P, Malet-Martino M, Sénard JM, Rouet P. NMR and cDNA array analysis prior to heart failure reveals an increase of unsatured lipids, a glutamine/glutamate ration decrease and a specific tenascriptome adaptation in obese rat heart. J Mol Cell Cardiol 2007 ; 42(3) : 526-539

Moro C, Klimcakova E, Lafontan M, Berlan M, Galitzki J. Evidence for phosphodiesterase-5A and neutral endopeptidase activities in human adipocyte : role in atrial natriuretic peptide-mediated lipolysis. British J Pharmacol 2007 (in press).

Moro C, Pillard F, De Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Atrial natriuretic peptide contribution to lipid mobilization and utilization during head-down bed rest in man. Am J Physiol Regul Integr Comp Physiol 2007. 293 : R612-R617.

Crassous PA, Denis C, Paris H, Sénard JM. Interest of a2-adrenergic agonists and antagonists in clinical practice : background, facts and perspectives. Curr Topics Médicament Chem 2007 ; 7 (2) : 187-194

Arellano C, Philibert C, Vachoux C, Woodley J, Houin G. The metabolism of midazolam and comparison with other CYP enzyme substrates during intestinal absorption : in vitro studies with rat everted Gut sac…J Pharm Pharmaceut Sci 2007, 10, 1, 26-36.

Harmancey R, Sénard JM, Rouet P, Pathak A, Smih F. Adrenomedullin and PAMP inhibit adipogenesis under the transcriptional control of insulin. Diabetes 2007 Mars ; 56(3) : 553-563.

Moro C, Pillard F, De Glisezinski I, Klimcakova E, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Subcutaneous adipose tissue lipolysis is mainly due to atrial natriuretic peptide in overweight men during exercise. International Journal of Obesity ; 31, suppl 1, may 2007.

Pillard F, Moro C, Harant I, Garrigue E, Lafontan M, Berlan M, Crampes F, De Glisenzinski I, Rivière D. Lipid oxidation according to intensity and exercise duration in overweight men and women. International Journal of Obesity ; 15, 2256-2262.

Polak J, Moro C, Bessière D, Hejnova J, Marquès MA, Bajzova M, Crampes F, Lafontan M, Berlan M, Stich V. Acute exposure to long-chain fatty acid impairs alpha2-adrenergic mediated antilipolysis in human adipose tissue. J Lip Res 2007, 48, 2236-2246.

PHARMACOLOGIE CLINIQUE

Goetz CG, Damier Ph, Hicking C, Laska E, Müller Th, Olanow CW, Rascol O, H Russ. Sarizotan as a treatment for dyskinesias in Parkinson’s disease : A double-blind placebo-controlled trial. Movement Disorders 2007 ; 22 : 179-186.

Gerdelat-Mas A, Simonetta-Moreau M, Thalamas C, Ory-Magne F, Slaoui T, Rascol O, Brefel-Courbon C. Levodopa raises objective painthresold in Parkinson’s disease : a RIII reflex study. J Neurol Neurosurg Psychiatry 2007, 78 : 1140-1142.

Goetz CC, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holoway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N. Movement Disorder Society - Sponsored Revision of the Unified Parkinson’s Disease Rating Scale : (MDS-UPDRS) : process, format and clinimetric testing plan. Movement Disorders 2007 ; 22 : 41-47.

Schrag A, Barone P, Brown RG, Leentjens AFG, McDonald WM, Starkstein S, Weintraud D, Poewe W, Rascol O, Sampaio C, Stebbing GT, Goetz CG. Depression rating scales in Parkinson’s disease : critique and recommendations. Movement Disorders 2007 ; 22 : 1077-1092.

Damier Ph, Thobois S, Witjas T, Cuny E, Derost Ph, Raoul S, Mertens P, Perragut JC, Lemaire JJ, Burbaud P, Rascol O and the French STARDYS group. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psych 2007 ; 64 : 170-176.

Ory-Magne F, Brefel-Courbon C, Simonetta-Moreau M, Fabre N, Lotterie JA, Chaynes P, Berry I, Lazorthes Y, Rascol O. Does ageing influence deep brain stimulation outcomes in Parkinson’s disease. Movement Disorders 2007 ; 22 : 1457-1463.

Ferreira J, Silva JM, Freire R, Pignatelli J, Correia Guesdes L, Feijo A, Rosa MM, Coelho M, Costa J, Noronha A, Hewett R, Marques Gomes A, Cirne de Castro JL, Rascol O, Sampaio C. Skin cancers and precancerous lesions in Parkinson’s disease patients. Movement Disorders 2007 ; 22 : 1471-1475.

Seppi K, Rascol O. Dementia with lewy body and Parkinson’s disease with dementia : can MRI make the difference ? Neurology 2007, 69 : 717-718.

Pathak A, Hanon O, Negre-Pages L, Sevenier F, on behalf of the OSCAR investigators. Rationale, design and methods of the OSCAR study : observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundam Clinic Pharmacol 2007, 21 : 199-205.

Jouret B, Ahluwalia N, Cristini C, Dupuy M, Nègre-Pages L, Grandjean H, Tauber M. Factors associated with overweight in preschool-age children in southwestern France. Am J Clin Nutr 2007, 85 : 1643-9.

Polak J, Moro C, Bessière D, Hejnova J, Marquès MA, Bajzova M, Crampes F, Lafonton M, Berlan M, Stich V. Short-term exposition to saturated fatty acids inhibits adrenergic alpha-2 antilipolytic effect in human adipose tissue. International Journal of Obesity ; 31, suppl 1, may 2007.

Moro C, De Glisezinski I, Crampes F, Pillard F, Thalamas C, Harant I, Marquès MA, Lafontan M, Berlan M. Atrial natriuretic peptide increases lipid mobilization and utilization during head-down bed rest in man. Fundam Clin Pharmacol 2007, 21, suppl 1, 98.

Polak J, MoroC, Kimcakova E, Kovacikova M, Barjova M, Vitkova M, Kovacova Z, Sotornik R, Berlan M, Viguerie N, Langin D, Stich V. The atrial natriuretic peptide and catecholamine-induced lipolysis and expression of related genes in adipose tissue in hypothyroid and hyperthyroid patients. Am J Physiol 2007, 293 : R612-R617.

Pillard F, Moro C, Harant I, Garrigue E, Guilland JC, Thalamas C, Lafontan M, Berlan M, Crampes F, De Glisezinski I. Lipid mobilization : a limiting factor of lipid oxidation in trained men. Fundam Clin Pharmacol 2007, 21, suppl 1, 99.

Moro C, Klimcakova E, Lolmede K, Berlan M, Lafontan M, Stich V, Bouloumie A, Galitzki J, Arner P, Langin D. Atrial natriuretic peptide inhibits the production of adipokines and cytokines liked to inflammation in human subcutaneous adipose tissue. Diabetologia 2007, 50 : 1038-1047.

Moro C, Pillard F, De Glisezinski I, Crampes F, Thalamas C, Harant I, Marques MA, Lafontan M, Berlan M. Sex differences in lipolysis-regulating mechanisms in overweight srjects : effect of exercise intensity. International Journal of Obesity 2007 ; 15, 2245-2255.

Holmberg B, Johansson JO, Poewe W, Wenning G, Quinn N, Mathias Ch, Tolosa E, Cardozo A, Dizdar N, Rascol O, Slaoui T, Growth-Hormone MSA Study Group, European MSA Study Group (EMSA-SG). Safety and tolerability of growth hormone therapy in multiple system atrophy : a double-blind, placebo-controlled study. Movement Disorders 2007 ; 22 : 1138-144.

Poewe WH, Rascol O, Quinn N, Tolosa E, Oertel WH, Martignoni E, Rupp M, Boroojerdi B, on behalf on the SP515 Investigators. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson’s disease : a double-blind, double-dummy, randomised controlled trial. Lancet Neurol 2007 ; 6 : 513-520.

Fuzier V, Fuzier R, Conan L, Montastruc JL. Nalador® (sulprostone) : précautions d’emploi et utilisation pratiqur dans l’hémorragie du post-partum. LPAR 2007, 379-385.

Pathak A, Sommet A, Montastruc JL. Interactions médicamenteuses chez le cardiaque très âgé. Arch Mal Cœur & Vaisseaux 2007, 158 : 13-21.

Conil JM, Georges B, Lavit M, Seguin T, Tack I, Samii K, Chabanon G, Houin G, Saivin S. Pharmacokinetics of ceftazidime and cefepime in burn patients : the importance of age and creatinine clearance. Int J Clin Pharmacol Toxicol 2007, 45, 10, 529-538.

Barone P, Goetz CG, Houben JJ, Koester J, Leentjens AF, Poewe W, Rascol O, Reichmann H, Schapira AH, Tolosa E. PRODESTstudy – Depressive symptoms in Parkinson’s disease : demographic data. Movement Disorders 2007, suppl 16, S183, 593.

Brefel-Courbon C, Payoux P, Ory F, Thalamas C, Rascol O. Nociceptive brain activation in painful patients with Parkinson’s disease. Movement Disorders 2007, suppl 16, S150, 489.

Conil JM, Georges B, Lavit M, Laguerre J, Samii K, Houin G, Saivin S. A population pharmakcokinetic approach toceftazidime use in burns patients : influence of glomerular filtration, gender and mechanical ventilation. Brit J Clin Pharmacol. 2007

Conil M, Georges B, Fourcade O, Seguin T, Houin G, Saivin S. Intermittent administration of ceftazidime to burns patients : influence of glomerular filtration. Int J Clin Pharmacol Toxicol 2007, 45, 10, 259-538.

Gandia Mailly P, Idier I, Houin G. Is once mesalazine equivalent to the currently used twice-daily regimen ?a study performed in 30 healthy volunteers. J Clin Pharmacol 2007, 47, 334-342.

Gandia P, Bour D, Maurette JM, Donazzolo Y, Duchene P, Bejot M, Houin G. A biovailability stuydy comparing two oral formulations containing zinc (zn bisglycinate vs zn gluconate) after a single administration to twelve healthy female volunteers. Int J Vit Nut Res 2007, 4, 243-248.

Giladi N, Boroojerdi B, Korczyn AD, Burn DJ, Clarke CE, Schapira AHV, on behalf of the SP513 investigators. Rotigotine transdermal patch in early Parkinson’s disease : a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007, 22 : 2398-2404.

Goetz CG, Laska E, Hicking C, Damier P, Müller T, Nutt J, Olanow CW, Rascol O, Russ H. Placebo influences on dyskinesia in Parkinson’s disease. Movement Disorders 2007, suppl 16, S243, 794.

Goetz CG, Tilley BC, Shaftman S, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees AJ, Leurgans S, Le Witt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi J, Van Hilten JJ. Clinimetric testing of the new UPDRS (MDS-UPDRS) vs. original version. Movement Disorders 2007, suppl 16, S6, 18.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

Boeuf O, Lapeyre-Mestre M, on behalf of the French Network of Centers for Evaluation and Information Pharmacodependence (CEIP). Survey of forged prescriptions to investigate risk of psychoactive medications abuse en France - Results of OSIAP survey. Drug Safety 2007, 30 : 265-276.

Lacroix I, Hurault C, Saivin S, Raoul V, Berrebi A, Souchet E, Desboeuf K, Montastruc JL, Damase-Michel C. Exposition in utero à des substances psychoactives : résultats de l’étude "NENUPHAR". Thérapie 2007, 62 : 177-183.

Sommet A, Bagheri H, Damase-Michel C, Pathak A, Montastruc JL. Tamiflu® et grippe aviaire. Pratiques 2007, 36 : 78-82.

Sommet A, Bagheri H, Montastruc JL. De la Pharmacovigilance à la gestion des risques. La Lettre du Pharmacologue 2007, 21 : 26-31.

Montastruc JL. Médicaments "antidiabétiques", médicaments "hypoglycémiants" : ne pas confondre !. Rev Prescrire 2007, 27 ; 288 : 793.

Montastruc P. La gymnastique est-elle née "produit de santé" ?. Rev Prescrire 2007, 27 ; 282 : 312-313.

Tavassoli N, Gardette V, Sommet A, Lapeyre-Mestre M, Bagheri H, Andrieu S, Vellas B, Montastruc JL. Interactions médicamenteuses des anticholinestérasiques : à propos de 1058 notifications spontanées dans la Banque Nationale Française de Pharmacovigilance. Rev Neurol 2007, 163 : 76-77.

Montastruc JL – Effets indésirablescardiovasculaires des AINS classiques : attention ! . Rev ADPHSO, 2007, 32,1, 58.

Montastruc JL –Attention aux extrapolations physiopathologiques hâtives à propos des médicaments. Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Les endoprothèses pharmaco actives sont-elles dangereuses ? Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Mort subite du sportif : imputabilité des androgènes ? Rev ADPHSO, 2007, 32,1, 66.

Montastruc JL – Bosentan. Rev ADPHSO, 2007, 32,1, 65.

Montastruc JL – Quatre décès sur cinq chez l’asthmatique pourraient être dus aux agonistes béta2 acrénergiques à longue durée d’action !. Rev ADPHSO, 2007, 32,1, 65.

Montastruc JL – Prométhazine et dépression respiratoire chez l’enfant. Rev ADPHSO, 2007, 32,1, 64.

Montastruc JL – Exposition in utéro au DES DISTILBENE® et troubles psychiatriques : des données rassurantes. Rev ADPHSO, 2007, 32,1, 64.

Montastruc JL – Arrêter les alpha-bloquants avant une opération de la cataracte. Rev ADPHSO, 2007, 32,1, 63.

Montastruc JL – Insuffisances rénales aigues sous immunoglobulines humaines polyvalentes I.V. Rev ADPHSO, 2007, 32,1, 62.

Montastruc JL – Campagne anti-tabac ou campagne publicitaire pour les médicaments ?. Rev ADPHSO, 2007, 32,1, 62.

Montastruc JL – Connaître les effets indésirables des glitazones. Rev ADPHSO, 2007, 32,1, 61.

Montastruc JL – Biphosphonates et douleurs osseuses. Rev ADPHSO, 2007, 32,1, 59.

Montastruc JL – Ostéonécrose de la mâchoire et biphosphonates : le point . Rev ADPHSO, 2007, 32,1.

Montastruc JL – Risque infectieux et anti-TNF Alpha . Rev ADPHSO, 2007, 32,1, 58.

Document à télécharger

Retour en haut de page

ANNEE 2006

Publié le 25/02/2008 à 15h31 (mis à jour le 26/08/2015 à 11h41)

PHARMACOLOGIE EXPÉRIMENTALE

M LAMANT, F SMIH, R HARMANCEY, A PATHAK, J RONCALLI, M GALINIER, X COLLET, P MASSABUAU, JM SENARD, P ROUET - Apo O, a novel apolipoprotein is an original glycoprotein upregulated by diabetes in human heart. J. Biol. Chem. 2006 Nov 24 ; 281(47) : 36289-302.

C MORO, M BERLAN – Cardiovascular and metabolic effects of natriuretic peptides. Fun. Clin. Pharmacol 2006 ; 20,41-49.

M LAFONTAN, M BERLAN, C SENGENES, C MORO, F CRAMPES, J GALITZKY – cAMP- and cGMP-dependent control of lipolysis and lipid mobilization in humans : putative targets for celle management. M Conn M, C Kordon, Y Christen. Insights into receptor function and new drug development targets. Ed Springer-Verlag Berlin Heidelberg 2006, 53-77.

C MORO, M BERLAN, M LAFONTAN - Physiological and pathophysiological features of the control of lipolysis and lipid mobilization by natriuretic peptides. J Soc Biol 2006, 200:67-76.

C MORO, E LOLMEDE, M BERLAN, M LAFONTAN, V STICH, A BOULOUMIE, J GALITZKIi, P ARNER, D LAGIN - Inhibition par l’ANP dans le tissu adipeux humain des cytokines et des adipokines liées à l’inflamation et à l’insulo-résistance. Springer, Décembre 2006,vol 1,n°24.

PHARMACOLOGIE CLINIQUE

MORO, J POLAK, J HEJNOVA, E KLIMCAKOVA, C CRAMPES, V STICH, M LAFONTAN, M BERLAN – Atrial natriuretic peptide stimulates lipid mobilization during repeated bouts of endurance exercise. Am. J. Physiol. 2006, 290:E864-E869.

E KLIMCAKOVA, J POLAK, C MORO, J HEJNOVA, M.M MAJERCIK, N VIGUERIE, M BERLAN, D LANGIN, V STICH - Dynamic strength training improves insulin sensitivity without altering plasma levels and gene expression of adipokines in subcutaneous adipose tissue in obese men. J. Clin. Endoc. Metab. 2006, 91 : 5107-5112.

J POLAK, E KLIMCAKOVA, C MORO, N VIGUERIE, M BERLAN, J HEJNOVA, B RICHTEROVA, I KRAUS, D LANGIN, V STICH - Effect of aerobic training on plasma levels and subcutaneous abdominal adipose tissue gene expression of adiponectine, leptin, interleukine-6 and tumor necrosis alpha in obese women. Metabolism 2006 ; 55:1375-1381.

AL BIRKENFEL, M BOSCHMANN, C MORO, F ADAMS, K HEUSSER, J TANK, A DIEDRICH, C SCHROEDER, G FRANKE, M BERLAN, FC LUFT, M LAFONTAN, J JORDAN - Propranolol blocks atrial natriuretic peptide-induced lipid oxidation, but not mobilization. J Clin Endoc Metab 2006, 91:5069-5075.

PATHAK A, SENARD JM - Blood pressure disorders during Parkinson’s disease : epidemiology, pathophysiology and management. Expert Rev Neurother 2006 ; 6(8) : 1173-1180.

F DESPAS, O XHAËT, JM SENARD, P VERWAERDE, G JOURDAN, D CURNIER, M GALINIER, A PATHAK - Chémoréflexes : de la physiologie à leur application clinique. Mt Cardio 2006 ; 2(3) : 321-327.

H REICHMANN, A BILSING, R EHRET, W GREULICH, JB SCHULZ, A SCHWARTZ, O RASCOL – Ergoline and non-ergoline derivatives in the treatment of Parkinson’s disease. J Neurol 2006, suppl. 4, 36-38

M HORSTINK, E TOLOSA, U BONUCCELLI, G DEUSCHL, A FRIEDMAN, P KANOVSKY, JP LARSEN, A lALLEES, W OERTEL, W POEWE, O RASCOL, C SAMPAIO – Review of the therapeutic management of Parkinson’s disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part I : early (uncomplicated) Parkinson’s disease. European Journal of Neurology 2006, 13 : 1170-1185

O RASCOL - Defining a minimal clinically relevant difference for the Unified Parkinson’s Rating Scale : an important but still unmet need. Mov Disord 2006 ; 21 : 1059-1061.

S ANDRIEU, O RASCOL, T LANG, H GRANDJEAN, B VELLAS - Disease modifying trials in Alzheimer disease : methodological and statistical issues. J Nutr Health Aging 2006 ; 10 : 116-117.

WH JOST, D ANGERSBACH, O RASCOL - Clinical studies with ropinirole in Parkinson’s disease and RLS. J Neurol 2006, 253 (suppl.4) : 16-21.

O RASCOL, DJ BROOKS ; AD KORCZYN, PP DEDEYN, CE CLARKE, AE LANG, M ABDALLA for the 056 Study Group - Development of dyskinesias in a 5-year trial of ropinirole and l-dopa. Mov Disord 2006 ; 21 : 1844-1850.

O. RASCOL, C. SAMPAIO - Experimental therapeutics of Parkinson’s disease and the development of new symptomatic medicines for Parkinson’s disease. In : “Parkinson’s disease and Movement Disorders, Fifth Edition, edited by Joseph Jankovic and Eduardo Tolosa. Chapter 11. Lippincott Williams & Wilkins, a division of Wolters Kluvers Health, Inc., Philadelphia, 2006.

C. SAMPAIO, O. RASCOL - Disease-modifying strategies In Parkinson’s disease. In : “Parkinson’s disease and Movement Disorders, Fifth Edition, edited by Joseph Jankovic and Eduardo Tolosa. Chapter 9. Lippincott Williams & Wilkins, a division of Wolters Kluvers Health, Inc., Philadelphia, 2006.

O RASCOL, C BREFEL-COURBON, L NEGRE-PAGES, W REGRAGUI, A GERDELAT-MAS, T SLAOUI - Douleur chronique et maladie de Parkinson : un symptôme trop souvent méconnu. La Lettre du Neurologue 2006 ; 4 (suppl) : 36-40 .
O RASCOL, B DUBOIS, A CASTRO CALDAS, S SENN, S DEL SIGNORE, A LEES, on behalf of the Parkinson REGAIN Study Group - Early piribedil monotherapy of Parkinson’s disease. A planned 7-month report of the REGAIN Study. Mov Disord 2006, 21, 2110-2115.

A PATHAK - Prévention pharmacologique de la mort subite : que nous ont appris les essays clinique ?- A.I.M.2006-n°118.

A PATHAK, S VELEZ-ROA, O XHAET, B NAJEM, P VAN DE BORNE - Dose-dépendent effect of dobutamine on chemoreflex activity in healthy volunteers. Brit J Clin Pharmacol- 2006, sept, 62 (3), pp 272-279.

O XHAET, P VAN DE BORNE, A PATHAK – Dynamic ventriculare repolarisation : Froom physiology to prognosis. Current Cardiology Reviews, 2006, 2, 000-000.

A HOUSSIERE, B NAJEM, A PATHAK, O XHAET, R NAEIJE, P VAN DE BORNE - Chemoreflex and metaboreflex reponses to static hypoxic exercice in aging humans. American College of Sports Medecine, 2006.

B NAJEM, P UNGER, N PREUMONT, JL JANSENS, A HOUSSIERE, A PATHAK, O XHAET, L GABRIEL, A FRIART, L DE ROY, JL VANDENBOSSCHE, P VAN DE BORNE - Sympathetic control after cardiac resynchronization therapy : responders versus nonresponders. Am J Physiol Heart Circ Physiol, 291 : H2647-H2652, 2006

B NAJEM, A HOUSSIERE, A PATHAK, C JANSSEN, D LEMOGOUM, O XHAET, N CUYLITS, P VAN DE BORNE - Acute cardiovascular and sympathetic effect of nicotine replacement therapy. Hypertension. 2006 ;47 : 1162-1167.

A PAVY-LE TRAON, R L HUGHSON, C THALAMAS, M GALITSKY, N FABRE , O RASCOL, JM SENARD – Cerebral autoregulation is preserved in multiple system atrophy : a transcranial doppler study. Movement Disorders, vol. 21, n°12, 2006, pp 2122

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

S LUGARDON, H ROUSSEL, R BOURREL, V SCIORTINO, JL MONTASTRUC, M LAPEYRE MESTRE – Profil des utilisateurs d’anti-inflammatoires non stéroïdiens. Thérapie 2006 ; 61:109-114.

K DESBOEUF, M GRAU, F RICHE, M FRADIN, J BEZ, JL MONTASTRUC, JM SENARD – Prevalence and costs of parkinsonian syndromes associated with orthostatic hypotension. Thérapie 2006, 61, 93-99.

JL MONTASTRUC – Les cinq "trop" des essais cliniques : plaidoyer pour une pharmacoépidémiologie pour tous. La Revue Prescrire, Juin 2006, tome 26, n°273, 471.

JL MONTASTRUC, A SOMMET, I LACROIX, P OLIVIER, G DURRIEU, C DAMASE-MICHEL, M LAPEYRE-MESTRE, H BAGHERI – Pharmacovigilance for evaluating adverse drug reactions : value, organization, and methods. Joint Bone Spine 73, 2006, 629-632.

JL MONTASTRUC, A SOMMET, I LACROIX, P OLIVIER, G DURRIEU, C DAMASE MICHEL, M LAPEYRE MESTRE, H BAGHERI – La Pharmacovigilance et l’évaluation du risque médicamenteux : intérêt, fonctionnement et méthodes. La Revue du Rhumastisme 2006 ; 73 : 1021-1024.

A ROUSSIN, M MIREPOIX, G LASSABE, V DUMESTRE TOULET, V GARDETTE, JL MONTASTRUC, M LAPEYRE MESTRE – Death related to a recreational abuse of propofol at therapeutic dose range. British Journal of Anaesthesia 2006, 97(2):268.

JL MONTASTRUC, A SOMMET, P OLIVIER, H BAGHERI, M GONY, M LAPEYRE MESTRE, C BREFEL COURBON, J FERREIRA, L SCHMITT, JM SENARD, O RASCOL – Médicaments, maladie de Parkinson et syndromes parkinsoniens : actualités de pharmacovigilance. Thérapie 2006 ;61:29-38.

M BAUDRANT, H BAGHERI, L CUZIN, A SOMMET, V BASSOUA, E GUITTON, E BONNET, D GARIPUY, F LUCAS, C AQUILINA, JL MONTASTRUC, P MASSIP – Analyse des effets indésirables des médicaments du VIH. Thérapie 2006, 61(2):171-176.

P NOIZE, M SAUER, P BRUNEVAL, M MOREAU, A PATHAK, H BAGHERI, JL MONTASTRUC – Valvular heart disease in a patient taking benfluorex. Fundamental Clin & Clinical Pharmacology 2006 ; 20 : 577-578.

JJ FERREIRA, K DESBOEUF, M GALITZKY, C THALAMAS, C BREFEL-COURBON, N FABRE, JM SENARD, JL MONTASTRUC, C SAMPAIO, O RASCOL - Sleep disruption, daytime somnolence and “sleep attacks” in Parkinson’s disease : a clinical survey in Parkinson’s disease patients and age-matched healthy volunteers. Eur J Neurology 2006,13:209-214.

P OLIVIER, JL MONTASTRUC – The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France. Pharmacoepidemiology and Drug Safety 2006 ; 15 : 808-812.

A CARVAJAL, D MACIAS, M SAINZ, S ORTEGA, LH MARTIN ARIAS, A VELASCO, H BAGHERI, M LAPEYRE MESTRE, JL MONTASTRUC – HMG CoA reductase inhibitors and impotence : two cases series from the Spanish and French drug monitoring systems. Drug Safety 2006 ; 29:143-149.

C CABOU, I LACROIX, J RONCALLI, M ELBAZ, D CAILLAUX, C DAMASE MICHEL, JM FAUVEL, JL MONTASTRUC – Infarctus du myocarde chez une jeune femme fumeuse sous contraception orale. Arch. Mal. cœur et vaisseaux, 99 ; 80-85.

N TAVASSOLI, H BAGHERI, A SOMMET, C DELPIERRE, F MARION LATARD, P MASSIP, C AQUILINA, E BONNET, M OBADIA, E LABAU, JL MONTASTRUC, J BERNARD – Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry. Pharmacotherapy 2006 ; 26:154-161

M LAPEYRE MESTRE, AM DE CASTRO, MP BAREILLE, JG DEL POZO, AA REQUEJO, LM ARIAS, JL MONTASTRUC, A CARVAJAL – Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain : analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006, 20:391-5.

S LUGARDON, K DESBOEUF, P FERNET, JL MONTASTRUC, M LAPEYRE MESTRE – Using a capture-recapture method to assess the frequency of adverse drug reactions in a French university hospital. British Journal of Clinical Pharmacology 2006, 62:2, 225-231.

E GUITTON, K BARANGE, H BAGHERI, JL MONTASTRUC, JP VINEL, S CLAEYSSENS, E BONNET, P MASSIP – Blood transaminase elevation with pegylated interferon alfa 2b plus ribavirin in an HIV/HCV coinfected haemophilic patient. Infection 2006 ;34:183-185.

F MICHENOT, A SOMMET, H BAGHERI, M LAPEYRE-MESTRE, JL MONTASTRUC - and the French Network of PharmacoVigilance Centres - Adverse drug reactions during the heat wave occurred in France in summer 2003 : a study from the French PharmacoVigilance Database. Pharmacoepidemiology and drug safety 2006 ;15:735-740.

jM SENARD – Le syndrome des jambes sans repos. La Revue Prescrire, Avril 2006, tome 26, n°271, 314.

JL MONTASTRUC – Fraude dans les essais cliniques. La Revue Prescrire, Novembre 2006, tome 26, n°277, 793

JL MONTASTRUC - Fallait-il accorder une AMM à une copie de buprénorphine ? Non. La Revue Prescrire décembre 2006, 26, 867-868.

M LAPEYRE-MESTRE - Fallait-il accorder une AMM à une copie de buprénorphine ? Oui. La Revue Prescrire décembre 2006, 26, 869.

JL MONTASTRUC, G DURRIEU, L NEGRE PAGES – Evaluation de l’effet d’une cure thermale dans l’otite séromuqueuse récidivante de l’enfant. La Presse Thermale et Climatique 2006 ; 143:7-123.

E GUITTON, JL MONTASTRUC, M LAPEYRE MESTRE and the French Network of PharmacovigilanceCentres – Influence of HCV or HBV coinfection on adverse drug reactions to antiretroviral drugs in HIV patients. Eur J Clin Pharmacol 2006 ; 62/243-249.

A SOMMET, B JUILLARD-CONDAT, P CESTAS, M LAPEYRE-MESTRE, JL MONTASTRUC - Methodes de mesure de la consommation medicamenteuse : application aux antibiothiques.Therapie 2006, 60(6), 553-559.

M DAMAGNEZ, A MAGNOUAT, J NIEZBORALA, M LAROZE, JC GASTON, JL MONTASTRUC - Medicaments contre- indiques chez l’enfant : analyse des prescriptions en medecine de ville dans le departement de l’aude.Therapie 2006,60(5),507-513.

I ABBDUL KASSAB, N BOUCHI, H BAGHERI, A GEAHCHAN - Mise en place d’un systeme national de recueil des effets indesirables des medicaments au liban : resultats de la premiere annee d’activite. Therapie 2006,60 (6),583-587.

JL MONTASTRUC - Premiere session specifique sur les etudes d’utilisation de medicaments au 9e congres de la societe Française de Pharmacologie. La lettre du Pharmacologue- vol 20- n°1- Janvier-fevrier-mars 2006.

Retour en haut de page

ANNEE 2005

Publié le 25/01/2007 à 14h03 (mis à jour le 04/09/2015 à 10h32)

PHARMACOLOGIE EXPÉRIMENTALE

A PATHAK, F SMIH, M GALINIER, P VERWAERDE, P ROUET, PP COUDERC, JL MONTASTRUC, JM SENARD – Insulin downregulates M2-muscarinic receptors in adult rat atrial cardiomyocites : a link between obesity and cardiovascular complications. Int J Obesity 2005, 29, 176-182

R HARMANCEY, JM SENARD, A PATHAK, F DESMOULIN, C CLAPAROLS, P ROUET, S SMITH – The vasoactive peptide adrenomedulllin is secreted by adipocytes and inhibits lipolysis through NO-mediated beta-adrenergic agonist oxidation. The FASEB Journal. Published online March 23, 2005.

C MORO, J POLAK, B RICHTEROVA, C SENGENES, T PELIKANOVA, J GALITZKY, V STICH, M LAFONTAN, M BERLAN – Differential regulation of atrial natriuretic peptide and adrenergic receptor dependent lipolytic pathways in human adipose tissue. Metabolism Clinical & Experimental 54, 2005, 122-131.

V BOURLIER, A ZAKAROFF-GIRARD, S DE BARROS, C PIZZACALLA, V DURAND DE SAINT FRONT, M LAFONTAN, A BOULOUMIE, J GALITZKY – Protease inhibitor treatments reveal specific involvement of matrix metalloproteinase 9 in human adipocyte differentiation – JPET 2005, 312, 1-8.

AL BIRKENFELD, M BOSCHMANN, C MORO, F ADAMS, K HEUSSER, G FRANKE, M BERLAN, FC LUFT, M LAFONTAN, J JORDAN – Lipid mobilization with physiological Atrial Natriuretic Peptide concentrations in humans. J Clin Endoc. Metab. 2005, 90, 3622-3628.

M LAFONTAN, C MORO, C SENGENES, J GALITZKY, C CRAMPES, M BERLAN – An unsuspected Metabolic Role for Atrial Natriuretic Peptides. The Control of Lipolysis, Lipid Mobilization, and Systemic Nonesterified Fatty Acids Levels in Humans. Arterioscler Thromb Vasc Biol. 2005 ;25:2032-2042.

C SENGENES, C MORO, J GALITZKY, M BERLAN, M LAFONTAN – Les peptides natriurétiques : une nouvelle voie de régulation de la lipolyse chez l’homme. Médecine/Sciences 2005 ; 21:61-5.

M LAFONTAN, M BERLAN – Les récepteurs adrénergiques de l’adipocyte : quelles implications dans l’obésité ? Médecine et Nutrition. 2005, 41, 9-20.

PHARMACOLOGIE CLINIQUE

O RASCOL, DJ BROOKS, E MELAMED, W OERTEL, W POEWE, F STOCCHI, E TOLOSA for the LARGO study group – Rasagiline as an adjunct to levodopa in patients with Parkinson’s disease and motor fluctuations (LARGO, lasting effect in adjunct therapy with rasagiline given once daily, study) : a randomised, double-blind, parallel-group trial. Lancet, 365, 947-954.

C BREFEL COURBON, P PAYOUX, C THALAMAS, F ORY, I QUELVEN, F CHOLLET, JL MONTASTRUC, O RASCOL - The effect of levodopa on pain threshold in Parkinson’s disease : a clinical and PET study. Mov Disord 2005 ; 20 : 1557-1563.

C THALAMAS, I RAJMAN, J KULISEVSKY, A LLEDO, A E MACKIE, O BLIN, T A GILLESPIE, M SEGER, O RASCOL – Pergolide, multiple-dose pharmacokinetics in patients with mild to moderate Parkinson disease. Clin Neuropharmacol, Vol 28, 120-125.

I LOUBLINOUX, D TOMBARI, J PARIENTE, A GERDELAT-MAS, X FRANCERIES, E CASSOL, O RASCOL, J PASTOR, F CHOLLET - Modulation of behaviour and cortical motor activity in healthy subjects by a chronic administration of a serotonin enhancer. Neuroimage 2005, 27 : 299-313.

A GERDELAT-MAS, I LOUBINOUX, D TOMBARI, O RASCOL, F CHOLLET, M SIMONETTA-MOREAU – Chronic administration of selective serotonin reuptake inhibitor (SSRI) paroxetine modulates human motor cortex excitability in healthy subjects. Neuroimage 2005, 27 : 314-322.

O. RASCOL - Assessing the risk of a necessary harm : placebo surgery in Parkinson’s disease. Neurology 2005 ; 65 : 982-983.

O. RASCOL - Transdermal delivery of dopaminergic agents. Neurology 2005, 65 (suppl1) : S1-S2.

O RASCOL - Rasagiline in the pharmacotherapy of Parkinson’s disease – a review. Expert Opin Pharmacother 2005, 6 : 2061-2075.

CG GOETZ, W POEWE, O RASCOL, C SAMPAIO - Evidence-Based Medical Review Update : Pharmacological and surgical treatments of Parkinson’s disease 2001-2004. Mov Disord 2005, 5 : 523-539.

Y BABA, Y TSUBOI, MC BAKER, J UITTI, ML HUTTON, DW DICKSON, M FARRER, JD PUTZKE, BK WOODRUFF, B GHETTI,JR MURRELL, BF BOEVE, RC PETERSEN, P VERPILLAT, A BRICE, MB DELISLE, O RASCOL, K ARIMA, MW DYSKEN, M YASUDA, T KOBAYASHI, N SUNOHARA, O KOMURE, S KUNO, AD SPERFELD, G STOPPE, J KOHLHASE, S PICKERING-BROWN, D NEARY, O BUGIANI, ZK WZOLEK - The effect of tau genotype on clinical features in FTDP-17. Parkinsonism Relat Disord 2005 ; 11 : 205-208.

F GESER, K SEPPI, M STAMPFER-KOUNTCHEV, M KÖLLENSPERGER, A DIEM, JP NDAYISABA, K OSTERGAARD, E DUPONT, A CARDOZO, E TOLOSA, M ABELE, R DODEL, T KLOCKGETHER, I GHORAYEB, F YEKHLEF, F TISON, C DANIELS, F KOPPER, G DEUSCHL, M COELHO, J FERREIRA, MM ROSA, C SAMPAIO, M BOZI, A SCHRAG, J HOOKER, H KIM, T SCARAVILLI, CJ MATHIAS, C FOWLER, N WOOD, N QUINN, H WIDNER, CF NILSSON, O LINDVZALL, N SCHIMKE, KM EGGERT, W OERTEL, F DEL SORBO, F CARELLA, A ALBANESE, MT PELLECCHIA, P BARONE, R DJALDETTI, G MECO, C COLOSIMO, A GONZALEZ-MANDLY, J BERCIANO, T GUREVICH, N GILADI, M GALITZKY, F ORY, O RASCOL, C KAMM, K BUERK, S MAAB, T GASSER, W POEWE, GK WENNING - The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 2005 ; 112 : 1677-1686.

S LESAGE, AL LEUTENEGGER, P IBANEZ, S JANIN, EBBA LOHMANN, A DÜRR, A BRICE, Y AGID, AM BONNET, M BORG, E BROUSSOLLE, PH DAMIER, A DESTÉE, F DURIF, M MARTINEZ, C PENET, P POLLAK, O RASCOL, T TISON, C TRANCHANT, M VÉRIN, F VIALLET, M VIDAILHET, JM WATER - LRRK2 haplotype analyses in European and North-African families with Parkinson’s disease : a common founder for the G2019S mutation dating from the 13th century. The American Journal of Human Genetics 2005, 77:330.

B VELLAS, S GAUTHIER, H ALLAIN, S ANDRIEU, JP AQUINO, G BERRUT, M BERTHEL, F BLANCHARD, V CAMUS, JF DARTIGUES, B DUBOIS, F FORETTE, A FRANCO, R GONTHIER, A GRAND, MP HERVY, C JEANDEL, ME JOEL, P JOUANNY, F LEBERT, P MICHOT, JL MONTASTRUC, F NOURHASHEMI, PJ OUSSET, J PARIENTE, AS RIGAUD, P ROBERT, G RUAULT, D STRUBEL, J TOUCHON, M VERNY, JM VETEL – Consensus sur la démence de type Alzheimer au stade sévère. Rev Neurol 2005, 161 : 868-877.

B VELLAS, S GAUTHIER, H ALLAIN, S ANDRIEU, JP AQUINO, G BERRUT, M BERTHEL, F BLANCHARD, V CAMUS, JF DARTIGUES, B DUBOIS, F FORETTE, A FRANCO, R GONTHIER, A GRAND, MP HERVY, C JEANDEL, ME JOEL, P JOUANNY, F LEBERT, P MICHOT, JL MONTASTRUC, F NOURHASHEMI, PJ OUSSET, J PARIENTE, AS RIGAUD, P ROBERT, G RUAULT, D STRUBEL, J TOUCHON, M VERNY, JM VETEL – Consensus Statement on dementia of Alzheimer type in the severe stage. The Journal of Nutrition, Health & Aging 2005, Vol 9, 5 : 330-338.

JL MONTASTRUC – Les antalgiques de palier 2 en pratique. Douleurs 2005, 6, 6, 347.

A PATHAK, M LAPEYRE-MESTRE, JL MONTASTRUC, JM SENARD – Heat-related morbidity in patients with orthostatic hypotension and primary autonomic failure. Mov Disorders 2005, 9, 1213-1219.

A PATHAK, D CURNIER, J FOURCADE, J RONCALLI, P K STEIN, P HERMANT, M BOUSQUET, P MASSABUAU, JM SENARD, JL MONTASTRUC, M GALINIER – QT dynamicity : a prognostic factor for sudden cardiac death in chronic heart failure. Eur J Heart Fail 2005, 7, 269-275.

M GALINIER, A PATHAK, J RONCALLI, P MASSABUAU – Obésité et insuffisance cardiaque. Archives des Maladies du Cœur et des Vaisseaux 2005, 39.

JM SENARD – Pyridostigmine in the treatment of orthostatic hypotension. Clin Auton Res 2005 ; 15 : 421-422.

JM SENARD, P ROUET – Dopamine beta-hydroxylase deficiency. Orphanet Encyclopedia, July 2005.

JM SENARD – Les symptoms neurovégétatifs au cours de la maladie de Parkinson. Parkinson 2005, 69, 12-14.

J POLAK, C MORO, E KLIMCAKOVA, J HEJNOVA, M MAJERCIK, N VIGUERIE, D LANGIN, M LAFONTAN, V STICH, M BERLAN – Dynamic strength training improves insulin sensitivity and functional balance between beta and alpha2-adrenergic pathways in subcutaneous adipose tissue of obese subjects. Diabetologia. 2005, 48, 2631-2640.

C MORO, F PILLARD, I DE GLISEZINSKI, I HARANT, D RIVIERE, V STICH, M LAFONTAN, F CRAMPES, L BERLAN - Training enhances ANP Lipid-Mobilizing Action in adipose tissue of overweight men. Medicine & Science in Sports & Exercise 2005, 1126.

M BERLAN, C MORO, F CRAMPES, M LAFONTAN – Comment optimiser l’utilisation des lipides pendant un exercice physique ? Effet de l’entraînement et différences sexuelles. Médecine et Nutrition. 2005, 41, 69-77.

M BERLAN, C MORO, F CRAMPES – Pratiqué à jeun, le sport est-il plus efficace sur la régulation pondérale ? Effet de l’entraînement et différences sexuelles. Sport Me

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

JL MONTASTRUC, H BAGHERI, I LACROIX, P OLIVIER, G DURRIEU, C DAMASE-MICHEL, M LAPEYRE-MESTRE – Nouvelles méthodes d’étude du risque médicamenteux : l’expérience du Centre Midi-Pyrénées de Pharmacovigilance. Bull. Acad. Natle Méd 2005, 189, 493-505.

G DURRIEU, P OLIVIER, JL MONTASTRUC – COX-2 inhibitors and arterial hypertension : an analysis of spontaneous case reports in the Pharmacovigilance database. Eur J Clin Pharmacol 2005 ;61 : 611-614.

JL MONTASTRUC, M LAPEYRE-MESTRE, S LUGARDON, A SOMMET – Adverse gastrointestinal outcomes and cyclo-oxygenase-2 inhibitors. 09 décembre 2005.->http://www.bmj.com/rapid-response/2011/10/31/adverse-gastrointestinal-outcomes-and-cyclo-oxygenase-2-inhibitors]

JL MONTASTRUC – Quelles leçons tirer des affaires "coxibs" ? Pratiques 2005, 79.

P OLIVIER, J CARON, F HARAMBURU, JL IMBS, AP JOINVILLE-BERA, G LAGIER, C SGRO, THIERRY VIAL, JL MONTASTRUC, M LAPEYRE-MESTRE – Validation d’une échelle de mesure : exemple de l’échelle française d’évitabilité des effets indésirables médicamenteux. Thérapie 2005, 60, 39-45.

E SOUCHET, M LAPEYRE-MESTRE, JL MONTASTRUC – Drug related falls : a study in the French Pharmacovigilance database. Pharmacoepidemiology & Drug Safety 2005, 14 : 11-16.

A PATHAK, V RAOUL, JL MONTASTRUC, JM SENARD – Adverse drug reactions related to drugs used in orthostatic hypotension : a prospective and systematic pharmacovigilance study in France. Eur J Clin Pharmacol 2005, 61:471-474.

N TAVASSOLI, H BAGHERI, L SAILLER, P BENKEMOUN, JL MONTASTRUC, P ARLET – Estimation of time devoted to adverse drug reactions assesment in an internal medicine department. Br J Clin Pharmacol 2005, 60 : 452-453.

H BAGHERI, M GONY, JL MONTASTRUC – A propos d’une campagne de vaccination contre la méningite C dans les Hautes-Pyrénées : réflexions de pharmacovigilance. Thérapie 2005 Mai-Juin, 60:287-294.

J BIGA, P VIGREUX, M LAPEYRE-MESTRE, JL MONTASTRUC – Douleurs musculaires et medicaments hypolipidémiants : etude transversale en consultation de cardiologie libérale. Thérapie 2005 Mai-Juin, 60:295-297.

JF TOURNAMILLE, F RIGAL-HUGUET, A PATHAK, JL MONTASTRUC, M LAPEYRE-MESTRE – Cardiac effects of cytokines produced after rituximab infusion. Bull Cancer 2005 ;Sep 92(9):769-71.

A SOMMET, C AZAIS-VUILLEMIN, H BAGHERI, O RASCOL, JL MONTASTRUC – Trimetazidine : a new cause for drug-induced parkinsonism ? Mov Disord 2005 ; 20 : 1080-1081.

H BAGHERI, A TREIL, L SAILLER, G MESPLE, P ARLET, JL MONTASTRUC – Réévaluation au cours du temps de l’imputabilité des effets indésirables déclarés par un Service de Médecine Interne. Thérapie 2005, 60(6) :1.

M DAMAGNEZ, A MAGNOUAT, J NIEZBORALA, M LAROZE, JC GASTON, JL MONTASTRUC – Médicaments contre-indiqués chez l’enfant : analyse des prescriptions en médicine de ville dans le départment de l’Aude. Thérapie 2005 ; 60(5) : 507-513.

J BIGA, F TABOULET, M LAPEYRE MESTRE, AM DUGUET, V SCIORTINO, JL MONTASTRUC – La prescription médicamenteuse en dénomination commune : perception des acteurs de santé en Midi-Pyrénées. Thérapie 2005, Juil-Août ; 60 (4):401-407.

H BAGHERI, J BIGA, JL MONTASTRUC – Dysfonction érectile d’origine médicamenteuse : effet indésirable sous-estimé en pharmacovigilance. Journal Officiel de la Société d’Andrologie de Langue Française 2005, 15, 200-207.

I LACROIX, A ARRAULT-OLANOR, A BERREBI, JL MONTASTRUC, C DAMASE MICHEL – Consommation de médicaments en période périnatale : étude comparative chez des femmes allaitant ou non leur enfant. Journal de Pédiatrie et de Puériculture 18, 2005, 379-385.

C DAMASE-MICHEL – Grossesse et médicaments. Réalités Gynécol-Obstétr, 2005, 99, 6-12.

M LAPEYRE-MESTRE – Médicaments détournés de leur usage thérapeutique : résultats 2004 de l’enquête OSIAP. Bulletin CIRDd Midi-Pyrénées, numéro spécial 9 novembre 2005.

TB MBONGUE, A SOMMET, A PATHAK, JL MONTASTRUC – “Medicamentation” of society, non-diseases and non-medications : a point of view from social pharmacology. Eur J Clin Pharmacol 2005, 61:309-313.

TB NGOUDO-MBONGUE, M NIEZBORALA, P SULEM, D BRIANT-VICENS, Y BANCAREL, P JANSOU, E CHASTAN, JL MONTASTRUC, M LAPEYRE-MESTRE – Psychoactive drug consumption : performance-enhancing behaviour and pharmacodependence in workers. Pharmacoepidemiol Drug Safety 2005, 14, 81-89.

I GASQUET, L NEGRE-PAGES, A FOURRIER, G NACHBAUR, A EL-HASNAOUI, V KOVESS, JP LEPINE – Usage des psychotropes et troubles psychiatriques en France : resultants de l’étude épidémiologique ESEMeD/MHEDEA 2000/(ESEMeD) en population générale. L’Encéphale 2005, 31, 195-206.

E GUITTON, C ARNAUD, E GODEAU, F NAVARRO, H GRANDJEAN – Statut socio-économique, comportements de santé et santé des adolescents français : l’enquête Health Behaviour in School-aged Children (HBSC). Rev Epidemiol Santé Publique, 2005, 53 : 383-392.

JL MONTASTRUC, H BAGHERI, JM SENARD, P OLIVIER, G DURRIEU, A SOMMET, M DESPLAS – Actualités en Pharmacovigilance in CDRom Forum Médical de Rangueil, 20 octobre 2005.

Retour en haut de page

ANNEE 2004

Publié le 18/01/2005 à 19h29 (mis à jour le 24/07/2023 à 10h20)

PHARMACOLOGIE EXPÉRIMENTALE

Philip-Couderc P., Pathak A., Smih F., Dambrin C., Harmancey R., Galinier M., Buys S., Senard J-M., Massabuau P., Roncalli J., Verwaerde P. and Rouet P. Uncomplicated Human Obesity Is Associated With Specific Cardiac Transcriptome : Involvement Of The Wnt Pathway. FASEB J. 2004.

C Moro, J Galitzki, C Sengenes, F Crampes, M Lafontan, M Berlan. Functional and pharmacological characterization of the natriuretic peptide-dependent lipolytic pathway in human fat celles. J Pharmacol Exp Ther, 2004, 308, 984-992.

B Richterova, V Stich, C Moro, J Polak, E Klimcakova, M Majercik, I Harant, N Viguerie, F Crampes, D Langin, M Lafontan, M Berlan. Effect of enducance training on adrenergic control of lipolysis in adopose tissue of obese women. J Clin Endoc Metab 2004, 89, 1325-1331.

V Stich, M Berlan. Physiological regulation of non-esterified fatty acids availability, lipolysis pathway. Proceedings of Nutritional Society 2004, 63,
369-374.

P Couderc, F Smih, JE Hall, A Pathak, J Roncalli, R Harmancey, P Massabuau, M Galinier, P Verwaerde, JM Senard, P Rouet. Analysis of cardiac transcriptome regulation during chronic high-fat diet in dogs. Physiol Genomics. 2004 ;19:32-40.

PHARMACOLOGIE CLINIQUE

P Damier, S Thobois, T Witjas, P Derkinderen, J Xie, P Azulay, E Broussolle, P Burbaud, F Durif, O Rascol. Traitement par stimulation pallidale continue des dyskinésies tardives provoquées par les neuroleptiques : résultats préliminaires d’une étude pilote multicentrique du groupe Stardys. Rev Neurol (Paris) 2004, 180, 1, 1S20-1S21.

Pathak A, Senard JM. Pharmacology of orthostatic hypotension in Parkinson’s disease : from pathophysiology to management. Expert Rev Cardiovasc Ther. 2004 May ;2(3):393-403.

CW Olanow, P Damier, CG Goetz, T Mueller, J Nutt, O Rascol, A Serbanescu, F Deckers, H Russ. Multicenter, Open-Label, Trial of Sarizotan in Parkinson’s disease patients with levodopa-induced dyskinesias (the SPLENDID study). CW Olanow, P Damier, CG Goetz, T Mueller, J Nutt, O Rascol, A Serbanescu, F Deckers, H Russ. Clin Neuropharmacol 2004, 27, 58-62.

Waters CH, Sethi KD, Hauser RA, Molho E, Bertoni JM. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations : a 3-month, randomized, placebo-controlled study. Zydis Selegiline Study Group. Mov Disord. 2004 Apr ;19(4):426-32.

F Durif, B Debilly, M Galitzky, D Morand, F Viallet, M Borg, S Thobois, E Broussolle, O Rascol. Clozapine improves dyskinesias in Parkinson’s disease : a double-blind placebo-controlled study. Neurology 2004, 62, 381-388.

P Pollak, F Tison, O Rascol, A Destee, JJ Pere, JM Senard, F Durif, I Bourdeix. Clozapine in drug induced psychosis in Parkinson’s disease : a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry. 2004 ; 75:689-95.

W Olanow, Y Agid, Y Mizuno, A Albanese, U Bonucelli, P Damier, Y De Yebenes, O Gershanik, M Guttman, F Grandas, M Hallet, O Hornykiewicz, P Jenner, R Katzenschlager, WJ Langston, P Lewitt, E Melamed, MA Mena, PP Michel, C Mytilineou, JA Obeso, W Poewe, N Quinn, R Raisman-Vozari, AH Rajput, O Rascol, C Sampaio, F Stocch. Levodopa in the treatment of Parkinson’s disease : current controversies. Mov Disord 2004, 19, 997-1005.

JC Zijlmans, B Debilly, O Rascol, AJ Lees, F Durif. Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson’s disease patients : pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study. Mov Disord 2004, 19,
1006-1011.

F Bracco, A Battaglia, C Chouza, E Dupont, O Gershanik, JF Marti Masso, JL Montastruc, and Pkds 009. The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease : final results of a 5-year, double-blind, levodopa controlled study. CNS Drugs, 2004, 733-746.

P Angibaud, C Gaultier, O Rascol. Atypical parkinsonism and annonaceae consumption in New Caledonia. Mov Disorders 2004, 5, 603-605

CG Goetz, W Poewe, O Rascol, C Sampaio, GT Stebbins, C Counsell, N Giladi, RG Holloway, CG Moore, GK Wenning, MD Yahr, L Seidl. Movement Disorder Society task force report on the Hoehn and Yahr staging scale : status and recommendations. The Movement Disorder Society task force on rating scales for Parkinson’s Disease. Mov Disord 2004, 19, 1020-1028.

GK Wenning, F Tison, K Seppi, A Diem, F Yekhef, I Ghorayeb, F Ory, M Galitzky, T Scaravilli, B Bozi, C Colosimo, NP Quinn, O Rascol, C Sampaio, W Poewe. and the European MSA Study Group (EMSA-SG). Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 2004, 19, 1391-1402.

P Ibanez, E Lhomann, P Pollak, F Durif, C Tranchant, Y Agid, A Durr, A Brice, AM Bonnet, M Borg, E Broussolle, P Damier, A Destee, M Martinez, C Penet, O Rascol, F Tison, M Verin, F Viallet, M Vidailhet, JM Warter. Absence of NR4A2 exon 1 mutations in 108 families with autosomal dominant Parkinson’s disease. Neurology 2004, 62, 2133-2134.

R Vidal, B Ghetti, M Takao, C Brefel-Courbon, E Uro-Coste, BS Glazier, M Siani, MD Benson, P Calvas, L Miravalle, O Rascol, MD Delisle. Intracellular ferritin accumulation in neural and extraneural tissue characterizes a neurodegenerative disease associated with a mutation in the Ferritin Light Polypeptide gene. J Neuropathol Exp Neurology 2004, 63, 363-380.

P Philip-Couderc, A Pathak, F Smih, C Dambrin, R Harmancey, S Buys, M Galinier, P Massabuau, J Roncalli, JM Senard, P Rouet. Human obesity is associated with a specific cardiac transcriptome : involvement of the Wnt pathway. FASEB J. 2004 ; 18:1539-40.

P Maury, C Baixas, J Roncalli, P Couderc, M Delay, A Pathak, M Galinier. Resumption of atrioventricular conduction by levosimendan after radiofrequency, ablation of the AV Node : does levosimendan have potential as medical therapy in atrioventricular conduction disease ? Pace, 27, 1314-1316

C Moro, F Crampes, C Sengenes, I De Glisenzinsk, J Galitzky, C Thalamas, M Lafontan, M Berlan. Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans. FASEB J 2004, 18, 908-910.

A Pathak. Choosing the right statin. Newsweek, 2004, Feb 16, 18.

PHARMACOÉPIDÉMIOLOGIE, PHARMACOLOGIE SOCIALE, PHARMACOVIGILANCE, PHARMACODÉPENDANCE, ADDICTOVIGILANCE

M LAPEYRE-MESTRE, P SULEM, M NIEZBORALA, T BIENVENU N GOUNDO-MBONGUE, D BRIAND-VINCENS, P JANSOU, Y BANCAREL, E CHASTAN, JL MONTASTRUC – Conduite dopante en milieu professionnel : étude auprès d’un échantillon de 2106 travailleurs de la région toulousaine. Thérapie 2004, 59, 615-623.

J MICALLEF, V PRADEL, X THIRION, P JOLLIET, M LAPEYRE-MESTRE – Utilisation des bases de données de l’Assurance Maladie par les Centres d’Evaluation et d’Information sur la Pharmacodépendance : exemples, intérêts et perspectives. Thérapie 2004, 59, 581-588.

Bagheri H, Simiand E, Montastruc JL, Magnaval JF. Adverse drug reactions to anthelmintics. Ann Pharmacother. 2004 Mar ;38(3):383-8. Epub 2004 Jan 23.-.

Lacroix I, Berrebi A, Chaumerliac C, Lapeyre-Mestre M, Montastruc JL, Damase-Michel C. Buprenorphine in pregnant opioid-dependent women : first results of a prospective study. Addiction. 2004 Feb ;99(2):209-14.

Lapeyre-Mestre M, Gregoire N, Bugat R, Montastruc JL. Vinorelbine-related cardiac events : a meta-analysis of randomized clinical trials. Fundam Clin Pharmacol. 2004 Feb ;18(1):97-105.

JL Montastruc, A Pathak, H Bagheri.Valvulopathies sous pergolide : la saga des fibroses dues aux dérivés de l’ergot de seigle continue ! Rev Neurol (Paris) 2004, 160, 1, 19-21.

Montastruc JL. "Medicamentation" of society : an example of social pharmacology.Prescrire Int. 2004 Feb ;13(69):38-9.

Lacroix I, Lapeyre-Mestre M, Bagheri H, Pathak A, Montastruc JL.
Nonsteroidal anti-inflammatory drug-induced liver injury : a case-control study in primary care. Club de Reflexion des cabinets de Groupe de Gastro-Enterologie (CREGG) ; General Practitioner Networks. Fundam Clin Pharmacol. 2004 Apr ;18(2):201-6.

Sanz E, Hernandez MA, Kumari M, Ratchina S, Stratchounsky L, Peire MA, Lapeyre-Mestre M, Horen B, Kriska M, Krajnakova H, Momcheva H, Encheva D, Martinez-Mir I, Palop V. Eur J. Pharmacological treatment of acute otitis media in children. A comparison among seven locations : Tenerife, Barcelona and Valencia (Spain), Toulouse (France), Smolensk (Russia), Bratislava (Slovakia) and Sofia (Bulgaria). Clin Pharmacol. 2004 Mar ;60(1):37-43.

G Durrieu, E Gorsse, JL Montastruc. La presse grand public est-elle une source d’information sur le dopage dans le sport ? Thérapie, 2004, 59, 89-91.

JL Montastruc, G Durrieu. Tremblements et mouvements anormaux aigus d’origine médicamenteuses. Thérapie, 2004, 59, 97-103.

N Nguyen, V Pradel, J Micallef, JL Montastruc, O Blin. Les syndromes parkinsoniens médicamenteux. Thérapie, 2004, 59, 105-112.

Dugue A, Bagheri H, Lapeyre-Mestre M, Tournamille JF, Sailler L, Dedieu G, Salvayre R, Thouvenot JP, Massip P, Montastruc JL. Detection and incidence of muscular adverse drug reactions : a prospective analysis from laboratory signals. Eur J Clin Pharmacol. 2004 Apr 28.

Sanz E, Hernandez MA, Ratchina S, Stratchounsky L, Peire MA, Lapeyre-Mestre M, Horen B, Kriska M, Krajnakova H, Momcheva H, Encheva D, Martinez-Mir I, Palop V. Drug utilisation in outpatient children. A comparison among Tenerife, Valencia, and Barcelona (Spain), Toulouse (France), Sofia (Bulgaria), Bratislava (Slovakia) and Smolensk (Russia). Eur J Clin Pharmacol. 2004  ;60:127-34.

JL Montastruc. Pharmacologie : gare au mirage de la « sélectivité ». Rev Prescr, 2003, 236, 152-153.

M Lapeyre-Mestre. Supervised prescription of methadone plus heroin is more effective than methadone alone. Evidence-based Healthcare, 2004, 8, 110-111.

Angibaud G, Gaultier C, Rascol O. Atypical parkinsonism and Annonaceae consumption in New Caledonia. Mov Disord. 2004
May ;19(5):603-4.

JL Montastruc, B Bongue. « Non-médicaments » pour « non-maladies » ? Trait d’Union, 2004, n° 100, 20-21.

JL Montastruc, H Bagheri, P Olivier. Bilan 2003 de Pharmacovigilance. Rev ADPHSO, 2004, 1, 31-32.

JL Montastruc. Compte-rendu de la 5ème Rencontre de Pharmacologie Sociale : Les études cliniques contrôlées : une composante de la pharmacologie sociale. Rev ADPHSO, 2004, 1, 32.

JL Montastruc. Oui à une information indépendante ! Rev ADPHSO, 2004, 1, 32.

JL Montastruc. Pression de prescription : étude pilote en médecine
générale. Rev ADPHSO, 2004, 1, 33.

JL Montastruc. Défaillance dans la chaîne thérapeutique et inefficacité des médicaments. Rev ADPHSO, 2004, 1, 33.

M Baubrant, MA Tran. Le coup de chaleur : un sujet d’actualité. Rev ADPHSO, 2004, 1, 33.

JL Montastruc. A propos de iatrogénèse. Rev ADPHSO, 2004, 1, 34.

JL Montastruc. Urticaire chronique et médicaments. Rev ADPHSO, 2004, 1, 34.

A Pathak, MA Tran. Jus de pamplemousse et médicaments. Rev ADPHSO, 2004, 1, 34.

AFSSAPS. Traitement hormonal substitutif et risque de cancer du sein. Communiqué de l’AFSSAPS du 18 août 2003. Rev ADPHSO, 2004, 1, 35- 36.

C Damase-Michel. Mémo : les traitements hormonaux substitutifs de la ménopause (THS). Rev ADPHSO, 2004, 1, 36.

JL Montastruc. Les effets indésirables thrombotiques veineux des oestrogènes diffèrent selon leur voie d’administration. Rev ADPHSO, 2004, 1, 36.

C Damase-Michel. Informer sur les risques de la prise d’antiinflammatoires non stéroïdiens à partir du 6ème mois de grossesse. Rev ADPHSO,
2004, 1, 36-37.

JL Montastruc. Qu’en est-il des effets indésirables (EI) rénaux des coxibs ? Rev ADPHSO, 2004, 1, 37.

JL Montastruc. Les coxibs majorent-ils le risque thrombotique ? Rev ADPHSO, 2004, 1, 37.

JL Montastruc. Les AINS réduisent-ils l’activité anti-agrégante de l’aspirine ? Rev ADPHSO, 2004, 1, 37-38.

JL Montastruc. Inhibiteurs de l’enzyme de conversion (IEC) diurétiques et anti-inflammatoires non stéroïdiens (AINS) : une association dangereuse. Rev ADPHSO, 2004, 1, 38-39.

JL Montastruc. Les médicaments antirétroviraux et infarctus du m
Jyocarde. Rev ADPHSO, 2004, 1, 38.

JL Montastruc.Valvulopathies cardiaques sous pergolide CELANCE°. Rev ADPHSO, 2004, 1, 38-39.

JL Montastruc. Quel rôle pour les médicaments antiépileptiques dans la survenue de la mort subite chez l’épileptique ? Rev ADPHSO, 2004, 1, 39.

JL Montastruc. Convulsions et dyscrasies sanguines sous mirtazapine
(NORSET°).Rev ADPHSO, 2004, 1, 39.

JL Montastruc. Topiramate EPITOMAX° : oligohydrose et hyperthermie. Rev ADPHSO, 2004, 1, 39.

JL Montastruc. L’ecstasy peut-elle déterminer un syndrome parkinsonien ? Rev ADPHSO, 2004, 1, 39-40.

JL Montastruc. Effets indésirables de la fluorescéine. Rev ADPHSO, 2004, 1, 40.

S Leclerc, E Garrigue. Inutile d’associer anti-H1 et corticoïdes dans l’allergie ! Rev ADPHSO, 2004, 1, 40.

JL Montastruc. Majoration du risque infectieux avec les antagonistes du TNF ALPHA. Rev ADPHSO, 2004, 1, 40.

P Olivier. Biphosphonates et effets indésirables oculaires.
Rev ADPHSO, 2004, 1, 41.

JL Montastruc. Vaccination hépatite B et maladies démyélinisantes type sclérose en plaques (SEP) : suite et fin. Rev ADPHSO, 2004, 1, 41.

Retour en haut de page

ANNEE 2003

Publié le 18/01/2005 à 19h27 (mis à jour le 26/02/2013 à 10h00)

PHARMACOLOGIE EXPÉRIMENTALE

PHARMACOLOGIE CLINIQUE

vol III.
(Pavy-Le Traon A, Pathak A, Sénard JM)- Efficacy and tolerability of entacapone in patients with Parkinson’s disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study. J Neural Transm. 2003 Mar ;110(3):239-51.
(Fenelon G, Gimenez-Roldan S, Montastruc JL, Bermejo F, Durif F, Bourdeix I, Pere JJ, Galiano L, Schadrack J.)

  • Les médicaments de l’hypotension orthostatique. La lettre du Neurologue. 2003 Octobre. Hors-série. 3-10.
    (Sénard JM, Pathak A, Pavy-Le-Traon A)
  • Les récepteurs AT1/AT2 de l’angiotensine II. De la physiopathologie au traitement des maladies cardiovasculaires. Actualités Innov Méd. 2003.
    (Pathak A, Galinier M)
  • A quoi sert l’angitensine cérébrale ? Actualités Innov Méd. 2003 ;87:32-34.
    (Pathak A, Sénard JM, Galinier M)
  • Inhibiteurs calciques et prévention des AVC. Actualités Innov Méd. 2003 ;89.
    (Pathak A)
  • How much phenotypic variation can be attributed to parkin genotype ? Ann Neurol. 2003 Aug ;54(2):176-85.
    (Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A ; French Parkinson’s Disease Genetics Study Group ; European Consortium on Genetic Susceptibility in Parkinson’s Disease)
  • Anomalies tensionnelles et maladie de Parkinson. ON/OFF Nukléus. 2003 Décembre.29.
    (Sénard JM)
  • HTA du diabétique : de nouvelles propiétés pour la nitrendipine. Actualités Innov Méd. 2003 ;86.
    (Pathak A)
  • Antimigraineux : faire le bon choix. Rev Prescr, 2003, 241, 552-553.
    (Sénard JM, Geraud G)
  • Dépistage de la neuropathie autonome cardique dans une population de diabétiques de type I. Rev Neurol. 2003 ;suppl n°3(15):J24.
    (Pavy-Le Traon A, Fontaine S, Martini J, Hanaraire-Broutin H, Sénard JM)
  • Les tests cardiovasculaires d’exploration du système nerveux autonome. Correspondances en pério-périnéologie 2003, 2,

PHARMACO, ÉPIDÉMIOLOGIE, SOCIALE, VIGILANCE, DÉPENDANCE

  • Interaction atorvastatine-clopidogrel ? De la pharmacologie à la cardiologie pratique. La lettre du cardiologue. 2003 Octobre ;368.
  • La « médicamentation » de la société : un exemple de pharmacologie sociale.
    (JL Montastruc, B M’bongue)
    Pratiques, 2003, 21, 6-9.
  • Guide des médicaments antiinfectieux lors de la grossesse et l’allaitement.
    (A Berrebi, C Damase-Michel, E Elefant)
    Editions Doin, Paris, 2003.
  • Pharmacologie : gare au mirage de la « sélectivité ».
    (JL Montastruc)
    Rev Prescr, 2003, 236, 152-153.
  • Comportement pathologique de jeu au cours d’une maladie de Parkinson traitée par lévodopa et bromocriptine. Rev Neurol. 2003 ;159(4):441-3.
    (Montastruc JL, Schmitt L, Bagheri H)
  • Les médicaments immunosuppresseurs en transplantation hépatique.
    (A Delavaud, C Damase-Michel)
    Hepat-Infos, 2003, 55, 4-7.
  • Médicaments : informer dès l’école. Rev Prescrire 2003, 23, 631.
    (JL MONTASTRUC)
  • Combien de noms de médicaments faut-il enseigner en pharmacologie dans les facultés de médecine ? Réflexions pédagogiques et propositions.
    (JL Montastruc, O Rascol, JM Senard, MA Tran, M Berlan, C Damase-Michel, M Lapeyre-Mestre, C Brefel-Courbon, H Bagheri, A Pathak, V Claverie)
    La Lettre du Pharmacologue, 2003, 3, 103-105
  • Consommation médicamenteuse et pharmacovigilance chez le sujet âgé. Revue de l’adphso. 2003 ;28(2):13-6.
    (Bagheri H)
  • Actualités en pharmacovigilance et pharmacoépidémiologie. Revue de l’adphso. 2003 ;28(1):29-36.
    (Montastruc JL)
  • Actualités en pharmacovigilance et pharmacoépidémiologie. Revue de l’adphso. 2003 ;28(2):1-12.
    (Montastruc JL)
  • Le risque iatrogène : rôle du médecin généraliste en matière de prévention individuelle et collective.
    (Ph Arlet, M Vidal, JL Montastruc, C Damase-Michel)
    Polycopié du Certificat Optionnel Interdisciplinaire DCEM, Faculté de Médecine de Toulouse-Purpan, Faculté de Médecine Toulouse-Rangueil.
  • Lecture et analyse de l’information médicale en médecine générale.
    (JL Montastruc)
    Polycopié du Certificat Optionnel Interdisciplinaire DCEM, Faculté de Médecine de Toulouse-Purpan, Faculté de Médecine Toulouse-Rangueil.
  • La Pharmacovigilance.
    (Jl Montastruc) Polycopié du Certificat Optionnel Interdisciplinaire DCEM, Faculté de Médecine de Toulouse-Purpan, Faculté de Médecine Toulouse-Rangueil.
Retour en haut de page

ANNEE 2002

Publié le 18/01/2005 à 19h06 (mis à jour le 26/02/2013 à 09h58)

PHARMACOLOGIE EXPÉRIMENTALE

  • Modifications précoces du transcriptome auriculaire dansl’hypertension artérielle associéeàl’obésité chez le chien
    (P Philip-Couderc, F Smih, M Pelat, P Verwaerde, A Pathak, S Buys, JL Montastruc, JM Senard et P Rouet)
    Archives des maladies du coeur et des vaisseaux, tome 95, n°7/8, juillet-août 2002
  • Etude de la repolarisation ventriculaire dans un modèle expérimental d’HTA associée à l’obésité
    (A Pathak, P Verwaerde, M Glainier, M Pelat, P Philip-Couderc, P Rouet, F Smih, S Buys, JL Montastruc et JM Senard)
    Archives des maladies du coeur et des vaisseaux, tome 95, n°7/8, juillet-août 2002

PHARMACOLOGIE CLINIQUE

  • "Sleep Attack" or "Unintended Sleep Episodes"Occur with Dopamine Agonists
    (K Ray Chaudhuri, Suvankar Pal and C Brefel-Courbon)
    Drug Safety 2002 : 25(7):473-483
  • A six -mounth multicentre, double-blind,bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson’s disease not optimally controlled by L-dopa
    (ER Brunt, DJ Brooks, AD Korczyn, JL Montastruc, F Stocchi)
    Journal of Neural Transmission(2002)109 : 489-502
  • Les dyskinesies tardives des neuroleptiques.
    (E Broussole, P Burbaud, P Damier, F Durif, O Rascol)
  • Troubles tensionnels au cours de la maladie de Parkinson
    (JM Senard)
  • Les Dyskinésies induite par la L-dopa dans la maladie de Parkinson (A Destée, O Rascol, M Vidailhet)
  • Stratégie médicamenteuse initiale
    (F Smih, P Rouet, S Lucas, A Mairal, C Sengenes, M Lafontan, S Vaulant, M Casado and D Langin)
  • Facteurs pharmacologiques à l’origine des dyskinésies
    (P Damier, O Rascol)
  • Facteurs pharmacologiques succeptibles de moduler l’expression des dyskinésies
    (P Damier, O Rascol, J Micallef)
  • Prévention des dyskinésies déterminées par la dopa chez les malades parkinsoniens ? Approches pharmacologiques
    (JL Montastruc, O Rascol)
  • Prise en charge médicaemnteuse des dyskinésies dopa-induites dans la maladie de Parkinson
    (O Blin, M Ziégler, A Benabid, O Rascol)
  • Propriétés pharmacodynamiques des agonistes dopaminergiques ? Quelle transférabilité en pratique clinique dans le traitement de la maladie de Parkinson
    (JL Montastruc, O Rascol)
    La lettre du Neurologue-n°-vol.VI-mars 2002
  • Maladie de Parkinson et système noradrénergique
    (C Brefel-Courbon ) Press Med 2002 ;31:1240-2
  • Treatment interventions for Parkinson’s disease : an evidence based assessment
    (O Rascol, c Goetz, W Koller, W Poewe, C Sampaio)
    Lhe Lancet-Vol 359-May 4,2002
  • Récepteurs dopaminergiques D1 et médicaments antiparkinsoniens
    (O Rascol, C Brefel-Courbon, N Fabre, C Thalamas, JM senard, JL Montastruc)
    Rev Neurol(Paris)2002 1S13
  • Prise en charge des dyskinésies par la lévodopa
    (O Rascol, JJ Ferreira, P Payoux, C Brefel-Courbon)
    Rev Neurol(Paris)2002 : 158 : HS, 7S117-7S124
  • Management of Parkinson’s disease : An Evidence-Based Review
    (CG Goetz, WC Koller, W Poewe, O Rascol, C Sampaio)
  • Anti-TNF et insuffisance cardiaque
    (A Pathak, JM Senard, JL Montastruc, M Galinier)
    Réalités cardiologiques-N°178-Juin 2002
  • Insuffisance cardiaque chronique et auto-immunité
    (A Pathak, JM Senard, M Galinier)
    Réalités cardiologiques-N°173-Juin 2002
  • Le coeur : organe clé dans le métabolisme des médicaments ?
    (A Pathak, JM Senard, JL Montastruc)
    La Lettre du Pharmacologue-Volume 16-n°4-5 juillet-octobre 2002

PHARMACO, ÉPIDÉMIOLOGIE, SOCIALE, VIGILANCE, DÉPENDANCE

  • Quels indicateurs d’efficacité des essais cliniques, pour quels résultats ?
    (A Anglès, K desboeuf, H Bagheri, M Lapeyre-Mestre, JL Montastruc)
    La lettre du Pharmacologue-Volume 16-n°1 janvier-février 2002 ?
  • Use of Codeine and Non-Codeine Cough Suppressants
    (P Olivier, K Maréchal, ME Llau,m Lapeyre-Mestre, C Damase-Michel and JL Montastruc)
    Clin Drug Invest 2002 ; 22(6):399-402
  • La Pharmacologie Sociale : une nouvelle branche de la Pharmacologie Clinique
    (JL Montastruc)
  • Qu’est ce que la pharmacologie sociale ?
    (JL Montastruc)
  • De la faculté à l’Hôpital...
    (LC Soula, L Bugnard )
  • Effets indésirables et risques de l’automédication
    (JL Montastruc, H Bagheri, C Damase-Michel, P Olivier, I Lacroix, M Lapeyre-Mestre)
    Pratiques Médicales et Thérapeutiques-n°24/25 septembre-octobre 2002
  • Médicaments et allaitement maternel
    (C Damase-Michel, M Rolland, J Tricoire, C Azogui-Assouline)
  • Intérêt de la pharmacoépidémiologie pour le praticien
    (JL Montastruc, M Lapeyre-Mestre, H Bagheri, C Damase-Michel)
  • L’"Antenne Médicale de Lutte contre le Dopage" de Toulouse, Centre "Pierre Dumas", est ouverte !
    (JL Montastruc )
  • Antenne Médicale de Lutte contre le Dopage de Toulouse
    (JL Montastruc)
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie
    (JL Montastruc )
    Revue de l’Adphso, Tome 27 n°1 pp 27-35, n°3 pp 1-15
  • Evaluation Médico-Economique d’une cure thermale à Ussat-Les-bains dans la maladie de Prakinson
    (C Brefel-Courbon, K Desboeuf, C Thalamas, M Galitzky, JM Senard,O Rascol et JL Montastruc )
    Revue Therm Clim 2002 ; 139 : 99-108
Retour en haut de page

ANNEE 2001

Publié le 18/01/2005 à 18h56 (mis à jour le 26/02/2013 à 09h58)

PHARMACOLOGIE EXPÉRIMENTALE

PHARMACOLOGIE CLINIQUE

  • Hypertrophie ventriculaire gauche et variabilité sinusale au cours de l’hypertension artérielle
    (M. Galinier, A. Pathak, J. Fourcade, J. Souk Aloun, P. Massabuau, D. Curnier, S. Boveda, C. Baixas, J.M. Fauvel et J.M. Senard)
    Archives des Maladies du coeur et des vaisseaux, tome 94, n°8, août 2001
  • Stratégies pharmacothérapeutiques actuelles et futures dans la prise en charge de la maladie de Parkinson
    (C. Brefel-Courbon et O. Rascol)
    Dts Manage Health Outcomes 2001 ; 9 Spec.Issue1:31-39
  • Dyskinésies induites par la lévodopa chez le parkinsonien : nouvelles données avec les agonistes dopaminergiques
    (O. Rascol, C. Brefel-Courbon, N. Fabre, J.M. Senard, J.L. Montastruc) Rev Neurol(Paris)2001 : 1S21
  • Réorganisation fonctionnelle après accident vasculaire cérébral : modulation pharmacologique
    (F. Chollet, I. Loubinoux, J. Pariente, C. Carel, J-F Albucher, C. Manelfe, O. rascol, B. Guiraud-Chaumeil)
    Rev Neurol(Paris)2001 : 1S23

PHARMACO, ÉPIDÉMIOLOGIE, SOCIALE, VIGILANCE, DÉPENDANCE

  • Prévention des effets indésirables des médicaments
    (F. Haramburu, C. Riché, J-L Montastruc, J-P Blayac)
    Thérapie 2001 ; 56:273-274
  • Evitabilité des effets indésirables dans un service d’admissions médicales
    (P. Olivier, O. Boulbès, M. Tubery, P. Carles, J-L Montastruc, M. Lapeyre-Mestre)
    Thérapie 2001 ; 56:275-278
  • Atteintes hépatiques et médicaments anti-inflammatoires non stéroïdiens : étude cas/non cas dans la Banque Nationale de Pharmacovigilance
    (M-P Bareille, J-L Montastruc, M. Lapeyre-Mestre)
    Thérapie 2001 ; 56:51-55
  • Bilan du suivi des questions « médicaments et grossesse » au Centre Midi-Pyrénées de Pharmacovigilance
    (T Lemoine, I Lacroix, M. Lapeyre-Mestre, J-L Montastruc, C Damase-Michel)
    Thérapie 2001 ; 56:287-293
  • Différences inter-régionales des dysthyroïdiesà l’amiodarone : comparaison des notifications spontanées en Aquitaine, Midi-Pyrénées et Languedoc-Roussillon
    (H. Bagheri, M. Lapeyre-Mestre, C. Levy, F. Haramburu, D. Hillaire-Buys, J-P Blayac, J-L Montastruc)
    Thérapie 2001 ; 56:301-306
  • Modafinil and Pramipexole-Associated Somnolence
    (J-L Montastruc, O. Rascol)
    Movement Disorders Vol 16 n°4, 2002, pp 783-784
  • Somnolence diurne anormale, “attaques de sommeil” et médicaments antiparkinsoniens
    (O. Rascol, J. Ferreira, J-L Montastruc)
    Rev Neurol(Paris) ; 157:1313-1323
  • Analyse coût/efficacité de la prise en charge diagnostique et thérapeutique des carcinomes d’origine indéterminée
    (K. Desboeufs, L. Molinier, M-O Carrère, R. Bugat, M. Boisseau, M. Machelard-Sauvage, J-J Voigt, J. Pous)
    Bulletin du cancer.Vol.88, Numéro 11 Novembre 2001
  • Pharmacoepidemiology for everybody !
    (B. Begaud, J. Wiley et Sons)
  • Risques cardiovasculaires du sildénafil (Viagra) ?
    (J-L Montastruc)
  • Les “coxibs” dans l’actualité
    (J-L Montastruc)
  • Réflexions d’un pharmacologue
    (J-L Montastruc)
    La Revue Prescrire octobre 2001/Tome 21 N°221
  • Le Rohypnol : résultats d’une enquête réalisée auprès des pharmaciens de la Région Midi-Pyrénées en août 2000
    (E. Souchet)
    Graphiti 2001,30,7
  • Actualités en Pharmacovigilance
    (H Baghéri)
    Revue de l’Asphso Tome 26 n°2, 2001-pp. 1-3
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie
    (JL Montastruc)
    Revue de l’Asphso Tome 26 n°2, 2001-pp. 1-8 et 5-12
  • Thermalisme et qualité de vie résultats d’une étude utilisant le Questionnaire SF-36
    (V Bongard, M Lapeyre-Mestre, P Duchêne-Marulaz, JJ Boubes, JL Montastruc)
    Presse thermale et climatique 2001 ; 138:121-124
Retour en haut de page

ANNEE 2000

Publié le 18/01/2005 à 18h47 (mis à jour le 26/02/2013 à 09h54)

PHARMACOLOGIE EXPÉRIMENTALE

  • Recent developments on lipolysis regulation in humans and discovery of a new lipolytic pathway
    (M Lafontan, C Sengenes, J Galitzky, M Berlan, I De Glisezinski, F Crampes, V Stich, D Langin, P Barbe and D Rivière)
    International Journal of obesity(2000) 24, Suppl 4, S47-S52

PHARMACOLOGIE CLINIQUE

  • Prévention des dyskinésies déterminées par la L-dopa chez les parkinsoniens
    (JL Montastruc, O. Rascol) Neuro-psy Numéro spécial-Septembre 2000
  • Facteurs pharmacologiques à l’origine des dyskinésies
    (P Damier, O. Rascol)Neuro-psy Numéro spécial-Septembre 2000
  • Facteurs pharmacologiques susceptibles de moduler les dyskinésies (P Damier, O. Rascol, J Micallef) Neuro-psy Numéro spécial-Septembre 2000
  • Les médicaments antiparkinsoniens du futur Map Monde 2000, 8-10
  • Célance : un agoniste dopaminergique au mécanisme d’action original
    (JL Montastruc)
  • [Depressed low frequency power of heart rate variability as an independent preditor of sudden death in chronic heart failure
    (M Galinier, A Pathak, J Fourcade, C Androdias, D Curnier, S Varnous, S Boveda, P Massabuau, JM Senard and JP Bonhoure)
    European Heart Journal (2000) 21,475-482

PHARMACO, ÉPIDÉMIOLOGIE, SOCIALE, VIGILANCE, DÉPENDANCE

  • Coût des effets indésirables des médicaments anticancéreux au Centre de lutte contre le cancer de Midi-Pyrénées
    (M Lapeyre-Mestre, AL Couffignal, C Bonhomme, R Bugat, JL Montastruc)
    Journal d’Economie Médicale 2000, T, 18, N°6,331-341
  • Radiopharmaceuticals
    (H Bagheri and JAM Tafani)
    Meyler’s Side Effects of Drugs, 14th Edition 2000
  • Oméprazole et Sudation excessive
    La Revue Prescrire octobre 2000/Tome 20 N°212 page 837
  • Glaucome et corticoïde par voie orale
    La Revue Prescrire octobre 2000/Tome 20 N°203 page 121
  • Syndrome malin des neuroleptiques et syndrome sérotoninergique : diagnostics positifs et différentiels et étiologies médicamenteuse
    (JL Montastruc, H Bagheri, JM Senard)
    La lettre du pharmacologue-Volume 14-n°7-setpembre 2000
  • Obésité, travail et consommation médicamenteuse
    (M Lapeyre-Mestre, D briant, P Jansou, JL Montastruc et les Médecins du Service Médical Inter-Entreprises de Toulouse)
    Performances Humaines et Techniques Novembre-Décembre 1999 n°102
  • Pharmaco-épidémiologie des antidépresseurs
    La lettre du pharmacologue-Volume 14-n°9-10 novembre-décembre 2000
    A Pharmacoeconomic Evaluation of Botulinum Toxin in the Treatment of Spasmodic Torticollis Clin Neuropharmacol. 2000 Jul-Aug ;23(4):203-7
    (C Brefel-Courbon,Marion Simonetta-Moreau, C Moré, O Rascol, M Clanet, JL Montastruc and M Lapeyre-Mestre)
  • [Santé mentale des adolescents en Midi-Pyrénées : Actes et prescriptions pharmaceutiques chez les 0-19ans
    (P Siau, JP Raynaud, JL Montastruc)
  • Evaluation du potentiel de pharmacodépendance des médicaments
    Le Bulletin de l’ORSMIP n°49/00
  • L’Utilisation détournée de médicaments antisifs à bas de codéine constitue-elle un mode d’entrée dans la pharmacodépendance ?
    (P Olivier, ME Llau, M Lapeyre-Mestre, JL Montastruc)
    Le Bulletin de l’ORSMIP n°49/00
  • Biarritz(2) : les ordonnances suspectes comme indicateur d’ abus et de pharmacodépendance
    (M Lapeyre-Mestre, ME Llau, C damase-Michel, JL Montastruc et le réseau des CEIP français)
  • Ropinirole and Parkinson’s disease
    (WJ Weiner, SA Factor, O Rascol)
    N Engl. J Med Volume 343 Number 12
  • Prise en charge médicamenteuse des dyskinésies induites par la L-dopa dans la maladie de Parkinson
    (O Blin, M Ziégler, A Benabid, O Rascol)
    Neuro-psy Numéro Special-septembre 2000
  • Sport et thermalisme en Midi-Pyrénées
    (M Lapeyre-Mestre)
  • Actualités en Pharmacovigilance
    (H Bagheri-Charabiani)
    Revue de l’ADPHSO Tome 25 n)1, 2000-pp.53-57
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie :
    Communiqué de l’agence Française de sécurité sanitaire des produits de santé du 5 octobre 1999 Viagra : actualisation des données de pharmacovigilance
    (JL Montastruc)
    Revue de l’ADPHSO Tome 25 n°1, 2000-pp. 23-32
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie :
    Prescription et consommation des médicaments vasodilatateurs
    (JL Montastruc)
    Revue de l’ADPHSO Tome 25 n°2, 2000-pp. 1-2
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie :
    A propos du rapport bénéfice/risque du millepertuis
    (JL Montastruc)
    Revue de l’ADPHSO Tome 25 n°3, 2000-pp. 1-5
  • Actualités en Pharmacovigilance et Pharmacoépidémiologie :
    Inhibiteurs de l’HMG-COA réductase et interactions médicamenteuses
    (JL Montastruc)
    Revue de l’ADPHSO Tome 25 n°4, 2000-pp. 1-8
Retour en haut de page

ANNEE 1999

Publié le 18/01/2005 à 18h42 (mis à jour le 26/02/2013 à 09h50)

PHARMACOLOGIE EXPÉRIMENTALE

  • Adrenergic receptors in brown and white adipocytes : structure, functions and regulations.
    (M Lafontan, D Langin, P Valet, JS Saulnier-Blache, J Galitzky, C Carpéné, M Berlan)
    Progress in obesity Research : 8. Ed B. Guy-Grand and G. ailhaud. Proceedings of the 8th International Congress on Obesity. 365-371
  • Aggregating human platelets stimulate expression of vascular endothelial growth factor in cultured vascular smooth muscle cells through a synergistic effect of transforming growth factor-bêta1 and platelet-derived growth factor AB.
    (N Kronemann, A Bouloumié, S Bassus, CM Kirchmaier, R Busse, VB Schini-Kerth)
    Circulation, 1999, 100, 855-860.

PHARMACO, ÉPIDÉMIOLOGIE, SOCIALE, VIGILANCE, DÉPENDANCE

  •  [Potentiation of the acenocoumarol anticoagulanteffect by acetaminophren->www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=Pubmed&list_uids=10332548&dopt=Abstract" class='spip_out' rel='external'>Pharmaocovigilance et Pharmacoépidémiologie : Principes, définition, méthodes et actualités en neurologie

    Ann Pharmacother. 1999 Apr ;33(4):506 (JL Montastruc)

    Effets indésirables des cures thermales : à propos d’une étude de vigilance thermale prospective systématique à Bagnère-de-Bigorre.
    (JL Montastruc, R Dutkiewicz, ME Llau-Bousquet,-Melou, M Lapeyre-Mestre)

    • Quinolones and pregnancy
      (C Damase-Michel)
      Prescrire International, 1999, 8, 29-31
    • Clozapine in drug-induced psychosis in Parkinson’s disease.
      (P Pollak, A Destee, F Tison, JJ Péré, J Bordeix, A Agid, F Durif, C Geny, C Prunieer-Levilon, O Rascol, S Sangla, M Verin, F Viallet, C Tranchant)
      Lancet, 1999, 353, 2042-2042
    • Lack of pharmacokinetic interaction between ropinoriole and theophylline in parkinsonian patients
      (C Thalamas, C Brefel-Courbon, A Lopez-Gil, K Fitzpatrick, S Cooper, S Eagle, JL Montastruc, O Rascol)
      Eur J Clin Pharmacol, 1999, 55, 299-303
    • Effect of cholecystinine A antagonist, SR 27897 B, in Parkinson’s disease.
      (I Arnulf, C Brefel-Courbon, J Xie, M Vidailhet, O Rascol, P Pollak, AM Bonnet, F Cattelin, I Clavier, C Jaillon, Y Agid)
      J Neuro l Neurosurg Psychiatry
    • Assessment of the risk of dyskinesia with ropinirole in early Parkinson’s disease. : a 5 years randomized L-dopa-controlled study.
      (O Rascol, DJ Brooks, AD Korczyn, PP De Deyn, CE Clarke, AE Lang, on behalf of the 056 Study group)
      The New Engl J Med
      Potentiation of the anticoagulant effect of acenocoumarol by aminophen
      (H Bagheri, N Bachaud, JL Montastruc)
      Ann Pharmacotherapy, 1999, 33, 506.
    • Clozapine in drug-induced psychosis in Parkinson’s disease
      (The French Clozapine Parkinson Study Group)
      Lancet, 1999, 353, 2041
    • Effets indésirables neurologiques cansés par les médicaments.
      (G Geraud, JL Montastruc, MC Arné-Bes, C Brefel, Pa Delpla, N Fabre, JM Faucheux, O Rascol, JM Senard)
      Encycl Med Chir (Elsevier, Paris), Neurologie, 1999, 17-161-C-10, 20 p.
    • Prescription des antidépresseurs chez les médecins psychiatres et généralistes. A propos d’une étude de pharmacoépidémiologie réalisée en région Midi-Pyrénées.
      (K Desboeuf, M Lapeyre-Mestre, I Aptel, JJ Chalé, JL Montastruc) “ Mélanges pharmacologiques en hommage à Claude LAROUSSE ”. Helio, Nantes, 1 vol, 199, 179-186
    • Une recherche en médecine générale pour que la pharmacologie clinique soit un pont et non plus un fossé (P Montastruc )
      Le Bulletin de la section généraliste/URML-MP, 1999, 4, 9
    • Antihistaminiques H2 et grossesse.
      (C Damase-Michel)
      Med Féminin, 1998, 13, 31- (paru en 1999).
    • Syncopes “ vagales ” : trop de vague.
      (P Montastruc )
      Rev Prescr, 1999, 195, 399.
    • Terminologie.
      (JL Montastruc )
      Rev Prescr, 1999, 19, 558-559.
    • Folates et grossesse.
      (C Damase-Michel )
      Médecine au Féminin, 1999, 19, 5-8.
    • Effets indésirables des cures thermales : à propos d’une étude prospective systématique à Bagnères-de-Bigorre.
      (R Dutkiewicz, ME Llau-Bousquet-Melou, M Lapeyre-Mestre, JL Montastruc)
      PresseThermale et Climatique, 1999, 1, 9-13.
    • Echantillons : de la foire à l’orthopédie arboricole.
      (P Montastruc )
      Rev Prescr, 1999, 194, 314.
    • Le thermalisme en Midi-Pyrénées.
      (JL Montastruc)
      Sport et Santé, 3, 23-25.
    • Des états dépressifs à l’analgésie, ou comment on devient médicament.
      (JL Montastruc)
      La Lettre du Pharmacologue, 1999, 8, 190.
    • Génériques, état des lieux.
      (A Thomas, P Olivier, JL Montastruc )
      Le Concours Médical, 1999,121-40, 3160-3165.
    • Quels antidépresseurs paraissent avoir le meilleur rapport bénéfice/risque chez des jeunes et vieux parkinsoniens ?
      O Rascol
      La Lettre du Neurologue, 1999, 6, 386-387.
    • Pharmacologie clinique et pharmacovigilance, comment les cellules communiquent-elles
      (C Merial)
      de l’ADPHSO, 1999, 2, 1-2.
    • Le bégaiement d’origine médicamenteuse.
      (D Bechery )
      Rev de l’ADPHSO, 1999, 2, 2-3.
    • Interaction méthadone et antiprotéases.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 3.
    • Médicaments hyperkaliémiants.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 3-4.
    • Lithiases des voies urinaires et inhibiteurs des protéases.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 4.
    • Syncopes d’origine médicamenteuse.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 4-5.
    • L’exposition prénatale à l’ecstasy provoque-t-elle des malformations congénitales ? Un suivi prospectif de 92 grossesse.
      (S Cismondo )
      Rev de l’ADPHSO, 1999, 2, 5-6.
    • Rôle des poumons dans la pharmacocinétique des médicaments.
      (V Pelagatti )
      Rev de l’ADPHSO, 1999, 2, 6-7.
    • Mécanismes des diarrhées d’origine médicamenteuse dans la population âgée.
      (JC Baille )
      Rev de l’ADPHSO, 1999, 2, 7-8.
    • Trop de médicaments prescrits pendant la grossesse.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 8-9.
    • Prescription et consommation des antidépresseurs.
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 9-10.
    • Progestérone et atteinte hépatique pendant la grossesse.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 10-11.
    • Troubles du rythme cardiaque et antihistaminiques H1.
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 11.
    • Effets indésirables médicamenteux chez l’enfant.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 12.
    • Effets indésirables de la quinine dans l’indication “ crampes musculaires ”.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 12.
    • Sucrafalte et bezoard.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 12-13.
    • Hoquet d’origine médicamenteuse.
      (H Bagheri, JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 13.
    • Prescription et consommation des antibiotiques en ville.
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 13-14.
    • Les valvulopathies aux anorexigènes existent !
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 14.
    • A propos du risque cancérigène de la puvathérapie.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 15.
    • Effets indésirables du ritonavir.
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 2, 15-16.
    • Méthémoglobinémie et “ poppers ”.
      (ME Llau-Bousquet-Melou, JL Montastruc)
      Rev de l’ADPHSO, 1999, 2, 16.
    • Interactions médicamenteuses.
      (JL Montastruc)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 30-35.
    • La prescription médicamenteuse aux âges extrêmes de la vie.
      (JM Senard, E Autret )
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 36-42.
    • Médicaments et grossesse.
      (C Damase-Michel )
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 43-44.
    • Médicaments et allaitement.
      (C Damase-Michel)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 45-48.
    • Etats pathologiques et prescription des médicaments : Reins et médicaments. Maladies hépatiques.
      (B Chamontin, JL Montastruc )
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 57-58.
    • Rédaction de l’ordonnance.
      (C Damase-Michel)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 63-68.
    • Prescrire des médicaments non autorisés.
      (JL Montastruc)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 69-70.
    • Automédication : quelle place pour le médecin ?
      (JL Montastruc)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 71-73.
    • Effet placebo.
      (C Damase-Michel)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 74-77..
    • Les 11 questions à se poser avant de prescrire.
      (JL Montastruc )
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 82.
    • Savoir lire et utiliser le Vidal.
      (JM Senard)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 83.
    • S’informer sur le médicament : un devoir pour le médecin.
      (JL Montastruc)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999,84-88
    • Substances dopantes.
      (JL Montastruc)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 90-92.
    • Pharmacodépendance.
      (C Damase-Michel, M Lapeyre-Mestre)
      Polycopié du Certificat de Synthèse Clinique et Thérapeutique (CSCT) DCEM IV, Faculté de Médecine Toulouse Rangueil, 1999, 93-100.
    • La pharmacovigilance : définition et méthodes de travail. Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”.
      11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés de Médecine de Toulouse-Purpan et Toulouse-Rangueil. Toulouse, 21 octobre 1999.
      (JL Montastruc)
    • Effets indésirables médicamenteux conduisant à l’hôpital (enquêtes nationales et régionales). Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”.
      11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés de Médecine de Toulouse-Purpan et Toulouse-Rangueil. Toulouse, 21 octobre 1999.
      (M Lapeyre-Mestre, M Tubery)
    • Prescription des médicaments pendant la grossesse. Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”.
      11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés
      (I Lacroix )
    • Actualités de pharmacovigilance (1). Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”.
      11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés de Médecine de Toulouse-Purpan et Toulouse-Rangueil. Toulouse, 21 octobre 1999.
      (H Bagheri )
    • Actualités de Pharmacovigilance (2). Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”.
      11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés de Médecine de Toulouse-Purpan et Toulouse-Rangueil. Toulouse, 21 octobre 1999.
      (MP Bareille)
    • La pharmacovigilance : un exemple de recherches en médecine générale. Compte-rendu au Symposium “ La Pharmacovigilance pour le Praticien ”. 11ème Forum Médical de Rangueil, réunion commune de FMC, Facultés de Médecine de Toulouse-Purpan et Toulouse-Rangueil. Toulouse, 21 octobre 1999.
      (H Bagheri)
    • Médicaments antiépileptiques et risque de syndrome de Stevens-Johnson.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 1.
    • Communiqué de presse de l’Agence Française de Sécurité Sanitaire des Produits de Santé.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 1-2.
    • Céphalées dues aux triptans.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 2.
    • Déclaration des pharmacodépendance et des abus aux Centres d’Evaluation et d’Informations sur les Pharmacodépendances (CEIP).
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 2-3.
    • Avis du CSP sur les médicaments anorexigènes.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 3-4.
    • Albumines humaines : prudence !
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 4.
    • Troubles gustatifs d’origine médicamenteuse.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 4-5.
    • Nouveaux effets indésirables du citalopram (SEROPRAM°).
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 5.
    • Contraceptifs oraux (CO) et risque cardiovasculaire.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 5.
    • Benzodiazépines et accidents de la route.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 6.
    • Ritonavir (NORVIR°) : hépatites aiguës.
      (JL Montastruc )
      Rev de l’ADPHSO, 1999, 3, 6.
    • Corticoïdes inhalés et cataracte.
      (JL Montastruc)
      Rev de l’ADPHSO, 1999, 3, 6-7.
    • Une nouvelle classe pharmacologique : les inhibiteurs de la catéchol-O-méthyltransféranse (ICOMT).
      (JL Montastruc)
      Lettre du Pharmacologue, 1999, suppl au n° 10, 5-6.
Retour en haut de page